2008/09 Annual Report - Hartford Hospital!
2008/09 Annual Report - Hartford Hospital!
2008/09 Annual Report - Hartford Hospital!
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Hartford</strong> <strong>Hospital</strong> Research Program<br />
<strong>2008</strong>/<strong>09</strong> <strong>Annual</strong> <strong>Report</strong>
Welcome<br />
A Message From The Vice President For Research<br />
The past two years have presented serious economic<br />
challenges across many sectors of our society including<br />
medical research. During this period some grant makers<br />
and funders were forced to cut back or suspend their<br />
programs in the interest of a brighter economic forecast.<br />
At the same time, these years were characterized by<br />
unprecedented opportunity. For example, the American<br />
Recovery and Reinvestment Act of 20<strong>09</strong> ear marked<br />
billions of dollars to support advancements in biomedical<br />
and behavioral research, research infrastructure, faculty<br />
recruitment and academics with the primary aim of creating<br />
and preserving U.S. jobs in these and related sectors.<br />
In the midst of these challenges and opportunities <strong>Hartford</strong><br />
<strong>Hospital</strong> investigators have continued to press onward,<br />
obtaining $11.7 million in funding for research studies<br />
during fiscal year 20<strong>09</strong>, an amount that represents a<br />
22.8% increase in external funding over last year. In 20<strong>09</strong>,<br />
research was identified as a key value of our organization,<br />
and consequently “Academic Excellence” was added as a<br />
pillar on the <strong>Hospital</strong>’s Balanced Scorecard. This addition<br />
acknowledges the world-class work being carried out by<br />
our investigators and highlights the hospital’s culture of<br />
innovation in which physicians perform research because<br />
they are genuinely committed to asking important scientific<br />
questions that will change the practice of medicine here and<br />
nationally.<br />
The Research Program is proud to recognize the<br />
achievements of <strong>Hartford</strong> <strong>Hospital</strong> investigators in<br />
this <strong>2008</strong>-20<strong>09</strong> Biennial <strong>Report</strong>. We are committed to<br />
supporting them as they continue to meet the challenges<br />
and opportunities that the coming decade will bring to<br />
health care and medical research. In closing, I would also<br />
like to take the opportunity to thank the dedicated staff<br />
of Research Administration for their excellent support of<br />
Research at <strong>Hartford</strong> <strong>Hospital</strong>, and a special note of thanks<br />
to Dr. Tara McLaughlin, for her excellent work in preparing<br />
our Biennial <strong>Report</strong>.<br />
Sincerely,<br />
Laurine Bow, PhD<br />
Vice President for Research
Contents<br />
1<br />
Research program summary<br />
3 Financial summary<br />
4 External funding<br />
5 Internal funding<br />
6 Committees<br />
7 Research administration<br />
10 Clinical research center<br />
12 Preclinical research facility<br />
13 Genomas<br />
18 Cardiology<br />
35 Center for anti-infective research<br />
43 Medicine<br />
47 Neurology<br />
50 Nursing<br />
53 Oncology<br />
64 Orthopedics<br />
65 Pathology<br />
69 Psychiatry<br />
89 Radiology<br />
91 Surgery<br />
98 Traumatology & emergency medicine<br />
106 Urology<br />
107 Women’s health<br />
115 Other departments & collaborations
Research Program Summary<br />
At the close of 20<strong>09</strong>, over 600 active research projects were<br />
on going <strong>Hartford</strong> <strong>Hospital</strong><br />
<strong>Hartford</strong> <strong>Hospital</strong> investigators initiated over 350 new<br />
studies in FY 08 and <strong>09</strong> and produced over 870 scientific<br />
publications, abstracts and presentations during this period<br />
Research Program Initiatives<br />
During This Period Include:<br />
• New Research Program website (www.hartfordhealth.org/<br />
research)<br />
• Research Rundown newsletter distributed electronically to<br />
over 500 recipients including <strong>Hartford</strong> <strong>Hospital</strong> investigators,<br />
medical staff and external researchers<br />
• Research Week 20<strong>09</strong> featured research symposium, speakers,<br />
poster display and information<br />
Research Program also Supported<br />
Several Special Awards:<br />
• Pressure Ulcer Prevention Database awarded CQIA Silver<br />
Innovation Prize<br />
• Falls Prevention Program awarded 20<strong>09</strong> CQIA Innovation<br />
Silver Award<br />
• Stroke Center awarded American Stroke Association’s<br />
Get With The Guidelines Stroke (GWTG–Stroke) Silver<br />
Performance Achievement Award<br />
<strong>Hartford</strong> <strong>Hospital</strong>: Committed to<br />
Research Excellence…..<br />
Translational Research…<br />
$1.4 Million SBIR Grant: Dr. Gualberto Ruaño, and the Genomas<br />
team were awarded a $1.4 million, 3 year NIH SBIR grant to develop<br />
MRI+DNA- guided biomarker system for mental illness, bringing the total<br />
amount of NIMH funding secured by Genomas in collaboration with the<br />
Institute of Living to nearly $4 Million.<br />
CEHDL trial preliminary results applied in<br />
community setting:<br />
Results from the 5 year, NIH funded Center for Eliminating Health<br />
Disparities in Latinos (CEHDL) peer-counseling trial suggest that peer<br />
counseling is effective for diabetes management in Latino patients. The<br />
knowledge gained was applied in a community-based setting by PI Jyoti<br />
Chhabra, PhD and researchers at the University of Connecticut and the<br />
Hispanic Health Council through support group forums that took place in<br />
the <strong>Hospital</strong>’s Brownstone clinics.<br />
Federal Recovery Act Funding…<br />
Dr. Paul Thompson was awarded $865,207 Challenge Grant from the<br />
National Institutes of Health for a two-year project “CoEnzyme Q10 in<br />
Statin Myopathy”.<br />
Dr. Godfrey Pearlson was awarded Recovery Act Funding to expand<br />
studies of high-risk drinking in college students, represents $771,000 in<br />
direct costs awarded through a Challenge Grant from the National Institutes<br />
of Health/NIAAA for two-year project “Genetic Architecture of Alcohol<br />
Misuse Candidate Endophenotypes.”
<strong>2008</strong>/<strong>09</strong><br />
New Investigator Initiated Clinical Trial Support.…<br />
Dr. Paul Tulikangas awarded grant from Astellas Pharma Inc:<br />
The new $214,238 study will evaluate use of vaginal pessaries in the<br />
treatment of overactive bladder symptoms in women with pelvic<br />
organ prolapse.<br />
Other New Funding…<br />
Dr. Godfrey Pearlson: BARCS (Brain and Alcohol Research with<br />
College Students) study awarded $1.5 million NIAAA genetics grant<br />
to continue to study drinking and brain function in college students<br />
and to identify markers for vulnerability to dysfunctional drinking<br />
and alcohol toxicity.<br />
Evidence Based Practice Center: The EPC received awards<br />
through the University of Connecticut for over $600,000 for<br />
AHRQ-sponsored projects on the use of antiepileptics and human<br />
growth hormone.<br />
Beth Parker PhD and Cardiology Department Research Team:<br />
Awarded Biomedical Research Grant through State of Connecticut<br />
Tobacco Settlement Funds to study impact of smoking cessation<br />
on vascular function in chronic smokers- Represents a total of<br />
$267,187 in new funding.<br />
<strong>Hartford</strong> <strong>Hospital</strong> selected by Lance Armstrong<br />
Foundation to develop breast cancer<br />
survivorship program:<br />
<strong>Hartford</strong> <strong>Hospital</strong> was awarded one of only eight national<br />
community grants to develop a unique resource program for breast<br />
cancer survivors, was the only site in New England to be selected<br />
for this three-year grant representing $150,000. The evaluation<br />
component will involve Research Program Senior Scientists.<br />
2.
External<br />
Research Funding Received<br />
The external funds received are derived from the September accounting statement.<br />
All calculations are based on the fiscal cycle of October 1 - September 30.<br />
<strong>2008</strong> 20<strong>09</strong><br />
Psychiatry $3,856,000 $4,038,000<br />
Cardiology $1,423,000 $2,782,000<br />
Oncology $808,000 $1,608,000<br />
CAIRD* $1,691,000 $1,418,000<br />
Experimental Research $310,000 $413,000<br />
Medicine $197,000 $311,000<br />
Neurology/Neurosurgery $3<strong>09</strong>,000 $147,000<br />
Emergency Medicine/<br />
Traumatology $15,000 $141,000<br />
Orthopedics $77,000 $119,000<br />
Radiology $74,000 $60,000<br />
<strong>2008</strong> 20<strong>09</strong><br />
Pharmacy/EPC** $129,000 $45,000<br />
Women’s Health $29,000 $37,000<br />
Gastroenterology $5,000 $30,000<br />
Surgery $69,000 $24,000<br />
Anesthesia $3,000<br />
Miscellaneous Support<br />
(Research Admin) $538,000 $527,000<br />
TOTAL $9,530,000 $11,703,000<br />
$11,703,000<br />
$9,530,000<br />
1998 '00 '02 '04 '06 '08 20<strong>09</strong><br />
* Center for Anti-Infective Research and Development ** Evidence-based Practice Center
External Awards<br />
Federal, Foundation and State figures represent annual awards.<br />
All other figures represent new initial total awards.<br />
Federal<br />
<strong>2008</strong> 20<strong>09</strong><br />
Industry: Investigator Initiated<br />
<strong>2008</strong> 20<strong>09</strong><br />
Cardiology $1,529,570 $1,481,<strong>09</strong>7<br />
Emergency Medicine/<br />
Traumatology $35,220 $35,220<br />
Medicine $232,801 $384,551<br />
Neurology $83,195 $89,905<br />
Neurosurgery $12,600 $20,047<br />
Oncology $543,355 $117,570<br />
Pharmacy/EPC $685,361<br />
Psychiatry $4,322,960 $4,415,887<br />
Radiology $141,075 $72,387<br />
CAIRD $207,758 $1,012,219<br />
Cardiology $149,500 $115,116<br />
Emergency Medicine/<br />
Traumatology $18,500<br />
Oncology* $184,640 $404,785<br />
Pharmacy/EPC $100,000<br />
Psychiatry $214,875<br />
Surgery $13,306<br />
Total: $775,273 $1,645,426<br />
Total: $6,900,776 $7,302,025<br />
* represents funds received<br />
Foundation<br />
Industry: Clinical Trials<br />
Medicine $19,225 $23,341<br />
Neurology $550<br />
Oncology $47,756<br />
Pharmacy $5,184<br />
Psychiatry $70,000 $40,000<br />
Radiology $1,500<br />
Total: $89,775 $117,781<br />
State<br />
Cardiology $267,186<br />
Oncology $25,000 $25,000<br />
Psychiatry $5,000 $1,500<br />
Total: $30,000 $293,686<br />
CAIRD $822,428 $188,388<br />
Cardiology $1,264,493 $1,749,326<br />
Emergency Medicine/<br />
Traumatology $63,516<br />
Medicine $205,371 $144,238<br />
Neurology $22,500 $54,835<br />
Oncology $504,829 $5<strong>09</strong>,588<br />
Orthopedics $82,000<br />
Pre-clinical $233,648<br />
Psychiatry $19,000 $329,930<br />
Radiology $143,982 $30,000<br />
Surgery $1<strong>09</strong>,850 $12,250<br />
Women’s Health $44,163<br />
Pathology $22,750<br />
Total: $3,515,780 $3,041,305<br />
4.
Internal Awards<br />
Medical Staff Supported Awards<br />
The following projects received awards generously<br />
co-sponsored by the Medical Staff and the <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Fund:<br />
Alberghini, Tod, Transplant: Clinical significance of solid-phase assay (flow<br />
cytometric and Luminex) detection of pre-transplant HLA antibody as<br />
measured by graft survival in renal transplant recipients: A retrospective<br />
analysis. $9,954<br />
Anglade, Moise, MD, Cardiology: Use of N-Acetylcysteine for prevention of<br />
postoperative atrial fibrillation: A meta-analysis. $5,450<br />
Azemi, Talket, MD, Cardiology: Diagnostic and prognostic significance of<br />
ischemic electrocardiographic changes during vasodilator stress myocardial<br />
perfusion imaging. $9,507<br />
Blondin, Nick, Neurology: A stroke of luck: Can cerebral hemisphere predict<br />
thrombolysis and good outcome in an acute ischemic stroke? $2,250<br />
Clyne, Christopher, MD, Cardiology: Identifying atrial ablation lines through<br />
two-dimensional delayed enhancement MR imaging. $6,360<br />
Collins, Sarah, MD, Urogynecology: Perioperative exercise tolerance and<br />
pain control in women undergoing robotic vs. traditional abdominal sacral<br />
colpopexy. $8,428<br />
Corbera, Silvia, PhD, Psychiatry: Application of Event-Related Potentials<br />
(ERPs) to evaluate the effects of coaching on cognitive rehabilitation in<br />
schizophrenia. $300<br />
Eagye, Kathy, MPH, Center for Anti-infective Research and Development:<br />
Health outcomes investigation of infection in colorectal surgical procedures.<br />
$14,854<br />
Feeney, James, MD Traumatology and Emergency Medicine: Retrospective<br />
review of pre-hospital HMG Co- A reductase inhibitor use in hemorrhagic<br />
shock due to ruptured AAA. $450<br />
Lundbye, Justin, MD, Cardiology: Elevated plasma cytokines are a marker for<br />
unstable coronary syndrome: The <strong>Hartford</strong> Chest Pain Study. $10,777<br />
Lyle, Brian, MD, Cardiology: Follow up of patients with coronary artery<br />
disease who have undergone rapid aspirin desensitization<br />
prior to percutaneous coronary intervention. $5,826<br />
Mace, Melanie, PsyD, Psychology Testing: A survey of regional referring<br />
providers’ use of and perceived utility of neuropsychological services. $750<br />
Norberg, Melissa, PhD, Psychiatry: D-Cycloserine augmented CBT for prior<br />
treatment non-responders with OCD. $9,531<br />
Patel, Minita, MD, Urogynecology: The use of SennaS for prevention of postoperative<br />
constipation in urogynecologic surgery: A randomized, placebocontrolled,<br />
double blinded trial. $9,758<br />
Silverman, David, MD, Cardiology: Freedom from atrial fibrillation following<br />
radio-frequency ablation depends upon integrity of atrial function. $9,975<br />
Silverman, David, MD, Cardiology: Systolic strain abnormalities to predict<br />
hospital readmission in patients with heart failure and normal ejection<br />
fraction. $3,680<br />
Sood, Nitesh, MD, Cardiology: Heart rate variability and brain natriuretic<br />
peptide. $5,760<br />
Gross, Ronald,MD (Spinella, Phillip, MD,) Traumatology and Emergency<br />
Medicine: Relationship between age of RBCs transfused and mortality in<br />
critically ill trauma patients. $9,861<br />
Suozzi, James, MD, Traumatology and Emergency Medicine: Comparison of<br />
the Airtraq® optical laryngoscope to direct laryngoscopy by paramedics: A<br />
randomized, controlled, clinical trial. $8,969<br />
Thumar, Jaykumar, MD, Oncology: CD 133 expression and clinical outcome<br />
in patients with rectal cancer. $12,462<br />
Turner, Beth, PhD, Psychiatry: Simulated driving: Effects of road conditions.<br />
$9,811<br />
Open Competition Awards<br />
The following projects received funding through the Open Competition<br />
program in fiscal years <strong>2008</strong> and 20<strong>09</strong>:<br />
D’Agostino, Darrin, DO, Medicine: DNA-guided Warfarin management.<br />
$62,475<br />
Fischer, Edward, PhD, Cardiology: Community and patient attitudes towards<br />
seeking medical help: Development and standardization of a comprehensive<br />
attitude measure. $21,146<br />
Goethe, John, MD, Psychiatry: Research infrastructure for the Depression and<br />
Bipolar Disorders Center. $49,760<br />
Kuti, Joseph, PharmD, Center for Anti-infective Research and Development:<br />
The effect of hyperbaric oxygen therapy on the penetration of Linezolid into<br />
subcutaneous tissue of diabetics with lower extremity wounds. $74,847<br />
Parker, Beth, PhD Cardiology: Sex differences in the mechanisms underlying<br />
endothelial function. $78,685<br />
Stevens, Michael, PhD, Psychiatry: Linux cluster infrastructure enhancement.<br />
$74,513<br />
Vergara, Cunegundo, MD, Medicine: Creation of an ambulatory database to<br />
measure access to primary preventive care services. $61,000<br />
Wilber, Charles, MED. Psychiatry: Cognitive training in elderly with normal<br />
aging and mild cognitive impairments. $82,487<br />
The Research Program extends its appreciation to the<br />
Medical Staff for its continued support of research at<br />
<strong>Hartford</strong> <strong>Hospital</strong>.<br />
In addition to the projects listed above, Research Endowment and<br />
Medical Staff funds supported statistical analysis and database<br />
development through Small Grants, as indicated throughout this<br />
report.
Committees<br />
The Research Committee, Institutional Review Board<br />
and Institutional Animal Care and Use Committee<br />
each fulfill specific roles and responsibilities that are<br />
crucial to the conduct of research at <strong>Hartford</strong> <strong>Hospital</strong>.<br />
Research Committee<br />
The responsibilities of the Research Committee are fourfold.<br />
The Committee reviews the scientific merit of<br />
research projects and awards internal research funding. It<br />
also investigates any allegations of research misconduct and<br />
evaluates potential conflicts of interest.<br />
Institutional Review Board<br />
The Institutional Review board is charged with the ethical<br />
oversight of research projects involving human research<br />
subjects at <strong>Hartford</strong> <strong>Hospital</strong>. It conducts risk/benefits<br />
analyses of potential research studies and monitors ongoing<br />
studies for safety.<br />
Members<br />
Laurine Bow, PhD, Chair<br />
James Bowers, JD<br />
Karyl Burns, PhD<br />
Erika Cappelutti, MD<br />
William Crombleholme, MD<br />
Ellen Dornelas, PhD<br />
John Goethe, MD<br />
Joseph Kuti, PharmD<br />
Jeffrey Mather, MS<br />
Pavlos Papasavas, MD<br />
Godfrey Pearlson, MD<br />
Ilene Staff, PhD<br />
Cunegundo Vergara, MD<br />
Detlef Wencker, MD<br />
C. Michael White, PharmD<br />
Les Wolfson, MD<br />
Cathy Yavinsky, RN<br />
Members<br />
Robert D. Siegel, MD, Chair<br />
David O’Sullivan, PhD, Vice Chair<br />
Christopher Clyne, MD<br />
Cherie Bilbie, MS<br />
Alexandra Flowers, MD<br />
Margarita Garcia<br />
Yvette Gauthier<br />
John Goethe, MD<br />
Debra Hein, CNM<br />
Gary Heller, MD, PhD<br />
Rev. James Ibekwe, PhD<br />
Kevin Keating, MD<br />
Jacqueline Lyon, MD<br />
Leslie Lothstein, MD<br />
Joseph Nesta, MD<br />
James Rancourt, PharmD<br />
Richard M. Shulman, PhD<br />
THANK YOU!<br />
The Research Program would like to thank those individuals<br />
who completed their committee tenure during this report<br />
period.<br />
Research Committee:<br />
Jaber Aslanzadeh, MD<br />
Gary Heller, MD, PhD<br />
Kevin Keating, MD<br />
Jeffrey Kluger, MD<br />
Joanne Roy, RN, PhD<br />
IRB:<br />
George Perdrizet, MD, PhD<br />
(Vice Chair)<br />
Benjamin Goldfarb<br />
Jenifer Ash<br />
Tiffany R. Hubbard<br />
Joanne Roy, PhD<br />
Institutional Animal Care & Use<br />
Committee<br />
The Institutional Animal Care and Use Committee is<br />
charged with the ethical oversight of research projects<br />
involving animal research subjects.<br />
6.
Research Administration<br />
• Supports and facilitates the growth of research at<br />
<strong>Hartford</strong> <strong>Hospital</strong><br />
• Provides administrative oversight for all research activities at<br />
<strong>Hartford</strong> <strong>Hospital</strong><br />
• Centralized infrastructure includes Grants Administration,<br />
Human Research Protections, Database Design and<br />
Development and Proposal Design and Statistical Analysis.<br />
• The Clinical Research Center and the Preclinical Research<br />
Facility support research activities under the auspices of<br />
Research Administration.<br />
• Research Administration carries out its mission under the<br />
leadership of Laurine Bow, PhD, Vice President for Research.<br />
Grants and Contracts<br />
• Insures that grants and contracts are prepared according<br />
to the appropriate regulations and policies and that<br />
accounting procedures for research studies are followed<br />
correctly.<br />
• Provides financial oversight on research projects<br />
• Assists with contract negotiations for clinical trials and<br />
other research activities<br />
• Provides administrative guidance for all external grant<br />
submissions<br />
• Assists with budget preparation and accounting<br />
procedures<br />
• Informs hospital research community of regulatory<br />
changes that impact the research finances and contracts<br />
• Processed 62 grant applications to federal, foundation<br />
and state sources representing over $48,000,000 during<br />
fiscal year <strong>2008</strong> and 20<strong>09</strong><br />
Grants Administration Staff:<br />
Tammy Weirs, Manager, Grants and Contracts, 545 - 4412<br />
Anita Fowler, Grants Administrator, 545 - 2<strong>09</strong>3<br />
Christine Harvey, Administrative Associate to VP of Research, 545 - 5620<br />
Linda Thompson, Administrative Associate, 545 - 5611<br />
Human Research Protections<br />
Program (HRPP)<br />
• Offers a combined total experience of 20 years in conducting<br />
research studies and 32 years in Research Administration.<br />
• Provides oversight for the protection of human research subjects in<br />
accordance with international principles of Good Clinical Practice,<br />
U.S. Federal Regulations, and <strong>Hospital</strong> policies.<br />
• Provides public assurance that the rights, safety and well-being of<br />
research subjects are protected and that all research data obtained are<br />
credible.<br />
• Provides outreach and education on applying research regulations to<br />
the research community.<br />
• Provides administrative support to the Institutional Review Board and<br />
Institutional Animal Care and Use Committee.<br />
• Monitors ongoing research studies for compliance with all applicable<br />
regulations and policies.<br />
• Processed 1<strong>09</strong> full IRB reviews of new research projects and 125<br />
expedited reviews of new research projects during FY <strong>2008</strong> and 20<strong>09</strong>.<br />
• Working toward achieving full accreditation status by the Association<br />
for the Accreditation of Human Research Protection Programs<br />
(AAHRPP) by the close of 2010.<br />
HRPP Staff:<br />
Cherie Bilbie, MS, CCRP, Director, HRPP 545 - 0088<br />
Dottie Bearse, IRB Coordinator, 545 - 5647<br />
Corey Glider, IRB Administrator, 545 - 4410<br />
Susan Hughes, IRB Administrator, 545 - 4413<br />
Pamela Johnson, IRB Administrator, 545 - 0141<br />
Grants Administration. Left:<br />
(from left): Linda Thompson, Tammy Weirs, Christine Harvey, Anita Fowler<br />
HRPP Group. below:<br />
(from left): Dottie Bearse, Pamela Johnson, Cherie Bilbie, Susan Hughes, Corey Glider
Database Design and<br />
Development Group<br />
Creates databases, registries and specialized data collection<br />
instruments for numerous hospital departments including:<br />
• Brownstone Clinics<br />
• Diabetes Life Care<br />
• Surgery (Bariatrics, Nephrectomy)<br />
• Cardiology/ Cath lab<br />
• Tissue typing and Transplant registries<br />
• Oncology (Prostate cancer registry, Cancer Connect, TCC/Moffitt<br />
database)<br />
Responsible for Quality Management reporting such as:<br />
• NDNQI National Benchmark reporting<br />
• HCAHPS - Responsiveness initiative<br />
• Adverse event drug triggers<br />
• Central line insertion<br />
• Transformation of the ICU<br />
• Rapid Response Team Data Analysis<br />
• Eastern Rehabilitation Health Network Quality Survey<br />
Provides technical support to investigators processing research projects<br />
through the department’s electronic submission system<br />
Assists with queries of hospital’s administrative database in support of<br />
numerous grant applications<br />
Experienced with a range of platforms including:<br />
• Microsoft Access<br />
• SQL Server<br />
• Web Development<br />
• Teleform Design<br />
• ADT/Lab/HL7 Interfacing<br />
Database Design and Development<br />
Group Staff:<br />
Jeff Mather, MS, Director, Data Management, 545 - 3560<br />
Gil Fortunato, MBA, Systems Analyst, 545 - 3194<br />
Juan Gonzalez, Systems Analyst, 545 - 4474<br />
Da-dong Li, PhD, Research Technician, 545 - 4211<br />
Joseph Tortora, Systems Analyst, 545 - 3446<br />
Steve Wilcox, Systems Analyst, 545 - 6056<br />
Data Management Technical Support 545 - 5621<br />
Collaborates on award-winning Quality Improvement and<br />
benchmarking initiatives:<br />
• Falls Prevention<br />
• Pressure Ulcer Prevention<br />
• Get With The Guidelines National Stroke Benchmarking<br />
Database Design and Development Group<br />
(from left): Gil Fortunato, Steven Wilcox, Jeff Mather, Joseph Tortora, Juan Gonzalez<br />
(not pictured Da-Dong Li)<br />
8.
Research Administration<br />
Proposal Design and<br />
Statistical Analysis<br />
• Provides assistance with the scientific design of research studies and<br />
with statistical and data analysis<br />
• Supports the development of external grant applications<br />
• Has conducted public health research and program evaluation for<br />
many internal departments and external entities.<br />
• Has published numerous peer-reviewed manuscripts and presents<br />
research at a variety of scientific meetings<br />
Jyoti Chhabra, PhD:<br />
• Site-Principal Investigator on the 5-year, NIH-funded Center for<br />
Eliminating Health Disparities (CEHDL) clinical trial on diabetes<br />
peer-counseling<br />
• Provides methodological review for research projects involving the<br />
Brownstone Outpatient clinics and Nutrition Services<br />
• Member of the Education subcommittee of the How <strong>Hartford</strong><br />
<strong>Hospital</strong> Works (H3W) initiative<br />
David O’Sullivan, PhD:<br />
Ilene Staff, PhD:<br />
• Research Program Liaison and member, Research Committee<br />
• Provides methodological review and consultation for:<br />
Emergency Medicine/Trauma<br />
Oncology/Radiation Oncology<br />
Urology<br />
Neurology/Stroke Center<br />
Surgery<br />
Anesthesiology<br />
Infectious Disease/CAIRD<br />
Pulmonology<br />
Hematology<br />
Rheumatology<br />
Gynecologic Oncology (Breast)<br />
Orthopedic Surgery<br />
Integrative Medicine<br />
Proposal Design and Statistical Analysis Staff:<br />
Jyoti Chhabra PhD, 545 - 1004<br />
Tara McLaughlin PhD, 545 - 5065<br />
David O’Sullivan PhD, 545 - 4544<br />
Ilene Staff PhD, 545 - 0178<br />
• Vice Chairperson for the <strong>Hartford</strong> <strong>Hospital</strong> Institutional<br />
Review Board<br />
• Provides methodological review and consultation for:<br />
Cardiology<br />
Dentistry<br />
Endocrinology<br />
Gastroenterology<br />
Nursing<br />
Opthamology<br />
Toxicology<br />
Women’s Health<br />
Tara McLaughlin, PhD:<br />
• Primarily responsible for grant-writing for all research areas<br />
• Provides methodological review and consultation for:<br />
Preclinical research studies<br />
Psychiatry<br />
Pastoral/Palliative Care<br />
Community Projects with City of <strong>Hartford</strong><br />
Compiles monthly newsletter, Research Rundown<br />
Proposal Design and Statistical Analysis Group (from left): David O’Sullivan,Tara McLaughlin,<br />
Ilene Staff, Jyoti Chhabra
Clinical Research Center<br />
The Clinical Research Center (CRC) is an invaluable<br />
resource for clinicians interested in conducting research<br />
initiatives at <strong>Hartford</strong> <strong>Hospital</strong>. The CRC provides administrative<br />
and research coordinator support for research activities<br />
of the institution’s medical staff. Support is provided for both<br />
investigator- initiated studies as well as industry funded trials<br />
sponsored by pharmaceutical and medical device companies.<br />
While the CRC staff supports many experienced investigators<br />
they are also able to assist new investigators. As part of<br />
Research Administration, the CRC interacts with a multidisciplinary<br />
staff with expertise in areas of clinical research design,<br />
grant-writing, contract negotiation and budget review, IRB<br />
document preparation, database design and data analysis.<br />
Phase I – IV Study Center:<br />
The Study Center is located on the 6th floor of the<br />
Education and Resource Center building and is available to<br />
investigators by reservation to support Phase I – IV studies<br />
requiring overnight accommodations. The Center has a<br />
suite of 24 private sleep rooms with bathroom and shower<br />
facilities for each group of 4 rooms. Each room includes a<br />
bed with bedding, dresser, closet and desk as well as a wallmounted<br />
television. The Center also has a shared lounge<br />
area with television, DVD player, couches and chairs. The<br />
kitchen facility includes a large refrigerator, microwaves,<br />
toaster ovens and storage cabinet areas. An area for clinical<br />
assessments is available with an exam table, scale, blood<br />
pressure monitor and medical supplies. A specimen processing<br />
laboratory includes a centrifuge, refrigerator/freezer, sink and<br />
phlebotomy chair. The facility is alarmed and can be used<br />
to monitor patients and ensure subject compliance. Trained<br />
medical personnel with clinical trial experience are available<br />
to staff the Study Center. Additional staffing and supplies are<br />
available to meet the needs of individual studies<br />
Services:<br />
Services provided by the CRC include:<br />
• Marketing of services to potential study sponsors and<br />
referrals to our physician investigators<br />
• Marketing of trial opportunities to potential subjects<br />
• Study initiation and regulatory maintenance<br />
• Contract and budget preparation, regulatory documentation<br />
preparation and maintenance including IRB submission and<br />
continuing review<br />
• Coordinator study support<br />
• Patient screening, enrollment, randomization<br />
• Coordination of all study procedures (i.e., study visits, study<br />
drug administration, study-related interventions per study<br />
protocol)<br />
• Availability for all sponsor monitoring visits and audits<br />
• Data management<br />
• Completion of case report forms, query resolution<br />
• <strong>Report</strong>ing adverse events and other regulatory requirements<br />
to the IRB<br />
• Data entry<br />
Locations:<br />
The administrative office of the CRC is located in Research<br />
Administration on the 2nd floor of the ERC Building.<br />
Additionally, satellite offices are located throughout the<br />
hospital including offices in the Stroke Center and the Division<br />
of Cardiology. An outpatient clinical trials office is located in<br />
the medical building to facilitate studies being conducted by<br />
our private physician groups.<br />
10.
Clinical Research Center<br />
CRC Staff:<br />
The CRC has supported the clinical research activity of<br />
hospital investigators since 1993. The staff has grown<br />
to include 19 research professionals committed to<br />
providing excellence in clinical research. A Director<br />
and Study Center Coordinator provide management of<br />
the operational and financial areas of the department. A<br />
Research Pharmacy Technician is part of the CRC staff<br />
and assumes accountability for all investigational drug<br />
use at the institution. The CRC study coordination staff<br />
includes 14 Clinical Research Associates with clinical<br />
research certification through the Society of Clinical<br />
Research Associates (SOCRA) or the Association of<br />
Clinical Research Professionals (ACRP). Two of the<br />
coordinators also have experience in basic science<br />
research. The CRC is also staffed by two Clinical<br />
Research Assistants who support the study coordinators<br />
and provide other assistance with research tasks as<br />
needed.<br />
New Clinical Trial Initiatives:<br />
The CRC continues to support clinical research in<br />
Cardiology (Divisions of Preventive Cardiology,<br />
Arrhythmia Services, Interventional Cardiology<br />
and Heart Failure and Transplantation), Neurology,<br />
Gastroenterology, Orthopedic Surgery, Infectious<br />
Disease, Pulmonary Medicine, Trauma/Emergency<br />
Medicine, Interventional and General Radiology and<br />
Urogynecology. We were pleased to provide study<br />
coordination services to several additional hospital<br />
divisions this past year.<br />
Neurosurgery:<br />
The Neurosurgery Department has enlisted the<br />
coordinator support of the CRC to conduct several<br />
clinical trials. The trials will study the use of<br />
investigational interventions for patients requiring<br />
neurosurgical procedures.<br />
Colorectal Surgery:<br />
The CRC staff is coordinating an investigator initiated<br />
study being conducted by Kristina Johnson, MD,<br />
Connecticut Surgical Group. Dr. Johnson’s study<br />
will evaluate the use of a medication in laparoscopic<br />
colectomy patients and its effect on hospital length of<br />
stay.
PreClinical Research Facility<br />
<strong>Hartford</strong> <strong>Hospital</strong>’s preclinical research facility was established in 1952,<br />
and has provided support for numerous surgical specialties. The<br />
innovative research and training supported by the facility has resulted in many<br />
significant developments for the hospital, such as open-heart surgery, heart<br />
and liver transplants, and intra-coronary drug delivery via balloon catheters.<br />
The facility performs preclinical contract work including Good Laboratory<br />
Practices (GLP) and non-GLP studies. Three surgical suites are available for<br />
testing, training or research.<br />
The facility is licensed by the United States Department of Agriculture<br />
(USDA) and Accredited by the Association for Assessment and Accreditation<br />
of Laboratory Animal Care, International (AAALAC).<br />
Current Collaborators:<br />
FarmingtonPharma Corporation<br />
Maquet (formerly Datascope)<br />
Matrix Bioanalytical Laboratories<br />
Facility Capabilities:<br />
In Vivo Medical Device Testing<br />
In Vivo Biocompatibility Testing<br />
Surgical Research and Development<br />
Surgical Training Courses<br />
GLP and non-GLP studies<br />
Quality Assurance Program<br />
12.
Genomas<br />
Gualberto Ruaño, MD, PhD<br />
Director of Genetics Research, <strong>Hartford</strong> <strong>Hospital</strong><br />
President, Genomas<br />
Genomas (www.genomas.com) is the biotechnology anchor<br />
of the <strong>Hartford</strong> <strong>Hospital</strong> Genetics Research Center (GRC)<br />
and was inaugurated in 2004 by Gualberto Ruaño, MD, PhD.<br />
Dr. Ruaño, who holds MD and PhD degrees from Yale, and<br />
a baccalaureate from Johns Hopkins, has been an advocate of<br />
personalized medicine for 15 years, and is one of the leading<br />
medical experts in the field. Genomas is located on the<br />
<strong>Hartford</strong> <strong>Hospital</strong> campus in downtown <strong>Hartford</strong> and occupies<br />
4,000 sq. ft. of state-of-the-art laboratory and office space in<br />
the first floor of the Florence T. Crane building at<br />
67 Jefferson St<br />
Genomas® is a biomedical company advancing DNA-Guided<br />
medicine with products for personalized prescription of<br />
drugs used in the treatment of mental illness, diabetes, and<br />
cardiovascular disease (CVD). Their products eliminate trialand-error<br />
prescription with DNA-Guided medicine and enable<br />
physicians to treat with unprecedented precision, avoiding<br />
significant drug side effects, improving efficacy and enhancing<br />
patient compliance. Core applications are drug treatments<br />
of mood and thought disorders in mental illness and of<br />
cardiometabolic risk in diabetes and CVD. The products are<br />
developed in partnership with three leading Connecticut<br />
medical institutions, <strong>Hartford</strong> <strong>Hospital</strong>, The Institute of<br />
Living and the <strong>Hospital</strong> of Central Connecticut and with the<br />
University of Puerto Rico Medical Sciences.<br />
Andreas Windemuth, PhD<br />
Chief Technology Officer<br />
Genomas Inc.<br />
Gualberto Ruaño, MD, PhD<br />
President and CEO, Genomas Inc.<br />
Director of Genetics Research, <strong>Hartford</strong><br />
<strong>Hospital</strong><br />
As of November 20<strong>09</strong>, the GRC and Genomas have published<br />
32 peer-reviewed scientific articles and established an<br />
intellectual property portfolio of 8 patents pending as US<br />
applications. The research is being advanced in partnership<br />
with the National Institutes of Health which have awarded<br />
GRC and Genomas $4.8 M in grants as of November 20<strong>09</strong><br />
for PhyzioType System research and development. The<br />
company has won 3 Phase II SBIR awards subsequent to<br />
respective Phase I awards from NIH for PhyzioType product<br />
development. Clinical research and molecular diagnostics<br />
service are conducted at the Physiogenomics Laboratory and<br />
Laboratory of Personalized Health, respectively.<br />
PhysioGenomics Laboratory (PGL)<br />
PhysioGenomics Laboratory (PGL) Resources. PGL has<br />
installed the whole-genome Human-I BeadChip genotyping<br />
technology from Illumina, Inc. This technology merges<br />
parallel processing through nanoscale high resolution<br />
scanning. The genotyping analysis has the capacity of 8<br />
million SNP’s per day and is a proven technology. Genomas<br />
was one of the first biomedical companies with this capability<br />
fully deployed internally. For its genotyping approach,<br />
PGL has access to an expanding SNP database of 1,000,000<br />
high-confidence, mapped, and annotated SNP markers<br />
which merges parallel processing through fiber optics and<br />
nanoscale high resolution scanning. To increase throughput<br />
and quality PGL has added a Tecan Robot to provide pre-and<br />
post PCR automation of the Illumina genotyping protocol<br />
and an Autoloader to automate loading and scanning of the<br />
Illumina Bead Chips and Sentrix Arrays. PGL has two robotic<br />
systems in operation. A Qiagen BioRobot EZ1 is used to<br />
automate DNA extraction from blood or other samples, and a<br />
Perkin Elmer Janus liquid handling system is used to automate<br />
repetitive liquid handling tasks throughout the process.<br />
PGL Technology<br />
Physiogenomics Technology is a proprietary platform<br />
integrating genotypic and phenotypic measures to correlate<br />
gene variability with physiological variability (Fig. 1).<br />
Genomas has established a DNA repository and clinical<br />
registry of 6,000 patients in mental illness, diabetes and<br />
cardiovascular disease. The clinical data from these extensive<br />
cohorts is integrated systematically into the PhyzioClinica<br />
Database (Fig. 2).<br />
Mohan Kocherla MS, MS-MIS<br />
Research Scientist and Manager<br />
of Laboratory Operations<br />
Genomas Inc.<br />
David Villagra BS<br />
Research Associate<br />
Genomas Inc.<br />
Physiogenomics Technology is a medical application of<br />
sensitivity analysis and systems engineering. Sensitivity<br />
analysis is the study of the relationship between input<br />
and output from a system as determined by each system
component. Physiogenomics Technology utilizes the genes<br />
as the components of the system. The gene variability,<br />
measured by single nucleotide polymorphisms (SNPs), is<br />
correlated to physiological responses of a population, the<br />
output. Physiogenomics Technology determines how the SNP<br />
frequency varies among individuals similarly<br />
responding to the input over the entire range of the response<br />
distribution. The mechanisms of drug resistance and of<br />
common, clinically intensive side effects involve multiple<br />
physiological pathways suitable for Physiogenomics analysis.<br />
Genomas has branded their medical management products as<br />
PhyzioType Systems.<br />
Fig. 1 Physiogenomics Principles<br />
Genomas analyzes the genome to derive the optimal<br />
candidate genes for which SNPs are included in each<br />
PhyzioType System. This approach is carried out by means of<br />
PhyzioGenomic Arrays derived from selected cardio-metabolic<br />
and neuro-endocrine genes, from selected pharmacokinetic<br />
and pharmacodynamic genes, and from genome-wide<br />
representation as well as genomic controls. Physiogenomics<br />
utilizes nanotechnology-based platforms and biomedical<br />
systems engineering to integrate genomic variations with<br />
clinically validated predictions of drug response.<br />
PhyzioType Systems<br />
PhyzioType Systems for drug management have 3 components<br />
(Fig. 3): an ensemble of inherited, stable DNA markers from<br />
various genes, a bioclinical algorithm validated in clinical<br />
studies to ascertain the medical significance of a patient’s<br />
DNA marker configuration and a reporting portal enabling<br />
physicians to select the best drug based on each patient’s<br />
individual’s efficacy response and risk of developing side<br />
effects.<br />
Each PhyzioType Systems is designed to have the following<br />
properties:<br />
Clinically Actionable Information. Personalized information<br />
regarding an individual’s drug response for major drugs in a<br />
therapeutic class to provide treatment guidance to physicians<br />
Objective Results. Statistically predictive analysis which<br />
will allow the physician to objectively recommend an initial<br />
treatment course<br />
Noninvasive Tests. Performance using a sample of the patient’s<br />
peripheral blood<br />
Quality Control. All tests processed at Genomas’ Laboratory<br />
Fig. 2 Resources of the PhysioGenomics Laboratory<br />
Fig. 3 Components of the PhyzioType Systems<br />
of Personalized Health to provide consistent quality and<br />
ensure timely turnaround.<br />
Laboratory of Personalized Health LPH<br />
LPH Resources. Operational since 2005 as a Division of<br />
Genomas, LPH is a high-complexity molecular diagnostic<br />
reference laboratory licensed by the Connecticut Department<br />
of Public Health (license #CL-0644) and certified by<br />
the Centers for Medicare and Medicaid Services (ID<br />
#07D1036625) under CLIA (Clinical Laboratory Improvement<br />
Amendments). On March 20<strong>09</strong>, LPH underwent its third<br />
biannual inspection, and successfully met all criteria for<br />
continued operation. LPH has installed the Luminex®<br />
100 analyzer using xMAP® technology (Luminex Corp.,<br />
Austin, TX). LPH provides clinical DNA typing for the<br />
14.
Genomas<br />
HILOmet PhyzioType System for antidepressant and<br />
anxiolytic management to psychiatrists who refer patients<br />
for evaluation of innate drug metabolism capacity. The<br />
molecular diagnostic analysis is performed under contract to<br />
Clinical Laboratory Partners (a <strong>Hartford</strong> <strong>Hospital</strong> subsidiary)<br />
for distribution throughout Connecticut.<br />
LPH Technology: Psychiatry<br />
The HILOmet PhyzioType product consists of 3 tests<br />
for genotyping each of the 3 key CYP450 (Cytochrome<br />
P450) genes: CYP2D6, CYP2C9, and CYP2C19. These<br />
genes are critical for the metabolism of several psychiatric<br />
and cardiovascular drugs. Altogether, the HILOmet tests<br />
genotype a total of 34 functional variants of these 3 drug<br />
metabolism genes. The 3 genes and 34 variants interpreted<br />
as a combinatorial ensemble constitute the HILOmet<br />
PhyzioType System. The HILOmet product has already<br />
been employed to benchmark drug metabolism reserve for<br />
600 patients referred to LPH. Genomas researchers have<br />
compared the types and carrier prevalences of combinatorial<br />
HILOmet PhyzioType genotypes in Major Depressive<br />
Disorder (MDD) patients to a control group of nonpsychiatrically<br />
ill, medical outpatients. They conducted<br />
a case control study using 73 psychiatric outpatients<br />
diagnosed with depression and referred to The Institute of<br />
Living, for treatment resistance or intolerable side effects to<br />
psychotropic drugs. The controls were 120 cardiovascular<br />
patients from <strong>Hartford</strong> <strong>Hospital</strong> being treated for<br />
dyslipidemia but otherwise healthy and not psychiatrically<br />
ill. Within the psychiatric population, 57% of individuals<br />
were carriers of non wild-type alleles for 2-3 genes,<br />
compared to 36% in the control population (p
treatment resistant and drug intolerant patients, as well<br />
as children and adolescents. As the field of personalized<br />
healthcare advances to clinical practice, Genomas researchers<br />
foresee DNA-guided medicine being used to prevent adverse<br />
drug reactions, particularly in high-risk populations referred to<br />
tertiary hospitals.<br />
LPH Technology: Cardiologyw<br />
Pharmacogenetic studies from the past decade have revealed<br />
that common polymorphisms in 2 genes, cytochrome P450<br />
2C9 (CYP2C9) and Vitamin K epoxide reductase complex<br />
subunit 1 (VKORC1), greatly affect warfarin dose through<br />
different mechanisms. Genome wide scans have confirmed<br />
these findings. The most frequent polymorphisms of CYP2C9<br />
include *2 and *3 which are associated with decreases in 2C9<br />
enzyme activity to about 70% and 5% of the normal level,<br />
respectively. The FDA revised the Coumadin® (warfarin) label<br />
in August 2007 including discussion of these gene variants<br />
to personalize initial dose and subsequent management. The<br />
result is excess warfarin accumulation, elevated INR (>4.0) and<br />
possible hemorrhagic complications.<br />
Warfarin exerts an anticoagulant effect through its inhibition<br />
of the Vitamin K epoxide reductase multiprotein complex<br />
Fig.5<br />
(VKOR), part of which is subunit 1, encoded by VKORC1.<br />
VKOR is responsible for converting vitamin K epoxide to<br />
vitamin K hydroquinone which is an essential co factor<br />
required for the carboxylation of clotting factors II, VII, IX<br />
and X. A common polymorphism of the VKORC1 promoter<br />
sequence (-1639 G>A) results in decreased Vitamin K epoxide<br />
reductase enzyme activity as shown by in vitro promoter<br />
luciferase activity assays.<br />
As an illustration, the population wide impact of combinatorial<br />
genotyping for VKORC1 and CYP2C9 on effective warfarin<br />
dose is predicted for a cohort of outpatients at the <strong>Hartford</strong><br />
<strong>Hospital</strong> Preventive Cardiology clinic. The decreases were<br />
calculated using published algorithms that employ age,<br />
gender, weight, height, CYP2C9 genotype, and VKORC1<br />
genotype. Fig.5 presents the frequency of individual<br />
combinatorial genotypes for CYP2C9 and VKORC1 found in<br />
that population (horizontal axis) and the predicted decrease<br />
in effective warfarin dose associated with each combinatorial<br />
genotype (vertical axis). Warfarin therapeutic risk increases<br />
with the number of deficient alleles.<br />
New Projects<br />
Seip, Richard, PhD<br />
DNA as a Predictor of Effective Warfarin Levels. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $62,475.<br />
Cumulative percentage of the population<br />
Active Projects<br />
Seip, Richard, PhD<br />
Relationship of Muscle Injury to Muscle Hypertrophy. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $35,488.<br />
Publications<br />
de Leon J, Arranz MJ, Ruaño G. Products for pharmacogenetic<br />
testing in psychiatry: A review of features and clinical realities.<br />
Clinics in Laboratory Medicine, 28: 599-617, <strong>2008</strong>.<br />
de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz<br />
FJ. Exploring genetic variations that may be associated with the<br />
direct effects of some antipsychotics on lipid levels. Schizophrenia<br />
Research, 98: 40-46, <strong>2008</strong>.<br />
16.
Genomas<br />
Diaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, de Leon J.<br />
Acetyl-coenzyme A carboxylase α gene variations may be associated<br />
with the direct effects of some antipsychotics on triglyceride levels.<br />
Schizophrenia Research, 115: 136–140, 20<strong>09</strong>.<br />
LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip RL,<br />
Duconge J, Ruaño G. Integrating genomic based information into<br />
clinical Warfarin (Coumadin®) management: An illustrative case<br />
report. Connecticut Medicine, 72 (7): 399-403, <strong>2008</strong>.<br />
Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML,<br />
Kraemer WJ, Ruaño G. Physiogenomic comparison of human fat loss<br />
in response to diets restrictive of carbohydrate or fat. Nutrition and<br />
Metabolism, 5: (1):4 [Epub ahead of print], <strong>2008</strong>.<br />
Windemuth A, Calhoun V, Pearlson G, Kocherla M, Jaganathan K,<br />
Ruaño G. Physiogenomic analysis of localized fMRI brain activity<br />
in schizophrenia. Annals of Biomedical Engineering, 36 (6): 877-88,<br />
<strong>2008</strong>.<br />
Liu J, Pearlson G, Windemuth A, Ruaño G, Perrone-Bizzozero<br />
NI, Calhoun V. Combining fMRI and SNP data to investigate<br />
connections between brain function and genetics using parallel ICA.<br />
Human Brain Mapping, 30: 241-255, 20<strong>09</strong>.<br />
Ruaño G, Bernene J, Windemuth W, Bower B, Wencker D, Seip<br />
RL, Kocherla M, Holford TR, Petit W, Hanks S. Physiogenomic<br />
comparison of edema and BMI in patients receiving Rosiglitazone or<br />
Pioglitazone. Clinica Chimica Acta, 400: 48-55, 20<strong>09</strong>.<br />
Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M,<br />
Villagra D, Renta J, Holford TR, Santiago-Borrero PJ. Physiogenomic<br />
analysis of the Puerto Rican population. Pharmacogenomics, 10 (4):<br />
565-577, 20<strong>09</strong>.<br />
Ruaño G, Thompson PD, Villagra D, Bower B, Kocherla M,<br />
Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J,<br />
Holford TR, Wu AHB. High carrier prevalence of combinatorial<br />
CYP2C9 and VKORC1 genotypes affecting warfarin dosing.<br />
Personalized Medicine, 5 (3): 225-232, <strong>2008</strong>.<br />
Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower<br />
B, Szarek BL, Goethe JW. Increased carrier prevalence of deficient<br />
CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients<br />
referred to a tertiary psychiatric hospital. Personalized Medicine, 5<br />
(6): 579-587, <strong>2008</strong>.<br />
Ruaño G. DNA collage and personalized medicine. Connecticut<br />
Medicine, 72 (6): 322-cover, <strong>2008</strong>.<br />
Ruaño G. Bringing DNA-guided medicine to the Hispanic<br />
population. Puerto Rico Health Sciences Journal, 28 (3): 266-267,<br />
cover, 20<strong>09</strong>.
Cardiology<br />
Paul D. Thompson, MD<br />
Alan Ahlberg, MA • Jeremy Barbagallo, MA • Jill Cloutier<br />
RN • Christopher Clyne, MD • Eric Crespo, MD. • Giselle<br />
Cyr, RN • Marcin Dada, MD • Ellen Dornelas, PhD • Edward<br />
Fischer, PhD • Brenda Foxen, RN • Daniel Fram, MD<br />
Dalia Giedrimiene, MD, Ph.D • Danette Guertin, APRN<br />
Deborah Katten, RN • Francis Kiernan, MD • Jeffery Kluger,<br />
MD •Gary Heller, MD • Jeffrey Hirst, MD • Justin Lundbye,<br />
MD • Raymond McKay, MD • Roger Mennett, MS • Joseph<br />
Mitchel, DO • Deborah Murphy, RN • Beth A. Parker. PhD<br />
• Charles Primiano, MD • Donna M. Polk, MD • Joseph<br />
Radojevic, MD • Aleksandra Ras, BS • David Silverman, MD<br />
• Marilyn Siwy, RN • Cara Statz, PhD • Detlef Wencker, MD<br />
• Charles White, PharmD • Steven Zweibel, MD<br />
Research is a major emphasis for all faculty in the Division<br />
of Cardiology because it contributes directly to improving<br />
patient care and medical education. The Division of<br />
Cardiology and the Henry Low Heart Center are directed<br />
by Paul D. Thompson, MD. The Center has active research<br />
programs in heart failure, preventive cardiology, nuclear<br />
cardiology, electrophysiology and cardiac catheterization. In<br />
the last two years, the Division of Cardiology has published<br />
more than 120 empirical articles in peer reviewed publications<br />
and been awarded more than $1.8M in federally funded<br />
research projects, more than $2M in external and industry<br />
funding and $135,000 in <strong>Hartford</strong> <strong>Hospital</strong> endowment<br />
funding.<br />
Preventive Cardiology<br />
This division has several ongoing clinical trials focused on<br />
developing new approaches to treating cholesterol thereby<br />
reducing cardiovascular disease risk, evaluating the effect of<br />
the statin cholesterol drugs on muscle strength and aerobic<br />
performance, evaluating the effect of statins on brain function,<br />
examining the effects of exercise training on brain function,<br />
and utilizing smoking cessation and stress management to<br />
improve cardiac outcomes for patients with implantable<br />
cardioverter defibrillators. In 20<strong>09</strong>, Dr. Thompson was one<br />
of a very selective number of researchers to be awarded a<br />
challenge grant from the National Institute of Health. Along<br />
with co-investigators, Drs. Polk and Parker, he will examine<br />
the effects of Coenzyme Q10 (ubiquinol) supplementation<br />
on severity of skeletal muscle myopathy in patients with<br />
statin-associated myalgia. Dr. Thompson also is the principal<br />
investigator of a multi-site, federally funded clinical trial<br />
determining the incidence of statin-induced myalgia and<br />
the effects of statins on skeletal muscle strength and aerobic<br />
exercise performance. Additionally, the Department of<br />
Preventive Cardiology is working with Dr. Gualberto Ruano<br />
of Genomas and Dr. Eric Hoffman of Washington Children’s<br />
National Medical Center on two other NIH funded clinical<br />
trials investigating genetic differences underlying statinassociated<br />
muscle symptoms and the muscle strength response<br />
to resistance training, respectively.<br />
Two preventive cardiology fellows, Drs. Shishir Mathur and<br />
Afrooz Ardestani, have initiated studies which involve the<br />
participation of local runners. Dr. Mathur studied runners<br />
18.
Cardiology<br />
participating in the <strong>Hartford</strong> Marathon in October to<br />
determine whether marathon running is associated with<br />
improvements in genetic markers of aging as well as functional<br />
properties of high-density lipoprotein (HDL) cholesterol.<br />
Dr. Ardestani is examining markers of muscle damage before<br />
and after the Manchester Road Race in runners both taking<br />
and not taking statins to determine whether chronic statin<br />
use affects the muscle response to intense aerobic exercise.<br />
Both studies have utilized the participation of local running<br />
organizations and may yield valuable information about<br />
the benefits of exercise as well as the effects of cholesterollowering<br />
drugs on the muscle response to exercise.<br />
Preventive Cardiology is also home to multiple industry<br />
funded trials of cholesterol lowering medications. These<br />
studies, lead by Dr. Donna Polk are focused on new classes<br />
of cholesterol lowering drug aimed at raising HDL as well as<br />
drugs targeting the inflammatory process of athereosclerosis<br />
to try to further reduce the risk of heart disease. Additionally<br />
we are involved in several studies designed to evaluate the<br />
best treatment of diabetics after a heart attack to improve<br />
outcomes in this high risk group. Dr Polk and Dr. Parker are<br />
also involved in evaluating the role of the non invasive test<br />
carotid intimal medial thickness (cIMT) in the behavior of<br />
individuals with hyperlipidemia<br />
In <strong>2008</strong>, exercise physiologist Dr. Beth Parker joined the<br />
Department of Preventive Cardiology and has been funded<br />
by the CT Department of Public Health to determine the<br />
effects of smoking cessation on vascular function in chronic<br />
smokers. Dr. Parker is also the principal investigator of a<br />
research study that examines whether the vascular response to<br />
stress varies with age and sex in healthy humans. Both studies<br />
use noninvasive imaging techniques such as brachial artery<br />
reactivity and arterial stiffness and follow the theme as to how<br />
simple interventions can improve cardiovascular health.<br />
Drs. Parker, Polk and Thompson are also collaborating with<br />
Dr. Godfrey Pearlson in the Olin Neuropsychology Research<br />
Center to conduct studies on the effects of statin therapy<br />
on brain neuronal activation using functional magnetic<br />
resonance imaging. Emerging evidence suggests that statin<br />
therapy may influence the brain as well as blood lipids, and<br />
determining brain activation of individuals on and off statins<br />
allows researchers a direct look at the functional consequences<br />
of statin therapy. The collaborative research team of Drs.<br />
Parker, Thompson and Pearlson also completed a preliminary<br />
study on exercise training and the hippocampus, again<br />
using magnetic resonance imaging, to determine whether<br />
hippocampal structure changed after a 10 week program of<br />
aerobic exercise training.<br />
Preventive cardiology also has an active behavioral cardiology<br />
research program under the direction of psychologist,<br />
Ellen Dornelas, Ph.D. Working together with Matthew<br />
Burg, Ph.D. and Rachel Lampert, MD, from Yale University<br />
and collaboratively with Dr. Kluger from the Department<br />
of Electrophysiology and Arrhythmia Services, <strong>Hartford</strong><br />
<strong>Hospital</strong> is enrolling patients with implantable cardioverter<br />
defibrillators (ICDs) in a study funded by the National<br />
Heart Lung and Blood Institute that will test whether stress<br />
management effectively reduces risk of shock from ICD due<br />
to emotional stress. Additionally, Dr. Edward Fischer and Dr.<br />
Dornelas are co-principal investigators on a study examining<br />
community attitudes about seeking help from medical<br />
professionals.<br />
The research program in preventive cardiology is<br />
home to national recognized researchers in the fields<br />
of lipid management, cardiac function of elite athletes,<br />
exercise physiology, smoking cessation and behavioral<br />
cardiology. Studies conducted in preventive cardiology are<br />
interdisciplinary, collaborative and innovative, focused on<br />
improving cardiovascular and behavioral health in various<br />
patient populations.<br />
Heart Failure and Transplant Center<br />
(HFTC)<br />
This Center is home to cutting edge research performed at<br />
our newly designed, NIH funded translational research Center<br />
of the HFTC. This research center offers new insight and<br />
development of novel therapy and diagnosis of advanced heart<br />
failure. To better understand the relentless progression of<br />
heart failure, the translational research center studies the role<br />
of death receptor signaling pathways in heart muscle, skeletal<br />
muscle and serum as a marker for disease progression and as<br />
a tool to provide new therapies for advanced heart failure.<br />
Therapies involve new pharmaceutical, VAD and electro-
physiologic device therapy. The HFTC is also participating<br />
in six multi-national heart failure trials and two ventricular<br />
assist device (VAD) trials. These trials, headed by Dr.<br />
Detlef Wencker, are critical for many patients in end-stage<br />
cardiomyopathy that could offer potentially life saving<br />
support with most advanced therapies and technologies<br />
Nuclear Cardiology<br />
This division has a very active research program involving<br />
both SPECT and PET imaging techniques. Research into<br />
SPECT imaging techniques include a large database to<br />
evaluate outcomes for patients undergoing nuclear cardiology<br />
studies. The SPECT imaging techniques also involve<br />
new pharmaceuticals for stress including regadenoson<br />
and adenoscan. In addition, a program to evaluate new<br />
technologies developed to improve image quality and reduce<br />
patient time and radiation exposure is an important aspect of<br />
the research effort. PET perfusion imaging has become a very<br />
important part of nuclear cardiology. The Nuclear Cardiology<br />
Laboratory is conducting research into new radiotracers<br />
which holds potential to improve identification in patients<br />
with coronary artery disease. These tracers will identify at<br />
risk patients for ventricular cardiac arrest and may help direct<br />
patients towards ICD placement.<br />
Cardiovascular Pharmacy<br />
Research Group<br />
<strong>Hartford</strong> <strong>Hospital</strong> is fortunate to have a longstanding<br />
relationship with the University of Connecticut School of<br />
Pharmacy. Dr. Jeffrey Kluger has been working collaboratively<br />
with the Cardiovascular Pharmacy Research and the Pharmacy<br />
Outcomes group under the leadership of Drs. Mike White<br />
and Craig Coleman, respectively. This effort has resulted in<br />
the UCONN/HH Evidence Based Practice Center obtaining<br />
funding through the Federal Agency AHRQ. The contract<br />
evaluating comparative effectiveness of ACEI and ARB in<br />
patients with preserved cardiac function was completed.<br />
The group now has a contract to investigate the role of<br />
thrombolytic devices in coronary disease. The CV Pharmacy<br />
research is now enrolling patients in AFIST IV evaluating the<br />
role of Vitamin C in modifying inflammatory markers after<br />
cardiac surgery. In collaboration with Dr. Craig Coleman<br />
and Dr. Jeffrey Kluger there are multiple observational studies<br />
ongoing in the area of antiarrhythmic drug therapy including<br />
the role of adjuvant magnesium for atrial fibrillation. Other<br />
outcome studies have focused on our implantable defibrillator<br />
and syncope populations.<br />
Cardiac Electrophysiology and<br />
Arrhythmia Services<br />
<strong>Hartford</strong> <strong>Hospital</strong> is home to many federally and industry<br />
funded clinical trials focused on improving treatment for<br />
complex electrical cardiac disorders. These include the VEST-<br />
PREDICTS Trial –led by Dr. Zweibel, an NIH sponsored trial<br />
that examine whether a wearable defibrillator will save lives<br />
and improve cardiac outcomes months after an heart attack.<br />
Dr. Zweibel is also collaborating on the APPROPRIATE<br />
Trial –a study that will evaluate two different sensors (minute<br />
ventilation and accelerometer) in patients receiving a dualchamber<br />
pacemaker for the indication of chronotropic<br />
incompetence. Additionally, the PROVIDE Trial, under<br />
the leadership of Dr. Zweibel, will test different sets of<br />
ICD programming parameters to minimize shock therapy<br />
without increasing the risk of syncope or untreated ventricular<br />
tachycardia.<br />
Cardiac Electrophysiology is also one of 140 centers<br />
worldwide investigating the possible benefit of early<br />
implantation of cardiac resynchronization devices for<br />
reduction of heart failure hospitalization and total mortality<br />
in the MADIT-CRT trial. Dr. Christopher Clyne is principal<br />
investigator on the first multi-center NIH-sponsored study<br />
to investigate the effect of primary atrial fibrillation ablation<br />
versus drug therapy on total mortality and outcome. Also<br />
under Dr. Clyne’s direction is the <strong>Hartford</strong> Area Resuscitation<br />
Research Trial (HARRT), a project which will advance basic<br />
life support and AED operation into the West <strong>Hartford</strong><br />
Public High Schools. Dr. Eric Crespo is the site principal<br />
investigator on the Direct His Bundle Pacing to Implement<br />
Cardiac Resynchronization Therapy (DIRECT) Study, which<br />
is a multi-center clinical trial investigating a novel pacing<br />
technique (Direct His Bundle Pacing) as an alternative to<br />
conventional cardiac resynchronization therapy in patients<br />
with advanced heart failure.<br />
Echocardiography<br />
Current research projects in Echocardiography are under the<br />
direction of Dr. David Silverman and focus on examination<br />
diastolic dyssynchrony as a marker for diastolic heart failure<br />
(with Sanjeev Bahvnani, MD, Detlef Wencker MD and<br />
Sayeed Zaeem, MD) evaluation of the prognostic value<br />
of systolic strain in a series of patients with diastolic heart<br />
failure, analysis of appropriateness of echo ordering, and an<br />
examination of the prognostic value of plasma cytokine levels<br />
in patients presenting to the emergency room with chest pain.<br />
In collaboration with Dr Isaac Silverman in Neurology and<br />
Dr Jeffrey Kluger in Cardiology, we are building a program<br />
to examine utilization of echocardiography for several<br />
common diagnoses including stroke and syncope. This year<br />
the echocardiography laboratory reported its accumulated<br />
experience with echocardiographic imaging to guide<br />
prognosis following percutaneous device closure of patent<br />
foramen ovale.<br />
20.
Cardiology<br />
Cardiac Catheterization<br />
Research Program<br />
The research program of the cardiac catheterization<br />
laboratory led by Dr. Francis Kiernan and Raymond McKay,<br />
MD currently focuses on the development and testing of<br />
new interventional and cardiac imaging techniques, on the<br />
assessment of adjunctive interventional pharmacology, and<br />
on the maintenance and analysis of a comprehensive research<br />
database to tract clinical outcomes in all interventional<br />
patients. Previous research accomplishments by members of<br />
the catheterization laboratory have included the development<br />
of balloon aortic and mitral valvuloplasty, catheter-based<br />
local drug delivery, radiofrequency coronary angioplasty,<br />
and intra-cardiac ultrasound. Major contributions have also<br />
been made in the past by the catheterization laboratory<br />
physicians in the assessment of drug-coated stents, primary<br />
percutanaeous intervention for acute myocardial infarction,<br />
directional coronary atherectomy, catheter-based femoral<br />
arteriotomy closure, catheter-based thrombectomy, multiple<br />
new intracoronary stents, intracoronary brachytherapy, and<br />
left ventricular assist devices. In addition, catheterization<br />
physicians have served as principal investigators for over 30<br />
multi-center, national trials over the last five years.<br />
Cardiac Intensive Care Unit<br />
The CICU has multiple research projects underway under<br />
the leadership of Justin Lundbye, MD. These include the<br />
Hypothermia Database Project – a comprehensive database<br />
collection project. Drs. Lundbye, Silverman, Rabdiya and<br />
Ahmed are also working on the Cytokine Project – a study<br />
designed to predict cardiovascular outcomes using cytokine<br />
inflammatory markers. Drs. Lundbye and McKay are also<br />
overseeing the Proton Pump Inhibitor (PPI) and Plavix<br />
Projects and have analyzed outcome data from more than<br />
3000 patients treated at <strong>Hartford</strong> <strong>Hospital</strong>. Dr Lundbye is<br />
working on two prospective research trials, one looking at new<br />
CHF therapies and one looking at medications in patients with<br />
coronary artery disease to prevent future events. Multiple<br />
industry funded trials are also underway to examine new<br />
therapeutic approaches tested in hospitalized, critically ill<br />
cardiac patients.<br />
Publications<br />
Ahlberg AW, Baghdasarian SB, Athar H, Thompsen JP, Katten DM,<br />
Noble GL, Mamkin I, Shah AR, Leka IA, Heller GV. Symptomlimited<br />
exercise combined with dipyridamole stress: prognostic value<br />
in assessment of known or suspected coronary artery disease by use of<br />
gated SPECT imaging. J Nucl Cardiol. <strong>2008</strong> Jan-Feb;15(1):42-56.<br />
Akhtar S, Assaad S, Amin M, Holt NF, Barash PG, Silverman DG.<br />
Preoperative beta-blocker use: impact of national guidelines on<br />
clinical practice. J Clin Anesth. <strong>2008</strong> Mar;20(2):122-8.<br />
Angelopoulos TJ, Miles MP, Lowndes J, Sivo SA, Seip RL, Pescatello<br />
LS, Zoeller RF, Visich PS, Gordon PM, Moyna NM, Thompson PD.<br />
Apolipoprotein E genotype and sex influence C-reactive protein<br />
levels regardless of exercise training status. Metabolism. <strong>2008</strong><br />
Sep;57(9):1204-10.<br />
Angelopoulos TJ, Sivo SA, Kyriazis GA, Caplan JD, Zoeller RF,<br />
Lowndes J, Seip RL, Thompson PD. Doage and baseline LDL<br />
cholesterol levels determine the effect of regular exercise on plasma<br />
lipoproteincholesterol and apolipoprotein B levels? Eur J Appl<br />
Physiol. 2007 Nov;101(5):621-8.<br />
Anglade MW, Kluger J, White C,M, Aberle J, Coleman C.<br />
Thiazolidinedione use and post-operative atrial fibrillation:<br />
a US nested case-control study. Curr Med Res Opin. 2007<br />
Nov;23(11)2849-55.<br />
Augeri AL, Tsongalis GJ, Van Heest JL, Maresh CM, Thompson<br />
PD, Pescatello LS. The endothelial nitric oxide synthase-786<br />
T>C polymorphism and the exercise-induced blood pressure and<br />
nitric oxide responses among men with elevated blood pressure.<br />
Atherosclerosis. 20<strong>09</strong> Jun;204(2):e28-34. Epub <strong>2008</strong> Dec 16.<br />
Awad AA, Haddadin AS, Tantawy H, Badr TM, Stout RG,<br />
Silverman DG, Shelley KH. The relationship between the<br />
photoplethysmographic waveform and systemic vascular resistance. J<br />
Clin Monit Comput. 2007 Dec;21(6):365-72.<br />
Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA,<br />
Thompson PD, Moriarty PM. Effectiveness and tolerability of everyother-day<br />
rosuvastatin dosing in patients with prior statin intolerance.<br />
Ann Pharmacother. <strong>2008</strong> Mar;42(3):341-6.<br />
Baggish A, Thompson PD. Thick hearts, high stakes, great<br />
uncertainties: Screening athletes for hypertrophic cardiomyopathy.<br />
Heart. <strong>2008</strong> Oct 31. [Epub ahead of print]<br />
Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging:<br />
when should anti- schemic medications be withheld? J Nucl Cardiol.<br />
2007 Nov-Dec;14(6):775-81.<br />
Baghdasarian SB, Noble GL, Ahlberg AW, Katten D, Heller, GV.
Risk stratification with attenuation corrected stress Tc-99m sestamibi<br />
SPECT myocardial perfusion imaging in the absence of ECG-gating<br />
due to arrhythmias. J Nucl Cardiol 20<strong>09</strong>;16:533-9.<br />
Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra<br />
K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand<br />
KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA,<br />
Merli GJ, O’Gara PT, Thompson PD, Underberg JA. ACCF/<br />
AHA/ACP 20<strong>09</strong> competence and training statement: a curriculum<br />
on prevention of cardiovascular disease: a report of the American<br />
College of Cardiology Foundation/American Heart Association/<br />
American College of Physicians Task Force on Competence and<br />
Training (Writing Committee to Develop a Competence and Training<br />
Statement on Prevention of Cardiovascular Disease): developed in<br />
collaboration with the American Academy of Neurology; American<br />
Association of Cardiovascular and Pulmonary Rehabilitation;<br />
American College of Preventive Medicine; American College of<br />
Sports Medicine; American Diabetes Association; American Society<br />
of Hypertension; Association of Black Cardiologists; Centers for<br />
Disease Control and Prevention; National Heart, Lung, and Blood<br />
Institute; National Lipid Association; and Preventive Cardiovascular<br />
Nurses Association. J Am Coll Cardiol. 20<strong>09</strong> Sep 29;54(14):1336-63.<br />
Baker WL, Anglade MW, Baker EL, White CM, Kluger J, Coleman<br />
CI. Use of N- cetylcysteine to reduce post-cardiothoracic surgery<br />
complications: a meta-analysis. Eur J Cardiothorac Surg. 20<strong>09</strong><br />
Mar;35(3):521`-7. Epub 20<strong>09</strong> Jan 14. Review.<br />
Baker WL,Gutierrez-Williams G, White CM, Kluger J, Coleman C.<br />
Effect of cinnamon on glucose control and lipid parameters. Diabetes<br />
Care. <strong>2008</strong> Jan;31(1):41-3.<br />
Baker WL, Kluger J, White CM, Dale KM, Silver BB, Coleman CI.<br />
Effect of magnesium L-lactate on blood pressure in patients with<br />
an implantable cardioverter defibrillator. Ann Pharmacother. 20<strong>09</strong><br />
Apr;43(4):569-76. Epub 20<strong>09</strong> Mar 31.<br />
Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA,<br />
Coleman CI. Dopamine agonists in the treatment of early Parkinson’s<br />
disease: a meta-analysis. Parkinsonism Relat Disord. 20<strong>09</strong> May;<br />
15(4):287-94. Epub <strong>2008</strong> Sep 6.<br />
Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RA, Case<br />
JA, Cullom SJ. Multicenter investigation comparing a highly efficient<br />
half-time stress-only attenuation correction approach against standard<br />
rest-stress Tc-99m SPECT imaging.<br />
J Nucl Cardiol 20<strong>09</strong>;16:726-35.<br />
Bhavnani SP, Coleman Cl, White CM, Clyne CA, Yarlagadda<br />
R, Guertin D, Kluger J. Association between statin therapy and<br />
reductions in atrial fibrillation or flutter and inappropriate shock<br />
therapy. Europace. <strong>2008</strong> Jul;10(7):854-9<br />
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk<br />
WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR,<br />
Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth<br />
DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS;<br />
COURAGE Trial Research Group. Optimal medical therapy with or<br />
without PCI for stable coronary disease.<br />
N Engl J Med. 2007 Apr 12;356(15):1503-16.<br />
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk<br />
W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw<br />
L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS;<br />
COURAGE Trial Co-Principal Investigators and Study Coordinators.<br />
The evolving pattern of symptomatic coronary artery disease in the<br />
United States and Canada: baseline characteristics of the Clinical<br />
Outcomes Utilizing Revascularization and Aggressive DruG<br />
Evaluation (COURAGE) trial. Am J Cardiol.<br />
2007 Jan 15;99(2):208-12.<br />
Bower B, Klimek J, Yeston N, Ruano G. DNA-guided decision support.<br />
Hosp Health Netw. 2007 Nov;81(11):10.<br />
Coleman C, Baker WL, Kluger J, White CM. Antihypertensive<br />
medication and their impact on cancer incidence: a mixed treatment<br />
comparison meta-analysis of randomized controlled trials. J Hypertens.<br />
<strong>2008</strong> Apr;26(4)622-9.<br />
Coleman C, Kuger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D,<br />
White CM. Association between statin use and mortality in patients<br />
with implantable cardioverter-defibrillators and left ventricular systolic<br />
dysfunction. Heart Rhythm. <strong>2008</strong> Apr;5(4):507-10.<br />
Coleman C, Reinhart K, Kluger J, White CM. The effect of statins<br />
on the development of new-onset type 2 diabetes: a meta-analysis of<br />
randomized controlled trials. Med Res Opin. <strong>2008</strong> May;24(5):<br />
1359-62.<br />
Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger<br />
J; Dofetilide and Intravenous Magnesium Evaluation (DIME)<br />
Investigators. Intravenous magnesium sulfate enhances the ability of<br />
dofetilide to successfully cardiovert atrial fibrillation or flutter: results<br />
of the Dofetilide and Intravenous Magnesium Evaluation. Europace.<br />
20<strong>09</strong> Jul;11(7):892-5. Epub 20<strong>09</strong> Apr 6.<br />
Cosio-Lima LM, Seip R, Thompson PD, Lagasse MA, Hodges TH.<br />
Intertester reliability of brachial artery flow-mediated vasodilation<br />
using upper and lower arm occlusion in healthy subjects. Vasc Health<br />
Risk Manag. <strong>2008</strong>;4(3):731-4.<br />
Crespo E, Oliveira G, Honeycutt E, Becker R, Berger P, Moliterno<br />
D, Anstrom K, Abrams C, Kleiman N, Moll S, Rice L, Rodgers<br />
J, Steinhubl S, Tapson V, Granger C, Ohman E. Evaluation and<br />
management of suspected Heparin-induced thrombocytopenia in<br />
hospitalized patients: The complications after thrombocytopenia<br />
caused by heparin (CATCH) registry. Am Heart J. 20<strong>09</strong>;157(4):651-7.<br />
22.
Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson<br />
PD, McKay RG. Use of prehospital electrocardiograms for the<br />
treatment of patients with ST-segment elevation myocardial<br />
infarction. Conn Med 20<strong>09</strong>;73(2):69-72.<br />
de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ.<br />
Exploring genetic variations that may be associated with the direct<br />
effects of some antipsychotics on lipid levels. Schizophr Res. <strong>2008</strong><br />
Jan;98(1-3):40-6.<br />
Denktas AE, Athar H, Henry TD, Larson DM, Simons M, Chan RS,<br />
Niles NW, Thiele H, Schuler G, Ahn C, Sdringola S, Anderson HV,<br />
McKay RG, Smalling RW. Reduced- dose fibrinolytic acceleration of<br />
ST-segment elevation myocardial infarction treatment coupled with<br />
urgent percutaneous coronary intervention compared to primary<br />
percutaneous coronary intervention alone results of the AMICO<br />
(Alliance for Myocardial Infarction Care Optimization) Registry.<br />
JACC Cardiovasc Interv <strong>2008</strong>;1(5):504-10.<br />
Devaney JM, Tosi LL, Fritz DT, Gordish-Dressman HA, Jiang S,<br />
Orkunoglu-Suer FE, Gordon AH, Harmon BT,Thompson PD,<br />
Clarkson PM, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello<br />
LS, Visich PS, Zoeller RF,Brandoli C, Hoffman EP, Rogers MB.<br />
Differences in fat and muscle mass associated with a functional<br />
human Polymorphism in a post-transcriptional BMP2 gene regulatory<br />
element. J Cell Biochem. 20<strong>09</strong> Aug 15;107(6):1073-82.<br />
Dey D, Suzuki Y, Suzuki S, Ohba M, Slomka PJ, Polk D, Shaw<br />
LJ, Berman DS. Automated quantitation of pericardiac fat from<br />
noncontrast CT. Invest Radiol. <strong>2008</strong> Feb;43(2):145-53.<br />
Dornelas, E.A. (<strong>2008</strong>). Psychotherapy for Cardiac Patients:<br />
Behavioral Cardiology in Practice. Washington, DC: American<br />
Psychological Association Press.<br />
Fernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac<br />
tamponade: a rare complication of idiopathic hypereosinophilic<br />
syndrome.<br />
.J Cardiovasc Med (Hagerstown). 20<strong>09</strong> Feb;10(2):188-91.<br />
Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins<br />
and interstitial lung disease: a systematic review of the literature and<br />
of food and drug administration adverse event reports. Chest. <strong>2008</strong><br />
Oct;134(4):824-30.<br />
Fernandez AB, Keyes MJ, Pencina M, D’Agostino R, O’Donnell CJ,<br />
Thompson PD. Relation of corneal arcus to cardiovascular disease<br />
(from the Framingham Heart Study data set). Am J Cardiol. 20<strong>09</strong> Jan<br />
1;103(1):64-6. Epub <strong>2008</strong> Oct 4.<br />
Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg<br />
and 10 mg) twice a week in patients intolerant to daily statins. Am J<br />
Cardiol. <strong>2008</strong> Jun 15;101(12):1747-8.<br />
Gesquiere MJ, Awad AA, Silverman DG, Stout RG, Jablonka DH,<br />
Silverman TJ, Shelley KH. Impact of withdrawal of 450 ml of blood<br />
on respiration-induced oscillations of the ear plethysmographic<br />
waveform. J Clin Monit Comput. 2007 Oct;21(5):277-82.<br />
Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS,<br />
Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres<br />
JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging.<br />
Circulation. 20<strong>09</strong>;119:1056-1965.<br />
Giedrimas A, Giedrimiene D, Guertin D, White CM, Clyne<br />
CA, Kluger J. A comparison of outcomes for patients receiving<br />
implantable cardioverter defibrillators for primary vs secondaryprevention.<br />
Conn Med. <strong>2008</strong> Jun-Jul;72(6):329-33.<br />
Gold M, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J,<br />
Kroll M, Oza A. Optimization of superior vena cava coil position<br />
and usage for transvenous defibrillation. Heart Rhythm. <strong>2008</strong><br />
Mar;5(3):394-9.<br />
Gonzales JU, Parker BA, Ridout SJ, Smithmyer SL, Proctor DN.<br />
Femoral shear rate response to knee extensor exercise: an age and sex<br />
comparison. Biorheology. 20<strong>09</strong>;46(2):145-54<br />
Green CD, Thompson PD, Johnston PG, El-Tanani MK. Interaction<br />
between transcription factor, basal transcription factor 3, and the<br />
NH2-terminal domain of human estrogen receptor alpha. Mol Cancer<br />
Res. 2007 Nov;5(11):1191-200.<br />
Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick<br />
EH, Churchwell KB, Cooke CD, Corbett JR, Cullom SJ, Dahlberg<br />
ST, Druz RS, Ficaro EP, Galt JR, Garg RK, Germano G, Heller<br />
GV, Henzlova MJ, Hyun MC, Johnson LL, Mann A, McCallister<br />
BD Jr, Quaife RA, Ruddy TD, Sundaram SN, Taillefer R, Ward<br />
RP, Mahmarian JJ; American Society of Nuclear Cardiology.<br />
Myocardial perfusion and function: single photon emission computed<br />
tomography. J Nucl Cardiol. 2007 Nov-Dec;14(6):e39-60. Review.<br />
Heller GV, Katanick SL, Sloper T, Garcia M. Accreditation for<br />
Cardiovascular Imaging. JACC: Cardio Imaging <strong>2008</strong>;1:390-7.<br />
Hernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac<br />
tamponade: a rare complication of idiopathic hypereosinophilic<br />
syndrome. J Cardiovasc Med (Hagerstown). 20<strong>09</strong> Feb;10(2):188-91.<br />
Hubal MJ, Chen TC, Thompson PD, Clarkson PM. Inflammatory<br />
gene changes associated with the repeated-bout effect. Am J Physiol<br />
Regul Integr Comp Physiol. <strong>2008</strong> May;294(5):R1628-37.<br />
Irwin ML, Cadmus L, Alvarez-Reeves M, O’Neil M, Mierzejewski E,<br />
Latka R, Yu H, Dipietro L, Jones B, Knobf MT, Chung GG, Mayne<br />
ST. Recruiting and retaining breast cancer survivors into a randomized<br />
controlled exercise trial: the Yale Exercise and Survivorship Study.<br />
Cancer. <strong>2008</strong> Oct 1;113(7):1716.
Jablonka DH, Awad AA, Stout RG, Silverman DG, Shelley KH.<br />
Comparing the effect f arginine vasopressin on ear and finger<br />
photoplethysmography. J Clin Anesth. <strong>2008</strong> Mar;20(2):90-3.<br />
Jolicoeur E, Ohman E, Honeycutt E, Becker R, Crespo E, Oliveira<br />
G, Moliterno D, Anstrom J, Granger C. Contribution of bleeding<br />
and thromboembolic events to in- hospital mortality among patients<br />
with thrombocytopenia treated with Heparin. American J Cardiol.<br />
20<strong>09</strong>;104(2):292-297.<br />
Kapetanopoulos A, Ahlberg AW, Taub CC, Katten DM,<br />
Heller GV. Regional wall- motion abnormalities on post-stress<br />
electrocardiographic-gated technetium-99m sestamibi single-photon<br />
emission computed tomography imaging predict cardiac events. J<br />
Nucl Cardiol. 2007 Nov-Dec;14(6):810-7<br />
.<br />
Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA,<br />
O’Fallon KS, Gadarla M, Thompson PD. The creatine kinase<br />
response to eccentric exercise with atorvastatin 10 mg or 80 mg.<br />
Atherosclerosis. <strong>2008</strong> Sep;200(1):121-5.<br />
Kostek MA, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna<br />
NM, Visich PS, Zoeller RF, Price TB, Seip RL,Thompson PD,<br />
Devaney JM, Gordish-Dressman H, Hoffman EP, Pescatello<br />
LS. Myostatin and follistatin poly-morphisms interact with<br />
muscle phenotypes and ethnicity. Med Sci Sports Exerc. 20<strong>09</strong><br />
May;41(5):1063-71.<br />
LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R,<br />
Duconge J, Ruaño G. Integrating genomic based information into<br />
clinical warfarin (Coumadin) management: an illustrative case report.<br />
Conn Med. <strong>2008</strong> Aug;72(7):399-403. Erratum in: Conn Med. <strong>2008</strong><br />
Oct;72(9):572.<br />
Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L,<br />
Cullom SJ, Heller GV. Independent and incremental prognostic<br />
value of left ventricular ejection fraction determined by stress gated<br />
rubidium 82 PET imaging in patients with known or suspected<br />
coronary artery disease. J Nucl Cardiol. <strong>2008</strong> Nov-Dec;15(6):745-53.<br />
Lertsburapa K, White CM, Kluger J, Faheem O, Hammond<br />
J, Coleman C. Preoperative statins for the prevention of atrial<br />
fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg<br />
<strong>2008</strong> Feb;135(2):405-11.<br />
Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero<br />
NI, Calhoun V. Combining fMRI and SNP data to investigate<br />
connections between brain function and genetics using parallel ICA.<br />
Hum Brain Mapp. 2007 Dec 10.<br />
Mamkin I, Elkoustaf RA, Zhang Q, Mather JF, Kiernan FJ, McKay<br />
RG. Drug-eluting stent implantation results in effective treatment<br />
of small coronary artery disease (DESIRE Small CAD). Conn Med.<br />
2007;71(9):517-22.<br />
Mamkin I, Mather JF, Kiernan FJ, McKay RG. More studies are needed<br />
on gender-based outcomes in percutaneous coronary intervention with<br />
drug-eluting stents. Am J Cardiol. 2007;100(3):560-1.<br />
Mamkin I, Vaksman M, Kiernan FJ, McKay RG, Boden WE. Letter to<br />
Editor regarding “Weekend onset of acute myocardial infarction does<br />
not have a negative impact on outcome in Japan”. Circ J <strong>2008</strong>;72:864.<br />
Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS.<br />
Comparison of U.S. and Italian experiences with sudden cardiac<br />
deaths in young competitive athletes and implications for<br />
preparticipation screening strategies. Am J Cardiol. 20<strong>09</strong> Jul<br />
15;104(2):276-80. Epub 20<strong>09</strong> May 18.<br />
McBride BF, White CM, Kalus JS, Guertin DC, Clyne CA, Baker WL,<br />
Kluger J. The impact of carvedilol on the defibrillation threshold.<br />
Heart Lung. <strong>2008</strong> Jan-Feb;37(1):67- 1.<br />
McKay RG, Dada MR, Mather JF, Mennet RR, Murphy DJ, Maloney<br />
KW, Hirst JA, Kiernan FJ. Comparison of outcomes and safety of<br />
“facilitated” versus primary percutaneous coronary intervention in<br />
patients with ST-segment elevation myocardial infarction. Am J<br />
Cardiol. 20<strong>09</strong>;103(3):316-21.<br />
McKay RG, Murphy DJ, Cloutier J, Mather JF, Mennett RA, Dada<br />
MR, Shah AR, Kiernan FJ. Long-term efficacy and safety of sirolimuseluting<br />
vs bare-metal stents. Conn Med. <strong>2008</strong>;72(8):453-63.<br />
Mieres JH, Shaw LJ, Hendel RC, Heller GV. The WOMEN Study:<br />
What is the optimal method for ischemia evaluation in women? A<br />
multi-center, prospective randomized study to establish the optimal<br />
method for detection of coronary artery disease (CAD) risk in women<br />
at an intermediate-high pretest likelihood of CAD: study design. J<br />
Nucl Cardiol 20<strong>09</strong>;16:105-12.<br />
Moore TA, Sorokin AV, Hirst C, Thornton-Thompson S, Thompson<br />
PD. The accuracy of aneroid sphygmomanometers in the ambulatory<br />
setting. Prev Cardiol. <strong>2008</strong> Spring;11(2):90-4.<br />
Noble GL, Ahlberg AW, Kokkirala AR, Cullom SJ, Bateman TM, Cyr<br />
GM, Katten DM, Tadeo GD, Case JA, O’Sullivan DM, Heller GV.<br />
Validation of attenuation correction using transmission truncation<br />
compensation with a small field of view dedicated cardiac SPECT<br />
camera system. J Nucl Cardiol 20<strong>09</strong>;16:222-232.<br />
Oliveira G, Crespo E, Becker R; Honeycutt E, Abrams S, Anstrom K,<br />
Berger P, Davidson-Ray L, Eisenstein E, Kleiman N, Moliterno D,<br />
Moll S, Rice L, Rodgers J, Steinhubl S, Tapson V, Ohman E, Granger<br />
C. Incidence and prognostic significance of thrombocytopenia<br />
in patients treated with prolonged heparin therapy. Arch Intern<br />
Med. <strong>2008</strong>;168(1):94-102.<br />
24.
Oncken, C., Dornelas, E., Greene, J., Sankey, H., Glasmann, A.,<br />
Feinn, R.. Krnazler, H.R. (<strong>2008</strong>). Nicotine gum for pregnant<br />
smokers: A randomized controlled trial. Obstetrics & Gynecology,<br />
112, 859-867.<br />
Orkunoglu-Suer FE, Gordish-Dressman H, Clarkson PM, Thompson<br />
PD, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS,<br />
Visich PS, Zoeller RF, Harmon B, Seip RL, Hoffman EP, Devaney<br />
JM. INSIG2 gene poly-Morphism is associated with increased<br />
subcutaneous fat in women and poor response to resistance training<br />
in men. BMC Med Genet. <strong>2008</strong> Dec 23;9:117.<br />
Parker B, Proctor D. Commentary on Viewpoint: Exercise and<br />
cardiovascular risk reduction: time to update the rationale for<br />
exercise? Considering the role of sex in modulating direct effects of<br />
exercise on the vasculature. J Appl Physiol <strong>2008</strong> August;105(2):778<br />
Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Herr MD,<br />
Proctor DN. Sex differences in leg vasodilation during graded<br />
knee extensor exercise in young adults. J Appl Physiol 2007<br />
November;103(5):1583-91.<br />
Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Proctor DN.<br />
Sex-specific influence of aging on exercising leg blood flow. J Appl<br />
Physiol <strong>2008</strong> March;104(3):655-64.<br />
Parker BA, Smithmyer SL, Proctor DN. Hormone therapy is<br />
associated with preserved smooth muscle structure and dilation in the<br />
arterial vasculature of the leg in older women. Maturitas <strong>2008</strong> January<br />
20;59(1):46-54.<br />
Parker BA, Smithmyer SL, Ridout SJ, Ray CA, Proctor DN. Age and<br />
microvascular responses to knee extensor exercise in women. Eur J<br />
Appl Physiol <strong>2008</strong> June;103(3):343 -51.<br />
Parker BA, Trehearn TL, Meendering JR. Pick Your Poiseuille:<br />
Normalizing the Shear Stimulus In Studies of Flow-Mediated<br />
Dilation. J Appl Physiol <strong>2008</strong> November 13.<br />
Patten CA, Decker PA, Dornelas EA, Barbagallo J, Rock E, Offord<br />
K, Hurt R, Pingree S. (<strong>2008</strong>). Changes in readiness to quit and selfefficacy<br />
among adolescents receiving a brief office intervention for<br />
smoking cessation. Psychology, Health and Medicine, 13, 326-336.<br />
Pescatello LS, Blanchard BE, Van Heest JL, Maresh CM, Gordish-<br />
Dressman H, Thompson PD. The metabolic syndrome and the<br />
immediate antihypertensive effects of aerobic exercise: a randomized<br />
control design. BMC Cardiovasc Disord. <strong>2008</strong> Jun 10;8:12.<br />
Pistilli EE, Devaney JM, Gordish-Dressman H, Bradbury MK, Seip<br />
RL, Thompson PD, Angelopoulos TJ, Clarkson PM, Moyna NM,<br />
Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP.<br />
Interleukin-15 and interleukin-15R alpha SNPs and associations with<br />
muscle, bone, and predictors of the metabolic syndrome. Cytokine<br />
<strong>2008</strong> Jul;43(1):45-53.<br />
Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ,<br />
Burke LE, Marceau P, Franklin BA. American Heart Association<br />
Obesity Committee of Council on Nutrition, Physical Activity<br />
and Metabolism, Council on Nutrition, Physical Activity and<br />
Metabolism, Council on Cardiopulmonary Perioperative and Critical<br />
Care, Council on Cardiovascular Surgery and Anesthesia, Council on<br />
Cardiovas. Cardiovascular evaluation and management of severely<br />
obese patients undergoing surgery: a science advisory from the<br />
American Heart Association. Circulation. 20<strong>09</strong> Jul 7;120(1)86-95.<br />
Epub 20<strong>09</strong> Jun 15.<br />
Richards KA, Lleuser LP, Kluger J. Fortuitous therapeutic effect of<br />
Taser shock for a patient in atrial fibrillation. Ann Emerg Med. <strong>2008</strong><br />
Dec;52(6):686-8. epub <strong>2008</strong> June 2.<br />
Ruaño G. DNA collage and personalized medicine. Conn Med. <strong>2008</strong><br />
Jun-Jul;72(6):322.<br />
Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL,<br />
Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of<br />
edema and BMI in patients receiving rosiglitazone or pioglitazone.<br />
Clin Chim Acta. <strong>2008</strong>, Oct. 26.<br />
Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL,<br />
Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of<br />
edema and BMI in patients receiving rosiglitazone or pioglitazone.<br />
Clin Chim Acta. <strong>2008</strong> Oct 26.<br />
Ruffin RT Jr, Kluger J, Baker WL, Wills SM, White CM, Coleman<br />
C. Association between perioperative NSAID use and postcardiothoracic<br />
Esurgery atrail fibrillation, blood transfusions,<br />
and cardiovascular outcomes: a nested cohort study from the AF<br />
Suppression Trials (AFIST) I, II and III. Curr Med Res Opin. <strong>2008</strong><br />
Apr;24(4):1131-6.<br />
Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML,<br />
Kraemer WJ, Ruaño G. Physiogenomic comparison of human fat loss<br />
in response to diets restrictive of carbohydrate or fat. Nutr Metab<br />
(Lond). <strong>2008</strong> Feb 6;5:4.<br />
Sewright KA, Clarkson PM, Thompson PD. Statin myopathy:<br />
incidence, risk factors, and pathophysiology. Curr Atheroscler Rep.<br />
2007 Nov;9(5):389-96.<br />
Shafi N. Malek A, Silverman DI. Management of hypertension in<br />
Takayasu arteritis during pregnancy. J Clin Hypertension, 20<strong>09</strong>,<br />
11:383-5.<br />
Shafi N, McKay RG, Kiernan FJ, Silverman IE, Ahlquist M, Silverman<br />
I. Determinants and clinical significance of persistent residual<br />
shunting in patients with percutaneous patent Foramen Ovale<br />
Closure Devices. Int J Cardiol July 20<strong>09</strong>, epublication ahead of print.
Shah SA, Clyne CA, Henyan N, Migeed M, Yarlagadda R, Silver<br />
BB, Kluger J, White CM. Impact of magnesium sulfate on serum<br />
magnesium concentrations and intracellular electrolyte concentrations<br />
among patients undergoing radio frequency catheter ablation. Conn<br />
Med. <strong>2008</strong> May;72(5):261-5.<br />
Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan<br />
PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman<br />
BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G,<br />
Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates<br />
ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.<br />
Optimal medical therapy with or without percutaneous coronary<br />
intervention to reduce ischemic burden: results from the Clinical<br />
Outcomes Utilizing Revascularization and Aggressive Drug<br />
Evaluation (COURAGE) trial nuclear substudy. Circulation. <strong>2008</strong> Mar<br />
11;117(10):1283-91.<br />
Shaw LJ, Berman DS, Blumenthal RS, Budoff MJ, Faber TL, Goraya<br />
T, Halliburton SS, Hecht H, Kiat H, Koenig W, Malik S, Merhige<br />
M, Nasir K, Min JK, O’Keefe J, Polk DM, Raggi P, Rosenblatt JA,<br />
Schwartz RG, Taylor AJ, Thomas GS, Wijns W. Clinical imaging<br />
for prevention: directed strategies for improved detection of<br />
presymptomatic patients with undetected atherosclerosis--Part<br />
I: Clinical imaging for prevention. J Nucl Cardiol. <strong>2008</strong> Jan-<br />
Feb;15(1):e6-19. Review.<br />
Shaw LJ, Hendel RC, Heller GV, Borges-Neto S, Cerqueira M,<br />
Berman DS. Prognostic estimation of coronary artery disease<br />
risk with resting perfusion abnormalities and stress ischemia on<br />
myocardial perfusion SPECT. J Nucl Cardiol <strong>2008</strong>;15:762-73.<br />
Sheridan S, Crespo, E. Is the routine use of global coronary heart<br />
disease risk scores associated with clinical benefits or harms? A<br />
systematic review of the literature. BMC Health Services Research<br />
<strong>2008</strong>, 8:60.<br />
Siddiqi SA, Thompson PD. How do you treat patients with myalgia<br />
who take statins? Curr Atheroscler Rep. 20<strong>09</strong> Jan;11(1):9-14.<br />
Singh B, Bateman TM, Case JA, Heller GV. Attenuation artifact,<br />
attenuation correction, and the future of myocardial perfusion SPECT.<br />
J Nucl Cardiol 2007;14:153-64.<br />
Soman P, Lahiri A, Mieres JH, Calnon DA, Wolinsky D, Beller GA,<br />
Sias T, Burnham K, Conway L, McCullough PA, Daher E, Walsh MN,<br />
Wight J, Heller GV, Udelson JE. Etiology and pathophysiology of<br />
new-onset heart failure: Evaluation by myocardial perfusion imaging.<br />
J Nucl Cardiol 20<strong>09</strong>;16:82-91.<br />
Sood M, Coleman Cl, Kluger J, White CM, Padala A, Baker WL. The<br />
association among blood transfusions, white blood cell count, and the<br />
frequency of post-cardiothoracic surgery atrial fibrillation: A nested<br />
cohort study from the Atrial Fibrillation Suppression Trials I, II, and<br />
III. J Cardiothorac Vasc Anesth. <strong>2008</strong> Aug 28.<br />
Sorokin AV, Araujo CG, Zweibel S, Thompson PD. Atrial fibrillation<br />
in endurance trained athletes. Br J Sports Med. 20<strong>09</strong> Aug 11.<br />
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis,<br />
hyperlipidemia, and atherosclerotic risk: a systematic review.<br />
Atherosclerosis. 2007 Oct;194(2):293-9. Review.<br />
Talati R, Reinhart KM, White CM, Phung OJ, Sedrakyan A, Kluger<br />
J, Coleman CI, Outcomes of perioperative beta-blockade in patients<br />
undergoing noncardiac surgery: a meta-analysis. Ann Pharmacother.<br />
20<strong>09</strong> Jul;43(7):1181-8. Epub 20<strong>09</strong> Jun 16.<br />
Tercius AJ, Kluger J, Coleman C, White CM. Intravenous magnesium<br />
sulfate enhances the ability of intravenous ibutilide to successfully<br />
convert atrial fibrillation of flutter. Pacing Clin Elcetrophysiol, 2007<br />
Nov;30(11):1331-5.<br />
Thompson PD, Venero CV. A history of medical reports on the<br />
Boston Marathon: 112 years and still running. Med Sci Sports Exerc.<br />
20<strong>09</strong> Jun;41(6):1341-8.<br />
Thompson PD. Pre-participation screening of competitive athletes:<br />
seeking simple solutions to a complex problem. Circulation. 20<strong>09</strong><br />
Mar 3;119(8):1072-4. Epub 20<strong>09</strong> Feb 16.<br />
Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW,<br />
Katten D, Courter SA, Golub RJ, Case JA, Cullom SJ. A Multicenter<br />
evaluation of a new post-processing method with depth-dependent<br />
collimator resolution applied to full-time and half-time acquisitions<br />
without and with simultaneously acquired attenuation correction. J<br />
Nucl Cardiol 20<strong>09</strong>;16;714-25<br />
Venero CV, Thompson PD, Fernandez AB. Reduced high-density<br />
lipoprotein cholesterol in patients receiving rosiglitazone and<br />
fenofibrate. Am J Med. <strong>2008</strong> Oct;121(10):e3-4.<br />
Venero CV, Thompson PD. Managing statin myopathy. Endocrinol<br />
Metab Clin North Am. 20<strong>09</strong> Mar;38(1):121-36.<br />
Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness of<br />
thrice weekly ezetimibe. Am J Cardiol. <strong>2008</strong> Nov 1;102(9):1205-6.<br />
Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE,<br />
Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner<br />
RE, Inzucchi SE; Detection of Ischemia in Asymptomatic Diabetics<br />
(DIAD) Investigators. Resolution of asymptomatic myocardial<br />
ischemia in patients with type 2 diabetes in the Detection of Ischemia<br />
in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007<br />
Nov;30(11):2892-8.<br />
Walsh S, Kelsey BK, Angelopoulos TJ, Clarkson PM, Gordon PM,<br />
Moyna NM, Visich PS, Zoeller RF, Seip RL, Bilbie S, Thompson PD,<br />
Hoffman EP, Price TB, Devaney JM, Pescatello LS. The CNTF 1357<br />
G>A polymorphism and the muscle strength response to resistance<br />
training. J Appl Physiol. 20<strong>09</strong> Jul 23 [Epub ahead of print]<br />
26.
vWard RP, Al-Mallah MH, Grossman GB, Hansen CL, Hendel RC,<br />
Kerwin TC, McCallister BD Jr, Mehta R, Polk DM, Tilkemeier PL,<br />
Vashist A, Williams KA, Wolinsky DG, Ficaro EP; American Society<br />
of Nuclear Cardiology. American Society of Nuclear Cardiology<br />
review of the ACCF/ASNC appropriateness criteria for single-photon<br />
emission computed tomography myocardial perfusion imaging<br />
(SPECT MPI). J Nucl Cardiol. 2007 Nov-Dec;14(6):e26-38.<br />
Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan<br />
K, Ruaño G. Physiogenomic analysis of localized FMRI brain activity<br />
in schizophrenia. Ann Biomed Eng. <strong>2008</strong> Jun;36(6):877-88.<br />
Young LH, Wackers F J, Chyun DA, Davey JA, Barrett EJ, Taillefer<br />
R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk, N, Ratner RE,<br />
Inzucchi SE. Cardiac Outcomes After Screening for Asymptomatic<br />
Coronary Artery Disease in Patients with Type 2 Diabetes. JAMA<br />
20<strong>09</strong>;301(15):1547-1555.<br />
Zoeller RF, Ryan ED, Gordish-Dressman H, Price TB, Seip RL,<br />
Angelopoulos TJ, Moyna NM, Gordon PM, Thompson PD,<br />
Hoffman EP. Allometric scaling of isometric biceps strength in adult<br />
females and the effect of body mass index. Eur J Appl Physiol. <strong>2008</strong><br />
Nov;104(4):701-10.<br />
Abstracts<br />
Barmpouletos D, Stavens G, Ahlberg A, O’Sullivan DM, Katten<br />
DM, Heller GV. Risk Stratification of Diabetic Patients with Single<br />
Photon Emission Computed Tomography Myocardial Perfusion<br />
Imaging (SPECT-MPI): Does duration of Disease and Type of<br />
Therapy Matter? JACC: 20<strong>09</strong>;53:A291.<br />
Bhavnani S, Coleman C, Guertin D, White CM, Yarlagadda R, Clyne<br />
C, Kluger J. Clinical predictors of early mortality among patients<br />
receiving implantable cardioverter-defibrillators. Europace Journal<br />
20<strong>09</strong>, 11(Supplement 2), Abstract 507.<br />
Chawla D, Sood N, Guertin D, Zweibel S, Coleman C, Kluger<br />
J, Clyne C. Predictors of Pacemaker Dependence and Pacemaker<br />
Dependence as a Predictor of Mortality in Patients Implanted with<br />
Implantable Cardioverter Defibrillator. Heart Rhythm Society<br />
Meeting, May 20<strong>09</strong>.<br />
Ching G, Li D, McKay R, Mather J, Lundbye J. Proton Pump<br />
Inhibitors Increase Major Adverse Cardiac Events Among Post<br />
Percutaneous Coronary Intervention Patients on Clopidogrel.<br />
Circulation, 20<strong>09</strong>; 120:S936-S937<br />
Faheem O, Mohyuddin Y, Iqtidar AF, Guler AL, Chawla D, Ahlberg<br />
A, Heller, GV. Diabetics with Positive SPECT Myocardial Perfusion<br />
Imaging Referred for Catheterization: Gender Bias? JACC:<br />
20<strong>09</strong>;53:A297<br />
Guler AL, Chien P, Ahlberg A, Faheem O, Katten D, Heller GV.<br />
Attenuation Corrected SPECT Myocardial Perfusion Imaging<br />
Provides Highly Effective Risk Stratification for Future Cardiac<br />
Events. JACC: 20<strong>09</strong>;53:A287.<br />
Hendel RC, Mieres JH, Heller GV, Bairey-Merz CN, Boden WE,<br />
Shaw LJ. Prevalence of False Positive Exercise Electrocardiograms<br />
in Women? Results from the “What is the Optimal Method<br />
for Ischemia Evaluation in Women (WOMEN) Trial”. JACC:<br />
20<strong>09</strong>;53:A287.<br />
Lustgarten D, Neal S, Crespo E, Lobel R, Spector P, VanBuren P.<br />
Direct His Bundle Pacing Results in Significant QRS Narrowing in<br />
Patients Referred for Cardiac Resynchronization Therapy (CRT).<br />
Abstract presented at the Heart Rhythm Society Scientific Session in<br />
May 20<strong>09</strong>.<br />
Padala A, Shah AR, Ahlberg A, Kokkirala AR, Katten D, Heller<br />
GV. Value of Transient Ischemic Dilatation for Risk Stratification<br />
of Patients Undergoing Gated Rubidium-82 Positron Emission<br />
Tomography Imaging. JACC: 20<strong>09</strong>;53:A288.<br />
Parker, BA, Thompson, PD, Ruopp, KC, Meda, SA, Grimaldi, AS,<br />
Pearlson, GD (20<strong>09</strong>). Direct Effects Of Exercise Training On The<br />
Hippocampus In Humans. American College of Sports Medicine<br />
20<strong>09</strong> <strong>Annual</strong> Meeting, Seattle, WA. Med Sci Sports Exerc. 41(5)<br />
Supplement 1:8.<br />
Shephal K Doshi, MD, Jesus E. Val-Mejias, MD, Michael Pittaro,<br />
MD, Russell Reeves, MD, John Payne, MD, Richard Henthorn,<br />
MD, Mauricio Hong, MD, Steven Zweibel, MD, Mark Kroll, PhD,<br />
Robert Graumann, MS, Ashish L Oza, MS. Do similar T-Shock and<br />
Rescue Shock Waveforms, When Altered, Affect ULV based DFT<br />
Estimations? Heart Rhythm Society Meeting, May 20<strong>09</strong>.<br />
Sood N, Coleman C, Padala A, Kluger J, Guertin D, Clyne C.<br />
Association Between ICD Lead Diameter and ICD Lead Failure.<br />
Presented at Heart Rhythm Society National Meeting, Denver,<br />
Colorado, May 15th, <strong>2008</strong>, published in HRS Supplement, May,<br />
<strong>2008</strong>.<br />
Yekta A, Ruffin R, Ahlberg A, Katten D, Heller GV. Outcomes<br />
Analysis of Stress-Only Gated Myocardial Perfusion Imaging with<br />
Attenuation Correction in Patients with Suspected Coronary Artery<br />
Disease. JACC: 20<strong>09</strong>;53:A296.<br />
New Projects<br />
Federal<br />
Dornelas, Ellen, PhD<br />
Reducing Vulnerability to ICD Shock Treated Ventricular<br />
Arrhythmias. NHLBI/ Yale University, $412,725.<br />
Reducing Vulnerability to ICD Shock Treated Ventricular<br />
Arrhythmias (Substudy). NHLBI/ Yale University, $46,916.
Kluger, Jeffrey, MD<br />
Task Order 2, Project 1. Comparative Effectiveness of Medical<br />
Therapies for Stable Ischemic Heart Disease. ACE_ARB CER/AHRQ/<br />
University of Connecticut, $134,119.<br />
Thompson, Paul, MD<br />
Co Enzyme Q10 in Statin Myopathy. NIH/NCCAM, $865,207.<br />
DNA Diagnostic System for Statin Safety and Efficacy. NIH/<br />
Genomas, $74,812.<br />
Wencker, Detlef, MD<br />
Studies on Skeletal and Cardiac Muscle Apoptosis in Advanced<br />
Cardiac Failure. NIH, $562,115.<br />
White, Charles, PharmD<br />
Human Growth Hormone in Cystic Fibrosis. UCONN/AHRQ,<br />
$3,106.<br />
Foundation<br />
White, Charles, PharmD<br />
The Impact of Ascorbic Acid Therapy on Inflammatory Mediators in<br />
Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression<br />
Trial IV (AFIST IV) Pilot Study. The Gustavus and Louise Pfeiffer<br />
Research Foundation, $72,282.<br />
State<br />
Parker, Beth, PhD<br />
Does Smoking Cessation restore Vascular Function in Chronic<br />
Smokers? CT Department of Public Health, $267,187.<br />
Industry<br />
Clyne, Christopher, MD<br />
FREEDOM: A Frequent Optimization Study Using the QuickOpt<br />
Method. St. Jude Medical, $50,360.<br />
Heller, Gary, PhD, MD<br />
A Phase 2, Open-Label, Multicenter Study for the Development of<br />
One-Day Rest/Stress Cardiac Positron Emission Tomography (PET)<br />
Perfusion Imaging Protocols of BMS 747158. Lantheus Medical<br />
Imaging, $19,646.<br />
An Open-Label, Multicenter, Phase 3 Study to Demonstrate the<br />
Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying<br />
Subjects with Heart Failure who will Experience an Adverse Cardiac<br />
Event during 24 Months Follow-up. GE Healthcare, $13,839.<br />
Kiernan, Francis, MD<br />
A Clinical Evaluation of the Medtronic Endeavor Resolute<br />
Zotarolimus-Eluting Coronary Stent System in the Treatment of De<br />
Novo Lesions in Native Coronary Arteries with a Reference Vessel<br />
Diameter of 2.25 mm to 4.2 mm. Medtronic Vascular, $149,000.<br />
Kluger, Jeffrey, MD<br />
APPROPRIATE Assessment of Proper Physiologic Response<br />
with Rate Adaptive Pacing Driven by Minute Ventilation or<br />
Accelerometer. Boston Scientific Corp., $77,500.<br />
Lundbye, Justin, MD<br />
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-<br />
Controlled Study to Evaluate the 6 Months Efficacy and Safety of<br />
Aliskiren Therapy on Top of Standard Therapy, on Morbidity and<br />
Mortality When Initiated Early After <strong>Hospital</strong>ization for Acute<br />
Decompensated Heart Failure. Novartis Pharmaceutical Corp,<br />
$37,479.<br />
McKay, Raymond, MD<br />
IntraCoronary Treatment with Integrilin to Improve Angiographic<br />
Outcomes (IC Titan Timi-47). The Brigham and Women’s <strong>Hospital</strong>,<br />
$74,163.<br />
Polk, Donna, MD<br />
A Phase III, Double-Blind, Randomized Placebo-Controlled Study,<br />
to Evaluate the Effects of RO4607381 on Cardiovascular Risk in<br />
Stable CHD Patients, with a Documented Recent Acute Coronary<br />
Syndrome. Hoffman-LaRoche, $221,980.<br />
A Randomized, Double-Blind, Double-Dummy, Parallel Group,<br />
Phase 3 Efficacy and Safety Study of CGT-2168 Compared with<br />
Clopidogrel to Reduce Upper Gastrointestinal Events Including<br />
Bleeding and Symptomatic Ulcer Disease (CG 104). Parexel<br />
International, $169,543.<br />
Wencker, Detlef, MD<br />
A Multicenter, Randomized, Double-Blind, Placebo-Controlled<br />
Study of the Effects of KW-3902 Injectable Emulsion on Heart<br />
Failure Signs and Symptoms and Renal Function in Subjects with<br />
Acute Heart Failure Syndrome and Renal Impairment Who are<br />
<strong>Hospital</strong>ized. Averion International Corp., $103,575.<br />
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group<br />
Study to Assess The Effects of Intravenous BG9928 on Body Weight<br />
in Subjects with Acute Decompensated Heart Failure and Renal<br />
Insufficiency. Biogen Idec, $79,400.<br />
Recover II Trial: A Prospective Randomized Trial Investigating the<br />
Use of the Impella RECOVER LP 2.5 System in Patients with Acute<br />
Myocardial Infarction Induced Hemodynamic Instability. ABIOMED,<br />
Inc., $56,500.<br />
The Effect of Eplerenone Versus Placebo on Cardiovascular Mortality<br />
and Heart Failure <strong>Hospital</strong>ization in Subjects with NYHA Class II<br />
Chronic Systolic Heart Failure (EMPHASIS-HF). Pfizer, $60,450.<br />
Zweibel, Steven, MD<br />
PROVIDE: Programming Implantable Cardioverter Defibrillators in<br />
Patients with Primary Prevention Indication to Prolong Time to First<br />
Shock. St. Jude Medical, Scientific Studies Organization, $63,000.<br />
The Vest Prevention of Early Sudden Death Trial (VEST)<br />
PREDiction of ICD Therapies Study (PREDICTS). NIH/NHLBI/<br />
University of California, San Francisco, $325,438.<br />
28.
Industry (Investigator Initiated)<br />
Coleman, Craig, PharmD<br />
A Clinician’s Perspective on Rating the Strength of Evidence in a<br />
Systematic Review. Pfizer, $45,000.<br />
A Clinician’s Perspective on the Use of Meta-Regression in<br />
Systematic Review: Caveats and Cautions. Pfizer, $45,000.<br />
A Healthcare Decision Makers Guide to Reviewing and Using<br />
Meta-Analyses: A White Paper of the Health Outcomes, Policy, and<br />
Economics (HOPE) Collaborative Group. Pfizer, Inc., $25,000.<br />
Cost-Effectiveness of Aggrenox® in Reduction of Graft Failures<br />
Among Dialysis Patients: A Markov Model. Boehringer Ingelheim,<br />
$26,616.<br />
Evaluating the Impact of Study-Level Factors on Anticoagulation<br />
Control in US-Based Clinical Trials: A Meta-Analysis. Boehringer-<br />
Ingelheim, $44,500.<br />
Meta-Analysis of Dopamine Agonists, Catechol-o-methyltransferase<br />
Inhibitors and Monoamine Oxidase Type B Inhibitors for the<br />
Treatment of Advanced Parkinson’s Disease. BIPI, $15,000.<br />
Oral Hypoglycemic Medications and Their Impact on New-Onset<br />
Diabetes Mellitus Incidence: A Mixed Treatment Comparison Meta-<br />
Analysis of Randomized Controlled Trials. Takeda Pharmaceuticals,<br />
$58,500.<br />
Industry (Multi-center)<br />
Heller, Gary, PhD, MD<br />
A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-<br />
Controlled Study to Evaluate the Effect of Caffeine Intake on Single<br />
Photon Emission Computed Tomography (SPECT) Myocardial<br />
Perfusion Imaging (MPI) in Subjects Administered Regadenoson.<br />
Astellas Pharma Global Development, Inc., $90,242.<br />
A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial<br />
of LMI1195 in Healthy Subjects (Study Number: LMI1195-101).<br />
Lantheus Medical Imaging, $153,200.<br />
Kiernan, Francis, MD<br />
Protocol P07-6330: A Prospective, Single-Blind, Randomized,<br />
Multi-Center Study Comparing The Cypher Elite to The Cypher Bx<br />
VELOCITY Sirolimus-Eluting Stent Systems. Cordis Corporation,<br />
$85,000.<br />
Lundbye, Justin, MD<br />
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3,<br />
Randomized, Double-Blind, Evaluation of the Safety and Efficacy<br />
of Apixaban In Subjects with a Recent Acute Coronary Syndrome.<br />
Bristol-Myers Squibb Company, $130,606.<br />
McKay, Raymond, MD<br />
A Multicenter, Randomized, Double-Blind, Placebo-Controlled<br />
Study to Evaluate the Safety to Evaluate the Safety and Efficacy of<br />
SCH530348 in Addition to Standard of Care in Subjects With a<br />
History of Atherosclerotic Disease: Thrombin Receptor Antagonist<br />
in Secondary Prevention of Atherothrombotic Ischemic Events (TRA<br />
2P - TIMI 50). Schering Plough, $545,625.<br />
Polk, Donna, MD<br />
A Clinical Outcomes Study of Darapladib versus Placebo in Subjects<br />
with Chronic Coronary Heart Disease to Compare the Incidence of<br />
Major Adverse Cardiovascular Events (MACE). GlaxoSmithKline,<br />
$274,075.<br />
Wencker, Detlef, MD<br />
A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-<br />
Controlled Study to Evaluate the Efficacy and Safety of Relaxin in<br />
Subjects with Acute Heart Failure. Corthea, Inc., $71,260.<br />
Double-Blind, Placebo-Controlled, Multicenter Acute Study of<br />
Clinical Effectiveness of Nesiritide in Subjects With Decompensated<br />
Heart Failure (ASCEND-HF). Scios, Inc., $76,938.<br />
PROTECT II: A Prospective, Multi-center, Randomized Controlled<br />
Trial of the IMPELLA RECOVER LP 2.5 System versus Intra Aortic<br />
Balloon Pump (IABP) in Patients Undergoing Non Emergent High<br />
Risk PCI. ABIOMED, Inc., $85,000.<br />
Departmental<br />
Mathur, Shishir, MD<br />
Effects of Acute and Chronic Physical Activity on Genetic Damage<br />
and Lipoproteins. $19,500.<br />
McKay, Raymond, MD<br />
A Pilot Study to Assess the Histological Effects and Biomechanical<br />
Strength of a Novel, Knotless Suturing Technique. $22,363.<br />
Parker, Beth, PhD<br />
The Effect of Statins on Cognitive Function in Individuals with<br />
Statin-Associated Cognitive Complaints. $2,000.<br />
Thompson, Paul, MD<br />
Assessments of Muscle Outcomes in Clinical Patients with Statin<br />
Myalgia. $12,000.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Azemi, Talhat, MD<br />
Diagnostic and Prognostic Significance of Ischemic<br />
Electrocardiographic Changes During Vasodilator Stress Myocardial<br />
Perfusion Imaging. Small Grant, $9,507.
Clyne, Christopher, MD<br />
Identifying Atrial Ablation Lines through Two-Dimensional Delayed<br />
Enhancement MR Imaging. Small Grant, $6,300; St. Jude Medical,<br />
Scientific Studies Organization $5,000.<br />
Fischer, Edward, PhD<br />
Community and Patient Attitudes Towards Seeking Medical Help:<br />
Development and Standardization of a Comprehensive Attitude<br />
Measure. Open Competition, $21,146.<br />
Lundbye, Justin, MD<br />
Elevated Plasma Cytokines are a Marker for Unstable Coronary<br />
Syndrome: The <strong>Hartford</strong> Chest Pain Study. Small Grant, $10,777.<br />
Parker, Beth, PhD<br />
Sex Differences in the Mechanisms Underlying Endothelial Function.<br />
Open Competition, $78,685.<br />
Silverman -Cardiology, David, MD<br />
Freedom from Atrial Fibrillation Following Radio-Frequency Ablation<br />
Depends Upon Integrity of Atrial Function. Small Grant, $9,975.<br />
Systolic Strain Abnormalities to Predict <strong>Hospital</strong> Readmission In<br />
Patients with Heart Failure and Normal Ejection Fraction. Small<br />
Grant, $3,680.<br />
Sood, Nitesh, MD<br />
Heart Rate Variability and Brain Natriuretic Peptide. Small Grant,<br />
$5,760.<br />
Unfunded<br />
Anglade, Moise, MD<br />
Use of N-Acetylcysteine for Prevention of Postoperative Atrial<br />
Fibrillation: A Meta-Analysis.<br />
Book, Gregory, BS<br />
Automatic Extraction of Heart Valve Models from 64 Slice CT Data<br />
Using Active Appearance Models.<br />
Chaudhri, Priya, PhD<br />
The Effects of Sleep Disturbance on Adherence to Cardiac<br />
Rehabilitation.<br />
Chemmarappally, Shiny, RN<br />
Infusion Center Treatment Effect on Quality of Life in Congestive<br />
Heart Failure Patients.<br />
Coleman, Craig, PharmD<br />
Context-Based Learning by Pharmacy Students during their Clinical<br />
Rotations: The Role of Situated Learning in Experiential Education.<br />
Examining the Barriers to Updating Systematic Review Research: A<br />
Survey of Authors of Published Systematic Reviews in the Medical<br />
Literature.<br />
Heller, Gary, PhD, MD<br />
The Prognostic Role of Myocardial Perfusion Imaging in Elderly<br />
Patients Undergoing Stress Test? A Meta-Analysis. Statistical analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Humayun, Naeem, MD<br />
Does Cardiac Resynchronization Therapy (CRT) Increase<br />
Susceptibility to Malignant Arrhythmias?<br />
Iqtidar, Ali, MD<br />
Predictors of Rapid Aortic Dilatation in Adult Patients with a<br />
Bicuspid Aortic Valve. Statistical analysis supported through <strong>Hartford</strong><br />
<strong>Hospital</strong> Small Grant.<br />
Kluger, Jeffrey, MD<br />
Simple Bedside Method of Monitoring QTc in Patients with<br />
Pacemaker Receiving QTc Prolonging Drugs.<br />
Lundbye, Justin, MD<br />
A Quality Improvement Project on Congestive Heart Failure<br />
Readmission.<br />
Cardiac Intensive Care Unit Clinical Outcomes- A Quality<br />
Improvement Project.<br />
Clinical Outcomes Blanket Protocol for Induction of Hypothermia in<br />
Patients with Cardiac Arrest.<br />
Mendes, Beverly, APRN<br />
Phenomena of Inner Strength in Women Recovering Post Myocardial<br />
Infarction Coronary Stent: A Grounded Theory Study.<br />
Morales, Donna Chelle, MD<br />
Ethnic Differences in Depression Amongst Female Cardiac<br />
Rehabilitation Patients.<br />
Polk, Donna, MD<br />
The Effects of Carotid IMT Scans on Intent and Actual Likelihood to<br />
Change Health Behaviors.<br />
Rabdiya, Vimal, MD<br />
Is Left Ventricular Diastolic Dysfunction an Arrhythmogenic Marker<br />
in Patients with Implantable Cardioverter-Defibrillator and Relatively<br />
Preserved Left Ventricular Systolic Function?<br />
Richards, Kyle, MD<br />
Cardiac PET FDG and MR Imaging in Patients with Sarcoidosis: A<br />
Retrospective Study for Clinical Outcomes.<br />
Silverman, David, MD<br />
Do Repeat Echocardiograms Alter Clinical Outcomes? A Prospective<br />
Study. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant.<br />
Dyssynchrony Determines Prognosis in Diastolic Heart Failure.<br />
Evaluation of Load Independent Diastolic Function Using Velocity<br />
Vector Imaging- A Novel Technique.<br />
30.
Predictors of Success after Percutaneous Patent Foramen Ovale<br />
Closure for Stroke Prevention.<br />
Validation of Velocity Vector Imaging for Assessment of Diastolic<br />
Function.<br />
Wencker, Detlef, MD<br />
Effect of Neurohormonal Agents on Ejection Fraction of Chronic<br />
Heart Failure Patients.<br />
INTERMACS (Interagency Registry for Mechanically Assisted<br />
Circulatory Support).<br />
Zafian, Ruth, APRN<br />
An Exploratory, Descriptive Pilot Study to Examine the Quality of<br />
Hand-offs <strong>Report</strong>s at <strong>Hartford</strong> <strong>Hospital</strong> Using the ISBAR Technique.<br />
Active Projects<br />
Ahmed, Shafeeq, MD<br />
Is Cardiac Memory Blocked by Calcium Channel Blockers and<br />
Amiodarone?<br />
Bilbie, Stephen, MS<br />
Upper Arm Muscle Injury, Soreness, and Strength Changes<br />
Associated with Two Bouts of Resistance Exercise. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $10,000.<br />
Clyne, Christopher, MD<br />
Impact of Corticosteroids on Immediate Postoperative Recurrence<br />
of Atrial Tachyarrhythmias after Radiofrequency Catheter Ablation<br />
of Atrial Fibrillation. Interventional Electrophysiology Outcomes<br />
Protocol.<br />
Multicenter Automatic Defibrillator Implantation Cardiac<br />
Resynchronization Therapy (MADIT-CRT). University of Rochester/<br />
Guidant Corporation, $133,793.<br />
OPTION CRT/Atx (Cardiac Resynchronization Therapy & Atrial<br />
Therapy). BIOTRONIK, Inc., $59,698. Statistical analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Response of Cardiac Resynchronization Therapy Optimization with<br />
V-V Timing in Heart Failure Patients (RESPONSE HF). St. Jude<br />
Medical, $34,247.<br />
The Impact of Intravenous Magnesium on Atrial Vulnerability in<br />
Patients Receiving Radiofrequency Catheter Ablation for Atrial<br />
Fibrillation. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$40,894.<br />
Use of Gated Blood Pool Imaging to Predict Improvement with<br />
Bi-Ventricular Pacing - A Pilot Study. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $9,295.<br />
Coleman, Craig, PharmD<br />
Can HMG-CoA Reductase Inhibitors Decrease Atrial Fibrillation<br />
Following Cardiothoracic Surgery? A Retrospective Cohort<br />
Evaluation.<br />
Drug Assistance Program to Reduce Disparities in Health.<br />
Meta-Analyses of the Impact of Appropriate Antibiotic Therapy on<br />
Mortality in Patients with Ventilator-Associated Pneumonia and<br />
Blood Stream Infections. AstraZeneca, $20,625.<br />
Meta-Analysis of Therapies for Treatment of Early- and Late-Stage<br />
Parkinson’s Disease. Boehringer-Ingelheim Pharmaceuticals, $17,500.<br />
The Impact of Oral Magnesium L-Lactate on Occurrence of<br />
Ventricular Arrhythmias and Patient Perceived Quality of Life<br />
Among Patients with Implantable Cardioverter-Defibrillators: The<br />
Adjuvant Magnesium (AdMag) Trial Cost-Utility Analysis. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $9,952.<br />
Donahue, Stephen, BS<br />
CRUSADE (Can Rapid Risk Stratification of Unstable Angina<br />
Patients Suppress Adverse Outcomes with Early Implementation of<br />
the ACC/AHA Guidelines?). Millennium Pharm. & Schering Plough<br />
Pharm., $20,000.<br />
Dornelas, Ellen, PhD<br />
A 12 Week, Double-Blind, Placebo-Controlled, Multicenter Study<br />
with a 40 Week Follow-up Evaluating the Safety and Efficacy of<br />
Varenicline Tartrate 1 MG BID for Smoking Cessation in Subjects<br />
with Cardiovascular Disease. Pfizer, $160,327.<br />
Nicotine Replacement Treatment for Pregnant Smokers. NIH/<br />
University of Connecticut, $527,683.<br />
Study of treatment for Antepartum Depression in expecting Mothers<br />
(SAD-Moms). <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$73,000.<br />
Heller, Gary, MD, PhD<br />
A Prospective Comparison of Gated, Rest/Stress Rubidium-82<br />
Positron Emission Computed Tomography (PET) vs. Gated, Rest/<br />
Stress Technetium 99-M SPECT: A Pilot Study. Bracco Diagnostics,<br />
Inc., $285,802.<br />
An Open-Label Multi-Center, Phase 3 Study Evaluating the<br />
Prognostic Usefulness of I123-mIBG Scintigraphy for Identifying<br />
Subjects with Heart Failure who will Experience an Adverse Cardiac<br />
Event? ( Protocol PC MBG311 CPR). GE Healthcare (Amersham),<br />
$157,500.<br />
Assessment of Myocardial Perfusion and Left Ventricular Function<br />
from Stress and Rest Tc-99m Sestamibi Gated SPECT Imaging for<br />
the Prediction of Future Cardiac Events in Patient with Known or<br />
Suspected Coronary Artery Disease. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $44,280.
Attenuation Correction with the CardioMD Camera: Validation by<br />
Comparison with Attenuation Correction with the Vertex Cardio 60<br />
Camera. Nuclear Medicine Division - Philips Med. System, $100,632.<br />
Clinical Utility of Attenuation Correction of Pharmacologic Stress<br />
Tc-99 Sestamibi SPECT Myocardial Perfusion Imaging in Patients<br />
with Known or Suspected Coronary Artery Disease.<br />
Detection of Ischemia in Asymptomatic Diabetics (DiaD). Yale<br />
University School of Medicine, $289,843.<br />
Development of a Normal Database and Criteria for Abnormality for<br />
b Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid<br />
I 123) for Quantitative Imaging (Protocol MIP-BP22). Molecular<br />
Insight Pharmaceuticals, $50,<strong>09</strong>4.<br />
Evaluation of Astonish Processing Phase II. Philips Nuclear Medicine<br />
(Cleveland), Inc., $139,583.<br />
Impact of Stress Modality Upon Diagnosis and Risk Stratification in<br />
Patients with Left Bundle Branch Block (LBBB).<br />
Nuclear Cardiology Imaging Clinical Outcomes Blanket Protocol.<br />
Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Nuclear Imaging Database Research Project. Bristol Meyers Squibb<br />
Imaging, Inc., $95,000.<br />
Open-Label, Phase 2 Study of the Safety and Efficacy of ß-Methylp-[123I]-Iodophenyl-Pentadecanoic<br />
Acid (Iodofiltic Acid I 123)<br />
for Identification of Ischemic Myocardium Using Single Photon<br />
Emission Computed Tomography (SPECT) in Adults with Symptoms<br />
Consistent with Acute Coronary Syndrome (ACS). Molecular Insight<br />
Pharmaceuticals, $56,445.<br />
Progression of Coronary Artery Disease in Diabetic and Non-<br />
Diabetic Individuals as Measured by Serial Gated Myocardial<br />
Perfusion Imaging. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$10,074.<br />
Stress technetium-99m Sestamibi Gated SPECT Imaging in the<br />
Detection of Coronary Artery Disease in Patients with Dilated<br />
Cardiomyopathy. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$50,000.<br />
Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles<br />
in CAD: (SPARC). Brigham & Women’s <strong>Hospital</strong>, $50,375.<br />
The Prognostic Value of Left Ventricular Ejection Fraction From<br />
Cardiac PET Myocardial Perfusion Imaging in Patients with Known<br />
or Suspected Coronary Artery Disease. BRACCO, $78,738.<br />
The Role of Cardiac PET Perfusion Imaging in the Diagnosis of<br />
Coronary Disease in Patients with Diabetes Mellitus. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $48,394.<br />
Kiernan, Francis, MD<br />
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy<br />
of the Zomaxx Drug Eluting Coronary Stent System as Compared<br />
to the TAXUS Express Paclitaxel-Eluting Stent in de novo Coronary<br />
Artery Lesion. Abbott Vascular, $300,956.<br />
ARRIVE - Taxus Peri-Approval Registry: A Multi-Center Safety<br />
Surveillance Program. Boston Scientific Corporation, $114,410.<br />
CSP-424 Clinical Outcomes Utilizing Revascularization and<br />
Aggressive Drug Evaluation (COURAGE). Department of Veterans<br />
Affairs, $378,000.<br />
Humanitarian Use Device - JOSTENT Coronary Stent Graft.<br />
Protocol P00-6302 A Multicenter, Randomized, Double Blind Study<br />
of the SIROLIMUS-Coated BX Velocity Balloon Expandable Stent<br />
in the Treatment of Patients with De Novo Native Coronary Artery<br />
Lesions. Cordis, Inc., $102,000.<br />
Kluger, Jeffrey, MD<br />
MASTER: Microwave T Wave Alternans Testing for Risk<br />
Stratification of Post MI Patients. Medtronic, $120,023.<br />
The Adjuvant Magnesium Trial (AdMag): Assessment of the Impact<br />
of Oral Magnesium on ICD Firing and Quality of Life. Donaghue<br />
Foundation, $162,175.<br />
The Use of Magnesium to Improve Hemodynamics, Cholesterol and<br />
Glucose Control: A Substudy of AdMag. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $47,000.<br />
LaGasse, Marie<br />
Exercise Training and Endothelial Vasomotor Function in Patients<br />
with Coronary Artery Disease. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $52,575.<br />
Lundbye, Justin, MD<br />
Follow up of Patients with Coronary Artery Disease who have<br />
Undergone Rapid Aspirin Desensitization Before or After<br />
Percutaneous Coronary Intervention. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $5,826.<br />
McKay, Raymond, MD<br />
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute<br />
Coronary Syndrome Subjects Who Are to Undergo Percutaneous<br />
Coronary Intervention/TRITON-TIMI 38. Quintiles, Inc., $143,022.<br />
A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and<br />
Safety Study of AZD6140 Compared to Clopidogrel for Prevention<br />
of Vascular Events in Patients with Non-ST or ST Elevation Acute<br />
Coronary Syndromes (ACS) - PLATO. AstraZeneca Pharmaceuticals,<br />
$182,265.<br />
A Single-Center Registry to Investigate the Long-Term Safety and<br />
Efficacy of the Sirolimus-Eluting CYPHER Intracoronary Stent.<br />
Cordis, $140,410.<br />
Clinical Outcomes Blanket Protocol of Get-with-the-guidelines -<br />
Heart Failure (GWTG-HF) database.<br />
32.
Cardiology<br />
Novel Suture-based Arteriotomy Closure Device Feasibility Study.<br />
Departmental, $105.<br />
Percutaneous Coronary Intervention Clinical Outcomes Blanket<br />
Protocol. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong><br />
Small Grant.<br />
The Role of Glycemic Control During Cardiac Catheterization<br />
Procedures and Cardiac Events.<br />
Polk, Donna, MD<br />
A Preliminary Study of Statin-Associated Cognitive Impairment.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $34,588.<br />
Rock, Josh, DO<br />
Pulmonary Venous Catheter Ablation and its Effect on P-Wave<br />
Dispersion in Patients with Atrial Fibrillatoin.<br />
The Effects of Statin Therapy on the Development of Early Recurrent<br />
Atrial Fibrillation after Catheter-Based Pulmonary Vein Ablation.<br />
Ruaño, Gualberto, MD, PhD<br />
Genetic Modulation of Lipid Metabolic Response to Aerobic<br />
Exercise. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $50,000.<br />
Seip, Richard, PhD<br />
Relationship of Muscle Injury to Muscle Hypertrophy. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $35,488.<br />
Sood, Nitesh, MD<br />
Effect of Heart Rate on Ventricular Dyssynchrony.<br />
Thompson, Paul, MD<br />
(JUPITER) A Randomized, Double-Blind, Placebo-Controlled,<br />
Multicenter, Phase III Study of Rosuvastatin (Crestor\200) 20<br />
mg in the Primary Prevention of Cardiovascular Events Among<br />
Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of<br />
C-Reactive Protein (JUPITER) (Protocol No. 4522US/0011). PPD<br />
Development, LP, $102,250.<br />
Reduction of LDL Cholesterol in Subjects with Hypercholesterolemia<br />
Refractory to Current Conventional Treatment. B. Braun Medical,<br />
Inc., $91,875.<br />
A Randomized, Placebo Controlled, Parallel Group, Double-Blind<br />
Study of the Efficacy and Safety of Rimonabant in Abdominally<br />
Obese Subjects with Multiple Cardiovascular and Metabolic Risk<br />
Factors and with LDL-Cholesterol at NCEP ATP III Treatment<br />
Goal (Protocol Number L-0137). Sanofi-Aventis US, ICON Clinical<br />
Research, $77,967.<br />
B. Braun Medical Inc. Patient Registry for the H.E.L.P. System.<br />
Correlation of Cytochrome P450 and Drug Transport Gene<br />
Polymorphisms in Statin-Induced Myopathies. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $23,680.<br />
Determining the Reliability and Reproducibility of Brachial Artery<br />
Reactivity. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $13,125.<br />
Does Exercise Training Alter Hippocampal Size and Function<br />
in Humans: A Preliminary Study. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $56,317.<br />
Effects of Low and High Dose Atorvastatin On Exercise-Induced<br />
Muscle Injury. Merck & Co., Inc., $408,227.<br />
Functional SNP’s associated with Human Muscle Size and Strength (<br />
FAMUSS). NIAMS/Children’s National Medical Center, $447,280.<br />
Gene Expression Profiling and the Repeated Bout Effect: A<br />
Pilot StudyHF-ACTION: Heart Failure and A Controlled Trial<br />
Investigating Outcomes of Exercise TraiNing: Ancillary Study<br />
- Investigation of the Role of Genetic Variation in the Clinical<br />
Expression of Heart Failure. NHLBI, $685,000.<br />
Lipid Treatment Assessment Project 2 (L-TAP 2) Protocol<br />
#NRA5<strong>09</strong>0005. Pfizer, $6,250.<br />
A Multicenter, Randomized, Double-Blind, Titration Study to<br />
Evaluate and Compare the Efficacy and Safety of Ezetimibe Added<br />
On to Atorvastatin 40 mg Versus Up Titration to Atorvastatin 80 mg<br />
in Hypercholesterolemic Patients at High Risk for Coronary Heart.<br />
Merck & Co., Inc., $26,500.<br />
A Randomized Multicenter Crossover FUTURA Trial to Compare<br />
the Performance of the Plasmat® Futura Heparin Induced<br />
Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis System to<br />
the Approved Plasmat® Secura H.E.L.P. Apheresis System in the
Molecular Changes in Human Muscle with Unloading/Reloading.<br />
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group<br />
Evaluation of the Fixed Combination Torcetrapib/Atorvastatin,<br />
Administered Orally, Once Daily (QD), Compared with Atorvastatin<br />
Alone, on the Occurrence of Major Cardiovascular Events in Subjects<br />
with Coronary Heart Disease or Risk Equivalents. Pharmanet,<br />
$347,000.<br />
Skeletal Muscle Gene Expression in Patients with Statin-Induced<br />
Myalgia. Donaghue Medical Research Foundation, $239,996.<br />
The Effect of Statins on Skeletal Muscle Function. NIH, $3,007,870.<br />
White, Charles, PharmD<br />
Electrocardiographic (ECG) Evaluation of Transmural Dispersion<br />
of Repolarization and QT Prolongation in Patients Receiving<br />
Amiodarone or Pure Blockers of the Rapid Component of the<br />
Delayed Rectifier Potassium Channel (Sotalol or Dofetilide).<br />
The Impact of Short-Term High Intensity Statin Therapy Versus<br />
Low Intensity Statin Therapy on Inflammatory Mediators in<br />
Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression<br />
Trial IV (AFIST IV) Pilot Study. Gustavus and Louise Pfeifer Research<br />
Foundation, $74,583.<br />
34.
Center for<br />
Anti-Infective Research & Development<br />
David Nicolau, PharmD, FCCP, FIDSA, Director<br />
Charles Nightingale, PhD, Co-Director<br />
Joseph L. Kuti, PharmD, Associate Director<br />
Kathryn J. Eagye, MPH, Associate Director<br />
Mary Banevicius, BS, Research Supervisor<br />
Pamela Tessier, MS, Research Supervisor<br />
Christina Sutherland, BS, Research Assistant<br />
Debora Santini, BS, Research Assistant<br />
Lindsay Tuttle, BS, Research Assistant<br />
Henry Christensen, BS, Research Assistant<br />
Jennifer Hull, BS, Research Assistant<br />
Aryun Kim, PharmD, Postdoctoral Fellow<br />
Anthony Nicasio, PharmD, Postdoctoral Fellow<br />
Jared Crandon, PharmD, Postdoctoral Fellow<br />
Catherine Bulik, PhD, Postdoctoral Fellow<br />
Rebecca Keel, PhD, Postdoctoral Fellow<br />
Dora Wiskirchen, PhD, Postdoctoral Fellow<br />
Pashalina Konto, MD, Visiting Scholar, Papanikolaou<br />
<strong>Hospital</strong>, Thessaloniki, Greece<br />
Li Peng, Visiting Scholar, PUMC <strong>Hospital</strong>, Beijing, China<br />
Pornpan Koomanachai, MD, Visiting Scholar, Siriraj <strong>Hospital</strong>,<br />
Mahidol Univ.,Thailand<br />
The Center for Anti-Infective Research and Development<br />
(CAIRD) is recognized both nationally and internationally<br />
for its efforts surrounding the development and<br />
commercialization of anti-infective therapies. Over the<br />
past decade efforts have been undertaken to expand the<br />
preclinical study capabilities of CAIRD to further enhance<br />
our services to companies involved in the drug development<br />
of novel compounds. The CAIRD has enhanced its provision<br />
of analytical services for both investigator-sponsored studies<br />
and industry-sponsored investigations throughout the United<br />
States. Additionally, over the last five years the Center<br />
has managed and published on its global efforts to assist<br />
the prescriber with the optimal selection of antimicrobial<br />
therapies based on local epidemiology, resistance and<br />
the utilization of available dosing strategies. New global<br />
collaborative efforts will allow similar studies to be conducted<br />
for the foreseeable future.<br />
Within the institution, the CAIRD continues to focus its<br />
efforts on discovering the most clinically, as well as costeffective<br />
method of administering anti-infectives, efforts which<br />
began nearly 30 years ago via the founding insights of Drs.<br />
Richard Quintiliani and Charles Nightingale.<br />
The Center for Anti-Infective Research and Development at<br />
<strong>Hartford</strong> <strong>Hospital</strong> has a national and international reputation<br />
for being on the leading edge of Infectious Disease research<br />
and its clinical application. Throughout the course of the year,<br />
members of the Center have given numerous presentations<br />
involving both clinical practice and research related topics at<br />
various local, national and international meetings.<br />
New Projects<br />
Industry<br />
Kuti, Joseph, PharmD<br />
Bronchopulmonary Pharmacokinetics of Micafungin in Healthy Adult<br />
Volunteers. Astellas Pharma US, Inc., $148,862.<br />
A Phase 4, Open Label Study to Assess the Bronchopulmonary<br />
Pharmacokinetics of Anidulafungin and Voriconazole following<br />
Intravenous Administration in Healthy Subjects. Pfizer, Inc.,<br />
$259,259.<br />
Nicolau, David, PharmD<br />
Evaluation of AstraZeneca Novel Antimicrobials against<br />
Streptococcus Pneumoniae and Staphylococcus Aureus in Murine<br />
Pneumonia Models. Astra-Zeneca, Inc., $75,766.<br />
Evaluation of Novel AstraZeneca Anti-Infectives against<br />
Staphylococcus aureus in a Murine Thigh Model. Astra-Zeneca, Inc.,<br />
$102,766.<br />
Evaluation of Iclaprim against Staphylococcus aureus in a Murine<br />
Thigh Model. Arpida, Inc., $78,725.<br />
Evaluation of the Bactericidal Activity of High-Dose Doripenem<br />
Human Simulated Exposures Against Pseudomonas Aeruginosa in<br />
a Neutropenic Murine Thigh Infection Model. Johnson & Johnson<br />
PRD, $157,050.
Industry (Developmental)<br />
Nicolau, David, PharmD<br />
In Vivo Evaluation of CXA-101 ± Tazobactam Versus Piperacillin-<br />
Tazobactam using Human Simulated Exposures Against<br />
Phenotypically Diverse Gram-Negative Organisms. Calixa<br />
Therapeutics, Inc., $154,188.<br />
Evaluation of Lead Therapeutics Novel Antimicrobials Against<br />
Staphylococcus Aureus in a Murine Pneumonia Model. LEAD<br />
Therapeutics, Inc., $34,200.<br />
Industry (Investigator Initiated)<br />
Kuti, Joseph, PharmD<br />
In Vitro Pharmacodynamics of Pulmonary Exposures of Tigecycline<br />
Alone and in Combination with Rifampin or Meropenem Against<br />
Klebsiella spp. Producing the KPC-2 Carbapenemase. Wyeth<br />
Pharmaceuticals, $87,000.<br />
An in Vitro Pharmacodynamic Model of a Human Simulated<br />
High Dose, Prolonged Infusion Meropenem Regimen Against<br />
Klebsiella spp. Producing the KPC-2 Carbapenemase. AstraZeneca<br />
Pharmaceuticals, $77, 250.<br />
Daptomycin MICs against Vancomycin-Susceptible Staphylococcus<br />
aureus with Higher Vancomycin MICs: A Comparison of Three<br />
Testing Methods. Cubist Pharmaceuticals, $59,250.<br />
Nicolau, David, PharmD<br />
Comparison of Simulated Human Exposures of Telavancin and<br />
Vancomycin against Staphylococcus aureus with Increasing<br />
Vancomycin MICs in a Murine Pneumonia Model. Astellas Pharma,<br />
$130,615.<br />
Pharmacodynamic Evaluation of CB-182804 Against Acinetobacter<br />
Baumannii and Pseudomonas aeruginosa in a Murine Pneumonia<br />
Model. Cubist, $128,019.<br />
Assessment of Doripenem Stability within Two Infusion Devices: A<br />
Focus on Use in the Home Infusion Arena. Ortho McNeil Jasssen,<br />
$52,413.<br />
Ertapenem Utilization and Resistance Emergence Among Collateral<br />
Antimicrobials (EURECA). Merck & Co., Inc., $259,688.<br />
Tissue Penetration and Pharmacokinetics of Linezolid in Diabetic<br />
Patients with Chronic Wound Infections by In Vivo Microdialysis.<br />
Pfizer,Inc., $117,900.<br />
Evaluation of CEN-101 as Adjunctive Therapy for Staphylococcus<br />
aureus Pneumonia in a Murine Model. Centegen Inc., $50,719.<br />
In Vitro Evaluation of CXA-101 Potency Against Selected Isolates of<br />
Pseudomonas Aeruginosa. Calixa Inc., $19,688<br />
Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic<br />
Patients with Chronic Wound Infections by In Vivo Microdialysis.<br />
Wyeth, $122,927.<br />
Pharmacodynamic Profiling of Intravenous Antibiotics Against<br />
Prevalent US Derived Gram-Negative Organisms. Ortho McNeil<br />
Janssen, $71,000.<br />
A <strong>Hospital</strong> Specific Program to Assess Anti-Infective Minimum<br />
Inhibitory Concentrations (MICs) and Pharmacodynamic Target<br />
Attainment against Methicillin-Resistant Staphylococcus aureus<br />
Strains. Pfizer, Inc., $16,625.<br />
Evaluation of AlphaRx Novel Antimicrobials Against Staphylococcus<br />
Aureus in a Murine Pneumonia Model. AlphaRx, Inc., Ontario,<br />
Canada, $26,883.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Kuti, Joseph, PharmD<br />
The Effect of Hyperbaric Oxygen Therapy on the Penetration<br />
of Linezolid into Subcutaneous Tissue of Diabetics with Lower<br />
Extremity Wounds. Open Competition, $74,847.<br />
Eagye, Kathy, MPH<br />
Health Outcomes Investigation of Infection in Colorectal Surgical<br />
Procedures. Small Grant, $14,854.<br />
Unfunded<br />
Nicolau, David, PharmD<br />
Subcutaneous and Intravenous Tissue Levels of Cefazolin During<br />
Abdominoplasty: A Pilot Study.<br />
Active Projects<br />
Kuti, Joseph, PharmD<br />
Clinical Outcomes and Costs Associated with a Ventilator Associated<br />
Pneumonia Clinical Pathway in Intensive Care Units.<br />
Cost-effectiveness of telavancin versus vancomycin in the treatment<br />
of complicated gram-positive skin and skin structure infections.<br />
Theravance, Inc., $102,375.<br />
Pharmacoeconomics of Antifungals in the Treatment of Invasive<br />
Aspergillosis with a Focus on the Polyenes. Enzon Pharmaceuticals,<br />
$118,250<br />
Nicasio, Anthony, PharmD<br />
The Impact of Automated Testing on the Clinical Outcomes and<br />
Economics of Infections Due to Extended Spectrum Beta-lactamase<br />
Producing Enterobacteriaceae. Small Grant, $9,390.<br />
Nicolau, David, PharmD<br />
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals<br />
Systemic Antibacterials in the Rat Thigh Infection Model. Vertex<br />
Pharmaceuticals, Inc. $29,814.<br />
36.
Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals<br />
Novel Systemic Antibacterials in the Murine Model of Staphylococcus<br />
Aureus Intra-Abdominal Sepsis. Affinium Pharmaceuticals, $34,045.<br />
Bioanalytical Validation and Sample Analysis of Aztreonam in Human<br />
Plasma by HPLC for the Telavancin Clinical Program. Theravance,<br />
$28,000.<br />
Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals<br />
Novel Systemic Antibacterials in the Murine Staphylococcus Aureus<br />
Thigh Infection Model. Affinium Pharmaceuticals, $40,030.<br />
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals<br />
Novel Systemic Antibacterials in the Mouse S. aureus Thigh Infection<br />
Model. Vertex Pharmaceuticals, $85,<strong>09</strong>5.<br />
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals Novel<br />
Systemic Antibacterials in the Murine (Mouse) Model of Intra-<br />
Abdominal Sepsis. Vertex Pharmaceuticals, Inc., $16,706.<br />
Blanket Protocol: Efficacy of Vertex Pharmaceuticals Novel Systemic<br />
Antibacterials in the Murine (Rat) Model of Pneumococcal Intra-<br />
Abdominal Sepsis. Vertex Pharmaceuticals, Inc., $38,889.<br />
Bronchopulmonary Pharmacokinetic and Pharmacodynamic Profiles<br />
of Leofloxacin 750mg in Adults Undergoing Treatment of Acute<br />
Exacerbaction of Chronic Bronchitis. Orth-McNeil Pharmaceuticals,<br />
$211,341.<br />
Clinical and Economic Implication of Antibiotic Prophylaxis Failure in<br />
Elective Colorectal Surgery. Merck & Co., Inc., $57,505.<br />
Clinical Pharmacodynamics of Beta-lactam Antibiotics in Patients<br />
with Pseudomonas Aeruginosa Infections.<br />
Determination of Gatifloxacin Concentrations in Biological Matrixes.<br />
Armed Forces Radiobiology Research Institute, $6,300.<br />
Determination of Piperacillin and Tazobactam in Biological Matrixes.<br />
Wyeth Pharmaceuticals, $35,000.<br />
Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic<br />
Antibacterials in the Murine Staphylococcus Aureus Pneumonia<br />
Model. Affinium Pharmaceuticals, $86,288<br />
Evaluation of Ceftobiprole Against Staphylococcus aureus in a<br />
Murine Pneumonia Model Blanket Protocol. Johnson & Johnson<br />
Pharmaceuticals, $110,494.<br />
Evaluation of Destiny Pharma’s Novel Antimicrobials Against<br />
Staphylococcus Aureus in a Murine Thigh Model. Destiny<br />
Pharmaceuticals, $59,635.<br />
Evaluation of Novexecel Inc. Novel Antimicrobials Against<br />
Staphylococcus aureus in a Murine Thigh Model Blanket Protocol.<br />
Novexel, Inc., $125,231.<br />
Evaluation of Novexel Inc. Novel Antimicrobials against<br />
Staphylococcus aureus in a Murine Pneumonia Model. Novexel, Inc.,<br />
$111,010.<br />
Evaluation of Polymedix Inc. Novel Antimicrobials Against<br />
Staphylococcus aureus in a Murine Thigh Model - Blanket Protocol.<br />
PolyMedix, Inc., $92,542.<br />
Evaluation of the Bactericidal Activity of Doripenem Human<br />
Simulated Exposures Against Pseudomonas aeruginosa in<br />
a Neutropenic Mouse Thigh Model. Johnson & Johnson<br />
Pharmaceutical R&D, $169,040.<br />
Evaluation of the Impact of Inadequate Empirical Therapy Against<br />
Pathogens Causing Complicated Skin & Soft Tissue Infections.<br />
Wyeth Pharmaceuticals, $81,413.<br />
Evaluation of the Pharmacodynamic Profile of Novel Vertex<br />
Pharmaceuticals Compounds in Murine Models of Infection (Blanket<br />
Protocol). Vertex Pharmaceuticals, Inc., $52,186.<br />
HPLC Analysis of Daptomycin in Human Serum. Cubist<br />
Pharmaceuticals, $35,000.<br />
Identificeftazidime Susceptible Pseudomonas aeruginosa<br />
Among Clinical Isolates from <strong>Hartford</strong> <strong>Hospital</strong>. AstraZeneca<br />
Pharmaceuticals, $11,250.<br />
Murine (Rat) Staphylococcus aureus intra-abdominal sepsis model:<br />
efficacy of affinium pharmaceuticals novel systemic antibacterials.<br />
Affinium Pharmaceuticals, $18,625.<br />
Murine (Rat) Thigh Infection Model: Efficacy Evaluation of Affinium<br />
Pharmaceuticals Systemic Antibacterials. Affinium Pharmaceuticals,<br />
$19,569.<br />
OPTAMA: Evaluating in vivo Potency Against Important Gram-<br />
Negative Rods over the Period of 2002 to 2006. AstraZeneca<br />
Pharmaceuticals, $46,250.<br />
Pharmacodynamic Comparison of the Carbapenems against<br />
Extended-Spectrum Beta-Lactamases from the MYSTIC Surveillance<br />
Program. AstraZeneca, $51,875.<br />
Pharmacodynamic comparison of tigecycline versus other<br />
intravenous antimicrobials in the treatment of serious nosocomial<br />
infections #3074A1-102039. Wyeth Pharmaceuticals, $195,625.<br />
Pharmacodynamic Evaluation of Tigecycline Against Phenotypically<br />
Diverse S. sureus and E. coli in a Murine Thigh Model. Wyeth<br />
Pharmaceuticals, $235,823.<br />
Pharmacodynamic Evaluation of Tigecycline Against Staphylococcus<br />
Aureus and Acinetobacter Baumannii in a Murine Pneumonia Model.<br />
Wyeth Pharmaceuticals, $218,328.<br />
Pharmacodynamic Modeling of Antimicrobials in the Treatment<br />
of <strong>Hospital</strong> Acquired Pneumonia: Comparison with 2003<br />
OPTAMA <strong>Report</strong> and Agreement with ATS/IDSA Guidelines for<br />
the Management of <strong>Hospital</strong> Acquired Pneumonia. AstraZeneca<br />
Pharmaceuticals, $40,625.
Pharmacokinetics of Daptomycin in Patients Receiving Continuous<br />
Veno-Venous Hemodiafiltration (CVVHDF). Cubist Pharmaceuticals,<br />
$99,599.<br />
Provision and <strong>Report</strong>ing of Susceptibility Testing for <strong>Hospital</strong> Based<br />
Anti-Infectives. AstraZeneca Pharmaceuticals, $399,375.<br />
Risk Factors for Infection with Meropenem High-level Resistant<br />
Pseudomonas Aeruginosa and Impact on Mortality and <strong>Hospital</strong><br />
Costs. AstraZeneca Pharmaceuticals, $62,188.<br />
Tigecycline Concentration Determinations. Wyeth Pharmaceuticals,<br />
$35,000.<br />
Tissue Penetration and Pharmacokinetics of Daptomycin in<br />
Healthy and Diabetic Volunteers by In Vivo Microdialysis. Cubist<br />
Pharmaceuticals, $119,285.<br />
Trends in MIC Distributions of Several Antibiotics Against<br />
Pseudomonas aeruginosa over a 5-Year Period at a Large Urban<br />
Teaching <strong>Hospital</strong>. Wyeth Pharmaceuticals, $56,250.<br />
Urea Determination in Human Plasma and Bronchial Alveolar Lavage<br />
Fluid by a Colorimetric Method for the Telavancin Clinical Program.<br />
Theravance, $10,000. projects continued<br />
Publications<br />
Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment<br />
of a neonate with persistent vancomycin-resistant enterococcal<br />
bacteremia with a Daptomycin-containing regimen. Infection and<br />
Drug Resistance <strong>2008</strong>;1:9-11.<br />
Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection – not just<br />
a burden anymore. Connecticut Medicine 20<strong>09</strong>;73(3):407-411.<br />
Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon<br />
S, Deininger DD, Drumm JE, Gross CH, LeTriran A, Liao Y, Mani<br />
N, Nicolau DP, Perola E, Ronkin S, Swenson LL, Tang Q, Tesier PR,<br />
Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel<br />
dual targeting Aminobenzimidazole Urea Inhibitors of DNA Gyrase &<br />
Topoisomerase IV possessing potent antibacterial activity: Intelligent<br />
design and evolution through the judicious use of structure and SAR.<br />
Journal of Medicinal Chemistry <strong>2008</strong>;51(17):5243-5263.<br />
Courter J, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal<br />
exposure for-lactams via extended infusions in the pediatric<br />
population. Pediatric Blood & Cancer 20<strong>09</strong>;53:379-385.<br />
Crandon J, Nicolau DP. Oritavancin, a potential weapon in the<br />
battle against serious gram-positive pathogens. Future Microbiology<br />
<strong>2008</strong>;3:251-263.<br />
Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of<br />
Tigecycline against phenotypically diverse Staphylococcus aureus<br />
in a murine thigh model. Antimicrobial Agents & Chemotherapy<br />
20<strong>09</strong>;53(3):1165-1169.<br />
Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1- and<br />
2-Gram human simulated prolonged infusions of Doripenem against<br />
Pseudomonas aeruginosa. Antimicrobial Agents & Chemotherapy<br />
20<strong>09</strong>;53(10):4352-4356.<br />
Crandon JL, Kim A, Nicolau DP. Comparison of Tigecycline<br />
penetration into the epithelial lining fluid of infected and uninfected<br />
murine lungs. Journal of Antimicrobial Chemotherapy 20<strong>09</strong>;64:837-<br />
839.<br />
Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of the<br />
2002-2006 OPTAMA programs for the US <strong>Hospital</strong>s: Focus on gramnegative<br />
resistance. Annals of Pharmacotherapy 20<strong>09</strong>;43(2):220-227.<br />
Crandon JL, Kuti JL, Nicolau DP. Antimicrobial efficacy review.<br />
Pharmacy Practice News. 20<strong>09</strong>;(9):29-32 ; Infectious Disease Special<br />
Edition. 20<strong>09</strong>. McMahon Publishing Group.<br />
Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment<br />
of multidrug-resistant Klebsiella pneumoniae meningitis. Infectious<br />
Diseases in Clinical Practice 20<strong>09</strong>;17:66-68.<br />
Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical<br />
site infections: Does inadequate antibiotic therapy affect patient<br />
outcomes? Surgical Infections 20<strong>09</strong>;10(4):323-331.<br />
Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated<br />
with infection with Meropenem high-level resistant Pseudomonas<br />
aeruginosa. Infection Control and <strong>Hospital</strong> Epidemiology<br />
20<strong>09</strong>;3<strong>09</strong>(8):746-752.<br />
Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital<br />
length of stay and costs in patients with ventilator-associated<br />
pneumonia. Seminars in Respiratory and Critical Care Medicine<br />
20<strong>09</strong>;30:116-124.<br />
Eagye KJ, Nicolau DP. Incidence of infection and impact on hospital<br />
length of stay and costs in patients undergoing elective colorectal<br />
surgery. American Journal of Surgery 20<strong>09</strong>;198:359-367.<br />
Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP.<br />
Pharmacodynamic target attainment of oral α-lactams for the<br />
empiric treatment of acute otitis media in children. Pediatric Drugs<br />
<strong>2008</strong>;10(5):329-335.<br />
Gerding DN, Friedenberg FK, Nicolau DP. Clostridium Difficile<br />
infection: Guidance on optimal diagnosis and treatment. Continuing<br />
Medical Education Supplement, Advancing Knowledge in<br />
Healthcare, Inc., 20<strong>09</strong>;1-8.<br />
38.
Kiffer CRV, Kuti JL, Nicolau DP. Optimization of therapy using<br />
pharmacodynamic principles: The case for prolonged infusion<br />
-lactam antibiotic therapy. Brazilian Journal of Infectious Diseases<br />
<strong>2008</strong>;12(Suppl. 2):22-28.<br />
Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic<br />
profiling of Doripenem against Pseudomonas aeruginosa by<br />
simulating human exposures. Antimicrobial Agents & Chemotherapy<br />
<strong>2008</strong>;52(7):2497-2502.<br />
Kim A, Sakoulas G, Kuti JL, Nicolau DP. Prevalence of Methicillinresistant<br />
Staphylococcus aureus (MRSA) strains with Vancomycin<br />
MIC 2 μg/mL in New York City area hospitals and implications on<br />
pharmacodynamic target attainment. Infectious Diseases in Clinical<br />
Practice 20<strong>09</strong>;7(2):95-98.<br />
Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP.<br />
Penetration of Daptomycin into soft tissues in diabetic versus<br />
healthy volunteers by in vivo microdialysis. Antimicrobial Agents &<br />
Chemotherapy <strong>2008</strong>;52(11):3941-3946.<br />
Kim SW, Kuti JL, Nicolau DP. Review on inhaled antimicrobial<br />
therapies for respiratory infections. Current Infectious Disease<br />
<strong>Report</strong>s <strong>2008</strong>;10:29-36.<br />
Kioumis IP, Kuti JL, Nicolau DP. Antibiotic therapy: General<br />
considerations. Pharmacologic management of the orthopedic<br />
trauma patient. In Browner BB, Jupiter JB, Levine AM, Trafton PG,<br />
Krettek C, eds. Skeletal Trauma: Basic Science, Management, and<br />
Reconstruction, Volume I: General Principles, Spine, Pelvis. 4th ed,<br />
Philadelphia, PA: Saunders Elsevier 20<strong>09</strong>:258-264.<br />
Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: The first anti-MRSA<br />
Cephalosporin. Formulary <strong>2008</strong>;43:66-79.<br />
Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases<br />
Society of America/American Thoracic Society Criteria to Predict<br />
Severe Community Acquired Pneumonia Caused by Streptococcus<br />
pneumoniae. American Journal of Emergency Medicine 20<strong>09</strong>;27:968-<br />
974.<br />
Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparison<br />
of the cumulative fraction of response for 19 antibiotic regimens<br />
against nosocomial pathogens in Europe between 2002 and 2006.<br />
International Journal of Antimicrobial Agents 20<strong>09</strong>;33(4):348-353.<br />
Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of<br />
Tigecycline against Acinetobacter Baumannii in a murine pneumonia<br />
model. Journal of Antimicrobial Chemotherapy 20<strong>09</strong>;63(5):982-987.<br />
Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic model to<br />
assess Tigecycline predicted efficacy for hospital-acquired pneumonia.<br />
Journal of Chemotherapy <strong>2008</strong>;20(1): 69-76.<br />
Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance<br />
of Tigecycline versus common intravenous antibiotics for the empiric<br />
treatment of complicated skin and soft tissue infections. Surgical<br />
Infections <strong>2008</strong>;9(1):57-66.<br />
Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic<br />
comparison of Linezolid, Teicoplanin, and Vancomycin against<br />
clinical isolates of Staphylococcus aureus and coagulase-negative<br />
Staphylococci collected from hospitals in Brazil. Clinical<br />
Microbiology & Infection <strong>2008</strong>:14:116-123.<br />
Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated<br />
Vancomycin minimum inhibitory concentrations among Methicillinresistant<br />
Staphylococcus aureus isolated from patients with ventilator<br />
associated pneumonia at a Connecticut hospital. Connecticut<br />
Medicine 20<strong>09</strong>;73(6):337-340.<br />
Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empiric antibiotic<br />
therapy for ventilator-associated pneumonia in your ICU: Guidelines<br />
for implementing the guidelines. Seminars in Respiratory and Critical<br />
Care Medicine 20<strong>09</strong>;30:102-115.<br />
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Costeffectiveness<br />
of Telavancin versus Vancomycin for the treatment of<br />
complicated skin and skin structure infections. Pharmacotherapy<br />
<strong>2008</strong>;28(12):1471-1482.<br />
Laohavaleeson S, Lolans, Quinn JP, Kuti JL, Nicolau DP.<br />
Identification of the MexXY-OprM Efflux System in Pseudomonas<br />
aeruginosa with discordant Cefepime / Ceftazidime dusceptibility<br />
profiles. Infection and Drug Resistance <strong>2008</strong>;1:51-55.<br />
Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic<br />
characterization of Ceftobiprole in experimental pneumonia<br />
model caused by phenotypically diverse Staphylococcus aureus.<br />
Antimicrobial Agents & Chemotherapy <strong>2008</strong>;52(7):2389-2394.<br />
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti<br />
JL, Nicolau DP. Population pharmacokinetics of extended infusion<br />
high dosed-Cefepime in adult critically-ill patients with ventilator<br />
associated pneumonia. Antimicrobial Agents & Chemotherapy<br />
20<strong>09</strong>;53(4):1476-1481.<br />
Nicasio Am, Crandon JL, Nicolau DP. In vivo pharmacodynamic<br />
profile of Tigecycline against phenotypically diverse Escherichia coli<br />
and Klebsiella pneumoniae. Antimicrobial Agents & Chemotherapy<br />
20<strong>09</strong>;53(7):2756-2761.<br />
Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of<br />
automated screening and confirmation of extended spectrum<br />
-lactamase producing Enterobacteriaceae on antibiotic prescribing.<br />
Journal of Medical Microbiology <strong>2008</strong>;57:1147-1151.
Nicasio AM, Kuti JL, Nicolau DP. Pharmacotherapy of complicated<br />
urinary tract and intra-abdominal infections with Doripenem. Clinical<br />
Medicine: Therapeutics 20<strong>09</strong>;1:787-799.<br />
Nicasio AM, Kuti JL, Nicolau DP. The current state of multipledrug<br />
resistant gram-negative bacilli in North America: Insights from<br />
the Society of Infectious Diseases Pharmacists. Pharmacotherapy<br />
<strong>2008</strong>;28(2):235-249.<br />
Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E,<br />
Russomanno J, Kuti JL. Bronchopulmonary disposition of Micafungin<br />
in healthy adult volunteers. Antimicrobial Agents & Chemotherapy<br />
20<strong>09</strong>;53(3):1218-1220.<br />
Nicolau DP. Bugs vs. drugs: What is the pharmacist’s challenge?<br />
American Journal of Health-System Pharmacy <strong>2008</strong>;65(1) Suppl<br />
2:S2-S3.<br />
Nicolau DP. Carbapenems: A potent class of antibiotics. Expert<br />
Opinion on Pharmacotherapy <strong>2008</strong>;9(1):23-37.<br />
Nicolau DP. Containing costs and containing bugs: Are they<br />
mutually exclusive? Journal of Managed Care Pharmacy<br />
20<strong>09</strong>;15(Suppl)2:S12-S17.<br />
Nicolau DP. Management of complicated infections in the era of<br />
antimicrobial resistance: The role of Tigecycline. Expert Opinion on<br />
Pharmacotherapy 20<strong>09</strong>;10(7):1213-1222.<br />
Nicolau DP. Pharmacodynamic optimization of α -lactams in the<br />
patient care setting. Critical Care <strong>2008</strong>;12(Suppl 4):S1-5.<br />
Nicolau DP. Pharmacokinetic and pharmacodynamic properties of<br />
Meropenem. Clinical Infectious Diseases <strong>2008</strong>;47(Suppl 1):S32–40.<br />
Nicolau DP. Spotlight on Clostridium difficile infection: An<br />
educational resource for pharmacists. Pharmacy Times 20<strong>09</strong>;2:91-100.<br />
Nicolau DP. What is the 360-degree approach to defining success for<br />
VAP? Journal of Managed Care Pharmacy 20<strong>09</strong>;15(Suppl)5:S3-S4.<br />
Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of<br />
achieving requisite pharmacodynamic exposure for oral α -lactam<br />
regimens against Hemophilus influenzae in children. Pediatric Drugs<br />
<strong>2008</strong>;10(6):391-397.<br />
Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel G, Kahn<br />
JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier<br />
PR, Drusano GL. Identifying exposure targets for the treatment of<br />
Staphylococcal Pneumonia with Ceftobiprole. Antimicrobial Agents<br />
& Chemotherapy 20<strong>09</strong>;53(8):3294-3301.<br />
Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein<br />
EJ. Serum bactericidal activities of Moxifloxacin and Levofloxacin<br />
against aerobic and anaerobic intra-abdominal pathogens. Anaerobe<br />
<strong>2008</strong>;14(1):8-12.<br />
Abstracts<br />
Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of<br />
single doses (250, 500, 750, 1000 milligrams) of Levofloxacin against<br />
Fluoroquinolone-resistant strains of Escherichia coli. International<br />
Journal of Antimicrobial Agents <strong>2008</strong>;32:320-325.<br />
Bulik CC, Christensen H, Li P, Nicolau DP, Kuti JL. An In Vitro<br />
Pharmacodynamic Model of a Human Simulated High Dose,<br />
Prolonged Infusion Meropenem Regimen against Klebsiella spp.<br />
producing the KPC Carbapenemase. (Abstract No. 231). 20<strong>09</strong><br />
ACCP/ESCP International Congress on Clinical Pharmacy, Orlando,<br />
FL, April 20<strong>09</strong>.<br />
Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti<br />
JL. Pharmacodynamics (PD) of Human Simulated, High Dose,<br />
Prolonged Infusion Meropenem (MEM) Against Pseudomonas<br />
aeruginosa (PSA) and Carbapenemase Producing Klebsiella<br />
pneumoniae (KPC). (Abstract No. A1-019). 49th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy, San<br />
Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Bulik CC, Fauntleroy KA, Jenkins SG, Nicolau DP, Kuti JL.<br />
Comparison of Meropenem (MEM) MICs for Carbapenemase<br />
Producing Klebsiella pneumoniae (KPC) by E-Test, Broth<br />
Microdilution (BMD), and VITEK 2 Methods. (Abstract No.<br />
D-721). 49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy, San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Bulik CC, Nicolau DP. In Vivo Efficacy of 1g Human Simulated<br />
Prolonged Infusion DOR (DOR) against Carbapenemase<br />
Producing Klebsiella pneumoniae (KPC). (Abstract No. A1-<br />
014). 49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy, San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing Bactericidal<br />
Exposure For -lactams Using Extended Infusions in the Pediatric<br />
Population. (Abstract No. 332). 20<strong>09</strong> ACCP/ESCP International<br />
Congress on Clinical Pharmacy, Orlando, FL, April 20<strong>09</strong>.<br />
Crandon J, Kuti JL, Jones R, Nicolau DP. Pharmacodynamic Target<br />
Attainment Rates for 9 Antibiotics against Escherichia coli, Klebsiella<br />
spp., and Pseudomonas aeruginosa isolates in USA <strong>Hospital</strong>s.<br />
(Abstract No. 44). American College of Clinical Pharmacy, <strong>2008</strong><br />
Spring Research and Practice Forum, Phoenix, AZ, April 5 - 9, <strong>2008</strong>.<br />
40.
Center for<br />
Anti-Infective Research & Development<br />
Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft<br />
RF, Pope J, Russomanno J, Shore E, Nicolau DP, Kuti JL.<br />
Bronchopulmonary Disposition of Intravenous (IV) Voriconazole<br />
(VRC) and Anidulafungin (ANI) Given in Combination to Healthy<br />
Adults. (Abstract No. A1-423). 49th Interscience Conference<br />
on Antimicrobial Agents and Chemotherapy, San Francisco, CA,<br />
September 12-15, 20<strong>09</strong>.<br />
Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of<br />
Tigecycline Against Phenotypically Diverse Staphylococcus aureus<br />
in a Murine Thigh Model. (Abstract No. A-987). 48th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy / Infectious<br />
Diseases Society of America 46th <strong>Annual</strong> Meeting, Washington, DC,<br />
October 25-28, <strong>2008</strong>.<br />
Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical<br />
Pharmacodynamics (PD) of Cefepime (FEM) in Patients Infected<br />
with Pseudomonas aeruginosa (PSA). (Abstract No. A1-011).<br />
49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy, San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1 and<br />
2g Human Simulated Prolonged Infusion Doripenem Against<br />
Pseudomonas aeruginosa. (Abstract No. A1-013). 49th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy, San<br />
Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Crandon JL, Kim A, Nicolau DP. Tigecycline Penetration into the<br />
Epithelial Lining Fluid of Infected and Uninfected Murine Lungs.<br />
(Abstract No. 228). 20<strong>09</strong> ACCP/ESCP International Congress on<br />
Clinical Pharmacy, Orlando, FL, April 20<strong>09</strong>.<br />
Crandon JL, Kuti JL, Nicolau DP. Comparison of Simulated Human<br />
Exposures of Telavancin (TLV) and Vancomycin (VAN) against<br />
Methicillin Resistant Staphylococcus aureus (MRSA) with Ranging<br />
Vancomycin MICs in a Murine Pneumonia Model. (Abstract No. A1-<br />
1292). 49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy, San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Eagye KJ, Kuti JL, Nicolau DP. Prior Carbapenem Use Not<br />
Associated with Infection with Meropenem High-Level Resistant<br />
Pseudomonas aeruginosa (MRP). (Abstract No. K-3492). 48th<br />
Interscience Conference on Antimicrobial Agents and Chemotherapy<br />
/ Infectious Diseases Society of America 46th <strong>Annual</strong> Meeting,<br />
Washington, DC, October 25-28, <strong>2008</strong>.<br />
Eagye KJ, Nicolau DP. Change in Anti-pseudomonal Carbapenem<br />
Susceptibility (ACS) in 25 <strong>Hospital</strong>s Is Not Associated with the<br />
Use of Ertapenem (ERT). (Abstract No. K-2061). 49th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy, San<br />
Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Eagye KJ, Sutherland CA, Christensen H, Kuti JL, Nicolau DP.<br />
Prevalence of Pseudomonas aeruginosa (PSA) with Reduced<br />
Susceptibility to Piperacillin-Tazobactam (TZP) at 39 <strong>Hospital</strong>s.<br />
(Abstract No. C2-201). 48th Interscience Conference on<br />
Antimicrobial Agents and Chemotherapy / Infectious Diseases<br />
Society of America 46th <strong>Annual</strong> Meeting, Washington, DC, October<br />
25-28, <strong>2008</strong>.<br />
Kim A, Banevicius MA, Nicolau DP. In Vivo Efficacy of Doripenem<br />
Human Simulated Exposures against Pseudomonas aeruginosa.<br />
(Abstract No. 1<strong>09</strong>E). American College of Clinical Pharmacy, 2007<br />
<strong>Annual</strong> Meeting, Denver, CO, October 14-17, 2007.<br />
Kim A, Nicolau DP, Kuti JL. <strong>Hospital</strong> Costs and Outcomes of<br />
Patients Discharged with a Diagnosis of Pulmonary Aspergillosis in<br />
the United States. (Abstract No. 189). American College of Clinical<br />
Pharmacy, 2007 <strong>Annual</strong> Meeting, Denver, CO, October 14-17, 2007.<br />
Kim A, Sakoulas G, Kuti JL, Nicolau DP. Pharmacodynamic Analysis<br />
of Vancomycin versus Linezolid against Methicillin-Resistant<br />
Staphylococcus aureus Strains in New York (Abstract No. RP18).<br />
American Society of <strong>Hospital</strong> Pharmacists, 42nd <strong>Annual</strong> Midyear<br />
Clinical Meeting, Las Vegas, Nevada, December 2-6, 2007.<br />
Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP.<br />
Penetration of Daptomycin into Soft Tissues in Diabetic versus<br />
Healthy Volunteers by In Vivo Microdialysis. (Abstract No.<br />
A-1884). 48th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy / Infectious Diseases Society of America 46th <strong>Annual</strong><br />
Meeting, Washington, DC, October 25-28, <strong>2008</strong>.<br />
KimA, Koomanachai P, Nicolau DP. Pharmacodynamic Evaluation of<br />
Tigecycline against Acinetobacter Baumannii in a Murine Pneumonia<br />
Model. (Abstract No. A-041). 48th Interscience Conference on<br />
Antimicrobial Agents and Chemotherapy / Infectious Diseases<br />
Society of America 46th <strong>Annual</strong> Meeting, Washington, DC, October<br />
25-28, <strong>2008</strong>.
Kontou P, Kuti JL, Nicolau DP. Validation of the 2007 Infectious<br />
Diseases Society of America/American Thoracic Society (IDSA/<br />
ATS) Criteria in Predicting Severe Community Acquired Pneumonia<br />
(CAP) Caused by Streptococcus pneumoniae (SP). (Abstract No.<br />
L-677). 48th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy / Infectious Diseases Society of America 46th <strong>Annual</strong><br />
Meeting, Washington, DC, October 25-28, <strong>2008</strong>.<br />
Koomanachai P, Crandon JL, Banevicius MA, Li P, Nicolau DP.<br />
Pharmacodynamic Evaluation of Tigecycline against Staphylococcus<br />
aureus in a Murine Pneumonia Model. (Abstract No. A1-552). 49th<br />
Interscience Conference on Antimicrobial Agents and Chemotherapy,<br />
San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Kuti JL, Nicasio A, Shore E, Palter M, Pepe J, Nicolau DP. Outcomes<br />
of an Empiric Antibiotic Algorithm (EAA) for Ventilator Associated<br />
Pneumonia (VAP) that Considers Local MIC Distributions and<br />
Pharmacodynamics (Abstract No. 1026). 45th <strong>Annual</strong> Meeting of<br />
Infectious Diseases Society of America, San Diego, CA, October 4-7,<br />
2007.<br />
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness<br />
of Telavancin versus Vancomycin for the Treatment of Complicated<br />
Skin and Skin Structure Infections. (Abstract No. 185E). American<br />
College of Clinical Pharmacy, 2007 <strong>Annual</strong> Meeting, Denver, CO,<br />
October 14-17, 2007.<br />
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti<br />
JL, Nicolau DP. Population Pharmacokinetics of Extended Infusion<br />
High Dosed-Cefepime in Adult Critically-Ill Patients with Ventilator<br />
Associated Pneumonia. (Abstract No. A-1880). 48th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy / Infectious<br />
Diseases Society of America 46th <strong>Annual</strong> Meeting, Washington, DC,<br />
October 25-28, <strong>2008</strong>.<br />
Nicasio AM, Eagye KJ, Shore E, Palter M, Pepe J, Nicolau DP, Kuti<br />
JL. A Pharmacodynamic (PD) Based Clinical Pathway (CP) for<br />
Empiric Antibiotic Choice in Patients with Ventilator Associated<br />
Pneumonia (VAP). (Abstract No. K-490). 48th Interscience<br />
Conference on Antimicrobial Agents and Chemotherapy / Infectious<br />
Diseases Society of America 46th <strong>Annual</strong> Meeting, Washington, DC,<br />
October 25-28, <strong>2008</strong>.<br />
Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E,<br />
Russomanno J, Kuti JL. Bronchopulmonary Pharmacokinetics (PK)<br />
of Micafungin (MICA) in Healthy Adult Volunteers. (Abstract No.<br />
A-010). 48th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy / Infectious Diseases Society of America 46th <strong>Annual</strong><br />
Meeting, Washington, DC, October 25-28, <strong>2008</strong>.<br />
Stein GE, Smith C, Kepros J, Ji A, Nicolau DP, Dybas L, Saunders<br />
JP. Tigecycline Skin Penetration and Activity against Methicillin-<br />
Resistant Strains of Staphylococcus aureus (MRSA). (Abstract No.<br />
A1-554). 49th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy, San Francisco, CA, September 12-15, 20<strong>09</strong>.<br />
Tessier PR, Love W, Hayter I, Rhys- Williams W, Nicolau DP. A<br />
Novel XF Antibacterial, DPD-207, against Staphylococcus aureus<br />
(SA) in a Murine Thigh Infection Model. (Abstract No. F1-<br />
3969). 48th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy / Infectious Diseases Society of America 46th <strong>Annual</strong><br />
Meeting, Washington, DC, October 25-28, <strong>2008</strong>.<br />
Nicasio AM, Crandon JL, Nicolau DP. Pharmacodynamic Profile<br />
of Tigecycline Against Phenotypically Diverse Escherichia coli and<br />
Klebsiella pneumoniae in a Murine Thigh Model. (Abstract No.<br />
A-040). 48th Interscience Conference on Antimicrobial Agents and<br />
Chemotherapy / Infectious Diseases Society of America 46th <strong>Annual</strong><br />
Meeting, Washington, DC, October 25-28, <strong>2008</strong>.<br />
Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. <strong>Hospital</strong><br />
Costs Associated with a Pharmacodynamic Based Clinical Pathway<br />
for Empiric Antibiotic Choice in Patients Infected with Ventilator<br />
Associated Pneumonia. (Abstract No. 227). 20<strong>09</strong> ACCP/ESCP<br />
International Congress on Clinical Pharmacy, Orlando, FL, April<br />
20<strong>09</strong>.<br />
42.
Medicine<br />
New Projects<br />
Federal<br />
King, Mary, MD, Gerontology<br />
FOCUS Cognitive Ancillary Study. NHLBI/University of Maryland, $18,144.<br />
Foundation<br />
Kates, Richard, MD, Medicine<br />
Preventive IVIG Therapy for Congenital Heart Block (PITCH). Alliance for<br />
Lupus Research/ New York Univ School of Med, $10,100.<br />
Knauft, R. Frederic, MD, Pulmonology<br />
Cystic Fibrosis Foundation Therapeutics: Clinical Research Facilitation Award.<br />
Cystic Fibrosis Foundation/ University of Connecticut Health center, $9,125.<br />
Industry<br />
Cappa, Joseph, MD, Gastroenterology<br />
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50<br />
mg Versos Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to<br />
Moderate Erosive Gastroesophageal Reflux Disease (GERD) E3810-G000-303.<br />
Eisai/Quintiles, $64,140.<br />
A Randomized Double-Blind Parallel Study off Rabeprazole Extended-Release 50<br />
mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate<br />
to Severe Erosive Gastroesophageal Reflux Disease E3810-G000-301. Eisai/<br />
Quintiles, $64,140.<br />
A Multi-Center, Investigator-blinded, Randomized, 12-Month, Parallel-group,<br />
Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4g Asacol® Therapy<br />
QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative<br />
Colitis. Proctor and Gamble Pharmaceuticals (Multicenter), $27,400.<br />
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging<br />
Study of COLAL-PRED in the Treatment of Patients with Moderate to Severe<br />
Ulcerative Colitis. Prometheus (Multicenter), $111,663.<br />
Israel, Jonathan, MD, Medicine<br />
Prospective Observational Study on Predictors of Early On-Treatment Response<br />
and Sustained Virological Response in a Cohort of Treatment Naive HCV-<br />
Infected Patients Treated with Pegylated Interferons. Roche Laboratories, Inc.,<br />
$24,970.<br />
Knauft, R. Frederic, MD, Pulmonology<br />
A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial<br />
Evaluating Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis<br />
and Pseudomonas aeruginosa. Gilead Sciences (Multicenter), $32,575.<br />
Wettstein, Markus, MD, Endocrinology<br />
A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to<br />
Evaluate the Safety and Tolerability of 24 weeks Treatment with Vildagliptin<br />
(50 mg gd or 100 mg qd) versus Sitagliptin (25 mg qd) in Patients with Type 2<br />
Diabetes and Severe Renal Insufficiency. Novartis (MultiCenter), $24,721.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Seip, Richard, PhD, Medicine<br />
DNA as a Predictor of Effective Warfarin Levels. Open Competition, $62,475.<br />
Vergara, Cunegundo, MD, Ambulatory Care<br />
Creation of an Ambulatory Database to Measure Access to Primary Preventive<br />
Care Services. Open Competition, $61,000.<br />
Departmental<br />
D’Agostino, Darrin DO, MPH, Ambulatory Care<br />
The Effects of Massage on Bronchodilation in Asthmatics Enrolled in the ACE<br />
Program. $29,340.<br />
Reagan, Louise, APRN, Medicine<br />
The Effect of a Peer Delivered Motivational Message on Intention to Exercise for<br />
Hispanic Persons with Type 2 Diabetes (T2DM): An Experimental Pilot Study.<br />
$454.<br />
Unfunded<br />
Brown, Seth, Medicine<br />
Endoscopic Repair of Frontal Sinus Cerebrospinal Fluid Leaks.<br />
Karabin-Mah, Tessa, RD, Nutrition Services<br />
Food Frequency in Cystic Fibrosis.<br />
King, Mary, MD, Gerontology<br />
Do Properly Functioning Bed Alarms Reduce the Number of <strong>Hospital</strong> Falls?<br />
Pope, Samuel, MD, Pulmonology<br />
Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with<br />
Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited<br />
Treatment Options and Are at Risk for Disease Progression.<br />
Ranga, Kasturi, MD, Medicine
Does Hydration Status Impact Outcomes at the End of the First Year Post Renal<br />
Transplantation? Analytic support provided through <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant.<br />
Effects of Rapid Steroid Taper on Patient and Graft Survival Following Transplant.<br />
HLA Identical Renal Transplant: Single Center Outcome Study.<br />
Incidental Kidney Biopsies, Neither Indicated nor Protocol: Any Lessons to Learn?<br />
Prevalence of Malignancy in Renal Transplant Recipients: A Single Center<br />
Experience.<br />
Utility Of Renal Isotopic Scans In Predicting Delayed Graft Function Post Renal<br />
Transplant. Analytic support provided through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Reagan, Louise, APRN, Medicine<br />
A Narrative Analysis Pilot Study: Hispanic Patients’ Perspective of Managing their<br />
Chronic Illness.<br />
Vergara, Cunegundo, MD, Ambulatory Care<br />
Misperceptions and Barriers to Seeking Dermatologic Care in Minority<br />
Populations.<br />
The Effect of an Educational Intervention for Older Adults’ Osteoarthritis Pain: A<br />
Pilot Study.<br />
Active Projects<br />
Albino, Susan, BS, Pulmonology<br />
NICO Non-Invasive Cardiac Output/Respiratory Profile Monitor with Software<br />
for Spontaneous Breathing. Respironics, Inc., $7,000.<br />
Clinical Evaluation of the Respironics Capnostat 5 CO2 Sensor. Respironics, Inc.,<br />
$4,500.<br />
Clinical Evaluation of a Non-Invasive Cardiac Output (NICO2) and Respiratory<br />
Profile Monitor.<br />
Cappa, Joseph, MD Gastroenterology<br />
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter<br />
Study to Evaluate the Efficacy and Safety of DNK333 25mg B.I.D. Given Orally<br />
for 4 Weeks in Female Patients with Diarrhea-Predominant Irritable Bowel<br />
Syndrome (IBS-D). Novartis Pharmaceuticals, $12,300.<br />
A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trial to Assess<br />
the Safety and Efficacy of Asacol® 4.8 g/day (800 mg mesalamine tablet) versus<br />
Asacol® 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately<br />
Active Ulcerative Colitis. Proctor and Gamble Pharmaceuticals, $58,700.<br />
Chhabra, Jyoti, PhD, Research Administration<br />
Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic and<br />
Health Outcomes Among Latinos. NIH subcontract through the University of<br />
Connecticut, $1,081,928.<br />
Cooper, Brian, MD, Infectious Diseases<br />
A Randomized Trial of Hypertonic Saline/Heparin Flush Solution in the<br />
Prevention of Hemodialysis Catheter Related Bloodstream Infection. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $48,000.<br />
Czarnecki, Gregory, DO, Medicine<br />
Internal Medicine Clinical Assessment Program.<br />
King, Mary, MD, Gerontology<br />
Examining the Use of the Safety Screen to Predict Risk of <strong>Hospital</strong> Falls.<br />
Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Knauft R. Frederic, MD, Pulmonology<br />
Evaluation of Multiple Bioassays in Serum and Pleural Fluid to Estimate the<br />
Probability of Cancer in Patients Presenting with Undiagnosed Pleural Effusion.<br />
Fujirebio Diagnostic, Inc., $72,000.<br />
NOVARTIS TBM100C2302 - A Randomized, Open-label, Multicenter, Phase 3<br />
Trial to Assess Safety of Tobramycin Inhalation Powder Compared to TOBI® in<br />
Cystic Fibrosis Subjects. Novartis Pharmaceuticals, $47,845.<br />
Participation in the Cystic Fibrosis Patient Registry.<br />
Meyer, Ariel, DO, Medicine<br />
Evaluation of Systems Based Practice Changes on Patient Care Near Misses on<br />
the Medical Teaching Service at the University of Connecticut.<br />
Paquette, Anthony, MPH, Medicine<br />
Case Review: Successful Multi-Organ Donation from a Donor with Idiopathic<br />
Thrombocytopenia Purpura.<br />
Post, Jarrod, MD, Dialysis<br />
Hemodynamic Responses to Dialysate Sodium Individualization in Hemodialysis.<br />
Satellite Research Foundation LLC/Yale University, $27,751.<br />
Quintiliani Jr. Richard, MD, Infectious Diseases<br />
Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue<br />
Infections Proven to Be Due to Methicillin-Resistant Staphylococcus Aureus.<br />
Covance Inc., $63,556.<br />
Clonal Outbreak of Clostridium Difficile-Associated Disease with High<br />
Morbidity and Mortality. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$58,500.<br />
Ranga, Kasturi, MD, Medicine<br />
Thymoglobulin: Now or Later?<br />
Evaluation of long-term outcomes amongst living donor kidney transplant<br />
recipients from donors older than 50 years: Are they comparable to recipients<br />
of kidneys from donors less than 50 years of age? Statistical analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Assessment of Changes in Renal Function in Living Kidney Donors Post-<br />
Nephrectomy in the First Year After Donation.<br />
Robbins, Karen, RN, Dialysis<br />
Reiki: What are its Effects for Patients During Hemodialysis? <strong>Hartford</strong> <strong>Hospital</strong><br />
44.
Research Endowment Funds, $9,963.<br />
Rosson, Robert, MD, Gastroenterology<br />
A Multi-Center, Longitudinal Study of Drug- and CAM-Induced Liver Injury<br />
(Version 2.2). NIDDK/UCONN, $10,000.<br />
Incidence of Positive Screening Gastric Biopsies for Helicobacter Pylori in Clinic<br />
Patients at <strong>Hartford</strong> <strong>Hospital</strong>: Comparison with Chinese Patients at Shandung<br />
University <strong>Hospital</strong>.<br />
Shore, Eric, MD, Pulmonology<br />
Roche Integrin Antagonist Follow-up for Undetected PML. Roche, $600.<br />
Spada, Michael, MD, Ambulatory Care<br />
A Comparison of Symptoms of Acute Coronary Syndrome and Length of Time to<br />
Seeking Treatment Based on Gender and Race.<br />
Sundararajan, Lavanya, MD, Ambulatory Care<br />
A Pilot Study for Increasing Osteoporosis Awareness in Internal Medicine<br />
Residency Clinics.<br />
Vergara, Cunegundo, Ambulatory Care<br />
Hypertension Compliance and the Factors that Affect the Health Status and<br />
Behaviors of Hispanics in the Ambulatory Care Setting.<br />
Using Preoperative Electrocardiograms as a Predictive Marker for Perioperative<br />
Adverse Outcomes in Hispanic Patients Undergoing Elective Non-cardiac<br />
Surgery. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Publications, Presentations<br />
and Abstracts<br />
Calle C, Vega-López S, Puglisi M, Chhabra J, Pérez-Escamilla R,<br />
Volek J, and Fernandez M. Effects of a peer-counseled intervention<br />
on diet and risk factors for cardiovascular disease in Hispanics<br />
diagnosed with type 2 diabetes. Results from the DIALBEST trial.<br />
FASEB J. 20<strong>09</strong>. 23; 4: 910.3.<br />
Calle M, Vega-López S, Pérez-Escamilla R, Chhabra J, D’Agostino<br />
D, Damio G, and Fernandez M. Dietary habits and cardiovascular<br />
disease risk factors in Hispanics with type 2 diabetes mellitus enrolled<br />
in the DIALBEST trial. Preliminary results. FASEB J. <strong>2008</strong> 22:1084.11.<br />
Chhabra J, Vega-López S, Calle M, Putnik P, Fernandez M,<br />
D’Agostino D, Damio G, and Pérez-Escamilla R. Relationship<br />
between energy intake and weight in Latino adults with type 2<br />
diabetes, preliminary results: DIALBEST Trial. FASEB J. <strong>2008</strong><br />
22:875.4.<br />
Chhabra J, Vega-López S, D’Agostino D, and Pérez-Escamilla R.<br />
Does calcium intake relate to weight/BMI in Latinos with type 2<br />
Diabetes? Preliminary Results: DIALBEST Trial. Obesity. <strong>2008</strong>:<br />
Abstract Presentation/Publication Number: 681-P.<br />
Chhabra J, Vega-López S, D’Agostino D, Fernandez M, Segura-<br />
Pérez M, Damio G, Pérez-Escamilla R. Relationship of dietary<br />
micronutrient intake with fasting plasma glucose and HbA1c:<br />
DIALBEST Trial Preliminary Results. FASEB J. 20<strong>09</strong>. 23; 4: 550.3.<br />
Colby J, Wang F, Chhabra J, Pérez-Escamilla R. Predictors of<br />
medication non-adherence in an urban community with healthcare<br />
disparities. Presented at Eastern States Conference for Pharmacy<br />
Residents and Preceptors, American Society for Health-system<br />
Pharmacists Foundation Research Abstracts, Hershey Lodge,<br />
Hershey, PA, April 29 to May 1, 20<strong>09</strong>.<br />
Czarnecki, G. The diabetic patient. In Busconi B, Stevenson JH, eds.<br />
Sports Medicine Consult. New York, NT; Lippincott, Williams and<br />
Wilken. 20<strong>09</strong>.<br />
Czarnecki, G. The mature patient. In Busconi B, Stevenson JH, eds.<br />
Sports Medicine Consult. New York, NT; Lippincott, Williams and<br />
Wilken. 20<strong>09</strong>.<br />
Ghuman N, Patel V, de Palma J, Datla A, Nataraj S, Ranga K.<br />
De novo minimal change disease (MCD) following kidney<br />
transplantation. American Journal of Kidney Diseases, <strong>2008</strong>, 51 (4):<br />
B49.<br />
Kannan S, Bansal R, Nataraj S, Sathyan S, Ricci A, Ranga K. Need for<br />
diagnostic criteria for antibody mediated rejection (AMR) in pancreas<br />
after kidney transplantation. American Journal of Kidney Diseases,<br />
<strong>2008</strong>, 51(4): B56.<br />
Knauft W, Chhabra J, McCullough L. Gender differences in the<br />
time of presentation to the emergency department and outcome in<br />
patients with acute ischemic stroke. Stroke. 20<strong>09</strong>; 40(2): Abstract #<br />
2315.<br />
Kopecky R, Wang F, Vega-López S, D’Agostino D, Chhabra J, Pérez-<br />
Escamilla R. Evaluation of medication appropriateness in Latinos<br />
enrolled in the DIALBEST Trial. Presented at the 27th <strong>Annual</strong><br />
Eastern States Conference for Pharmacy Residents and Preceptors.<br />
Hershey, PA May <strong>2008</strong>.<br />
Nataraj S, Vellanki V, Dada A, Balarezo F, Ranga K. De novo focal<br />
segmental glomerulosclerosis following renal transplant in a patient<br />
with autosomal dominant polycystic kidney disease. American<br />
Journal of Kidney Diseases, <strong>2008</strong>, 51(4): B73.<br />
Ojo P, Ranga KV, Brown M, Hull D, Charpentier KP. Transplantation<br />
of a unilateral fused kidney with inferior ectopia: revascularization<br />
utilizing donor aorta and vena cava. Connecticut Medicine.<br />
72(10):585-8, <strong>2008</strong> Nov-Dec.<br />
Pérez-Escamilla R, Damio G, De Jesús J, Bow L, Chhabra J, and Bull<br />
N. (<strong>2008</strong>). The Connecticut Center of Excellence for Eliminating
Health Disparities among Latinos (CEHDL). Journal of Higher<br />
Education, Outreach and Engagement, 12(3):167-177.<br />
Pérez-Escamilla R, Vega-López S, Damio G, Segura-Pérez S,<br />
Fernandez M, Calle M, Samuel G, Chhabra J, D’Agostino D. Short<br />
and long term impact of diabetes peer counseling on HbA1c among<br />
Latinos: DIALBEST Trial preliminary results. FASEB J. 20<strong>09</strong>. 23; 4:<br />
336.8.<br />
Perez-Escamilla R, Vega-Lopez S, Segura-Perez S, Damio G,<br />
Fernandez M, Calle M, Samuel G, Chhabra J, and D’Agostino D.<br />
Impact of diabetes peer counseling on glycosylated hemoglobin<br />
among Latinos enrolled in the DIALBEST Trial: Preliminary results.<br />
FASEB J. <strong>2008</strong> 22:677.19.<br />
Putnik P, Calle M, Fernandez M, Damio G, Segura-Pérez S, Vega-<br />
López S, Chhabra J, and Perez-Escamilla R. Influence of acculturation<br />
on food label use and nutrient intakes among Latinos participating in<br />
the DIALBEST trial: Preliminary results. FASEB J. <strong>2008</strong> 22:681.5.<br />
Samuel G, Fernandez M, Chhabra J, Vega-López S, Segura-Pérez S,<br />
Damio G, Calle M, D’Agostino D, Pérez-Escamilla R. Determinants<br />
of fasting plasma glucose and HbA1c among Latinos with type 2<br />
diabetes: DIALBEST trial preliminary results. FASEB J. 20<strong>09</strong>. 23; 4:<br />
736.7.<br />
between fast food and fried food intake and metabolic risk factors in<br />
Latinos with type 2 diabetes: Preliminary results from the DIALBEST<br />
study. FASEB J. 20<strong>09</strong>. 23; 4: 550.1.<br />
Vega-López S, Chhabra J, D’Agostino D, and Pérez-Escamilla R.<br />
Socioeconomic and lifestyle determinants of increased body weight<br />
in a subgroup of Latinos with diabetes enrolled in the DIALBEST<br />
peer counseling trial: Preliminary findings. Obesity. <strong>2008</strong>: Abstract<br />
Presentation/Publication Number: 3<strong>09</strong>-P.<br />
Vergara C, Richards K, Faucher J. Using preoperative<br />
electrocardiograms as a predictive marker for perioperative adverse<br />
outcomes in Hispanic patients undergoing elective non-cardiac<br />
Surgery. New England SGIM Meeting, March 13, 20<strong>09</strong>. Boston, MA.<br />
Vergara C. Creating an ambulatory preventive care database. 4th<br />
<strong>Annual</strong> CEDHL Conference: Social Determinants of Health.<br />
University of Connecticut, Storrs. Rome Ballroom. May 19, 20<strong>09</strong>.<br />
Zar T, Aglieco F, Ranga KV. Quiz page April <strong>2008</strong>: deafness,<br />
preauricular pits, and renal failure. BOR syndrome or Melnick-Fraser<br />
syndrome. American Journal of Kidney Diseases.<br />
51(4):A44-6, <strong>2008</strong> Apr.<br />
Sathyan S, Khan F, Ranga K. A case of recurrent immunotactoid<br />
glomerulopathy in an allograft treated with Rituximab.<br />
Transplantation Proceedings, 20<strong>09</strong>, 41 (9): 3953-3955.<br />
Sathyan S, Khawaja Z, de Palma J, Brown M, Lally A, Hull D, Ranga<br />
K. Co-Existing peritubular capillary basement membrane lamination<br />
and podocyte effacement on EM in kidney transplant on CNI-free<br />
regimen. American Journal of Kidney Diseases, <strong>2008</strong>, 51(4): B86.<br />
Sathyan S, Nataraj S, Dada M, Ranga K. Clinical improvement in<br />
nephrogenic systemic fibrosis following renal transplantation: Should<br />
‘NSF Points’ be considered in allocation? American Journal of Kidney<br />
Diseases, <strong>2008</strong>, 51 (4): B86.<br />
Tausif Z, Fabio A, Ranga KV. Deafness, preauricular pits, and renal<br />
failure. American Journal of Kidney Diseases, <strong>2008</strong> (51): xliv-xlvi.<br />
Vega-López S, Calle M, Fernandez M, Chhabra J, D’Agostino D,<br />
Samuel G, Segura- Pérez S, Damio G, and Pérez-Escamilla R. Threemonth<br />
effect of diabetes peer counseling on plasma lipids of Latinos<br />
enrolled in the DIALBEST trial: Preliminary findings. FASEB J. <strong>2008</strong><br />
22:44.8.<br />
Vega-López S, Chhabra J, D’Agostino D, Calle M, Samuel G, Segura-<br />
Pérez S, Fernandez M, Damio G, Pérez-Escamilla R. Associations<br />
46.
Neurology<br />
The Departments of Neurology at <strong>Hartford</strong> <strong>Hospital</strong> and the<br />
University of Connecticut continue to receive NIH grants,<br />
foundation grants, drug studies and internal grant support<br />
exceeding one-million dollars. Active participation of faculty<br />
in the department strengthens its educational and clinical<br />
activities.<br />
Dr. Leslie Wolfson:<br />
Dr. Wolfson is the Principal Investigator (PI) on “Brain<br />
Changes and Risk Factors Causing Impaired Mobility”<br />
(RO1AG022<strong>09</strong>2), an NIA funded 4-year longitudinal study<br />
to define vascular disease risk factors leading to ischemic<br />
white matter lesions that compromise mobility, cognitive<br />
and urinary function. In conjunction with collaborator<br />
Dr. Godfrey Pearlson (Director of the Olin Center at the<br />
Institute of Living), the study includes magnetic resonance<br />
imaging performed at the Olin Center. Baseline results have<br />
demonstrated that damage to specific white matter structures is<br />
associated with slowed thinking, impaired mobility and urinary<br />
function and that that there is a stereotyped distribution/<br />
evolution to the development of white matter lesions making<br />
the total lesion volume an index of the severity of these<br />
impairments. The total white matter lesion volume accounts<br />
for ~10% of the variability of each of the three functions and<br />
is relatively easy to measure making it a valuable measure for<br />
geriatricians. We have begun to collect two year follow-up<br />
data and have already determined that ambulatory blood<br />
pressure predicts change in white matter lesion volume as<br />
well as changes in mobility. Thus blood pressure control may<br />
mitigate deterioration. A renewal application is planned for<br />
March 2010, the focus of which will be to determine whether<br />
blood pressure control leads to decreased white matter lesion<br />
accrual and better functional outcomes.<br />
Dr. Louise McCullough:<br />
Dr. McCullough is the Research Director of the Stroke Center.<br />
She was awarded two NIH RO1 grants studying ischemic<br />
mechanisms of cell death at UCHC.<br />
Stroke Center<br />
Over the past year we have continued to utilize the Stroke<br />
Center database at <strong>Hartford</strong> <strong>Hospital</strong> for research endeavors,<br />
both to better understand our own patient population and as<br />
a resource to support students and residents as they pursue<br />
research projects. Results from these projects are currently in<br />
press in the Journal of Stroke and Cerebrovascular Diseases<br />
(under the authorship of Dr. Blondin), and in the Journal of<br />
Women’s Health (under the authorship of Dr. Knauft). Two<br />
papers are in preparation under the authorship of Dr. Neer<br />
Zeevi. Three abstracts have also been prepared over the past<br />
year, two were presented at the American Geriatric Society<br />
and one is scheduled for presentation at the International<br />
Stroke Meeting (February 2010). We continue to encourage<br />
residents and fellows to utilize this database to obtain<br />
retrospective data for future studies.<br />
The Stroke Center has continued its strong involvement<br />
in acute and secondary stroke prevention trials. Dr. Isaac<br />
Silverman is the PI on the IMS-3 trial, an NINDS-sponsored<br />
Phase-3 randomized clinical trial (RCT) investigating IV t-PA<br />
+ endovascular approaches (e.g., MERCI, Penumbra, EKOS<br />
ultrasound, or IA t-PA) versus IV t-PA alone in the treatment<br />
of acute ischemic stroke. This trial includes patients with<br />
NIHSS >10 points who are randomized within the first 40<br />
minutes after starting IV t-PA infusion. Three patients have<br />
been enrolled to date.<br />
Dr. Joao Gomes will be the PI on the planned ICTUS trial.<br />
This NINDS-sponsored Phase-3 RCT will investigate the<br />
use of an endovascular cooling device (
a safety (Phase-1) evaluation for patients with ICH (
Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered<br />
During the Mild Pain Phase for the Acute Treatment of Multiple<br />
Migra. Glaxo Smith Kline, $41,594.<br />
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,<br />
Single Dose, Efficacy & Safety Outpatient Study of Staccato<br />
Prochlorperazine for Inhalation in Patients with Migraine Headaches.<br />
Alexza Pharmaceuticals, Inc., $41,400.<br />
A Study of Combination Product (Sumitriptan Succinate and<br />
Naproxen Sodium) in Migraine Subjects Who <strong>Report</strong> Poor Response<br />
or Intolerance to Eletriptan (Study 1 of 2). Glaxo Smith Kline<br />
Pharmaceuticals, $40,000.<br />
Gomes, João, MD<br />
NeuroThera Effectiveness and Safety Trial - 2 (NEST-2): A Double<br />
Blind, Randomized, Controlled, Parallel Group, Multicenter, Pivotal<br />
Study to Assess the Safety and Effectiveness of the Treatment of<br />
Acute Ischemic Stroke with the NeuroThera Laser System within 24<br />
hours from stroke onset. Parexel International, $16,130.<br />
PRoFESS: Prevention Regimen For Effectively Avoiding Second<br />
Strokes: A double-blind, active and placebo controlled study of<br />
Aggrenox vs. Clopidogrel, with and without Micardis. Boehringer-<br />
Ingelheim, $149,994.<br />
Siblings With Ischemic Stroke (SWISS). NIH / NINDS, $34,320.<br />
Spiegel, Gary, MD<br />
Evaluation of the Penumbra Stroke System in the Revascularization<br />
of Patients with Acute Ischemic Stroke Secondary to Intracranial<br />
Large Vessel Occlusive Disease. Penumbra, Inc., $22,500.<br />
Staff, Ilene, PhD<br />
Evaluation of Outcomes of Patients with Stroke Across the<br />
Continuum. Departmental, $24,600.<br />
Wolfson, Leslie, MD<br />
Brain Changes and Risk Factors Causing Impaired Mobility. Federal/<br />
University of Connecticut, $185,805.<br />
Phase I Study of Intravenous Thrombolysis plus Hypothermia<br />
for Acute Treatment of Ischemic Stroke. NINDS/University of<br />
California, $25,000.<br />
Hassan, Mohamed, MD<br />
A Multi-center, Open label Extension Study to Evaluate the Longterm<br />
Safety, Tolerability and Efficacy of E2007 as an Adjunctive<br />
Therapy in Levodopa Treated Parkinson’s Disease Patients with<br />
Motor Fluctuations. Eisai Medical Research Inc., $16,781.<br />
A Multi-Center, Randomized, Double-Blind Placebo-Controlled,<br />
Parallel Group Study of the Efficacy, Safety, & Tolerability of E2007<br />
in Levodopa Treated Parkinson’s Disease Patients with Motor<br />
Fluctuations. Quintiles, Inc., $84,435.<br />
Lee, Nora, MD<br />
Variability in stroke outcomes across the population.<br />
Silverman, Isaac, MD<br />
Insulin Resistance Intervention After Stroke (IRIS) Trial. NIH/Yale<br />
University Medical Center, $328,591.<br />
Publications<br />
Kaplan RF, Cohen RA, Moscufo N, Guttmann C, Chasman J, Buttaro<br />
M, Hall CH, Wolfson L. Demographic and biological influences on<br />
cognitive reserve. J Clin Exp Neuropsychol, 31:1-9, 20<strong>09</strong>.<br />
Kuchel GA, Moscufo N, Guttmann C, Zeevi N, Wakefield D,<br />
Schmidt J, DuBeau CE, Wolfson L. Localization of brain white<br />
hyperintensities and urinary incontinence in community dwelling<br />
older persons. J Gerontol Med Sci, 64A:902-9<strong>09</strong>, 20<strong>09</strong>.<br />
Moscufo N, Guttmann CRG, Meier D, Csapo I, Hildenbrand PG,<br />
Schmidt JA, Wolfson L. Brain regional lesion burden and impaired<br />
mobility in the elderly. Neurobiol Aging, May 8, 20<strong>09</strong>.<br />
White WB, Salzman P, Schwid SR for the Parkinson’s Rasagiline:<br />
Efficacy and Safety in the Treatment of “Off” Parkinson Study<br />
Group, Mohamed N. Hassan, Principal Site Investigator, UCHC.<br />
Hypertension, <strong>2008</strong>; 52:1-7.<br />
Multicenter, Randomized Controlled Trial to Evaluate the Safety and<br />
Efficacy of the STARFlex Septal Closure System Versus Best Medical<br />
Therapy in Patients with Stroke and/or Transient Ischemic Attack<br />
Due to Presumed Paradoxical Embolism Through a Patent Foramen<br />
Ovale (CLOSURE I Trial). NMT Medical, Inc., $120,000.
Nurses<br />
Participating in Research<br />
On Thursday, October 8, 20<strong>09</strong>, The Connecticut Nursing<br />
Research Alliance and the Institute for Healthcare Education<br />
held its 13th <strong>Annual</strong> Conference, “Raising the Voice of<br />
Nursing in Quality and Patient Safety” at <strong>Hartford</strong> <strong>Hospital</strong>.<br />
Over 300 nurses, faculty and nursing students attended from<br />
across Connecticut and neighboring states.<br />
Barbara Mackoff EdD, Visiting Professor at the Adelphi<br />
University School of Nursing, presented the keynote address<br />
titled “Nurse Manager Engagement: the Power of Positive<br />
Deviance.” Dr. Mackoff’s qualitative research, funded by the<br />
Robert Wood Johnson Foundation, identifies characteristics<br />
of successful, engaged nurse managers and reveals the cultural<br />
elements needed to grow ‘engaged’ nurse managers. Her<br />
forthcoming book on her research is due in early 2010. Dr.<br />
Mackoff is a consulting psychologist, a leadership educator<br />
and a core faculty member of The Nurse Management<br />
Fellowship Program of The American Association of Nurse<br />
Executives. The plenary address, “Quality and Safety<br />
Education for Nursing: Update on the National Initiative” was<br />
presented by Dori Taylor Sullivan PhD, RN, NE-BC, CNL,<br />
CPHQ. Dr. Sullivan is the Associate Dean for Academic<br />
Affairs at the Duke University School of Nursing.<br />
In addition to the keynote and plenary speakers, conference<br />
participants were given the opportunity to choose from a<br />
variety of oral abstract presentations and four skill-building<br />
sessions. These sessions included “The Process of Evidence<br />
Based Practice: From Formulating the Question to Writing the<br />
Abstract” by Barbara Aronson APRN, PhD, CNE, Associate<br />
Professor, Southern Connecticut State University; “Searching<br />
the Research Literature: Pub Med” by Lisa Carter MSLIS,<br />
Clinical Librarian for Nursing, <strong>Hartford</strong> <strong>Hospital</strong>; “From<br />
Pondering to Publication: Nurse-Author Panel” moderated<br />
by Karen Robbins MS, RN, CNN Nurse Educator, Dialysis,<br />
<strong>Hartford</strong> <strong>Hospital</strong>; and “Choosing a Research Design: Finding<br />
the Right Approach to Answer Your Research Questions”<br />
by Cynthia Adams, EdD, Director of Nursing, Capitol<br />
Community College.<br />
Several prizes were awarded in order to recognize excellence<br />
in nursing research and evidence based practice. The<br />
Excellence in Nursing Research Award was presented to<br />
Bonnie Edelen PhD, RN from Capitol Community College<br />
for her study “Measuring and Enhancing Clinical Decision-<br />
Making Ability Among Students in an Associate Degree<br />
Nursing Program.” Dr. Edelen’s study offers strategies<br />
that nurse educators can use to maximize and promote<br />
optimal student learning across a variety of clinical practice<br />
environments. The Excellence in Evidence-Based Practice<br />
Award went to Susan Thibeault MS, APRN, CRNA, EMTP<br />
of LIFESTAR at <strong>Hartford</strong> <strong>Hospital</strong> for her work in improving<br />
patient outcomes by enhancing infection control practices.<br />
Additionally Poster Awards were given to three recipients<br />
whose posters were judged by conference attendees to be of<br />
highest quality. First place went to Lynn Deasy RN, MPH,<br />
Danette Alexander RN, MSN, NEA-BC, Carolyn Bauer RNC,<br />
Kristen McClure RN, Susan Smith RN, Kim Murphy RN,<br />
and Laura Collins RN of <strong>Hartford</strong> <strong>Hospital</strong> for their poster<br />
“Partnering with Patients and their Families.” Second place<br />
went to Deborah Gingras MS, RN, CNS and Michelle Connor<br />
ASN, BA, RN of <strong>Hartford</strong> <strong>Hospital</strong> for “Use of Aromatherapy<br />
with Patients Undergoing Induction of Labor.” Third<br />
place went to Jacquelyn Calamari MSN, MS, RN, CEN of<br />
Middlesex <strong>Hospital</strong> for “Medication Errors in the Context of<br />
an Acute Care Setting.”<br />
Several attendees received raffle prizes including research<br />
books generously donated by Jeane Kalanta of Elsevier<br />
Medical Publishing. The food service, provided by Wayne<br />
Oden and his staff from <strong>Hartford</strong> <strong>Hospital</strong>’s Food & Nutrition<br />
Services, was superb. Special thanks are extended to the<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Department for an Education<br />
Grant that supported this conference.<br />
CT Nursing Research Alliance<br />
Conference Planning Team<br />
<strong>Hartford</strong> <strong>Hospital</strong>: Nancy Bafundo RN, MS, BC, Dawn<br />
Beland RN, MSN, Cynthia Belonick APRN, BC, Lisa Carter<br />
MSLIS, Cathy Chance RN, BS, Karen Cudworth RN, MSN,<br />
Deborah Gingras, MS, RN, CNS, Ginger Goddu RN, MSN,<br />
Andrea Hagstrom RN, MSN, CNOR, Eileen Hermann RN,MHS,<br />
Beverly Mendes APRN, PhD, Amy Schröder RNC, MSN, Linda<br />
Spivack RN, MSN<br />
50.
Linda Berger-Spivack, RN, MSN,<br />
VP Patient Care Services, <strong>Hartford</strong><br />
<strong>Hospital</strong> (at left) and Amy Schröder<br />
RNC, MSN, Chair CT Nursing<br />
Research Alliance welcome<br />
conference attendees.<br />
Dr. Barbara Mackoff delivers<br />
keynote address on Nurse Manager<br />
Engagement.<br />
Bristol <strong>Hospital</strong>: Shannon Grad RN, MSN<br />
and Fran Leach RN, MSN<br />
Capitol Community College: Cynthia Adams RN, EdD<br />
Central Connecticut State University: Meg Levvis MSN, PhD<br />
Eastern Connecticut Health Network: Linda Quirici RN,<br />
MSN, CCRN, APRN, BC<br />
Midstate Medical Center: Joanne Roy RN, PhD and<br />
Kathy Barta RN, MS, MSN, CCRN<br />
Quinnipiac University: Mary Ann Cordeau PhD, RN<br />
Saint Joseph College: Joyce Fontana RN, PhD<br />
Southern Connecticut State University: Barbara Aronson<br />
RN, PhD, CNE<br />
University of Connecticut: Jennifer Telford PhD, APRN<br />
University of <strong>Hartford</strong>: Anne Marie Buonocore PhD, RNC<br />
Windham <strong>Hospital</strong>: Anne Schmidt RN, MSN, APRN-BC<br />
New Projects<br />
The following list of projects highlights the role that nurses<br />
play in research at <strong>Hartford</strong> <strong>Hospital</strong>. Many of these projects<br />
are also listed in this report under other departments.<br />
Dr. Dori Taylor Sullivan shares an<br />
update from the Quality and Safety<br />
Education for Nursing National<br />
Initiative<br />
State<br />
Servodidio, Camille, RN, MPH, Oncology<br />
Will Housing a Research Nurse on site in a Private Practice Increase<br />
Recruitment and Enrollment into Cancer Clinical Trials? CCOT<br />
through Yale University, $25,000.<br />
Departmental<br />
Gail Nelson MS, RN, NEA-BC,<br />
Director of Professional Development<br />
and Performance Improvement,<br />
<strong>Hartford</strong> <strong>Hospital</strong> (at left) presents<br />
the Excellence in Evidence-Based<br />
Practice Award to Susan Thibeault<br />
MS, APRN, CRNA, EMTP of<br />
LIFESTAR, <strong>Hartford</strong> <strong>Hospital</strong><br />
Reagan, Louise APRN, Medicine<br />
The Effect of a Peer Delivered Motivational Message on Intention<br />
to Exercise for Hispanic Persons with Type 2 Diabetes (T2DM): An<br />
Experimental Pilot Study. Departmental, $454.<br />
Unfunded<br />
Chemmarappally, Shiny, RN, Cardiology<br />
Infusion Center Treatment Effect on Quality of Life in Congestive<br />
Heart Failure Patients.<br />
Gingras, Deborah, RN, Women’s Health<br />
Use of Aromatherapy with Patients Undergoing Induction of Labor.<br />
Nancy Bafundo RN, MS, BC,<br />
Nurse Educator, <strong>Hartford</strong> <strong>Hospital</strong><br />
(at left) presents the Excellence<br />
in Nursing Research Award to Dr.<br />
Bonnie Edelen of Capitol Community<br />
College.<br />
Kessler, Jeanne, RN, Medicine<br />
Risk Assessment for Skin Breakdown in a Geriatric Psychiatric In-<br />
Patient Population - A Pilot Study.
Ratcliffe, Tammy, RN, BSN, Nursing<br />
Central Line Infection Prevention (or Reduction) Implementation<br />
of and Evidence-Based Central Line Dressing Change Policy and<br />
Education in the ICU setting: A pilot Study.<br />
Roy, Joanne, RN, PhD, Nursing<br />
<strong>Hospital</strong> Nurses’ Lived Experience of Power.<br />
Reagan, Louise, APRN, Medicine<br />
A Narrative Analysis Pilot Study: Hispanic Patients’ Perspective of<br />
Managing their Chronic Illness.<br />
Shanaman, Jennifer, MS, Nursing<br />
Comparison of Team Behavior Assessment Between Different<br />
Surgical Specialty Staff Groups in a Large Teaching <strong>Hospital</strong>’s<br />
Operating Room Department.<br />
Thibeault, Susan, APRN, Emergency Medicine<br />
Reasons for Cancellation of LIFE STAR Transport by Requester.<br />
Mendes, Beverly, APRN, Cardiology<br />
Phenomena of Inner Strength in Women Recovering Post Myocardial<br />
Infarction Coronary Stent: A Grounded Theory.<br />
Zafian, Ruth, APRN, Cardiology<br />
An Exploratory, Descriptive Pilot Study to Examine the Quality of<br />
Hand-offs <strong>Report</strong>s at <strong>Hartford</strong> <strong>Hospital</strong> Using the ISBAR Technique.<br />
Active Projects<br />
Blair, Ellen, APRN, Psychiatry<br />
Inpatient Psychiatric Unit Medications and Falls Outcomes.<br />
Brown, Susanne, RN, MSN<br />
Women’s HealthDoes Simulation Training Improve Nursing and<br />
Resident’s Clinical Performance?<br />
Duclos-Miller, Patricia, MSN, Nursing<br />
Transition from Student to Graduate Nurse.<br />
Frakes, Michael, APRN, Emergency Medicine<br />
Effectiveness of a Read-and-Respond Checklist in Assuring Safety<br />
Behavior Compliance at a Rotor Wing Air Medical Program.<br />
• A Comparison of Pre-hospital Trauma Analgesia By Air and<br />
Ground EMS Providers. • Evaluation of Helicopter Air Medical<br />
Transport Utilization by Prospective Application of Consensus<br />
Criteria. • Effect of Line Oriented Flight Training On Team<br />
Behaviors and Beliefs at a Helicopter Air Medical Program.<br />
• Evaluation of a Modified Sign-Out Procedure on <strong>Hospital</strong><br />
Documentation of Medications Administered by Critical Care<br />
Transport Teams.<br />
Gonci, Mary-Ellen, APRN, Women’s Health<br />
Oral Health and its Implications During Pregnancy.<br />
Lloyd, Jennifer, RN, Nursing<br />
Nurses’ Experience in Caring for Patients with Substance Abuse.<br />
McDaniel, Aimee, RN, Nursing<br />
Evaluation of Dialysis/Transplant Nurses Knowledge and Selfefficacy<br />
Regarding Advance Directives.<br />
Murphy, Mary, RN, Nursing<br />
Pilot-Testing of a Tool Titled: Confidence Assessment in the<br />
Management of Simulated Patient “Cardiac Arrest” Situations.<br />
Nelson, Gail, RN, MSN, Nursing<br />
National Database of Nursing Quality Indicators.<br />
Robbins, Karen, RN, MSN, Medicine<br />
Reiki: What are its Effects for Patients During Hemodialysis?<br />
<strong>Hartford</strong> <strong>Hospital</strong> Small Grant, $9,963.<br />
Roy, Joanne, RN, PhD, Nursing<br />
Evidence Based Practice Fellowship Program: Prospective and<br />
Systematic Evaluation of an Organizational-level Evidence Based<br />
Practice Initiative.<br />
Satherlie-Deasy, Lynn, RN, Women’s Health<br />
Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy<br />
Outcomes Among Low-Income Latinas.<br />
Waszynski, Christine, APRN, Nursing<br />
Assessment of the Prevalence of Delirium in Three Unique<br />
Populations of <strong>Hospital</strong>ized Persons. Pauline A. Toner Fund<br />
UCONN School of Nursing, $1,500.<br />
Perspectives of Clinicians and Social Service Personnel on the Needs<br />
of Older Adults With HIV/AIDS. University of Connecticut, $750.<br />
Nursing Assessment, Management and Treatment of Delirium in<br />
<strong>Hospital</strong>ized Older Adults: Identifying Related Outcomes.<br />
Nursing Geriatric Resource Nurse Program Evaluation.<br />
Yavinsky, Cathy, RN, MSN, Nursing<br />
The Effect of a Specialized RN Intervention Designed to Maximize<br />
Patient-Provider Relationships on Adherence to Anti-depressant<br />
Medication. Donaghue Medical Research Foundation, $48,350.<br />
Young, Sara, MSN, Women’s Health<br />
Breastfeeding Education and Support Trial for Obese Women: Early<br />
Dyad Dynamics (BESTOW:EDD). University of Connecticut,<br />
$16,796.<br />
Breastfeeding Education and Support Trial for Obese Women<br />
(BESTOW). Donaghue Medical Research Foundation through the<br />
University of Connecticut, $20,590.
Andrew L. Salner, MD<br />
Director, Helen & Harry Gray Cancer Center<br />
Donna Handley<br />
VP, Cancer Services<br />
Oncology<br />
Cancer Clinical Research Office<br />
Camille Servodidio, RN, MPH, CRNO,<br />
OCN Coordinator<br />
Robert Siegel, MD, Medical Director, Cancer<br />
Clinical Research<br />
The Cancer Clinical Research Office (CCRO) is an active<br />
participant in a variety of national cooperative group research<br />
studies and several industry-supported trials. In 2007, <strong>Hartford</strong><br />
<strong>Hospital</strong> was selected as one of 16 community hospitals to<br />
participate in the NCI Community Cancer Centers Program<br />
Pilot (NCCCP). One of the charges of the NCCCP is to<br />
expand clinical trials and reduce disparities. The NCCCP pilot<br />
created a network of community hospitals that shared best<br />
practices and pooled strategies to recruit patients and endorse<br />
particular trials. Abstracts highlighting accomplishments were<br />
presented at both national meetings of the American Society<br />
of Clinical Oncologists and the Oncology Nurses Society.<br />
Through <strong>Hartford</strong> <strong>Hospital</strong>’s continuing affiliation with<br />
Dana Farber Partners/Cancer Care, the CCRO has had the<br />
opportunity to open several additional cancer clinical trials.<br />
The CCRO participates in multiple National Cancer Institute<br />
(NCI) trials sponsored by the Cancer and Leukemia Group B<br />
(CALGB), the Gynecologic Oncology Group (GOG), and the<br />
National Surgical Adjuvant Breast and Bowel Project (NSABP)<br />
as well as several pharmaceutical/industry trials. The NSABP<br />
has recently opened several new breast cancer treatment<br />
trials, active at <strong>Hartford</strong> <strong>Hospital</strong> under the leadership of Dr.<br />
Patricia DeFusco, principal investigator and the coordination<br />
of Susan Zahorodni, RN. NSABP B-40 involves chemotherapy<br />
before surgery for women with palpable breast masses with<br />
half of the women receiving bevacizumab, a drug which<br />
blocks a tumor’s blood supply, after surgery. NSABP B-42<br />
involves post-menopausal ER+/PR+ women diagnosed with<br />
invasive breast cancer to determine if five years of additional<br />
Letrozole will improve survival. The PACCT-1 trial will assign<br />
treatment regimens based on pathology specimens of women<br />
with ER+/PR+ node negative breast cancer.<br />
The CCRO has continued to recruit gynecologic oncology<br />
patients into GOG trials under the leadership of principal<br />
investigators Dr. Stacy Nerenstone and Dr. Amy Brown.<br />
Karen Cuddy, RN has joined the team this year as the GOG<br />
trial coordinator. GOG continues to sponsor cutting edge<br />
chemotherapy trials for gynecologic cancers. GOG # 212<br />
provides women who have recently received chemotherapy<br />
for ovarian cancer an opportunity for additional chemotherapy<br />
(standard of care Taxol vs. Xyotax, a drug which can be<br />
delivered over a shorter period of time) and compares them<br />
to women who receive standard of care physician observation<br />
prior to tumor recurrence. GOG # 213 is a treatment trial for<br />
women diagnosed with platinum-sensitive, recurrent ovarian,<br />
peritoneal primary or fallopian tube cancer. Women who are<br />
surgical candidates are randomized to cytodreductive surgery<br />
or none. If they are not surgical candidates they may be<br />
randomized to chemotherapy treatments of carboplatin and<br />
paclitaxel alone or in combination with bevacizumab.
<strong>Hartford</strong> <strong>Hospital</strong> participates in several Dana Farber and<br />
CALGB trials under the leadership of Dr. Robert Siegel,<br />
principal investigator and the coordination of Kathleen<br />
VanGelder, RN. CALGB 40101 compares Cytoxan and<br />
Adriamcyin chemotherapy versus Taxol in women with node<br />
negative breast cancer and CALGB 70301 is a companion<br />
study focusing on quality of life and employment. CALGB<br />
50501 is a phase II trial of bortezomib vs. lenalidomide for<br />
relapsed /refractory mantle cell lymphoma. Dana Farber 06-<br />
116 involves patients diagnosed with metastatic transitional<br />
cell carcinoma in which patients receive docetaxel with or<br />
without Zactima, a drug that inhibits blood vessel growth<br />
in cancers. The ASSURE trial compares sorafenib versus<br />
Sunitinib vesus a placebo for unfavorable renal carcinoma.<br />
The CCRO is involved in several pharmaceutical /industry<br />
trials under the leadership of Dr. Todd Alekshun, principal<br />
investigator and the coordination of Karen Burnham, RN,<br />
BSN, OCN. SNDX- 275-0301 is a Phase II randomized double<br />
blind study of exemestane with and without SNDX-275, a pill,<br />
in post-menopausal women diagnosed with local recurrent<br />
or metastatic ER+ breast cancer progressing on treatment<br />
with a non-steroidal aromatase inhibitor. The Sanofi-Aventis<br />
ECF6546 (VENICE) is a phase II randomized double<br />
blind trial comparing Aflibercept to placebo for metastatic<br />
androgen-independent prostate cancer.<br />
Finally, the best “treatment” for cancer is to either prevent it<br />
or detect it early. Since 1995, the CCRO has been involved<br />
in the Connecticut Breast & Cervical Cancer Early Detection<br />
Program (CBCCEDP), a state sponsored outreach program<br />
that provides clinical breast examinations, mammograms and<br />
cervical cancer screening to the underserved and underinsured<br />
women of the greater <strong>Hartford</strong> area. A total of 82 cancers<br />
have been detected since the inception of the program.<br />
These outreach efforts are funded by the Centers for Disease<br />
Control and Prevention (CDC) and organized by the State<br />
of Connecticut Department of Public Health. Dr. Merwood<br />
Jones serves as medical director, Nora Brugueras is the<br />
case manager, and Damaris Perez is the outreach educator.<br />
The CCRO continues in its ninth year of the CDC funded<br />
WISEWOMAN grant, which offers glucose and cholesterol<br />
screening, nutrition counseling, cooking and exercise<br />
demonstrations for women over 40 years old. The CBCCEDP<br />
has partnered with the American Heart Association to<br />
offer CBCCEDP participants under age 39 the opportunity<br />
to receive free cholesterol screenings and cardiovascular<br />
educational materials. The AVON Foundation Breast Care<br />
Fund grant supports community outreach and breast cancer<br />
education for underserved and underinsured women.<br />
These are intriguing times in cancer research and treatment.<br />
The CCRO remains committed to our patients and families<br />
through education, screening, and participation in clinical<br />
trials.<br />
CHESS Program<br />
Sherri Storms, BSN, RN-BC, Cancer Program<br />
Project Coordinator<br />
CHESS (Comprehensive Health Enhancement Support<br />
System) is an internet-based information and support system<br />
for patients with breast and prostate cancer who often have<br />
difficulty finding good information, who may be hesitant or<br />
unable to attend support groups, and who often feel pressured<br />
to make difficult decisions with little information. The CHESS<br />
program helps patients and their families become more<br />
actively involved in their treatment and recovery, making<br />
high quality information and social support easily accessible<br />
and helping patients make choices and decisions based on<br />
their individual needs. In partnership with the University<br />
of Wisconsin, <strong>Hartford</strong> <strong>Hospital</strong> has offered CHESS to its<br />
patients for more than 12 years, reaching over 1400 women<br />
with breast cancer and 400 men with prostate cancer. Thanks<br />
to our generous donors, we own 40 laptop computers available<br />
for loan to patients, who also receive training on how to<br />
use them. In addition to serving <strong>Hartford</strong> <strong>Hospital</strong> patients,<br />
we collaborate with Windham <strong>Hospital</strong> to offer CHESS to<br />
patients in the Eastern part of the state.<br />
This year we completed enrollment of 95 men into an<br />
innovative NCI-sponsored study, “Human and Computer<br />
Mentors for Prostate Cancer Patients” which aims to test<br />
the effectiveness of a Human Cancer Mentor vs. CHESS vs.<br />
a combination of CHESS and the Human Cancer Mentor<br />
on improving quality of life for men with prostate cancer.<br />
While the primary outcome measure is patient quality of<br />
life, secondary outcomes include patient preparedness for<br />
interactions with clinicians and mentors, self-efficacy, health<br />
care use, decision satisfaction, and considerations of treatment<br />
alternatives. This study will help us learn how a human cancer<br />
mentor might affect a prostate cancer patient’s quality of life<br />
and we expect that it will provide valuable information about<br />
ways that the Internet and other communication tools may be<br />
54.
used to improve the quality of life for all cancer patients.<br />
We are also collaborating with the University of Connecticut-<br />
Storrs Departments of Psychology and Family Studies on<br />
two Quality of Life studies, “Adjustment to Breast Cancer”<br />
and “Lifestyle Change Intervention for Recently Diagnosed<br />
Breast Cancer Survivors: Pilot Study”. The first study focuses<br />
on newly diagnosed breast cancer patients. Currently 55<br />
patients have been recruited into the study, the goals of which<br />
are: (1) to examine differences in treatment decision-making<br />
between African-American, Hispanic and Caucasian women<br />
with breast cancer at two time points post-surgery; (2) to<br />
examine whether specific socio-cultural and psychosocial<br />
factors are associated with treatment decision-making among<br />
African-American and Hispanic women with breast cancer; and<br />
(3) to examine whether certain coping strategies commonly<br />
employed by African-American and Hispanic women with<br />
breast cancer are associated with treatment decision-making.<br />
This study will provide valuable information how socio-cultural<br />
and psychosocial factors impact treatment decision-making<br />
and health disparities among minority breast cancer patients<br />
and will inform the development of interventions in this area.<br />
Our participation underscores our ongoing commitment to<br />
providing the very best in care to all of our cancer patients.<br />
“Lifestyle Change Intervention for Recently Diagnosed Breast<br />
Cancer Survivors” is a pilot study of health behavior change<br />
among breast cancer survivors completing their primary<br />
treatment. The study evaluates the effectiveness of mail-based<br />
lifestyle interventions in helping breast cancer survivors make<br />
and maintain important changes in diet and exercise, factors<br />
that are important for survivorship among breast cancer<br />
patients completing their primary treatment. Thus far we have<br />
recruited 22 patients from <strong>Hartford</strong> <strong>Hospital</strong> into the pilot<br />
study and we expect that the results will provide a springboard<br />
for <strong>Hartford</strong> <strong>Hospital</strong> and the University of Connecticut to<br />
collaborate on a larger Lifestyle Change Intervention Study.<br />
The Cancer Registry<br />
at <strong>Hartford</strong> <strong>Hospital</strong><br />
Debra Jacques, MSM, CTR, Manager,<br />
Cancer Registry<br />
The Cancer Registry at <strong>Hartford</strong> <strong>Hospital</strong> was established in<br />
1928 and contains over 85,000 cancer cases. It submits over<br />
2,500 new cancer cases to the Connecticut Tumor Registry<br />
each year, accounting for approximately 15% of all cancers<br />
reported statewide. All Connecticut hospitals and labs are<br />
required by Connecticut State statute to report all diagnoses<br />
of cancer to the Connecticut State Tumor Registry at the<br />
Department of Health, the oldest and most widely used<br />
central registry in the nation. The information housed in<br />
<strong>Hartford</strong> <strong>Hospital</strong>’s Cancer Registry provides valuable data on<br />
patient demographics and cancer incidence, information that<br />
has been used to support presentations, research, certificates<br />
of need and grant applications in addition to identifying areas<br />
for improvement in patient care.<br />
New Projects<br />
Federal<br />
Baker, William-Jeffrey, MD<br />
CALGB 50303: A Phase III Study of R-CHOP V. Dose-Adjusted<br />
EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse<br />
Large B-Cell Lymphomas. Cancer And Leukemia Group B, $53,400.<br />
CALGB 50501: A Phase II Trial of Bortezomib + Lenalidomide for<br />
Relapsed/Refractory Mantle Cell Lymphoma. Cancer And Leukemia<br />
Group B, $10,000.<br />
Brown, Amy, MD<br />
A Phase II Evaluation of AMG 706 in the Treatment of Persistent or<br />
Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal<br />
Carcinoma. GOG, $8,361.<br />
GOG 205: A Phase II Trial of Radiation Therapy and Weekly<br />
Cisplatin Chemotherapy for the Treatment of Locally-Advanced<br />
Squamous Cell Carcinoma of the Vulva. GOG, $16,500.<br />
GOG 126R: A Phase II Evaluation of Abraxane® in the Treatment<br />
of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian<br />
Tube, or Primary Peritoneal Cancer. GOG, $3,300.<br />
GOG 136: Acquisition of Human Gynecologic Specimens and<br />
Serum to be Used in Studying the Causes, Diagnosis, Prevention<br />
and Treatment of Cancer. GOG/HOCCT, $33,000.<br />
GOG 213: A Phase III Randomized Controlled Clinical<br />
Trial of Carboplatin and Paclitaxel Alone or in Combination<br />
with Bevacizumab Followed by Bevacizumab and Secondary<br />
Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian,<br />
Peritoneal Primary and Fallopian Tube Cancer. GOG, $27,720.<br />
GOG 224: A Randomized Controlled Phase II Evaluation of<br />
(MEGACE) Megestrol in Different Dose and Sequence in the<br />
Treatment of Endometrial Intraepithelial Neoplasia (EIN) from a<br />
Referred Cohort of a Typical Endometrial Hyperplasia (AEH) or<br />
EIN. GOG, $9,350.
GOG 229F: A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC<br />
#724770, IND #BB100137, NCI Supplied Agent) in the Treatment of<br />
Recurrent or Persistent Endometrial Carcinoma. GOG, $5,280.<br />
GOG 239: A Phase II Trial of AZD6244 In Women with Recurrent<br />
Low-Grade Serous Carcinoma of the Ovary. GOG, $6,160.<br />
GOG 87M: A Phase II Evaluation of Trabectedin (Yondelis®,<br />
R279741, IND #75,111) In The Treatment of Advanced, Persistent,<br />
or Recurrent Uterine Leiomyosarcomas. GOG, $3,300.<br />
GOG 0232C: A Phase II Evaluation of Paclitaxel (Taxol®,NSL<br />
#673089) Carboplatin (Paraplatin®, NSL #241240) and BSI-201<br />
(NSC #7466045, IND #71,677) in the Treatment of Advanced,<br />
Persistent, or Recurrent Uterine Carcinomas. GOG/HOCCT,<br />
$2,860.<br />
GOG 0235: A Prospective, Longitudinal Study of YKL-40 in<br />
Patients with FIGO Stage III or IV Invasive Epithelial Ovarian,<br />
Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary<br />
Chemotherapy. GOG, $19,800.<br />
GOG-0238: A Randomized Trial of Pelvic Irradiation with or<br />
without Concurrent Weekly Cisplatin in Patients with Pelvic-Only<br />
Recurrence of Carcinoma of the Uterine Corpus. GOG, $11,000.<br />
DeFusco, Patricia, MD<br />
B-44-I: A Multicenter Phase III Randomized Trial of Adjuvant<br />
Therapy for Patients with HER2 Positive Node-Positive or High<br />
Risk Node-Negative Breast Cancer Comparing Chemotherapy<br />
Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus<br />
Bevacizumab. NSABP (Genetech), $160,600.<br />
Nerenstone, Stacy, MD<br />
A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the<br />
Treatment of Recurrent or Persistent Endometrial Carcinoma. GOG,<br />
$4,290.<br />
GOG 170M: A Phase II Evaluation of Dasatinib in the Treatment of<br />
Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary<br />
Peritoneal Cancer. GOG/HOCCT, $2,860.<br />
GOG-0249: A Phase III Trial Of Pelvic Radiation Therapy Versus<br />
Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin<br />
Chemotherapy In Patients With High Risk, Early Stage Endometrial<br />
Carcinoma. GOG, $25,300.<br />
Siegel, Robert, MD<br />
A Phase III Randomized, Double-Blind, Placebo Controlled Trial<br />
of North American Ginseng Extract (CVT-E002; COLD-fX®) to<br />
Prevent Respiratory Infection and Reduce Antibiotic Use in Patients<br />
with Chronic Lymphocytic Leukemia. CALGB, $1,818.<br />
CALGB 10404: A Randomized Phase II Study of Three Fludarabine<br />
/ Antibody Combinations for Patients with Symptomatic, Previously<br />
Untreated Chronic Lymphocytic Leukemia. CALGB, $10,000.<br />
CALGB 30607: A Randomized, Phase III, Double-Blind Placebo-<br />
Controlled Trial of Sunitinib (NSC #736511, IND #74019) as<br />
Maintenance Therapy in Non-Progressing Patients Following an<br />
Initial Four Cycles of Platinum-Based Combination Chemotherapy<br />
in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. CALGB,<br />
$8,000.<br />
CALGB 30704: A Randomized Phase II Study To Assess The<br />
Efficacy Of Pemetrexed Or Sunitinib (NSC #736511, IND #74019)<br />
Or Pemetrexed Plus Sunitinib In The Second-Line Treatment Of<br />
Advanced Non-Small Cell Lung Cancer. CALGB, $10,000.<br />
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin<br />
or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab<br />
(C225), or with the Combination of Bevacizumab and Cetuximab for<br />
Patients with Untreated Metastatic Adenocarcinoma of the Colon or<br />
Rectum. CALGB, $25,800.<br />
CALGB 9665: The Leukemia Tissue Bank (companion to CALGB<br />
10404). CALGB, $2,000.<br />
CALGB90203: Randomized Phase III Study Of Neo-Adjuvant<br />
Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy<br />
Versus Immediate Radical Prostatectomy in Patients with High-Risk,<br />
Clinically Localized Prostate Cancer. CALGB, $17,500.<br />
DF07-199: A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab<br />
for Node-Negative HER2-Positive Breast Cancer. Dana Farber Cancer<br />
Institute, $26,000.<br />
DF05-043: Randomized Controlled Study of Docetaxel plus 6-month<br />
Androgen Suppression and Radiation Therapy vs. 6-Month Androgen<br />
Suppression and Radiation Therapy for patients with High-Risk<br />
Localized or Locally Advanced Prostate Cancer. Dana-Farber,<br />
$27,000.<br />
DF06-116: A Randomized Phase II Study of Docetaxel +/- Zactima<br />
(ZD6474) in Metastatic Transitional Cell Carcinoma. Dana Farber,<br />
$25,000.<br />
DFCI07-214: A Phase II Study of Bevacizumab in Combination with<br />
Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast<br />
Cancer. Dana Farber, $16,800.<br />
E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin<br />
and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab<br />
in Patients with Stage II Colon Cancer at High Risk for Recurrence to<br />
Determine Prospectively the Prognostic Value of Molecular Markers.<br />
ECOG via CTSU, $12,510.<br />
56.
ECOG E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for<br />
Unfavorable Renal Carcinoma. ECOG via CTSU, $8,000.<br />
ECOG 1505: A Phase III Randomized Trial of Adjuvant<br />
Chemotherapy with or without Bevacizumab for Patients with<br />
Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer.<br />
ECOG via CTSU, $25,500.<br />
ECOG E1A06: An Intergroup Phase III Randomized Controlled<br />
Trial Comparing Melphalan, Prednisone and Thalidomide (MPT)<br />
Versus Melphalan, Prednisone and Lenalidomide (Revlimid)<br />
(MPR) in Newly Diagnosed Multiple Myeloma Patients Who<br />
Are Not Candidates for High-Dose Therapy. ECOG Via CTSU,<br />
$11,250.<br />
COG E2804: The BeST Trial: A Randomized Phase II Study of<br />
VEGF, RAF kinase, and mTOR Combination Targeted Therapy<br />
(CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced<br />
Renal Cell Carcinoma. ECOG via CTSU, $10,000.<br />
Sorosky, Joel, MD<br />
GOG-0237: Comparative Analysis of CA-IX, p16, Proliferative<br />
Markers and Human Papilloma Virus (HPV) in the Diagnosis of<br />
Significant Cervical Lesions in Patients with a Cytologic Diagnosis<br />
of Atypical Glandular Cell (AGC). GOG, $6,600.<br />
Foundation<br />
Salner, Andrew, MD<br />
Assessing Quality of Life in Young Adult Cancer Survivors. Lance<br />
Armstrong Foundation/UCONN Storrs, $30,000.<br />
Breast Cancer Survivorship: A Patient Navigator Program. Lance<br />
Armstrong Foundation, $47,756.<br />
Lifestyle Change Intervention for Recently Diagnosed Breast Cancer<br />
Survivors: Pilot Study. UCONN Research Foundation, $2,000.<br />
DeFusco, Patricia, MD<br />
NSABP Protocol B 41: A Randomized Phase III Trial of Neoadjuvant<br />
Therapy for Patients with Palpable and Operable HER2-Positive<br />
Breast Cancer Comparing the Combination of Trastuzumab Plus<br />
Lapatinib to Trastuzumab and to Lapatinib Administered with<br />
Weekly Paclitaxel Following AC Accompanied by Correlative<br />
Science Studies to Identify Predictors of Pathologic Complete<br />
Response. NSABP Foundation Inc., $32,813.<br />
Industry<br />
Siegel, Robert, MD<br />
ACORN/Onyx NU07B1: A Double Blind, Randomized Phase IIb<br />
Study Evaluating the Efficacy and Safety of Sorafenib Compared<br />
to Placebo when Administered in Combination with Paclitaxel<br />
in Patients with Locally Recurrent or Metastatic Breast Cancer.<br />
ACORN, $43,815.<br />
C1<strong>09</strong>53/2036/ON/US: A Randomized, Double Blind, Placebo<br />
Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy<br />
of Armodafinil Treatment (150 mg/day) for Patients with Fatigue<br />
Associated with Taxane Chemotherapy. CEPHALON, INC., $80,081.<br />
GTx, Inc. Protocol Number: G200502 Double-Blind, Placebo-<br />
Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle<br />
Wasting (cachexia) in Patients with Cancer. GTx Inc., $56,520.<br />
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry. Alexion<br />
Pharmaceuticals Inc., $19,625.<br />
Pfizer A6181<strong>09</strong>4: A Phase 3 Study of SU011248 in Combination<br />
with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-line<br />
Advanced Disease Setting in Patients Having Breast Cancer. North<br />
American Shared Services, $185,381.<br />
Pfizer A7471028: A Randomized Phase II Trial of PF-00299804 versus<br />
Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer<br />
After Failure of at Least One Prior Chemotherapy Regimen. Pfizer<br />
Inc./ North American Shared Services, $180,686.<br />
Industry (Investigator Initiated)<br />
Salner, Andrew, MD<br />
Total Cancer Care: A Partnership with High Risk and/or Diagnosed<br />
Cancer Patients For Life. H. Lee Moffitt Cancer Center & Research<br />
Institute, Inc., $2,942,143.<br />
Industry (Multicenter)<br />
Baker, William-Jeffrey, MD<br />
A Worldwide, Observational Registry collecting Longitudinal Data on<br />
the management of Chronic Myelogenous Leukemia (CML) patients<br />
(The WORLD CML Registry) in routine practice. Novartis, $38,375.<br />
Siegel, Robert, MD<br />
A Prospective, Non-Interventional Multicenter Registry in Iron<br />
Overloaded Lower-Risk Myelodysplastic Patients. Novartis, $69,000.<br />
EFC10203: A Multicenter, Open-Label, Randomized Study<br />
Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/<br />
m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with<br />
Advanced Pancreatic Cancer Previously Treated with a Gemcitabine<br />
Based-Regimen. Sanofi-aventis, $79,350.<br />
EFC6546, A Multicenter, Randomized, Double blind Study<br />
Comparing the efficacy and Safety of Aflibercept Versus Placebo<br />
administered Every 3 Weeks in Patients Treated with Docetaxel /<br />
Prednisone for Metastatic Androgen-Independent Prostate Cancer.<br />
Sanofi Aventis, $155,788.
Protocol PGT307: Paclitaxel poliglumex (CT-2103)/Carboplatin vs<br />
Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve<br />
Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with<br />
Estradiol >25 pg/mL. Cell Therapeutics, $72,983.<br />
State<br />
Salner, Andrew, MD<br />
Development of Culturally Appropriate Educational Approaches<br />
to Enhance Clinical Trial Participation Among Underserved<br />
Populations in the Greater <strong>Hartford</strong> Area. Connecticut Clinical<br />
Oncology Trials Network/Yale University, $25,000.<br />
Servodidio, Camille, RN, MPH<br />
Will Housing a Research Nurse on site in a Private Practice<br />
Increase Recruitment and Enrollment into Cancer Clinical Trials?<br />
Connecticut Clinical Oncology Trials Network/Yale University,<br />
$25,000.<br />
Departmental<br />
Salner, Andrew, MD<br />
Chart Review- Treatment of Base of Tongue Cancer. $200. Analytic<br />
support provided through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Evaluation of Community Based Prostate Cancer Screening Program.<br />
$23,910.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds<br />
Thumar, Jaykumar, MD<br />
CD133 Expression and Clinical Outcome in Patients with Rectal<br />
Cancer. Small Grant, $12,462.<br />
Unfunded<br />
Brown, Amy, MD<br />
A Retrospective Comparison of Clinical Outcomes Between<br />
Laparotomy and Robotic Hysterectomy for Endometrial Cancer.<br />
Buckley, Judith, MD<br />
Prevalence and Significance of Perineural Invasion as a Feature of<br />
Invasive Breast Cancer.<br />
Salner, Andrew, MD<br />
Outcomes and Survival Rates of Adenoid Cystic Carcinoma in 62<br />
Patients: A <strong>Hospital</strong> Registry Based Study.<br />
Survivors of Cancer in Adolescents and Young Adults (YES Project).<br />
Active Projects<br />
Baker, William-Jeffrey, MD<br />
A Phase II Study Of Fludarabine + Rituximab Induction Followed<br />
by Alemtuzumab (Campath-1H, NSC #715969, IND #10864)<br />
Consolidation in Untreated Patients with B-Cell Chronic<br />
Lymphocytic Leukemia. CALGB / Dana-Farber, $8,400.<br />
Brown, Amy, MD<br />
GOG # 210: A Molecular Staging Study of Endometrial Carcinoma.<br />
GOG/ Tufts New England Medical Center, $11,616.<br />
GOG 2<strong>09</strong>: Randomized Phase III Trial of Doxorubicin / Cisplatin /<br />
Paclitaxel and G-CSF Versus Carboplatin / Paclitaxel in Patients with<br />
Stage III & IV or Recurrent Endometrial Cancer. GOG, $6,313.<br />
GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and<br />
Radiation Versus Cisplatin and Tirapazamine (IND #46525) and<br />
Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervival Carcinoma<br />
Limited to the Pelvis. GOG, $6,601.<br />
GOG 215: A Phase II Randomized Study of the Effect of Zoledronic<br />
Acid (Zometa) versus Observation on Bone Mineral Density of the<br />
Lumbar Spine in Women who Elect to Undergo Risk-Reducing<br />
Surgery that Results in Removal of Both Ovaries. GOG, $3,960.<br />
GOG0170K (0170): A Phase II Evaluation of Mifepristone in the<br />
Treatment of Recurrent or Persistent Ovarian or Primary Peritoneal<br />
Cancer. GOG, $6,313.00<br />
The Utility of Coronal CT Reformatting in Predicting Extent of<br />
Disease in Ovarian Cancer and Pelvic Mass Patients.<br />
Buckley, Judith, MD<br />
Partial Breast Radiation Therapy-A Paradigm Shift.<br />
Standardized Uptake Value in PET as a Predictor of Survival in<br />
Esophageal Cancer.<br />
DeFusco, Patricia, MD<br />
NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate<br />
Therapy vs. Placebo in Early Stage Breast Cancer Patients Receiving<br />
Systemic Chemotherapy and/or Tamoxifen or No Therapy. NSABP,<br />
$15,000.00<br />
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin<br />
(LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of Patients<br />
with Stages II and III Carcinoma of the Colon (C-07 NSABP).<br />
NSABP Protocol - P-2 Study of Tamoxifen and Raloxifene (STAR) for<br />
the Prevention of Breast Cancer MIN21-CON. NSABP, $75,000.<br />
NSABP B-33: A Randomized, Placebo-Controlled, Double-Blind Trial<br />
Evaluating the Effect of Exemestane in Clinical Stage T1-3 NO-1 MO<br />
58.
Postmenopausal Breast Cancer Patients Completing at Least Five<br />
Years of Tamoxifen Therapy. NSABP, $1,000.<br />
A Clinical Trial Comparing Anastrozole with Tamoxifen in<br />
Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS)<br />
Undergoing Lumpectomy with Radiation Therapy. NSABP,<br />
$21,000.<br />
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of<br />
5-Flouroracil, Epirubicin and Cyclophosphamide (FEC) to Four<br />
Cycles of Adriamycin and Cyclophosphamide (AC), With or<br />
Without Celocoxib, in Patients with Node-Negative Breast Cancer.<br />
NSABP, $16,000<br />
NSABP B-38 A phase III Adjuvant Trial Comparing Three<br />
Chemotherapy Regimens in Women with Node-Positive Breast<br />
Cancer: Docetaxel / Doxorubicin / Cyclophosphamide (TAC);<br />
Dose-Dense (DD) Doxorubicin / Cyclophosphamide Followed by<br />
DD Paclitaxel (DD AC>P). NSABP, $19,000.<br />
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-<br />
FU), Leucovorin, And Oxaliplatin (mFOLFOX6) Every Two Weeks<br />
With Bevacizumab To The Same Regimen Without Bevacizumab<br />
For The Treatment Of Patients With Resected Stages II And III<br />
Carcinoma of the Colon. NSABP, $19,000.<br />
A Randomized Phase III Study of Conventional Whole Breast<br />
Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women<br />
With Stage 0, I or II Breast Cancer. NSABP/RTOG, $20,900.<br />
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five<br />
Years of Letrozole Compared to Placebo in Patients Completing<br />
Five Years of Hormonal Therapy Consisting of an Aromatase<br />
Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging<br />
Disease-Free Survival in Postmenopausal Women with Hormone<br />
Receptor Positive Breast Cancer. NSABP, $23,100.<br />
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients<br />
with Palpable and Operable Breast Cancer Evaluating the Effect on<br />
Pathological Complete Response (pCR) of Adding Capecitabine<br />
or Gemcitabine to Docetaxel when Administered Before AC<br />
(Adriamycin - Cytoxan) -with or without Bevacizumab and<br />
Correlative Science Studies Attempting to Identify Predictors of<br />
High Likelihood for pCR with Each of the Regimens. NSABP,<br />
$10,450.<br />
NSABP-B-31. A Randomized Trial Comparing The Safety And<br />
Efficacy of Adriamycin And Cyclophosphamide Followed By Taxol<br />
(AC-T) To That Of Adriamycin And Cyclophosphamide Followed<br />
By Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer<br />
Patients Who Have Tumors That Overexpress HER2.<br />
A Randomized Trial Comparing Preoperative Doxorubicin<br />
(Adriamycin) Cyclophosphamide (AC) to Preoperative AC<br />
Followed by Preoperative Docetaxel (Taxotere) and to Preoperative<br />
AC Followed by Postoperative Docetaxel in Patients with Operable<br />
Carcinoma of the Breast.<br />
A Trial to Evaluate the Worth of Tumor Biomarkers Obtained by FNA<br />
or Core Biopsy in Predicting Response to Preoperative Chemotherapy<br />
and Long-Term Outcome in Patients with Operable Breast Cancer<br />
Who are Participating in NSABP Protocol B-27.<br />
A Trial to Evaluate the Worth of Serum ErbB-2 Extracellular Domain<br />
and Serum ErbB-2 Antibodies in Predicting Response to Preoperative<br />
Chemotherapy and Long-Term Outcome in Patients with Operable<br />
Breast Cancer Who are Participating in NSABP Protocol B-27.<br />
NSABP B-30: A Three Arm Randomized Trial to Compare Adjuvant<br />
Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T);<br />
Adriamycin and Cyclophosphamide (ATC) in Breast Cancer Patients<br />
with Positive Axillary Lymph Nodes.<br />
A Clinical Trial to Evaluate the Worth of Tamoxifen in Conjunction<br />
with Lumpectomy and Breast Irradiation for the Treatment of<br />
Noninvasive Intraductal Carcinoma (DCIS) of the Breast (B-24).<br />
A Clinical Trial to Determine the Worth of Tamoxifen and the<br />
Worth of Breast Radiation in the Management of Patients with<br />
Node-negative, Clinically Occult, Invasive Breast Cancer Treated by<br />
Lumpectomy (B-21).<br />
Breast Conservation Rates in Breast Cancer Surgery: Comparison<br />
Based On Ethnicity, Race, and Insurance Status.<br />
A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol)<br />
Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast<br />
Cancer Patients with Positive Axillary Nodes (B-28)<br />
.<br />
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus<br />
Leucovorin (LV) with 5-Fluorouracil (5-FU) Plus LV in the Treatment<br />
of Patients with Stages II and III Carcinoma of the Colon (C-06).<br />
Angiogenesis in Breast Cancer: A Retrospective Analysis of<br />
Patients with Stage III or IV Disease Before and After Neoadjuvant<br />
Chemotherapy.<br />
Flowers, Alexandra, MD<br />
Pilot Study of Combination Temozolamide and 6-Thioguanine<br />
Chemotherapy for Patients with Recurrent Malignant Gliomas.<br />
NOVARTIS EPO906: An Open-Label, Multi-Center, Phase II Study<br />
to Evaluate the Activity of Patupilone (EPO906), in the Treatment of<br />
Recurrent or Progressive Brain Metastases in Patients with Non-Small<br />
Cell Lung Cancer. Novartis Pharmaceuticals, $180,339.<br />
Leopold, Kenneth, MD<br />
RTOG 0232, A Phase III Study Comparing Combined External Beam<br />
Radiation And Transperineal Interstitial Permanent Brachytherapy
With Brachytherapy Alone for Selected Patients with Intermediate<br />
Risk Prostatic Carcinoma. RTOG, $20,700.<br />
RTOG 0214, A Phase III Comparison Of Prophylactic Cranial<br />
Irradiation Versus Observation In Patients With Locally Advanced<br />
Non-Small Cell Lung Cancer. RTOG, $18,200.<br />
Nerenstone, Stacy, MD<br />
GOG #182: A Phase III Randomized Trial of Paclitaxel and<br />
Carboplatin Versus Triplet or Sequential Doublet Combinations in<br />
Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma.<br />
GOG, $1,500.<br />
GOG #199: Prospective Study of Risk-Reducing Salpingo-<br />
Oophorectomy and Longitudinal CA-125 Screening Among<br />
Women at Increased Genetic Risk of Ovarian Cancer. GOG,<br />
$20,000.<br />
GOG 212: A Randomized Phase III Trial of Maintenance<br />
Chemotherapy Comparing 12, Monthly Cycles of Single Agent<br />
Paclitaxel or Ct-2103 (Ind #70177), Versus No Treatment Until<br />
Documented Relapse in Women With Advanced Ovarian or<br />
Primary Peritoneal Cancer who Achieve a Complete Clinical<br />
Response to Primary Platinum/Taxane Chemotherapy. GOG,<br />
$49,500.<br />
GOG 218: A Phase III Trial of Carboplatin and Paclitaxel Plus<br />
Placebo versus Carboplatin and Paclitaxel Plus Concurrent<br />
Bevacizumab (RhuMab VEGF, NSC #704865, IND#7921) Followed<br />
by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent<br />
and Extended Bevacizumab in Women with Newly Diagnosed,<br />
Previously Untreated Suboptimal Advanced Stage Epithelial<br />
Ovarian and Peritoneal Cancer. GOG/The <strong>Hospital</strong> of Central<br />
Connecticut at New Britain, $49,368.<br />
Phase III Randomized Trial of 12 Months vs 3 Months of Paclitaxel<br />
in Patients with Advanced Ovarian Cancer Who Attain a Clinically<br />
Defined Complete Response (CR) Following Platinum/Paclitaxelbased<br />
Chemotherapy (GOG 178)<br />
.<br />
Randomized Clinical Trial for the Treatment of Women with<br />
Selected Stage IC and II (A,B,C) and Selected Stage IA and IB<br />
Ovarian Cancer (GOG95).<br />
A Randomized Phase III Trial of IV Carboplatin (AUC6) and<br />
Paclitaxel 175 mg/m2 Q 21 days x 3 courses Plus Low Dose<br />
Paclitaxel 40 mg/m2/wk versus IV Carboplatin (AUC6) and<br />
Paclitaxel 175/mg/m2 Q 21 days x 3 courses Plus Observation in<br />
Patients with Early Stage Ovarian Carcinoma (GOG 175).<br />
Rotondaro, Roxanne, MPH<br />
Pilot Study on Mobile Mammography: Estimating Eligibility and<br />
Participation in a Senior Housing Setting.<br />
Salner, Andrew, MD<br />
Prognostic Value of HER2 Status in High Risk Node Negative Breast<br />
Cancer. Departmental, $3,200.<br />
Clinical and Quality of Life Outcomes Following Diagnosis of Prostate<br />
Adenocarcinoma. Departmental, $27,000; matching funds generously<br />
provided by the Medical Staff.<br />
Centers of Excellence in Cancer Communication: Component and<br />
Couple Analysis of Cancer Communication (CHESS Program). NCI/<br />
University of Wisconsin, $101,362.<br />
Center of Excellence in Cancer Communications - Mentor Integration<br />
Project (CHESS Program). NCI/University of Wisconsin, $101,362.<br />
Web-Based Support for Informal Caregivers in Cancer (CHESS<br />
- Comprehensive Health Enhancement Support System). The<br />
University of Wisconsin/NIH, $127,244.<br />
Human and Computer Mentors for Prostate Cancer Patients - CHESS<br />
Program. NCI/University of Wisconsin, $111,559<br />
NCI NCCP Pilot Program. NCI/SAIC-Fredericks, $1,457,633.<br />
Reaching Urban African American Men with Prostate Cancer<br />
Screening Information. CDC/National Cancer Prevention & Control<br />
Program, $258,670.<br />
The Effects of Training and Follow-up Patients Contact on Utilization<br />
of the Internet-Based Information and Support Program CHESS<br />
(Comprehensive Health Enhancement Support System). <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $10,000.<br />
City of <strong>Hartford</strong> Comprehensive Cancer Prevention and Control Plan.<br />
City of <strong>Hartford</strong>-Health & Human Services Dept., $25,000.<br />
Environment, Gene, and Testicular Cancer Risk (<strong>Hartford</strong> <strong>Hospital</strong>).<br />
Environment, Gene, and Testicular Cancer Risk (Windham <strong>Hospital</strong>).<br />
Meningioma: Risk Factors and Quality of Life (Windham <strong>Hospital</strong>).<br />
Meningioma: Risk Factors and Quality of Life (<strong>Hartford</strong> <strong>Hospital</strong>).<br />
Psychosocial Needs Assessment of Colorectal Cancer Patients and<br />
Partners in the First Year After Diagnosis (Qualitative Research Phase).<br />
Self-Determined Length and Patterns of Usage for the Internet-Based<br />
Information and Support Program CHESS (Comprehensive Health<br />
Enhancement Support System) “Living with Breast Cancer.”<br />
Psychosocial Needs of Colorectal Cancer Patients and Partners in the<br />
First Year After Diagnosis<br />
60.
Siegel, Robert, MD<br />
Retrospective Analysis of Breast Cancers Negative for Estrogen<br />
Receptor, Progesterone Receptor and HER-2/neu (Basal Like Cancers).<br />
Departmental, $1,600.<br />
Phase III Chemoprevention Trial of Selenium Supplementation in<br />
Persons with Resected Stage I Non-Small Lung Cancer (CALGB<br />
79803/E5597) CALGB, $1,500.<br />
CALGB #99811 - A Phase II Study of Neo-Adjuvant Paclitaxel,<br />
Estramustine and Carboplatin (TEC) Plus Androgen Ablation Prior to<br />
Radiation Therapy in Patients with Poor Prognosis Localized Prostate<br />
Cancer. Dana Farber / Partners Cancer Care, $8,000.<br />
Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel<br />
(4 cycles) as Adjuvant Therapy for Breast Cancer in Women with<br />
0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study<br />
(CALGB 40101). CALGB / Dana Farber Cancer Institute, $8,000.<br />
Phase III Trial Evaluating the Role of Ovarian Function Suppression<br />
and the Role of Exemestane as Adjuvant Therapies for Premenopausal<br />
Women with Endocrine Responsive Breast Cancer (IBCSG 24002<br />
SOFT). CTSU/IBCSG , $8,000.<br />
CALGB 80101: Phase III Intergroup Trial of Adjuvant Chemoradiation<br />
After Resection of Gastric or Gastroesophageal Adenocarcinoma.<br />
Dana Farber Cancer Institute, $4,000.<br />
A Randomized, Phase III Trial Of Exemestane Versus Anastrozole<br />
In Postmenopausal Women With Receptor Positive Primary Breast<br />
Cancer (CALGB). NCIC/CALGB, $6,000.<br />
ECOG PACCT-1: Program For The Assessment Of Clinical Cancer<br />
Tests: Trial Assigning Individualized Options for Treatment: The<br />
TAILORx Trial. ECOG, $21,000.<br />
ECOG E2603: A Double-blind, Randomized, Placebo-Controlled<br />
Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus<br />
Carboplatin, Paclitaxel and placebo in Patients with Unresectable<br />
Locally Advanced or Stage IV Melanoma. ECOG via CTSU, $15,400.<br />
NCCTG N0147: A Randomized Phase III Trial Of Oxaliplatin<br />
(OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without<br />
Cetuximab (C225) After Curative Resection For Patients With Stage<br />
III Colon Cancer CALGB via Dana-Farber, $20,000.<br />
CALGB 70301: A Clinical Trial to Determine The Quality of Life,<br />
Employment and Informal Care Cost d, Placebo-controlled, Phase<br />
III Study of AE941 in Addition to Combined Modality Treatment<br />
Chemotherapy/ Radiotherapy) for Locally Advanced Unresectable<br />
Non-Small-Cell Lung Cancer (AE-941). NCI/Cancer Treatment<br />
Evaluation Program, $40,750.<br />
Phase III Trial of Novel Epothilone Plus Capecitabine versus<br />
Capecitabine alone in Patients with Advanced Breast Cancer<br />
Previously Treated with or Resistant to an Anthracycline and<br />
who are Taxane Resistant. Bristol Myers Squibb via Dana Farber,<br />
$24,375.<br />
S0016, “A Phase III Trial Of CHOP + Rituximab Vs CHOP +<br />
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab)<br />
For Treatment Of Newly Diagnosed Follicular Non-Hodgkin’s<br />
Lymphomas. SWOG via Dana Farber/CALGB, $6,000.<br />
A Phase III, Randomized Study of Gemcitabine [fixed-dose rate<br />
infusion] and Oxaliplatin (NSC2666046) versus Gemcitabine<br />
[fixed-dose rate infusion] versus Gemcitabine [30-min infusion] in<br />
Pancreatic Carcinoma. Eastern Cooperative Oncology Group- Dana<br />
Farber Cancer Institute,$8,000.<br />
A Phase III, Open-Label, Extension Study of Eculizumab in Patients<br />
with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal<br />
Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH<br />
(C04-001), SHEPHERD (C04-002) or X03-001 Studies. Alexion<br />
Pharmaceuticals, Inc., $50,988.<br />
An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase<br />
2 Study of S-1 as 2nd Line Therapy for Patients with Metastatic<br />
Pancreatic Cancer, Protocol Number TPU-S1201. TAIHO Pharma<br />
USA, Inc., $84,812.<br />
GPC Protocol SAT3-03-01: A Multi-Center, Multi-National,<br />
Double-Blind, Randomized Phase III Study Of Satraplatin Plus<br />
Prednisone or Placebo Plus Prednisone In Patients With Hormone<br />
Refractory Prostate Cancer Previously Treated With One Cytotoxic<br />
Chemotherapy Regimen. Pharmanet, $66,176.<br />
A Phase II Randomized Double-blinded Efficacy and Safety Study of<br />
Three Doses of TAS-108, Administered Orally in Postmenopausal<br />
Patients with Locally Advanced or Locally Recurrent Inoperable or<br />
Progressive Metastatic Breast Carcinoma Following Standard First or<br />
Second Line Endocrine Therapy. Quintiles, Inc., $138,113.<br />
Protocol 2055-003 - A Phase 2, Multi-Center, Randomized, Open-<br />
Label Study of Two Dose Levels of IMOxine (TM) (HYB2055 for<br />
injection) in Patients with Metastatic or Locally Recurrent Clear<br />
Cell Renal Carcinoma. Idera Pharmaceuticals, $70,638.<br />
TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction<br />
Efficacy and Safety Clinical Investigation, Randomized, Multi-<br />
Center, Double-Blind, Placebo-Controlled, Using Eculizumab in<br />
Paroxysmal Nocturnal Hemoglobinuria Patients (C04-001). Alexion<br />
Pharmaceuticals, Inc., $40,910.<br />
A Multicenter, Open-Label, Single-Arm, Two-Stage Phase II Study<br />
of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered<br />
Intravenously Every 2 Weeks in Subjects with Platinum-,<br />
Taxane-, and Erlotinib-Resistant Advanced Non-Small-Cell Lung
Adenocarcinoma. Sanofi Aventis, $246,775.<br />
Alexion EXPLORE: EXamination of PNH, by Level Of CD59 on REd<br />
and white blood cells, in bone marrow failure syndromes. Alexion<br />
Pharmaceuticals, Inc., $27,100.<br />
Phase III Double-blinded Randomized Trial of 13-Cis Retinoic Acid<br />
(13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Nonsmall<br />
Cell Lung Cancer (ECOG-91025).<br />
A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs<br />
Fludarabine Phosphate + Chlorambucil in Previously Untreated B-Cell<br />
Chronic Lymphocytic Leukemia (C9011).<br />
A Phase II Study of Neoadjuvant Chemotherapy and Radiation<br />
Therapy in the Management of High-risk, High-grade, Soft Tissue<br />
Sarcomas of the Extremities and Body Wall (ECOG R9514).<br />
Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20<br />
Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse<br />
Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology<br />
Non-Hodgkin’s Lymphoma (CALGB 9793, formerly ECOG E4494).<br />
A Randomized Phase III Trial of Sequential Chemotherapy Using<br />
Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent<br />
Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or<br />
21 Day Intervals in Women with Node Positive Stage II/IIIA Breast<br />
Cancer (ECOG C9741)<br />
A Phase III Randomized Double Blinded Study of Letrozole Versus<br />
Placebo in Women with Primary Breast Cancer Completing Five or<br />
More Years of Adjuvant Tamoxifen (CALGB Study #49805)<br />
Stein, Kevin, PhD<br />
National Quality of Life Study (Study of Cancer Survivors).<br />
National Quality of Life Study (Study of Cancer Survivors)/ Windham<br />
<strong>Hospital</strong>.<br />
Publications<br />
Alekshun TJ, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle<br />
peripheral T-cell lymphoma. Journal of Clinical Oncology, 26: 501-<br />
503, Jan 20, <strong>2008</strong>.<br />
Brown AK, Madom L, Moore R, Granai CO, DiSilvestro P. The<br />
prognostic significance of lower uterine segment involvement in<br />
surgically staged endometrial cancer patients with negative nodes.<br />
Gynecologic Oncology, 105:55-58, 2007.<br />
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of<br />
bevacizumab in persistent or recurrent epithelial ovarian cancer or<br />
primary peritoneal cancer: a Gynecologic Group Study. Journal of<br />
Clinical Oncology, 25: 5165-71., November 20, 2007.<br />
Fernandez AB, Ahmed S, Duncan BV, Firshein S and Kluger J. Cardiac<br />
tamponade: a rare complication of idiopathic hypereosinophilic<br />
syndrome. Journal of Cardiovascular Medicine, 10: 188-91, February<br />
20<strong>09</strong>.<br />
Goldstein M, Siegel R. Thymoma developing 30 years after mantle<br />
radiation for Hodgkin’s lymphoma. Connecticut Medicine, 73: 521-<br />
523. 20<strong>09</strong>.<br />
Kapadia P and Bona R. Acquired deficiency of vitamin K-dependent<br />
clotting factors due to brodifacoum ingestion. Connecticut Medicine,<br />
72: 207-<strong>09</strong>, April <strong>2008</strong>.<br />
Madom LM, Brown AK, Lui F, Moore RG, Granai CO, Disilvestro<br />
PA. Lower uterine segment involvement as a predictor for lymph node<br />
spread in endometrial cancer. Gynecologic Oncology,<br />
107:75-78, 2007.<br />
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW,<br />
Granai CO, Bast Jr., RC, Lu K. Utility of a novel serum tumor<br />
biomarker HE4 in patients with endometrioid adenocarcinoma of the<br />
uterus. Gynecologic Oncology, 110: 196-201, <strong>2008</strong>.<br />
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T,<br />
Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast Jr.<br />
RC. The use of multiple novel tumor biomarkers for the detection<br />
of ovarian carcinoma in patients with a pelvic mass. Gynecologic<br />
Oncology, 108:404-408, <strong>2008</strong>.<br />
Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller<br />
CM,Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK.<br />
A novel multiple marker bioassay utilizing HE4 and CA125 for<br />
the prediction of ovarian cancer in patients with a pelvic mass.<br />
Gynecologic Oncology, 112:40-46, 20<strong>09</strong>.<br />
Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M,<br />
Noto R, Brard L, Granai CO. Isolated Sentinel lymph node dissection<br />
with conservative management in patients with squamous cell<br />
carcinoma of the vulva: A prospective trial. Gynecologic Oncology,<br />
1<strong>09</strong>:65-70, <strong>2008</strong>.<br />
Nieves L, Currie J, Hoffman J, Sorosky JI. Ototoxicity after<br />
intraperitoneal chemotherapy: a case report. International Journal of<br />
Gynecological Cancer, 17: 1133-5. September – October 2007.<br />
Nieves L, Hoffman J, Allen G, Currie J and Sorosky JI. Placental-site<br />
trophoblastic tumor with PET scan-detected surgically treated lung<br />
metastasis. International Journal of Clinical Oncology, 13: 263-5,<br />
June <strong>2008</strong>.<br />
Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz<br />
62.
Oncology<br />
HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA The effect of<br />
anti-VEGF therapy on immature myeloid cell and dendritic cells in<br />
cancer patients. Cancer Immunol Immunother, <strong>2008</strong> Aug;57(8):1115-<br />
24. Epub <strong>2008</strong> Jan 10.<br />
Schnatz PF, Murphy JL, O’Sullivan DM, Sorosky JI. Patient choice:<br />
comparing criteria for selecting an obstetrician-gynecologist based<br />
on image, gender, and professional attributes. American Journal of<br />
Obstetrics & Gynecology, 197: 548. November 2007.<br />
Servodidio CA. What Makes a Community Clinical Research Program<br />
Successful? ONS Connect, 15: December <strong>2008</strong>.<br />
Servodidio CA. Technology is Illuminating the Full Spectrum. MGND<br />
New Media. December 30, <strong>2008</strong>.<br />
Sharma R, Usmani S, Siegel R. Primary squamous cell carcinoma of<br />
breast in background of phyllodes tumor-A case report. Connecticut<br />
Medicine, 73: 341-343; 20<strong>09</strong>.<br />
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology, 112: 186,<br />
February <strong>2008</strong>.<br />
Weren J, Schnatz PF, Mandavilli S, Allen G, Murphy JL, Greene JF,<br />
Egan JF, Sorosky JI. Prevalence of the human papillomavirus in an<br />
inner-city indigent population with previously normal Pap tests.<br />
Journal of Lower Genital Tract Disease, 12: 287-92, October <strong>2008</strong>.<br />
Abstracts<br />
Grubbs SS, Gonzalez M, Krasna M, Siegel R, Bryant D, Tsechetter L<br />
et al. Tracking clinical trial accrual strategies and barriers via a webbased<br />
screening tool. Proc ASCO # 6586. 20<strong>09</strong>.<br />
Hawkins RP, Pingree S, Shaw B, Serlin RC, Swoboda C, Han J,<br />
Carmack-Taylor C. and Salner A. Mediating processes and effects<br />
of two communication interventions for breast cancer patients.<br />
Presented at the annual meeting of the International Communication<br />
Association, TBA, Montreal, Quebec, Canada, May 21, <strong>2008</strong>.<br />
Karak S and Ricci A Jr. Prevalence and significance of perineural<br />
invasion (PIN) in invasive breast carcinoma. USCAP (United State and<br />
Canadian Academy of Pathology), March 20<strong>09</strong>.<br />
Rustagi T, Siegel R. ‘Zollinger-Ellison Syndrome with subsequent<br />
association of insulinoma. Presented at the 6th <strong>Annual</strong> ISGIO<br />
Conference, 20<strong>09</strong>.
Orthopedics<br />
New Projects<br />
Industry<br />
Kime, Charles, MD<br />
A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness<br />
of Total Facet Arthroplasty in the Treatment of Degenerative Spinal<br />
Stenosis. Archus Orthopedics, $82,000.<br />
Active Projects<br />
Browner, Bruce, MD<br />
Evaluation of Osteoporosis Outreach and Education Initiative. Merck & Co., Inc,<br />
$100,365.<br />
Caputo, Andrew, MD<br />
FDA-HDE (Humanitarian Device Exemption) Approved Ascension PIP Finger<br />
Joint.<br />
Krompinger, W. Jay, MD<br />
Evaluation of Outcomes Following Lumbar Spine Fusion Surgery at <strong>Hartford</strong><br />
<strong>Hospital</strong>: Phase I. <strong>Hartford</strong> <strong>Hospital</strong> Small Grant, $9,725.<br />
Lewis, Courtland, MD<br />
Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients<br />
Undergoing Surgical Hip Fracture Repair (FOCUS). National Heart, Lung &<br />
Blood Institute, University of Medicine & Dentistry of New Jersey, $700.<br />
Functional Status, Morbidity and Mortality in Cemented versus Uncemented<br />
Hemiarthroplasty: A Prospective Randomized Trial. Zimmer Corporation,<br />
$166,492.<br />
A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel<br />
Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban<br />
in Subjects Undergoing Elective Total Knee Replacement Surgery. Bristol-Myers<br />
Squibb, $172,860.<br />
Mastella, Daniel, MD<br />
Does Simultaneous Carpal Tunnel Release Improve Outcomes Following Distal<br />
Radius Open Reduction and Internal Fixation: A Retrospective Review.<br />
Sullivan, Raymond, MD<br />
A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical<br />
Trial to Evaluate the Safety and Effectiveness of GEM OS1 Compared to<br />
Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions.<br />
Biomimetic Therapeutics, $168,825.<br />
64.
Pathology<br />
William T. Pastuszak, MD, Chairman, Jaber Aslanzadeh, PhD<br />
Margaret Assaad, MD, Fabiola Balarezo, MD, Richard Cartun, PhD<br />
Thomas Ciesielski, MD, Joseph DiGiuseppe, MD, Jonathan Earle, MD<br />
Mary Fiel-Gan, MD, Lisa Laird, MD, Saverio Ligato, MD<br />
Gregory Makowski, PhD, Srinivas Mandavilli, MD, Laila Mnayer, PhD<br />
Richard Muller, MD, William Rezuke, MD, Andrew Ricci, MD<br />
Peter Shen, MD, Bradford Sherburne, MD, Dean Uphoff, MD<br />
Terry Voytek, MD, Rebecca Williams, MD<br />
The Department of Pathology and Laboratory Medicine (DPLM)<br />
through its biomedical and chemical research initiatives seeks to<br />
improve the understanding of the mechanisms of human disease and<br />
acquire knowledge that will assist in clinical diagnosis and development<br />
of new therapies that will improve cellular, molecular and genetic disease<br />
manifestations. Research-based knowledge provides the fundamental<br />
basis for translating information into clinically useful diagnostic testing<br />
and treatment for patients served at <strong>Hartford</strong> <strong>Hospital</strong>. DPLM oversees<br />
state-of-the-art equipment and technologies that support complex analysis<br />
of biochemical, infectious, molecular, cytogenetic and tissue markers of<br />
disease as demonstrated by the Department’s current research projects.<br />
Several divisions of DPLM conduct independent research and<br />
development. The Division of Hematology conducts research in use of<br />
immunologic and molecular techniques in the diagnosis and classification<br />
of hematologic and lymphoid malignancies. Anatomic Pathology uses<br />
immunohistochemistry to investigate a variety of pathologic disorders.<br />
Microbiology has investigated the application of molecular diagnostics to<br />
infectious diseases. The Department is fortunate to have a staff member<br />
with credentials in both Molecular Pathology and Cytogenetics which has<br />
opened new opportunities for research and development in both Anatomic<br />
and Clinical Pathology within the Department.<br />
New Projects<br />
Industry<br />
Mnayer, Laila, PhD<br />
A Multi-Center Blinded Reproducibility Study of the XTAG Cystic Fibrosis Core<br />
Panel v2 and XTAG Cystic Fibrosis Expanded Panel v2. Luminex Molecular<br />
Diagnostics, $22,750.<br />
Unfunded<br />
Cartun, Richard, PhD<br />
The Role of Lymphangitis in Crohn’s Disease.<br />
DiGiuseppe, Joseph, MD<br />
Flow Cytometric Evaluation of CD49f in Precursor B-cell Acute Lymphoblastic<br />
Leukemia.<br />
Active Projects<br />
Bowers, George, MD<br />
Development of a Reference System for the Measurement of the Activity<br />
of Erythrocyte Choline Estrase “Eche” in Human Blood. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $6,500.<br />
Roper, Liz, MS<br />
Use of Laboratory Tests and a Neural Network for the Detection of Myocardial<br />
Ischemia in Patients with Acute Coronary Syndromes. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $10,000.<br />
Robert McComb recieved support through med staff funds for manuscript<br />
preperation during this reporting period.<br />
Publications<br />
Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT,<br />
Hernandez BY, Reichman M, Dolled-Filhart MP, O’Regan RM, Garcia-Closas M,<br />
Perou CM, Jatoi I, Cartun RW, Sherman ME. Human epidermal growth factor<br />
receptor-2 and estrogen receptor expression, a demonstration project using the<br />
residual tissue repository of the Surveillance, Epidemiology, and End Results<br />
(SEER) program. Breast Cancer Res Treat. 20<strong>09</strong> Jan;113(1):189-96.<br />
Aslanzadeh J, Zheng X, IL H, Tetreault J, Ratkiewicz I, Meng S, Hamilton1<br />
P, Tang YW. Prospective evaluation of rapid antigen tests for diagnosis of<br />
Respiratory Syncytial Virus and Human Metapneumovirus Infections. J Clin<br />
Microbiol 46(5):1682-1685, <strong>2008</strong>.<br />
Asthana N, Mandich D, Ligato S. Esophageal polypoid dysplasia of gastric<br />
foveolar phenotype with focal intramucosal carcinoma associated with Barrett’s<br />
Esophagus. Am J Surg Pathol Vol. 32 (10), pp1581-1585, <strong>2008</strong>.<br />
Berzolla C, Mandavilli S, Sorosky J. Dysplasia and malignancy in endocervical<br />
polyps. J Women’s Health. 16(9):1317-1321, 2007.
Csako G, Makowski GS. Clinical chemistry of neurological and psychiatric<br />
diseases and body fluids. In Self Assessment in Clinical Laboratory Sciences II, Wu<br />
AHB (ed.), AACC Press, Washington, DC pp 219-234, <strong>2008</strong>.<br />
DiGiuseppe JA. Acute lymphoblastic leukemia: Diagnosis and detection of<br />
minimal residual disease following therapy. Clin Lab Med 27:533-549, 2007.<br />
DiGiuseppe JA. Flow cytometric immunophenotyping of plasmacytic neoplasms.<br />
Am J Clin Pathol 127:172-174, 2007.<br />
DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor<br />
B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual<br />
disease detection. Cytometry Part B (Clinical Cytometry). 76B:150-155.<br />
Glaser SL, Gulley ML, Clarke CA, Keegan TH, Chang ET, Shema SJ, Craig FE,<br />
DiGiuseppe JA, Dorfman RF, Mann RB, Anton-Culver H, Cozen W, Ambinder RF.<br />
Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California<br />
populations. Int J Cancer 123:1499-1507, <strong>2008</strong>.<br />
Hurford MT, Altman AJ, DiGiuseppe JA, Sherburne BJ, Rezuke WN. Unique<br />
pattern of nuclear TdT immunofluorescence distinguishes normal precursor B cells<br />
(hematogones) from lymphoblasts of precursor B-lymphoblastic leukemia. Am J<br />
Clin Pathol 129:700-705, <strong>2008</strong>.<br />
Lee CJ, Park JH, Ciesielski TE, Thomson JG, Persing JA. Retinoids, 585-nm laser,<br />
and carbon dioxide laser: A numeric comparison of neocollagen formation in<br />
photoaged airless mouse skin. Aesth Plast Surg 32:894-901, <strong>2008</strong>.<br />
Ligato S, Mandich D, Cartun RW. Utility of Glypican-3 in differentiating<br />
hepatocellular carcinoma from other primary and metastatic lesions in FNA of the<br />
liver: An immunocytochemical study. Mod Pathol Vol. 21, 5, 626-631, <strong>2008</strong>.<br />
Ligato S. Zhao H. Mandich D, Cartun RW. KOC and S100A4 protein<br />
immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology<br />
for diagnosing pancreatobiliary malignancies. Diag Cytopath Vol. 36, No 8, 561-<br />
567, <strong>2008</strong>.<br />
Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening<br />
and confirmation of extended-spectrum b-lactamase-producing members of the<br />
Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol 57:1147–1151,<br />
<strong>2008</strong>.<br />
Schnatz PF, Mandavilli SR, O’Sullivan DM. The prevalence of cervical HPV and<br />
cytologic abnormalities in association with reproductive factors of rural Nigerian<br />
women. J Women’s Health (Larchmt). 17(2):279-85, March <strong>2008</strong>.<br />
Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti G,<br />
Menozzi D, Oldaker TA, Orfao de Matos A, Rabellino E, Stone EC, Walker C.<br />
Clinical flow cytometric analysis of neoplastic hematolymphoid cells; Approved<br />
Guideline-Second Edition. CLSI document H43-A2, Clinical and Laboratory<br />
Standards Institute, 2007.<br />
Werden J, Schnatz PF, Mandavilli S, Sorosky JI. Prevalence of the HPV in an<br />
inner-city indigent population with previously normal Pap tests. J Low Genit<br />
Tract Dis 12(4):287-92, October <strong>2008</strong>.<br />
Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker<br />
T, Shenkin M, Stone E, Wallace P. Bethesda International Consensus<br />
recommendations on the immunophenotypic analysis of hematolymphoid<br />
neoplasia by flow cytometry: Optimal reagents and reporting for the flow<br />
cytometric diagnosis of hematopoietic neoplasia. Cytometry Part B (Clin<br />
Cytometry) 2007; 72B:S14-22, 2006.<br />
Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA,<br />
Peplonska B, Hewitt SM, Cartun RW, Mandich D, Sasano H, Evans DB, Sutter<br />
TR, Sherman ME. Hormonal markers in breast cancer: coexpression, relationship<br />
with pathologic characteristics, and risk factor associations in a population-based<br />
study. Cancer Res. 2007 Nov 1;67(21):10608-17.<br />
Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd<br />
AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson<br />
PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc<br />
Consensus Committee. Consensus recommendations on estrogen receptor<br />
testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol<br />
Morphol. <strong>2008</strong> Dec;16(6):513-20.<br />
Zhao HD, Davydova L, Mandich D, Cartun RW, Ligato S. S100A4 protein and<br />
Mesothelin expression in dysplasia and carcinoma of extrahepatic bile duct. Am J<br />
Clin Pathol 127, 3:374-384, March 2007.<br />
Zhao HD, Mandich D, Cartun RW, Ligato S. Expression of KOC in pancreatic<br />
FNA cytology for diagnosing invasive pancreatic adenocarcinoma. Diag<br />
Cytopath Vol. 35, 700-704, 2007.<br />
Ogawa F, Mino-Kenudson M, Shimizu M, Ligato S, Lauwers G. Gastroduodenitis<br />
associated with yttrium 90-microsphere selective internal radiation. Arch Pathol<br />
Lab Med Vol. 132, 1734-1738. November <strong>2008</strong>.<br />
66.
Pathology<br />
Abstracts and Presentations<br />
Aslanzadeh J, Bisaillon C, Pajor J, Meng S, White-Abell J, Gauthier C, Newsom B,<br />
Missett C, Ratkiewicz I, Li, Frankin J, Chappell, Tang YW. Detection of Human<br />
Meta Pneumovirus in Respiratory Samples from an Adult Patient Population. 25th<br />
<strong>Annual</strong> Clinical Virology Symposium and <strong>Annual</strong> Meeting of the Pan-American<br />
Society for Clinical Virology, 20<strong>09</strong>.<br />
Aslanzadeh J, Hamilton P, Miller J, Maldonada Y, Ratkiewicz I. Evaluation of Gen-<br />
Probe APTIMA COMBO 2 Assay Performed on Tigris DTS System for Detecting<br />
Chlamydia trachomatis and Neisseria gonorrhoeae. 108th <strong>Annual</strong> Meeting of the<br />
American Society for Microbiology, <strong>2008</strong>.<br />
Aslanzadeh JH, Li J, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang YW.<br />
Performance of Rapid Tests for Detection of Respiratory Syncytial Virus and<br />
Human Meta Pneumovirus. 23rd <strong>Annual</strong> Clinical Virology Symposium and <strong>Annual</strong><br />
Meeting of the Pan-American Society for Clinical Virology, 2007.<br />
Aslanzadeh J, Zheng X, Li H, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang<br />
YW. Prospective Evaluation of Rapid Antigen Tests for Diagnosis of Respiratory<br />
Syncytial Virus and Human Meta pneumovirus Infections. 18th <strong>Annual</strong> Meeting of<br />
European Society of Clinical Microbiology and Infectious Diseases, <strong>2008</strong>.<br />
Cartun RW. Technical Issues in Immunohistochemistry. Invited address at the<br />
Third <strong>Annual</strong> International Retreat on Applied Immunohistochemistry and<br />
Molecular Morphology. January 26-30, 20<strong>09</strong> - Duck Key, FL.<br />
Cartun RW. Advances in Histology and Immunohistochemistry Techniques.<br />
Invited address at Leica-Microsystems 20<strong>09</strong> Educational Symposia Series. May 13,<br />
20<strong>09</strong> - Jersey City, NJ. Invited address at Leica-Microsystems 20<strong>09</strong> Educational<br />
Symposia Series August 12, 20<strong>09</strong> - Dallas, TX.<br />
Currie C, Brown A, Sorosky J, Mandavilli S, Joyner A, Currie, J. (Abstract #27)<br />
Endometrioid Carcinoma of Fallopian Tube with Metastasis and Extension to<br />
the Obturator Space: A Case <strong>Report</strong>. New England Association of Gynecologic<br />
Oncologists, 20<strong>09</strong> Meeting.<br />
Gorusu M, Menon M, Firshein SI, Dekker PT, DeFusco PA, Rezuke W, Sharma<br />
R, Mnayer LO. Philadelphia Chromosome–Negative Chronic Myeloid Leukemia:<br />
Tailored Monitoring. Clinical Lymphoma & Myeloma, Vol. 9, No. 2, 171-182,<br />
20<strong>09</strong>.<br />
Gull, Batti, Balarezo. Vascularity in Obstructive vs. Infected Tonsils.<br />
Otolaryngology – Head & Neck Surgery, Vol. 137, Issue 2, pp. P96, 2007.<br />
He W, Hodges K, Windemuth K, Mnayer LO, Mandavilli S, , UroVysion Tm<br />
FISH Assay for Detection of Urothelial Carcinoma: A Tertiary Care <strong>Hospital</strong><br />
Experience with149 Cases. American Society of Cytopathology, Houston,<br />
Texas, 2007.<br />
He W, Mandavilli S. Utility of p63 and CK34BE12 Antibodies in Diagnosis of<br />
Urothelial Carcinoma in Cytology Specimens. Cancer Cytopathology. Oct 25,<br />
<strong>2008</strong>. 114 (5), page 363.<br />
Ibrahim G, White S, Karak SG, Ricci Jr. A. Histopathologic and Staging<br />
Characteristics of ER/PR/HER “triple positive” Mammary carcinoma. Mod<br />
Pathol 22(1) supp 47A.<br />
Joyner A, Sorosky J, Currie C, Mandavilli S, Brown A, and Currie J. (Abstract<br />
#29) Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery<br />
Embolization for Leiomyomas: A Case <strong>Report</strong>. New England Association of<br />
Gynecologic Oncologists, 20<strong>09</strong> Meeting.<br />
Karak SG and Ricci Jr A. Prevalence of Significance of Perineural Invasion in<br />
Invasive Breast Carcinoma. Mod Pathol. 22(1) supp 49A.<br />
Ligato S, Mandich D, Cartun RW. Is Immunohistochemical Analysis of<br />
DNA Mismatch Repair Proteins (MMR) in Unselected Sebaceous Neoplasms<br />
Warranted as a Screening Test for Muir-Torre Syndrome? 98th USCAP <strong>Annual</strong><br />
Meeting. Section E – Dermatopathology Section Proffered paper Denver<br />
Colorado, <strong>2008</strong>.<br />
Mandavilli S. Effusion Cytology with an Emphasis on Ancillary Studies. Invited<br />
lecturer at IX Internal CME Meeting on Surgical Pathology and Cytology at<br />
NIMHANS, Bangalore, India (January 26-28, <strong>2008</strong>).<br />
Nataraj, Vellanki, Dada, Balarezo, Ranga. De Novo Foal Segmental<br />
Glomerulosclerosis (FSG) Following Renal Transplant in a Patient with<br />
Autosomal Dominant Polycystic Kidney Disease (ADPKD). American Journal<br />
of Kidney Diseases, Vol. 51, Issue 5, pp. B73, <strong>2008</strong>.<br />
Parab MS, Ahmad N, Fuller SG, DiGiuseppe JA. Changes in Antigen Density<br />
During Remission Induction in Precursor B-cell Acute Lymphoblastic Leukemia<br />
Detected by Flow Cytometric Immunophenotyping. Mod Pathol 20:353-4A,<br />
2007.<br />
Parab M, Mandich D, Cartun RW, Ligato S. Biliary Brush Cytology Combined<br />
with Immunocytochemical Staining for IMP3 Provides Superior Diagnostic<br />
Sensitivity for Detection of Pancreatobiliary Malignancies. 22nd European<br />
Congress of Pathology. Florence, Italy. Cytopathology Section, 4-9 September<br />
20<strong>09</strong>.
Platt L., Brown A.K., Mandavilli S., Currie J., Sorosky J. <strong>Hartford</strong> <strong>Hospital</strong>,<br />
<strong>Hartford</strong>, CT. Complex Atypical Hyperplasia and the Incidence of Endometrial<br />
Cancer at the Time of Hysterectomy. New England Association of Gynecologic<br />
Oncologists, 20<strong>09</strong> Meeting, June 20<strong>09</strong>.<br />
Rotundo E, Waszczak W, O’Donell M, Mandavilli SR. Thyroid FNA Diagnosis<br />
of Cellular Follicular Lesion: A Clinico-pathologic Study of 161 Cases. American<br />
Society of Cytology, Houston, TX, November 2007.<br />
Shinoda-Matsuoka H, DiGiuseppe JA. Overexpression of CD49f in Precursor<br />
B-cell Acute Lymphoblastic Leukemia: Efficiency of Minimal Residual Disease<br />
(MRD) Detection by Flow Cytometric Immunophenotyping Compared with<br />
Commonly Used Markers. Mod Pathol 22:388A, 20<strong>09</strong>.<br />
Sun Y, Waszczak W, Mandavilli S. Significance of Ductal Epithelial Cells in<br />
Nipple Discharge Cytology Specimens. Cancer Cytopathology. Oct 25, <strong>2008</strong>.<br />
114 (5), page 352. Presented American Society of Cytopathology Meeting,<br />
November 20, <strong>2008</strong>.<br />
Tetreault J, Aslanzadeh J. Measures to Control False Negative and False Positive<br />
Blood Cultures in a Large Tertiary Care <strong>Hospital</strong>. 107th <strong>Annual</strong> Meeting of the<br />
American Society for Microbiology, 2007.<br />
Umenyi C, Schnatz P, Waszczak W, Mandavilli SR. Incidence of HR-HPV and<br />
Cervical Dysplasia in Nigeria. American Society of Cytology, Houston, TX,<br />
November 2007.<br />
White S, Ibrahim G, Karak SG, Mnayer L, Ricci Jr. A. Proliferative Activity and<br />
HER2-FISH Results on Hormone Receptor Positive/HER2 Positive (Luminal Type<br />
B) Breast Cancer. Mod Pathol 22(1) supp 74A.<br />
68.
Psychiatry<br />
Harold I. Schwartz, MD<br />
Psychiatrist-in-Chief; Vice President, Behavioral Health<br />
The research enterprise at The Institute of Living is organized in four<br />
specialized centers. The Olin Neuropsychiatry Research Center, directed<br />
by Godfrey Pearlson, M.D., focuses on studies of the major psychiatric<br />
disorders using brain imaging and electrophysiological techniques along<br />
with genetic analysis. The Anxiety Disorders Center, directed by David<br />
Tolin, Ph.D., researches treatments for Obsessive-Compulsive Disorder<br />
(OCD), Panic Disorder, Compulsive Hoarding and other disorders on<br />
the anxiety spectrum. The Braceland Center for Mental Health and<br />
Aging (Karen Blank, M.D., Director) addresses issues related to memory<br />
in normal aging and in individuals with Alzheimer’s Disease or other<br />
dementing processes. Finally, the Burlingame Center for Psychiatric<br />
Research and Education, directed by John Goethe, M.D., focuses on<br />
outcomes and best practices research as well as pharmacogenetics,<br />
metabolic syndrome and treatment resistant mood disorders.<br />
The success of our research enterprise can be measured through grants<br />
awarded, the dissemination of important findings and the synergy<br />
between our research efforts and our training and clinical programs. As<br />
for grants, the Olin Neuropsychiatry Research Center alone was awarded<br />
$7.2 million in new federal funding in fiscal year 20<strong>09</strong>. A reflection of<br />
the huge dissemination of information from these centers can be seen in<br />
the lists of publications from each. The synergy between our research<br />
and clinical and training programs is a building block of excellence at the<br />
IOL and continues to grow stronger every year.<br />
Godfrey Pearlson, MD: Director<br />
Faculty:<br />
Godfrey Pearlson, MD, Center Director and Director of COBBRA Lab<br />
(COgnition, Brain, Behavior, Research and Allelic Variation)<br />
Michael Stevens, PhD, Director, CND Lab (Clinical Neurosciences and<br />
Development) and Director of Child and Adolescent Research at IOL<br />
David Glahn, PhD, Director ADAPTING Lab (Affective Disorders and<br />
Clinical Trials, Imaging, Neurocognition and Genetics)<br />
Michal Assaf, MD, Senior Scientist,<br />
Pawel Skudlarski, PhD, Senior Scientist<br />
Post-Doctoral Fellows:<br />
Beth Anderson, PhD, Christopher Hyatt, PhD, Suzanne Witt, PhD,<br />
Anderson Winkler, PhD<br />
The mission of the Olin Center is to be at the forefront of research<br />
in major psychiatric and psychological disorders, in particular<br />
schizophrenia, mood disorders and addictions. Techniques employed<br />
by Center faculty include functional and structural magnetic resonance<br />
imaging (MRI) and electrophysiology (EED, ERPs). Our newly designed<br />
Website is at http://www.nrc-io.org.<br />
Center faculty have active research interests in many aspects of cognitive<br />
function including normal aging, working and long term memory,<br />
spatial navigation, salience detection, orienting processes, response<br />
inhibition, error monitoring, language emotional processing, theory of<br />
mid and attention. We examine these cognitive and emotive processes<br />
in schizophrenia, Alzheimer’s disease, manic-depressive illness, Major<br />
Depressive Disorder, disruptive behavior disorders such as ADHD or<br />
Conduct Disorder, alcohol & drug abuse, post-traumatic stress disorder<br />
and psychopathy. The Center is supported in part by multiple grants<br />
from the National Institute of Health, (NIAAA, NIMN, NINDS, NIA<br />
and NIDA) totaling several million dollars annually. Center faculty have<br />
been exceptionally successful in being awarded NIH grants in the past<br />
year. Faculty also provide mentorship and training for IOL residents and<br />
undergraduate, graduate, and postdoctoral fellows.<br />
With the publication of the Human Genome and the arrival of<br />
GENOMAS at <strong>Hartford</strong> <strong>Hospital</strong>, genetic testing is becoming an integral
OLIN Neuropsychiatry Research Center<br />
part of research at the Olin Research Center. All research subjects now<br />
have samples taken for genetic characterization, and neuroimaging<br />
projects are increasingly taking on a genetic component. Notably, a<br />
recent collaborative study between ONRC and Genomas identified a<br />
series of risk genes for schizophrenia that contribute to abnormal brain<br />
activation during an attention task. This finding is the basis of a new grant<br />
seeking biological risk markers of schizophrenia.<br />
Increasing attention is being paid to Alzheimer’s disease and joint projects<br />
involving both the Olin Research Center and the Memory Disorders<br />
Center were recently refunded. Additional collaborations have begun<br />
with Child and Adolescent Psychiatry in the areas of ADHD, adolescent<br />
depression, and autism and with the addictions program for research on<br />
alcohol and drug abuse. These include collaborations with Yale, Trinity<br />
College and CCSU. Research scanning on the Olin Center’s 3 Tesla<br />
scanner continues to grow – we have scanned over 7000 research subjects<br />
since the Center opened in 2002. We have been able to hire more staff.<br />
At a time when federal grant dollars are shrinking, and only about 5% of<br />
federal grant submissions are being funded, the Olin Center continues to<br />
have large-scale new grants funded.<br />
OLIN Center Publications<br />
Acheson A, Robinson JL, Glahn DC, Lovallo WR, Fox PT. Differential activation<br />
of the anterior cingulate cortex and caudate nucleus during a gambling simulation<br />
in persons with a family history of alcoholism: studies from the Oklahoma Family<br />
Health Patterns Project. Drug Alcohol Depend. 20<strong>09</strong> Feb 1;100(1-2):17-23.<br />
Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in<br />
schizophrenia: a selective review. Schizophr Res. 20<strong>09</strong> Apr;1<strong>09</strong>(1-3):24-37.<br />
Allen AJ, Meda SA, Skudlarski P, Calhoun VD, Astur R, Ruopp KC, Pearlson GD.<br />
Effects of alcohol on performance on a distraction task during simulated driving.<br />
Alcohol Clin Exp Res. 20<strong>09</strong> Apr;33(4):617-25.<br />
Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram<br />
administration may disrupt contextual information processing in healthy males. Eur<br />
Psychiatry. 20<strong>09</strong> Aug 18. PMID: 19695841.<br />
Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram<br />
administration may disrupt contextual information processing in healthy males. Eur<br />
Psychiatry. 20<strong>09</strong> Aug 18.<br />
Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan<br />
RW. Patterns of cranial, brain and sulcal CSF volumes in male and female<br />
deficit and nondeficit patients with schizophrenia. Psychiatry Res. <strong>2008</strong> Feb<br />
28;162(2):91-100.<br />
Assaf M, Jagannathan K, Calhoun V, Kraut M, Hart J Jr, Pearlson G. Temporal<br />
sequence of hemispheric network activation during semantic processing: a<br />
functional network connectivity analysis. Brain Cogn. 20<strong>09</strong> Jul;70(2):238-46.<br />
PMID: 19307050.<br />
Astur RS, Shipman SL. Factors affecting the hippocampal BOLD response during<br />
spatial memory. Behav Brain Res. <strong>2008</strong> Mar 5;187(2):433-41.<br />
Astur RS, Newhouse P, Newhouse C. Sex differences in visual-spatial learning<br />
using a virtual water maze in pre-pubertal children. Behav Brain Res. 2007 Oct<br />
1;183(1):1-7.<br />
Bearden CE, Cannon TD, Chiang MC, Glahn DC, Lee AD, Reiss AL,<br />
Thompson PM, Toga AW, van Erp TG. Neural phenotypes of common and rare<br />
genetic variants. Biol Psychol. <strong>2008</strong> Sep;79(1):43-57.<br />
Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti<br />
M, Dierschke N, Hayashi KM, Klunder AD, Glahn DC, Brambilla P, Sassi<br />
RB, Mallinger AG, Soares JC. Three-dimensional mapping of hippocampal<br />
anatomy in unmedicated and lithium-treated patients with bipolar disorder.<br />
Neuropsychopharmacology. <strong>2008</strong> May;33(6):1229-38.<br />
Bearden, C.E., Glahn DC, Thompson, P.M., Dalwani, M., Hayashi, K.M., Lee,<br />
A.D., Nicoletti, M., Trakhtenbroit, M., et al., Reply: Lithium and Increased<br />
Cortical Gray Matter-More Tissue or More Water? Biol Psychiatr, 2007.<br />
Bearden, C.E., Thompson, P.M., Dalwani, M., Glahn DC, Hayashi, K.M.,<br />
Lee, A.D., Nicoletti, M., Trakhtenbroit, M., et al., Greater cortical gray matter<br />
density in lithium-treated patients with bipolar disorder. Biol Psychiatry, 2007.<br />
62(1): p. 7-16.<br />
Bearden, C.E., van Erp, T.G., Glahn DC, Dutton, R.A., Tran, H., Zimmermann,<br />
L., Sun, D., Geaga, J.A., et al., Mapping cortical thickness in children with<br />
22q11.2 deletions. Cereb Cortex, 2007. 17(8): p. 1889-98.<br />
Bearden, C.E., Thompson, P.M., Glahn DC, Dutton, R.A., Frey, B.N., Peluso,<br />
M.A., Nicoletti, M., Dierschke, N., et al., Three-dimensional mapping of<br />
hippocampal anatomy in unmedicated and lithium-treated patients with bipolar<br />
disorder. Neuropsychopharmacology, <strong>2008</strong>. 33(6): p. 1229-38.<br />
70.
Calhoun VD, Maciejewski PK, Pearlson GD, Kiehl KA. Temporal lobe and<br />
“default” hemodynamic brain modes discriminate between schizophrenia and<br />
bipolar disorder. Hum Brain Mapp. <strong>2008</strong> Nov;29(11):1265-75.PMID: 17894392.<br />
Calhoun VD, Kiehl KA, Pearlson GD. Modulation of temporally coherent brain<br />
networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp.<br />
<strong>2008</strong> Jul;29(7):828-38.<br />
Caprihan A, Pearlson GD, Calhoun VD. Application of principal component<br />
analysis to distinguish patients with schizophrenia from healthy controls based on<br />
fractional anisotropy measurements. Neuroimage. <strong>2008</strong> Aug 15;42(2):675-82.<br />
Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, Pearlson<br />
GD, Schretlen DJ. Neuropsychological impairment in deficit vs. non-deficit<br />
schizophrenia. J Psychiatr Res. <strong>2008</strong> Sep;42(11):930-7.<br />
Contreras J, Hare L, Camarena B, Glahn D, Dassori A, Medina R, Contreras S,<br />
Ramirez M, Armas R, Munoz R, Mendoza R, Raventos H, Ontiveros A, Nicolini<br />
H, Palmer R, Escamilla M.The serotonin transporter 5-HTTPR polymorphism is<br />
associated with current and lifetime depression in persons with chronic psychotic<br />
disorders. Acta Psychiatr Scand. 20<strong>09</strong> Feb;119(2):117-27. PMID: 19016667.<br />
Cykowski MD, Coulon O, Kochunov PV, Amunts K, Lancaster JL, Laird AR, Glahn<br />
DC, Fox PT. The central sulcus: an observer-independent characterization of sulcal<br />
landmarks and depth asymmetry. Cereb Cortex. <strong>2008</strong> Sep;18(9):1999-20<strong>09</strong>. PMID:<br />
18071195.<br />
Demirci O, Clark VP, Magnotta VA, Andreasen NC, Lauriello J, Kiehl KA,<br />
Pearlson GD, Calhoun VD. A Review of Challenges in the Use of fMRI for Disease<br />
Classification / Characterization and A Projection Pursuit Application from Multisite<br />
fMRI Schizophrenia Study. Brain Imaging Behav. <strong>2008</strong> Sep 1;2(3):147-226.<br />
PMID: 19562043.<br />
Demirci O, Stevens MC, Andreasen NC, Michael A, Liu J, White T, Pearlson<br />
GD, Clark VP, Calhoun VD. Investigation of relationships between fMRI brain<br />
networks in the spectral domain using ICA and Granger causality reveals distinct<br />
differences between schizophrenia patients and healthy controls. Neuroimage.<br />
20<strong>09</strong> Jun;46(2):419-31.<br />
Driesen NR, Leung HC, Calhoun VD, Constable RT, Gueorguieva R, Hoffman<br />
R, Skudlarski Impairment of working memory maintenance and response in<br />
schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry.<br />
<strong>2008</strong> Dec 15;64(12):1026-34. PMID: 18823880.<br />
Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of<br />
first-episode and chronic schizophrenia: an anatomical likelihood estimation metaanalysis.<br />
Am J Psychiatry. <strong>2008</strong> Aug;165(8):1015-23. PMID: 18381902.<br />
Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL,<br />
Bullmore E, Fox PT. Meta-analysis of gray matter anomalies in schizophrenia:<br />
application of anatomic likelihood estimation and network analysis. Biol Psychiatry.<br />
<strong>2008</strong> Nov 1;64(9):774-81. PMID: 18486104.<br />
Glahn D, Reichenberg A, Frangou S, Ormel H. Psychiatric neuroimaging: joining<br />
forces with epidemiology. Eur Psychiatry. <strong>2008</strong> Jun;23(4):315-9.<br />
Glahn, D.C., Almasy, L., Blangero, J., Burk, G.M., Estrada, J., Peralta,<br />
J.M., Meyenberg, N., Adjudicating neurocognitive endophenotypes for<br />
schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2007. 144B(2): p.<br />
242-9.<br />
Glahn, D.C., Lovallo, W.R. and Fox, P.T. Reduced amygdala activation in young<br />
adults at high risk of alcoholism: studies from the Oklahoma family health<br />
patterns project. Biol Psychiatry, 2007. 61(11): p. 1306-9.<br />
Glahn, D.C., Paus, T. and Thompson, P.M. Imaging genomics: mapping the<br />
influence of genetics on brain structure and function. Hum Brain Mapp, 2007.<br />
28(6): p. 461-3.<br />
Glahn, D.C., Thompson, P.M. and Blangero, J. Neuroimaging endophenotypes:<br />
strategies for finding genes influencing brain structure and function. Hum Brain<br />
Mapp, 2007. 28(6): p. 488-501.<br />
Glahn, D., Reichenberg, A., Frangou, S. and Ormel, H., Psychiatric<br />
neuroimaging: Joining forces with epidemiology. Eur Psychiatry. <strong>2008</strong><br />
Jun;23(4):315-9.<br />
Goldstein G, Panchalingam K, McClure RJ, Stanley JA, Calhoun VD, Pearlson<br />
GD, Pettegrew JW. Molecular neurodevelopment: an in vivo 31P-1H MRSI<br />
study. J Int Neuropsychol Soc. 20<strong>09</strong> Sep;15(5):671-83.<br />
Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in<br />
bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert<br />
meeting report. Eur Neuropsychopharmacol. <strong>2008</strong> Nov;18(11):787-93.<br />
Gordon RJ, Seamon JG, Pearlson GD. An fMRI study of neurocognitive<br />
functioning in schizophrenia with a mere exposure paradigm. Schizophr Res.<br />
20<strong>09</strong> Mar;108(1-3):290-2. PMID: 18835759.<br />
Guo Y, Pagnoni G. A unified framework for group independent component<br />
analysis for multi-subject fMRI data. Neuroimage. <strong>2008</strong> Sep 1;42(3):1078-93.<br />
PMID: 18650105.<br />
Hare E, Glahn DC, Dassori A, Raventos H, Nicolini H, Ontiveros A, Medina R,<br />
Mendoza R, Jerez A, Muñoz R, Almasy L, Escamilla MA. Heritability of age of<br />
onset of psychosis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet.<br />
20<strong>09</strong> Apr 6. PMID: 19350535.<br />
Holmes M, K., Bearden CE, Barguil M, Fonseca M, Serap Monkul E, Nery FG,<br />
Soares JC, Mintz J, Glahn DC. Conceptualizing impulsivity and risk taking in<br />
bipolar disorder: importance of history of alcohol abuse. Bipolar Disord. 20<strong>09</strong><br />
Feb;11(1):33-40.PMID: 19133964.<br />
Hong CC, Harris JC, Pearlson GD, Kim JS, Calhoun VD, Fallon JH, Golay<br />
X, Gillen JS, Simmonds DJ, van Zijl PC, Zee DS, Pekar JJ. fMRI evidence for<br />
multisensory recruitment associated with rapid eye movements during sleep.<br />
Hum Brain Mapp. 20<strong>09</strong> May;30(5):1705-22.PMID: 18972392.
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung<br />
MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer’s Disease<br />
Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment<br />
and Alzheimer’s disease: implications for sequence of pathological events in<br />
Alzheimer’s disease. Brain. 20<strong>09</strong> May;132(Pt 5):1355-65. PMID: 19339253.<br />
<strong>2008</strong> Mar;2(1):21-26.PMID: 19<strong>09</strong>6528.<br />
Meda SA, Bhattarai M, Morris NA, Astur RS, Calhoun VD, Mathalon DH,<br />
Kiehl KA, Pearlson GD. An fMRI study of working memory in first-degree<br />
unaffected relatives of schizophrenia patients. Schizophr Res. <strong>2008</strong> Sep;104(1-<br />
3):85-95. Epub <strong>2008</strong> Aug 3.PMID: 18678469.<br />
Jafri MJ, Pearlson GD, Stevens M, Calhoun VD. A method for functional<br />
network connectivity among spatially independent resting-state components in<br />
schizophrenia. Neuroimage. <strong>2008</strong> Feb 15;39(4):1666-81. PMID: 18082428.<br />
Meda SA, Calhoun VD, Astur RS, Turner BM, Ruopp K, Pearlson GD. Alcohol<br />
dose effects on brain circuits during simulated driving: an fMRI study. Hum<br />
Brain Mapp. 20<strong>09</strong> Apr;30(4):1257-70.PMID: 18571794.<br />
Karlsgodt, K.H., Glahn, D.C., van Erp, T.G., Therman, S., Huttunen, M.,<br />
Manninen, M., Kaprio, J. The relationship between performance and fMRI signal<br />
during working memory in patients with schizophrenia, unaffected co-twins, and<br />
control subjects. Schizophr Res, 2007. 89(1-3): p. 191-7.<br />
Kiehl KA, Pearlson GD, Stevens MC. An FMRI auditory oddball study of<br />
combined-subtype attention deficit hyperactivity disorder. Am J Psychiatry. 2007<br />
Nov;164(11):1737-49.PMID: 17974940.<br />
Kim D, Burge J, Lane T, Pearlson GD, Kiehl KA, Calhoun VD. Hybrid ICA-<br />
Bayesian network approach reveals distinct effective connectivity differences in<br />
schizophrenia. Neuroimage. <strong>2008</strong> Oct 1;42(4):1560-8. PMID: 18602482.<br />
Kim D, Pearlson GD, Kiehl KA, Bedrick E, Demirci O, Calhoun VD. A method<br />
for multi-group inter-participant correlation: abnormal synchrony in patients<br />
with schizophrenia during auditory target detection. Neuroimage. <strong>2008</strong> Feb<br />
1;39(3):1129-41. PMID: 17996465.<br />
Liotti M, Pliszka SR, Perez R 3rd, Luus B, Glahn D, Semrud-Clikeman M.<br />
Electrophysiological correlates of response inhibition in children and adolescents<br />
with ADHD: influence of gender, age, and previous treatment history.<br />
Psychophysiology. 2007 Nov;44(6):936-48. PMID: 17666028.<br />
Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A,<br />
Cascella N, Keshavan M, Kates W, Buchanan R, Sharma T, Pearlson GD. A large<br />
scale (N=400) investigation of gray matter differences in schizophrenia using<br />
optimized voxel-based morphometry. Schizophr Res. <strong>2008</strong> Apr;101(1-3):95-<br />
105. Epub <strong>2008</strong> Apr 18.PMID: 18378428.<br />
Michael AM, Calhoun VD, Pearlson GD, Baum SA, Caprihan A. Correlations<br />
of diffusion tensor imaging values and symptom scores in patients with<br />
schizophrenia. Conf Proc IEEE Eng Med Biol Soc. ;<strong>2008</strong>:5494-7.PMID:<br />
19163961.<br />
Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung<br />
RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho<br />
BC, Bockholt HJ, Calhoun VD. Functional brain networks in schizophrenia:<br />
a review. Front Hum NeuGlahnci. 20<strong>09</strong>;3:17. Epub 20<strong>09</strong> Aug 17.PMID:<br />
19738925.<br />
Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung<br />
RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho<br />
BC, Bockholt HJ, Calhoun VD. Does function follow form?: Methods to fuse<br />
structural and functional brain images show decreased linkage in schizophrenia.<br />
Neuroimage. 20<strong>09</strong> Sep 3 PMID: 19733247.<br />
Liu J, Kiehl KA, Pearlson G, Perrone-Bizzozero NI, Eichele T, Calhoun VD.<br />
Genetic determinants of target and novelty-related event-related potentials in the<br />
auditory oddball response. Neuroimage. 20<strong>09</strong> Jul 1;46(3):8<strong>09</strong>-16. PMID: 19285141.<br />
Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of<br />
41 functional neuroimaging studies of executive function in schizophrenia. Arch<br />
Gen Psychiatry. 20<strong>09</strong> Aug;66(8):811-22.PMID: 19652121.<br />
Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V.<br />
Combining fMRI and SNP data to investigate connections between brain function<br />
and genetics using parallel ICA.<br />
Hum Brain Mapp. 20<strong>09</strong> Jan;30(1):241-55.PMID: 18072279.<br />
Matsuo, K., Glahn, D.C., Peluso, M.A., Hatch, J.P., Monkul, E.S., Najt, P., Sanches,<br />
M., et al., Prefrontal hyperactivation during working memory task in untreated<br />
individuals with major depressive disorder. Mol Psychiatry, 2007. 12(2): p. 158-66.<br />
Meda SA, Stevens MC, Potenza MN, Pittman B, Gueorguieva R, Andrews MM,<br />
Thomas AD, Muska C, Hylton JL, Pearlson GD. Investigating the behavioral and<br />
self-report constructs of impulsivity domains using principal component analysis.<br />
Behav Pharmacol. 20<strong>09</strong> Sep;20(5-6):390-9.PMID: 19724194.<br />
Meda SA, Gelernter J, Gruen JR, Calhoun VD, Meng H, Cope NA, Pearlson GD.<br />
Polymorphism of DCDC2 Reveals Differences in Cortical Morphology of Healthy<br />
Individuals-A Preliminary Voxel Based Morphometry Study. Brain Imaging Behav.<br />
Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller<br />
BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer’s Disease<br />
Neuroimaging Initiative. Episodic memory loss is related to hippocampalmediated<br />
beta-amyloid deposition in elderly subjects. Brain. 20<strong>09</strong> May;132(Pt<br />
5):1310-23. Epub <strong>2008</strong> Nov 28.PMID: 19042931.<br />
Najt, P., Perez, J., Sanches, M., Peluso, M.A., Glahn, D. and Soares, J.C.,<br />
Impulsivity and bipolar disorder. Eur Neuropsychopharmacol, 2007. 17(5):313-<br />
20.<br />
Nery FG, Hatch JP, Glahn DC, Nicoletti MA, Monkul ES, Najt P, Fonseca<br />
M, Bowden CL, Cloninger CR, Soares JC. Temperament and character traits<br />
in patients with bipolar disorder and associations with comorbid alcoholism<br />
or anxiety disorders. J Psychiatr Res. <strong>2008</strong> Jun;42(7):569-77. Epub 2007 Aug<br />
6.PMID: 17675066.<br />
72.
Pearlson G. Multisite collaborations and large databases in psychiatric<br />
neuroimaging: advantages, problems, and challenges. Schizophr Bull. 20<strong>09</strong><br />
Jan;35(1):1-2. Epub <strong>2008</strong> Nov 20. PMID: 19023121.<br />
Pearlson GD, Folley BS. Endophenotypes, dimensions, risks: is psychosis analogous<br />
to common inherited medical illnesses? Clin EEG Neurosci. <strong>2008</strong> Apr;39(2):73-7.<br />
Review. PMID: 18450172.<br />
Pearlson GD, Folley BS. Schizophrenia, psychiatric genetics, and Darwinian<br />
psychiatry: an evolutionary framework. Schizophr Bull. <strong>2008</strong> Jul;34(4):722-33.<br />
Epub 2007 Nov 21. Review.PMID: 18033774.<br />
Peluso MA, Glahn DC, Matsuo K, Monkul ES, Najt P, Zamarripa F, Li J, Lancaster<br />
JL, Fox PT, Gao JH, Soares JC. Amygdala hyperactivation in untreated depressed<br />
individuals. Psychiatry Res. 20<strong>09</strong> Aug 30;173(2):158-61. Epub 20<strong>09</strong> Jun 28.PMID:<br />
19545982.<br />
Peluso, M.A., Hatch, J.P., Glahn, D.C., Monkul, E.S., Sanches, M., Najt, P.,<br />
Bowden, C.L. Trait impulsivity in patients with mood disorders. J Affect Disord,<br />
2007. 100(1-3): p. 227-31.<br />
Rabins PV, Pearlson G. Treating dementia: progress and promise. Am J Geriatr<br />
Psychiatry. 20<strong>09</strong> Sep;17(9):723-5. PMID: 1970<strong>09</strong>45.<br />
Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC.<br />
Prefrontal activation deficits during episodic memory in schizophrenia. Am J<br />
Psychiatry. 20<strong>09</strong>, Aug;166(8):863-74. Epub 20<strong>09</strong> May 1. Review. PMID: 19411370.<br />
Rapin I, Dunn MA, Allen DA, Stevens MC, Fein D. Subtypes of language disorders<br />
in school-age children with autism. Dev Neuropsychol. 20<strong>09</strong>;34(1):66-84. PMID:<br />
19142767.<br />
Robinson JL, Bearden CE, Monkul ES, Tordesillas-Gutiérrez D, Velligan DI,<br />
Frangou S, Glahn DC. Fronto-temporal dysregulation in remitted bipolar patients:<br />
an fMRI delayed-non-match-to-sample (DNMS) study. Bipolar Disord. 20<strong>09</strong><br />
Jun;11(4):351-60.PMID: 19500088.<br />
Robinson JL, Laird AR, Glahn DC, Lovallo WR, Fox PT. Meta-analytic<br />
connectivity modeling: Delineating the functional connectivity of the human<br />
amygdala. Hum Brain Mapp. 20<strong>09</strong> Jul 14. [Epub ahead of print]PMID: 19603407.<br />
Robinson JL, Monkul ES, Tordesillas-Gutiérrez D, Franklin C, Bearden CE, Fox<br />
PT, Glahn DC. Fronto-limbic circuitry in euthymic bipolar disorder: evidence for<br />
prefrontal hyperactivation. Psychiatry Res. <strong>2008</strong> Nov 30;164(2):106-13. Epub <strong>2008</strong><br />
Oct 19.PMID: 18930635.<br />
Rogers, J., Kochunov, P., Lancaster, J., Shelledy, W., Glahn, D., Blangero, J. and<br />
Fox, P., Heritability of brain volume, surface area and shape: an MRI study in an<br />
extended pedigree of baboons. Hum Brain Mapp, 2007. 28(6): p. 576-83.<br />
Sabb FW, Bearden CE, Glahn DC, Parker DS, Freimer N, Bilder RM. A<br />
collaborative knowledge base for cognitive phenomics. Mol Psychiatry. <strong>2008</strong><br />
Apr;13(4):350-60. Epub <strong>2008</strong> Jan 8.PMID: 18180765.<br />
Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon<br />
B, Jinnah HA. Serum uric acid and brain ischemia in normal elderly adults.<br />
Neurology. 2007 Oct 2;69(14):1418-23.PMID: 179<strong>09</strong>154.<br />
Schretlen DJ, Testa SM, Winicki JM, Pearlson GD, Gordon B. Frequency<br />
and bases of abnormal performance by healthy adults on neuropsychological<br />
testing. J Int Neuropsychol Soc. <strong>2008</strong> May;14(3):436-45.PMID: 18419842.<br />
Schretlen DJ, Winicki JM, Meyer SM, Testa SM, Pearlson GD, Gordon B.<br />
Development, psychometric properties, and validity of the Hopkins Adult<br />
Reading Test (HART). Clin Neuropsychol. 20<strong>09</strong> Aug;23(6):926-43.PMID:<br />
19191072.<br />
Shane MS, Stevens MC, Harenski CL, Kiehl KA. Double dissociation between<br />
perspective-taking and empathic-concern as predictors of hemodynamic<br />
response to another’s mistakes.<br />
Soc Cogn Affect Neurosci. 20<strong>09</strong> Jun;4(2):111-8. Epub 20<strong>09</strong> Feb 25.PMID:<br />
19244454.<br />
Shipman SL, Baker EK, Pearlson G, Astur RS. Absence of established sex<br />
differences in patients with schizophrenia on a two-dimensional object array<br />
task. Psychiatry Res. 20<strong>09</strong> Apr 30;166(2-3):158-65. Epub 20<strong>09</strong> Mar 10.PMID:<br />
19278735.<br />
Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD. Diffusion<br />
tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res.<br />
<strong>2008</strong> Jan;98(1-3):157-62. Epub 2007 Nov 26.PMID: 18031994.<br />
Skudlarski P, Jagannathan K, Calhoun VD, Hampson M, Skudlarska BA,<br />
Pearlson G. Measuring brain connectivity: diffusion tensor imaging validates<br />
resting state temporal correlations. Neuroimage. <strong>2008</strong> Nov 15;43(3):554-61.<br />
Epub <strong>2008</strong> Aug 15.PMID: 18771736.<br />
Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, Filippini N,<br />
Watkins KE, Toro R, Laird AR, Beckmann CF. Correspondence of the brain’s<br />
functional architecture during activation and rest. Proc Natl Acad Sci U S A.<br />
20<strong>09</strong> Aug 4;106(31):13040-5. Epub 20<strong>09</strong> Jul 20.PMID: 19620724.<br />
Stevens MC, Skudlarski P, Pearlson GD, Calhoun VD. Age-related cognitive<br />
gains are mediated by the effects of white matter development on brain network<br />
integration. Neuroimage. 20<strong>09</strong> Dec;48(4):738-46. Epub 20<strong>09</strong> Jul 3.PMID:<br />
19577651.<br />
Stevens MC, Pearlson GD, Calhoun VD. Changes in the interaction of restingstate<br />
neural networks from adolescence to adulthood. Hum Brain Mapp. 20<strong>09</strong><br />
Aug;30(8):2356-66.PMID: 19172655.<br />
Stevens MC, Pearlson GD, Kiehl KA. Brain network dynamics during error<br />
commission. Hum Brain Mapp. 20<strong>09</strong> Jan;30(1):24-37.<br />
Stevens MC. The developmental cognitive neuroscience of functional<br />
connectivity.<br />
Brain Cogn. 20<strong>09</strong> Jun;70(1):1-12. Epub 20<strong>09</strong> Jan 29. Review.PMID: 19185406.
Sui J, Adali T, Pearlson GD, Calhoun VD. An ICA-based method for the<br />
identification of optimal FMRI features and components using combined groupdiscriminative<br />
techniques. Neuroimage. 20<strong>09</strong> May 15;46(1):73-86. Epub 20<strong>09</strong> Feb<br />
10.PMID: 19457398.<br />
Sui J, Adali T, Pearlson GD, Clark VP, Calhoun VD. A method for accurate group<br />
difference detection by constraining the mixing coefficients in an ICA framework.<br />
Hum Brain Mapp. 20<strong>09</strong> Sep;30(9):2953-70.PMID: 19172631.<br />
van Erp TG, Therman S, Pirkola T, Tuulio-Henriksson A, Glahn DC, Bachman P,<br />
Huttunen MO, Lönnqvist J, Hietanen M, Kaprio J, Koskenvuo M, Cannon TD.<br />
Verbal recall and recognition in twins discordant for schizophrenia. Psychiatry Res.<br />
<strong>2008</strong> Jun 30;159(3):271-80. Epub <strong>2008</strong> Apr 28.PMID: 18442861.<br />
Vannorsdall TD, Waldstein SR, Kraut M, Pearlson GD, Schretlen DJ. White matter<br />
abnormalities and cognition in a community sample. Arch Clin Neuropsychol.<br />
20<strong>09</strong> May;24(3):2<strong>09</strong>-17. Epub 20<strong>09</strong> Jul 18.PMID: 19617597.<br />
Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL.<br />
Comparing the efficacy of interventions that use environmental supports to<br />
improve outcomes in patients with schizophrenia. Schizophr Res. <strong>2008</strong> Jul;102(1-<br />
3):312-9. Epub <strong>2008</strong> Apr 18.PMID: 18374542.<br />
Velligan, D.I., Diamond, P., Glahn, D.C., Ritch, J., Maples, N., Castillo, D.<br />
and Miller, A.L., The reliability and validity of the Test of Adaptive Behavior in<br />
Schizophrenia (TABS). Psychiatry Res, 2007. 151(1-2): p. 55-66<br />
Velligan, D.I., Diamond, P.M., Maples, N.J., Mintz, J., Li, X., Glahn, D.C. and<br />
Miller, A.L., Comparing the efficacy of interventions that use environmental<br />
supports to improve outcomes in patients with schizophrenia. Schizophr Res. <strong>2008</strong><br />
Jul;102(1-3):312-9.<br />
Weiser M, Reichenberg A, Kravitz E, Lubin G, Shmushkevich M, Glahn DC, Gross<br />
R, Rabinowitz J, Noy S, Davidson M. Subtle cognitive dysfunction in nonaffected<br />
siblings of individuals affected by nonpsychotic disorders. Biol Psychiatry. <strong>2008</strong><br />
Mar 15;63(6):602-8. Epub 2007 Sep 7.PMID: 17825797.<br />
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE,<br />
Cannistraro P, Jenike MA, Rauch SL. Augmentation of behavior therapy<br />
with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. <strong>2008</strong><br />
Mar;165(3):335-41; quiz 4<strong>09</strong>. Epub <strong>2008</strong> Feb 1.PMID: 18245177.<br />
Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan K, Ruaño<br />
G. Physiogenomic analysis of localized FMRI brain activity in schizophrenia. Ann<br />
Biomed Eng. <strong>2008</strong> Jun;36(6):877-88. Epub <strong>2008</strong> Mar 11.PMID: 18330705.<br />
Wynn JK, Green MF, Engel S, Korb A, Lee J, Glahn D, Nuechterlein KH, Cohen<br />
MS. Increased extent of object-selective cortex in schizophrenia. Psychiatry Res.<br />
<strong>2008</strong> Nov 30;164(2):97-105. Epub <strong>2008</strong> Oct 19.PMID: 18938066.<br />
Xu L, Pearlson G, Calhoun VD. Joint source based morphometry identifies linked<br />
gray and white matter group differences. Neuroimage. 20<strong>09</strong> Feb 1;44(3):777-89.<br />
Epub <strong>2008</strong> Oct 18.PMID: 18992825.<br />
Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD. Source-based<br />
morphometry: the use of independent component analysis to identify gray<br />
matter differences with application to schizophrenia. Hum Brain Mapp. 20<strong>09</strong><br />
Mar;30(3):711-24.PMID: 18266214.<br />
Zhao, X., Li, G., Glahn, D.C., Fox, P.T. and Gao, J.H., Derivative temporal<br />
clustering analysis: detecting prolonged neuronal activity. Magn Reson Imaging,<br />
2007. 25(2): p. 183-7.<br />
Zuo L, Luo X, Listman JB, Kranzler HR, Wang S, Anton RF, Blumberg HP,<br />
Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, Price<br />
LH, Lappalainen J, Cramer J, Krystal JH, Gelernter J. Population admixture<br />
modulates risk for alcohol dependence. Hum Genet. 20<strong>09</strong> Jun;125(5-6):605-13.<br />
Epub 20<strong>09</strong> Mar 22.PMID: 19306106.<br />
Olin Center Abstracts<br />
Assaf M, Jagannathan K, Miller L, Sahl R, Schultz R and Pearlson<br />
G. Mentalization Network Gray Matter Volume Abnormalities<br />
in Autism Spectrum Disorders. International Meeting for Autism<br />
Research <strong>2008</strong> <strong>Annual</strong> Meeting Proceedings.<br />
Assaf M, Jagannathan K, Moult M, Lorenzoni R, Kraut K, Hart J<br />
and Pearlson G. Semantic Memory Retrieval Brain Abnormalities<br />
in Schizophrenia: State vs. Trait? 20<strong>09</strong> International Congress on<br />
Schizophrenia Research, San Diego, CA.<br />
Assaf, M, Jagannathan, K., Miller, L, O’Boyle, J., Pearlson, G., Sahl,<br />
R., Schultz, R. T. Stevens, M. Default Mode Network in Patients<br />
with High Functioning Autism Spectrum Disorders during Resting<br />
State fMRI. Presented at the International Meeting for Autism<br />
Research, 20<strong>09</strong>: Chicago, IL.<br />
Bellis C, Freed KA, Curran JE, Winkler AM, Carless M, Johnson MP,<br />
Göring HH, Dyer TD, Almasy L, Fox PT, Kochunov P, Duggirala<br />
R, Glahn DC, Moses EK, Blangero J. Deep sequencing of VPS13A<br />
reveals effects on brain function and structure. 59th <strong>Annual</strong> Meeting<br />
of the American Society of Human Genetics, 20-24 October 20<strong>09</strong>,<br />
Honolulu, HI, USA.<br />
Book GA, Thomas AD, Johnson MR, Hylton JL, Andrews MM,<br />
Assaf M and Pearlson GD. Reward Processing in Social Competitive<br />
Task in Subjects with Familial History of Alcoholism. <strong>2008</strong> ICANA<br />
conference.<br />
Calhoun, V.D, Folley, B.S., Meda, S.A., Pearlson, G.D, Stevens,<br />
M.C. Evidence for anomalous network connectivity during working<br />
memory in schizophrenia: An ICA based analysis. Poster presented<br />
at the annual meeting of the Society for Biological Psychiatry, <strong>2008</strong>:<br />
Washington, DC.<br />
74.
Cykowski M, Lancaster JL, Ingham RJ, Ingham J, Winkler AM,<br />
Kochunov P, Fox PT.An omnibus test for case-control studies utilizing<br />
Tract-Based Spatial Statistics (TBSS). 14th Human Brain Mapping, 15-<br />
19th June <strong>2008</strong>, Melbourne, Victoria, Australia.<br />
Della-Justina HM, Winkler AM, Manczak T, de Oliveira PH, de<br />
Araújo DB, Carvalho Neto A, Zwick A, Gamba HR. Development of<br />
a galvanic vestibular stimulator for fMRI exams. 15th Human Brain<br />
Mapping, 18-23 June 20<strong>09</strong>, San Francisco, CA, USA.<br />
Jagannathan K, Pearlson G, Calhoun VD, Kraut MA, Hart J Jr and<br />
Assaf M. Functional network connectivity in schizophrenia during<br />
semantic memory task. Society of Biological Psychiatry <strong>2008</strong> <strong>Annual</strong><br />
Meeting.<br />
Jagannathan K, Assaf M, Calhoun VD, Kraut MA, Hart J Jr and<br />
Pearlson G. Functional network connectivity in semantic memory.<br />
CNS <strong>2008</strong> Anuual Meeting.<br />
Jagannathan K, Assaf M, Calhoun VD, and Pearlson G. Functional<br />
network connectivity in semantic object recall task using independent<br />
component analysis. ISMRM <strong>2008</strong> <strong>Annual</strong> meeting.<br />
Jagannathan K, Moult M, Pearlson GD and Assaf M. Abnormal<br />
Functional Connectivity in the Default Mode Network in<br />
Schizophrenia: State vs. Trait? Society of Biological Psychiatry 20<strong>09</strong><br />
<strong>Annual</strong> Meeting, Vancouver, CA.<br />
Jagannathan K, Calhoun VD, Gelernter J, Liu J, Bolognani F,<br />
Assaf M, Pearlson GD. Genetic associations of brain structural<br />
networks in schizophrenia-a preliminary study. American College<br />
of Neuropsychopharmacology. ACNP 20<strong>09</strong> <strong>Annual</strong> Meeting,<br />
Hollywood, FL.<br />
Jagannathan, K, Moult, M, Pearlson, G.D., Sharma, R., Stevens,<br />
M.C., von Pechmann, D. Event-Related Spectral Perturbations In<br />
Schizophrenia And Healthy Controls During Auditory Oddball<br />
Performance. Presented at EPIC XV: The 15th International Congress<br />
on Event-Related Potential of the Brain, 20<strong>09</strong>: Indianapolis, IN.<br />
Kochunov P, Glahn DC, Winkler AM, Duggirala R, Olvera RL,<br />
Cole S, Dyer TD, Almasy L, Fox PT, Blangero J. Analysis of genetic<br />
variability and whole genome linkage of whole-brain, subcortical,<br />
and ependymal hyperintense white matter volume. Stroke<br />
20<strong>09</strong>;40(12):3685-90<br />
Kochunov P, Winkler AM, Blangero J, Lancaster JL, Almasy L, Fox PT,<br />
Glahn DC.<br />
Genetics of DTI-derived parameters of cerebral white matter. A<br />
track-based heritability and linkage study in extended pedigree. 15th<br />
Human Brain Mapping, 18-23 June 20<strong>09</strong>, San Francisco, CA, USA.<br />
Kochunov P, Blangero J, Winkler AM, Cole S, Almasy L, Lancaster<br />
JL, Fox PT, Glahn DC. Heritability and linkage analysis of<br />
hyperintense (FLAIR) white matter lesion volumes in normal aging.<br />
15th Human Brain Mapping, 18-23 June 20<strong>09</strong>, San Francisco, CA,<br />
USA.<br />
Kochunov P, Blangero J, Winkler AM, Lancaster JL, Kochunova<br />
V, Mangin JF, Cachia A, Fox PT, Glahn DC. Heritability of gyral<br />
surface area and gyral gray matter thickness. 15th Human Brain<br />
Mapping, 18-23 June 20<strong>09</strong>, San Francisco, CA, USA.<br />
Kochunov P, Glahn DC, Cole S, Dyer TD, Almasy L, Winkler AM,<br />
Lancaster JL, Kochunova V, Fox PT. Genetics of cerebral aging.<br />
Heritability and linkage analysis of cerebral health markers in a large<br />
multifamily pedigree. 15th Human Brain Mapping, 18-23 June 20<strong>09</strong>,<br />
San Francisco, CA, USA.<br />
Miller L, Assaf M, Book G and Pearlson G. Face Building: An fMRI<br />
investigation of brain activation of faces versus houses, objects, and<br />
patterns in individuals with high functioning autism. <strong>2008</strong> Cognitive<br />
Neuroscience Society <strong>Annual</strong> Meeting, San Francisco, CA.<br />
Miller L, Jagannathan K, O’Boyle J, Schultz R, Stevens M, Sahl R,<br />
Pearlson G and Assaf M. Default Mode Network in Patients with<br />
High Functioning Autism Spectrum Disorders During Resting State<br />
fMRI. International Meeting for Autism Research 20<strong>09</strong> <strong>Annual</strong><br />
Meeting Proceedings. Chicago, IL.<br />
Pearlson G.D., Stevens M.C. Szeles D.M. Age-related Differences in<br />
Mental Timekeeping: an fMRI study. Poster presented at the annual<br />
meeting of the Society for Biological Psychiatry, <strong>2008</strong>: Washington,<br />
DC.<br />
Skudlarski P, Skudlarska B, Pearlson G. Age Related Changes in the<br />
Brain Connectivity Revealed and Characterized by Fusion of Two<br />
Neuroimaging Modalities : Diffusion Tensor Imaging and Resting<br />
State Functional Connectivity. American Geriatric Society 20<strong>09</strong>,<br />
Chicago, IL.<br />
Skudlarski P, Anderson K, Stevens M, Pearlson G. Schizophrenia<br />
Disconnection Analyzed by Conjunction of fMRI Resting<br />
Connectivity and Diffusion Tensor Imaging. Human Brain Mapping<br />
20<strong>09</strong>, San Francisco, CA.<br />
Skudlarski P, Anderson K, Pearlson G. Functional Connectivity Is<br />
More Closely linked to Anatomical Connectivity in Schizophrenia.<br />
International Conference Schizophrenia Research 20<strong>09</strong>, San Diego,<br />
CA.<br />
Winkler AM, Kochunov P, Dierschke NA, Lancaster JL, Fox PT,<br />
Glahn DC. An automatic segmentation tool for white matter<br />
hyperintensities using FLAIR and T1-weighted images. 15th Human<br />
Brain Mapping, 18-23 June 20<strong>09</strong>, San Francisco, CA, USA.
Anxiety Disorders Center<br />
Winkler AM, Kochunov P, Fox PT, Duggirala R, Almasy L,<br />
Blangero J, Glahn DC. Heritability of volume, surface area and<br />
thickness for anatomically defined cortical brain regions estimated<br />
in a large extended pedigree. 15th Human Brain Mapping, 18-23<br />
June 20<strong>09</strong>, San Francisco, CA, USA.<br />
Winkler AM, Kochunov P, Dierschke NA, Fox PT, Blangero<br />
J, Glahn DC. Heritability of gray matter density estimated in<br />
large extended pedigrees. 64th <strong>Annual</strong> Meeting of the Society of<br />
Biological Psychiatry, 14-16 May 20<strong>09</strong>, Vancouver, BC, Canada.<br />
Winkler AM, Nichols TE, Glahn DC. On non-normality, nonparametric<br />
tests and pooling permutations over space for Voxel<br />
Based Morphometry. 14th Human Brain Mapping, 15-19th June<br />
<strong>2008</strong>, Melbourne, Victoria, Australia.<br />
David F. Tolin, PhD, Director<br />
Faculty and Staff:<br />
David F. Tolin, PhD, ABPP, Director<br />
Gretchen J. Diefenbach, PhD, Senior Scientist<br />
Scott Hannan, PhD, Staff Psychologist<br />
Elizabeth Moore, PhD, Staff Psychologist<br />
Christina Gilliam, PhD, Staff Psychologist<br />
Samantha Morrison, PhD, Postdoctoral Fellow<br />
Anna Villavicencio, PhD, Postdoctoral Fellow<br />
Christina Ryan, Research Assistant<br />
Dianna Hidalgo, Research Assistant<br />
Diana Harrington, Research Assistant<br />
The mission of the Anxiety Disorders Center (ADC) at The Institute<br />
of Living is to provide evidence-based psychosocial treatment<br />
for anxiety-related problems, to conduct meaningful research on the<br />
nature and treatment of anxiety, and to provide education for students,<br />
staff, and the community. Areas of clinical emphasis include obsessivecompulsive<br />
disorder and obsessive-compulsive spectrum disorders,<br />
generalized anxiety disorder, panic disorder, social phobia, and<br />
posttraumatic stress disorder.<br />
Compulsive Hoarding Research: The ADC has developed the nation’s<br />
largest and most comprehensive program of research on compulsive<br />
hoarding. In one recently-completed study, Psychopathology of<br />
Compulsive Hoarding (sponsor: NIMH), we interviewed large<br />
numbers of patients with compulsive hoarding, patients with obsessivecompulsive<br />
disorder, and participants without mental disorders in order<br />
to define the phenomenon of compulsive hoarding and differentiate<br />
it from obsessive-compulsive disorder. An ongoing study, Neural<br />
Mechanisms of Compulsive Hoarding (sponsor: NIMH), uses functional<br />
magnetic resonance imaging (fMRI) to examine brain activity during a<br />
decision-making task in compulsive hoarding patients with and without<br />
major depressive disorder, obsessive-compulsive disorder patients,<br />
and individuals without mental disorders. In Neuropsychological<br />
Functioning in Compulsive Hoarding (sponsor: <strong>Hartford</strong> <strong>Hospital</strong>),<br />
we are examining brain-behavior relationships by assessing a variety<br />
of cognitive functions in individuals with and without compulsive<br />
76.
hoarding. Finally, we recently completed Treatment of Compulsive<br />
Hoarding (sponsor: NIMH), the aim of which was to develop and test a<br />
cognitive-behavioral intervention for patients with compulsive hoarding.<br />
This year, Dr. Tolin submitted three additional NIMH grants related<br />
to compulsive hoarding. Two of these propose to augment cognitivebehavioral<br />
therapy with the stimulant medication methylphenidate<br />
(study 1) or cognitive remediation exercises (study 2). The third grant,<br />
a continuation of the fMRI study, proposes to examine changes in neural<br />
activity among hoarders receiving cognitive-behavioral therapy.<br />
Obsessive-Compulsive Disorder (OCD) and Obsessive-Compulsive<br />
Spectrum Research: We recently completed enrollment for the study<br />
Stepped Care for Obsessive-Compulsive Disorder (sponsor: NIMH),<br />
the aim of which is to develop and test a variant of cognitive-behavioral<br />
therapy for OCD in which patients start with a largely self-directed<br />
treatment and move to progressively more intensive treatment as needed.<br />
We also finished D-Cycloserine Augmentation of Behavior Therapy<br />
for Obsessive-Compulsive Disorder (unfunded), a pilot study in which<br />
the n-methyl d-aspartate (NMDA) receptor agonist d-cycloserine was<br />
added to traditional cognitive-behavioral therapy. Results of that study<br />
(published in American Journal of Psychiatry) were promising and<br />
led to the development of a multi-site grant proposal to the National<br />
Institute of Mental Health. We are currently conducting a follow-up<br />
study, D-Cycloserine for OCD Treatment Nonresponders (sponsor:<br />
<strong>Hartford</strong> <strong>Hospital</strong>), in which cognitive-behavioral therapy plus openlabel<br />
d-cycloserine are provided for patients who have failed to respond<br />
to cognitive-behavioral monotherapy. We have also partnered with<br />
Columbia University and the University of Pennsylvania to collaborate<br />
on the study Maximizing Treatment Outcome for OCD (sponsor:<br />
NIMH), which compares cognitive-behavioral therapy and the<br />
medication risperidone for OCD patients who have not responded fully<br />
to antidepressant medications.<br />
Older Adult Research: Dr. Gretchen Diefenbach has developed several<br />
studies investigating anxiety-related concerns in older adults. In one<br />
study, Screening for GAD among Frail Elderly (sponsor: NIMH), we<br />
examined optimal ways to assess frail older individuals receiving home<br />
care services for generalized anxiety disorder and related concerns.<br />
Another study, The Nature and Impact of Anxiety Symptoms upon<br />
Psychosocial Functioning of Older Adults with Major Depressive<br />
Disorder (sponsor: <strong>Hartford</strong> <strong>Hospital</strong>), examined differences between<br />
older depressed patients with and without anxiety symptoms who<br />
were attending the Geriatric Day Program at the Institute of Living.<br />
Finally, the recently-completed study Cognitive Enhancing Effects<br />
of D-Cycloserine among Non-Demented Elderly (sponsor: <strong>Hartford</strong><br />
<strong>Hospital</strong>) examined whether d-cycloserine can affect cognitive processes<br />
such as learning, memory, and attention in older adults with ageappropriate<br />
cognitive function.<br />
Panic Disorder Research: We recently completed the study Augmenting<br />
Exposure Therapy with an NMDA Agonist: A Pilot Study (sponsor:<br />
<strong>Hartford</strong> <strong>Hospital</strong>), in which we examined the effect of adding<br />
d-cycloserine to brief cognitive-behavioral therapy for adults with panic<br />
disorder. Results of that study (currently in preparation for submission)<br />
led to the development of our current study, Exposure, D-Cycloserine<br />
Enhancement, and Genetic Modulators in Panic Disorder (sponsor:<br />
NIMH), in which we are conducting a larger version of the study<br />
and examining genetic factors associated with response to cognitivebehavioral<br />
therapy and d-cycloserine. A parallel study, A Multi-Center,<br />
Double-Blind, Fixed Dose Trial Examining the Safety and Efficacy of Org<br />
25935 vs. Placebo as Augmentation to Cognitive Behavioral Therapy in<br />
Subjects with Panic Disorder (sponsor: Organon/Schering-Plough), tests<br />
whether an alternative NMDA receptor agonist can augment cognitivebehavioral<br />
therapy.<br />
Anxiety Disorders Center<br />
Peer Reviewed Publications<br />
Aikins, D.E., Johnson, D.C., Borelli, J.K., Klemanski, D., Morrissey, P.M., Southwick,<br />
S., & Tolin, D.F. (20<strong>09</strong>). Thought suppression failures in combat PTSD: A<br />
cognitive load hypothesis. Behaviour Research and Therapy, 47, 744-751.<br />
Corcoran, K. M., Woody, S. R., & Tolin, D. F. (<strong>2008</strong>). Recognition of facial<br />
expressions in obsessive-compulsive disorder. Journal of Anxiety Disorders, 22,<br />
56-66.<br />
Diefenbach, G.J., Abramowitz, J.S., Norberg, M., & Tolin, D.F. (2007). Changes<br />
in quality of life following cognitive-behavior therapy for obsessive-compulsive<br />
disorder. Behaviour Research and Therapy, 45, 3060-3068.<br />
Diefenbach, G. J., Tolin, D. F., Meunier, S. A., & Gilliam, C. M. (20<strong>09</strong>). Assessment<br />
of anxiety in older home care recipients. The Gerontologist, 49, 141-153.<br />
Diefenbach, G. J., Tolin, D. F., Meunier, S., & Worhunsky, P. (<strong>2008</strong>). Emotion<br />
regulation and trichotillomania: a comparison of clinical and nonclinical hair pulling.<br />
Journal of Behavior Therapy and Experimental Psychiatry, 39, 32-41.<br />
Frost, R. O., Steketee, G., Tolin, D. F., & Renaud, S. (<strong>2008</strong>). Development and<br />
validation of the Clutter Image Rating. Journal of Psychopathology and Behavioral<br />
Assessment, 32, 401-417.<br />
Frost, R. O., Tolin, D. F., Steketee, G., Fitch, K. E., & Selbo-Bruns, A. (20<strong>09</strong>).<br />
Excessive acquisition in hoarding. Journal of Anxiety Disorders, 23, 632-639.<br />
Norberg, M. M., Diefenbach, G. J., & Tolin, D. F. (<strong>2008</strong>). Quality of life and<br />
anxiety and depressive disorder comorbidity. Journal of Anxiety Disorders, 22,<br />
1516-1522.<br />
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (<strong>2008</strong>). A meta-analysis of d-<br />
cycloserine and the facilitation of fear extinction and exposure therapy. Biological<br />
Psychiatry, 63, 1118-1126.
Olatunji, B.O., Cisler, J., & Tolin, D.F. (2007). Quality of life in the anxiety disorders:<br />
A meta-analytic review. Clinical Psychology Review, 27, 572-581.<br />
Olatunji, B. O., Williams, B. J., Haslam, N., Abramowitz, J. S., & Tolin, D. F.<br />
(<strong>2008</strong>). The latent structure of obsessive-compulsive symptoms: A taxometric<br />
study. Depression and Anxiety, 25, 956-968.<br />
Olatunji, B.O., Williams, N.L., Tolin, D.F., Sawchuk, C.N., Abramowitz, J.S.,<br />
Lohr, J.M., & Elwood, L. (2007). The Disgust Scale: Item analysis, factor structure,<br />
and suggestions for refinement. Psychological Assessment, 19, 281-297.<br />
Tolin, D. F., Brady, R. E., & Hannan, S. E. (<strong>2008</strong>). Obsessional beliefs and symptoms<br />
of obsessive-compulsive disorder in a clinical sample. Journal of Psychopathology<br />
and Behavioral Assessment, 30, 31-42.<br />
Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Keuthen, N.J., Moore,<br />
P., Piacentini, J., Stein, D.J., & Woods, D.W. (<strong>2008</strong>). The Trichotillomania Scale<br />
for Children: Development and validation. Child Psychiatry and Human Development,<br />
39, 331-349.<br />
Tolin, D.F., Franklin, M.E., Diefenbach, G.J., Anderson, E., & Meunier, S.A.<br />
(2007). Pediatric trichotillomania: Descriptive psychopathology and an open trial<br />
of cognitive-behavioral therapy. Cognitive Behaviour Therapy, 36, 129-144.<br />
Tolin, D.F., Frost, R.O., & Steketee, G. (2007). An open trial of cognitivebehavioral<br />
therapy for compulsive hoarding. Behaviour Research and Therapy, 45,<br />
1461-1470.<br />
Tolin, D. F., Frost, R. O., Steketee, G., & Fitch, K. E. (<strong>2008</strong>). Family burden of<br />
compulsive hoarding: Results of an internet survey. Behaviour Research and<br />
Therapy, 46, 334-344.<br />
Tolin, D. F., Frost, R. O., Steketee, G., Gray, K. D., & Fitch, K. E. (<strong>2008</strong>). The<br />
economic and social burden of compulsive hoarding. Psychiatry Research, 160,<br />
200-211.<br />
Tolin, D.F., Hannan, S., Maltby, N., Diefenbach, G.J., Worhunsky, P., & Brady,<br />
R.E. (2007). A randomized controlled trial of self-directed versus therapistdirected<br />
CBT for OCD patients with prior medication trials. Behavior Therapy,<br />
38, 179-191.<br />
Tolin, D. F., Kiehl, K. A., Worhunsky, P., Book, G. A., & Maltby, N. (20<strong>09</strong>). An<br />
exploratory study of the neural mechanisms of decision-making in compulsive<br />
hoarding. Psychological Medicine, 38, 1-12.<br />
Tolin, D.F., Robison, J.T., Gaztambide, S., Horowitz, S., & Blank, K. (2007).<br />
Ataques de nervios and psychiatric disorders in older Puerto Rican primary care<br />
patients. Journal of Cross-Cultural Psychology, 38, 659-669.<br />
Tolin, D. F., Whiting, S., Maltby, N., Diefenbach, G. J., Lothstein, M. A.,<br />
Hardcastle, S., Catalano, A., & Gray, K. D. (20<strong>09</strong>). Intensive (daily) behavior<br />
therapy for school refusal: A multiple baseline case series. Cognitive and<br />
Behavioral Practice, 16, 332-344.<br />
Tolin, D.F., Worhunsky, P., Brady, R.E., & Maltby, N. (2007). The relationship<br />
between obsessive beliefs and thought control strategies in a clinical sample.<br />
Cognitive Therapy and Research, 31, 307-318.<br />
Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H.E.,<br />
Cannistraro, P., Jenike, M.A., & Rauch, S.L. (<strong>2008</strong>). Augmentation of behavior<br />
therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of<br />
Psychiatry, 165, 335-341.<br />
Anxiety Disorders Center Non-Peer<br />
Reviewed Articles<br />
Tolin, D. F. (20<strong>09</strong>). Alphabet soup: ERP, CT, and ACT for OCD. Cognitive and<br />
Behavioral Practice, 16, 40-48.<br />
Tolin, D.F., & Breslau, N. (2007). Sex differences in risk of PTSD. PTSD Research<br />
Quarterly, 18, 1-7.<br />
Tolin, D.F., & Lohr, J.M. (20<strong>09</strong>, Fall). Psychologists, American Psychological<br />
Association, and torture. Clinical Science, 4-10.<br />
Books and Book Chapters<br />
Edelberg, M., & Tolin, D. F. (<strong>2008</strong>). The Posttraumatic Cognitions Inventory. In G.<br />
Reyes, J. D. Elhai, & J. Ford (Eds.), Encyclopedia of psychological trauma (pp. 480-<br />
481). New York: John Wiley & Sons.<br />
Franklin, M.E., & Tolin, D.F. (2007). Treating trichotillomania: Cognitive behavior<br />
therapy for hair pulling and related problems. New York: Springer.<br />
Franklin, M.E., Tolin, D.F., & Diefenbach, G.J. (2007). Trichotillomania. In<br />
Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder:<br />
Subtypes and spectrum conditions (pp. 139-159). New York: Elsevier.<br />
Frost, R.O., & Tolin, D.F. (<strong>2008</strong>). Compulsive hoarding. In S. Taylor, J. S.<br />
Abramowitz, & D. McKay (Eds.), Clinical handbook of obsessive-compulsive<br />
disorder and related problems (pp. 76-94). Baltimore: Johns Hopkins University<br />
Press.<br />
Meunier, S.A., Maltby, N.A., & Tolin, D.F. (<strong>2008</strong>). Compulsive hoarding. In M.<br />
Hersen (Series & Vol. Ed.) & J. Rosqvist (Vol. Ed.), The handbook of assessment,<br />
conceptualization, and treatment: Vol. 1 (pp. 728-752). New York: John Wiley &<br />
Sons.<br />
Tolin, D.F., Frost, R.O., & Steketee, G. (2007). Buried in treasures: Help for<br />
compulsive acquiring, saving and hoarding. New York: Oxford University Press.<br />
Tolin, D.F., & Maltby, N. (<strong>2008</strong>). Motivating treatment-refusing patients with<br />
obsessive-compulsive disorder. In H. Arkowitz, H.A. Westra, W.R. Miller, & S.<br />
Rollnick (Eds.), Motivational interviewing in the treatment of psychological problems<br />
(pp. 85-108). New York: Guilford Press.<br />
78.
Tolin, D.F., & Meunier, S.A. (2007). Contamination and decontamination. In<br />
Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder:<br />
Subtypes and spectrum conditions (pp. 3-18). New York: Elsevier.<br />
Tolin, D.F., & Steketee, G. (2007). General issues in psychological treatment for<br />
OCD. In M.M. Antony, C.L. Purdon, & L.J. Summerfeldt (Eds.), Psychological<br />
treatment of OCD: Fundamentals and beyond (pp. 31-59). Washington, DC:<br />
American Psychological Association.<br />
Treadwell, K. R. H., & Tolin, D. F. (2007). Clinical challenges in the treatment of<br />
pediatric OCD. In E. A. Storch, T. K. Murphy, & G. R. Geffken (Eds.), A comprehensive<br />
handbook of child and adolescent obsessive-compulsive disorder (pp.<br />
273-294). Mahwah, NJ: Lawrence Erlbaum Associates.<br />
Anxiety Disorders Center Abstracts<br />
Chasson, G.S., Buhlmann, U., Tolin, D.F., Rowley, T., Welsh, K.S., & Wilhelm,<br />
S. (20<strong>09</strong>, March). How much quicker? Accelerating OCD recovery using<br />
d-cycloserine to enhance exposure and response prevention. Paper presented at<br />
the <strong>Annual</strong> Meeting of the Anxiety Disorders Association of America, Santa Ana<br />
Pueblo, NM.<br />
Cisler, J., Lohr, J. M., Tolin, D. F., Olatunji, B. O., Willems, J. L., & Brady, R. E.<br />
(<strong>2008</strong>, November). Development and initial validation of the Contamination<br />
Aversion Scale. Paper presented at the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Orlando, FL.<br />
Diefenbach, G.J., Tolin, D.F., & Edelberg, M. (2007, November). Predicting<br />
quality of life among older adults with major depressive disorder: The potential<br />
role of worry severity. Presented to the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Philadelphia.<br />
Diefenbach, G.J., Tolin, D.F., Meunier, S.A., Gilliam, C., & Edelberg, M. (2007,<br />
November). Psychometric properties of anxiety measures among elderly receiving<br />
home health care services. Presented to the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Philadelphia.<br />
Fabricant, L., Frost, R.O., Tolin, D.F., & Steketee, G. (2007, November). The role<br />
of homework in the treatment of compulsive hoarding. Presented to the <strong>Annual</strong><br />
Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Fitch, K.E., Ring, K.M., & Tolin, D.F. (<strong>2008</strong>, November). Long-term effectiveness<br />
of cognitive-behavioral therapy for anxiety in an adult outpatient clinic sample.<br />
Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Orlando, FL.<br />
Fitch, K.E., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November).<br />
Compulsive hoarding: Assessing insight. Presented to the <strong>Annual</strong> Meeting of the<br />
Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Frost, R.O., Steketee, G., Tolin, D.F., Sorrentino, C., Carlson, S., & Brady, R.E.<br />
(2007, November). Cognitive-behavioral therapy for compulsive hoarding:<br />
Results from a controlled trial. In D.F. Tolin (Chair), The nature and treatment<br />
of compulsive hoarding. Symposium presented to the <strong>Annual</strong> Meeting of the<br />
Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Gibson, A., Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (<strong>2008</strong>,<br />
November). Ethical considerations in the treatment of compulsive hoarding.<br />
Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Orlando, FL.<br />
Gilliam, C.M., Brady, R.E., & Tolin, D.F. (2007, November). Changes in obsessive<br />
beliefs following CBT among individuals with OCD. Presented to the <strong>Annual</strong><br />
Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Gilliam, C.M., Diefenbach, G.J., Catayong, K.D., Pearlson, G.D., Blank, K.,<br />
& Tolin, D.F. (<strong>2008</strong>, November). Emotion regulation and anxiety disorders: A<br />
lifespan perspective. Presented to the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Orlando, FL.<br />
Gilliam, C.M., Diefenbach, G.J., Tolin, D.F., & Edelberg, M.L. (2007, November).<br />
The role of metacognitive beliefs and experiential avoidance in late-life anxiety.<br />
Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Philadelphia.<br />
Gilliam, C.M., Tolin, D.F., Diefenbach, G.J., Carlson, S.E., Whiting, S.E.,<br />
Norberg, M.M., & Meunier, S.A. (<strong>2008</strong>, November). Stepped care for obsessivecompulsive<br />
disorder: A replication and extension. Presented to the <strong>Annual</strong><br />
Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL.<br />
Gilliam, C.M., Tolin, D.F., & Pineault, J. (2007, November). Attentional bias<br />
in panic disorder: The impact of cognitive behavioral treatment. Presented to<br />
the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive Therapies,<br />
Philadelphia.<br />
Hannan, S.E., Diefenbach, G.J., Meunier, S.A., Norberg, M.M., & Tolin, D.F.<br />
(<strong>2008</strong>, November). Intensive treatment for pediatric OCD: Results from an<br />
outpatient treatment setting. Presented to the <strong>Annual</strong> Meeting of the Association<br />
of Behavioral and Cognitive Therapies, Orlando, FL.<br />
Hannan, S.E., Edelberg, M., & Tolin, D.F. (2007, November). Factors associated<br />
with work impairment in individuals with diagnoses of anxiety and depressive<br />
disorders. Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and<br />
Cognitive Therapies, Philadelphia.<br />
Hannan, S.E., & Tolin, D.F. (2007, November). Examination of the validity of<br />
therapist rated and patient rated Clinical Global Impression scores. Presented to<br />
the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive Therapies,<br />
Philadelphia.<br />
Hannan, S.E., Tolin, D.F., Meunier, S.A., Norberg, M.M., Gilliam, C.M., &<br />
Diefenbach, G.J. (<strong>2008</strong>, November). Intensive treatment for OCD: Results<br />
from a psychiatric hospital outpatient treatment setting. Presented to the <strong>Annual</strong><br />
Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL.<br />
Koby, D. G., Tartar, S., Carlson, S., Meunier, S. A., Lovejoy, D. W., Kurtz, M., &<br />
Tolin, D. F. (<strong>2008</strong>, November). Emerging evidence for frontal lobe dysfunction<br />
in compulsive hoarding. Paper presented at the <strong>Annual</strong> Meeting of the National<br />
Academy of Neuropsychology, New York.
Loew, B., Talbott, S. N., Khanna, M., Diefenbach, G. J., Tolin, D. F., & Franklin,<br />
M. E. (<strong>2008</strong>, November). Family functioning in pediatric trichotillomania: Results<br />
from a randomized, controlled trial. Paper presented at the <strong>Annual</strong> Meeting of<br />
the Association of Behavioral and Cognitive Therapies, Orlando, FL.<br />
Meunier, S.A., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November). The<br />
impact of significant life events on hoarding symptom severity and course. In D.F.<br />
Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium<br />
presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Philadelphia.<br />
Muroff, J., Steketee, G., Rasmussen, J., Gibson, A., Frost, R.O., & Tolin, D.F.<br />
(2007, November). Group cognitive and behavioral treatment (CBT) for<br />
compulsive hoarding. In D.F. Tolin (Chair), The nature and treatment of<br />
compulsive hoarding. Symposium presented to the <strong>Annual</strong> Meeting of the<br />
Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Oh, M., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K. E. (<strong>2008</strong>, November).<br />
Indecisiveness and compulsive hoarding. Paper presented at the <strong>Annual</strong> Meeting<br />
of the Association of Behavioral and Cognitive Therapies, Orlando, FL.<br />
Olatunji, B. O., Ciesielski, B. G., & Tolin, D. F. (20<strong>09</strong>, March). A meta-analytic<br />
review of the specificity of anger in PTSD. Paper presented at the <strong>Annual</strong><br />
Meeting of the Anxiety Disorders Association of America, Santa Ana Pueblo,<br />
NM.<br />
Pekareva-Kochergina, A., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K.<br />
E. (<strong>2008</strong>, November). OCD symptoms and associated features in early- versus<br />
late-onset hoarding. Paper presented at the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Orlando, FL.<br />
Rasmussen, J. L., Muroff, J., Steketee, G., Tolin, D. F., & Frost, R. O. (<strong>2008</strong>,<br />
November). Family psychopathology in an internet study of compulsive<br />
hoarding. Paper presented at the <strong>Annual</strong> Meeting of the Association of Behavioral<br />
and Cognitive Therapies, Orlando, FL.<br />
Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November).<br />
Prevalence and associated characteristics of squalor in an internet sample of<br />
compulsive hoarders. Presented to the <strong>Annual</strong> Meeting of the Association of<br />
Behavioral and Cognitive Therapies, Philadelphia.<br />
Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). The<br />
Home Environment Index: A measure of squalor in compulsive hoarding.<br />
Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Philadelphia.<br />
Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). Enhancing motivation<br />
in treatment for compulsive hoarding. Presented to the <strong>Annual</strong> Meeting of the<br />
Association of Behavioral and Cognitive Therapies, Philadelphia.<br />
Tolin, D. F. (<strong>2008</strong>, July). Enhancing the efficacy of behavior therapy for OCD with<br />
d-cycloserine. Presented to the International Congress of Psychology, Berlin.<br />
Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Woods, D.W.,<br />
Keuthen, N.J., Moore, P., Piacentini, J., & Stein, D.J. (2007, November). The<br />
Trichotillomania Scale for Children: Development and validation. Presented to<br />
the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive Therapies,<br />
Philadelphia.<br />
Tolin, D. F., Frost, R. O., & Steketee, G. (<strong>2008</strong>, July). Buried in treasures:<br />
Cognitive-behavioral therapy for compulsive hoarding. Presented to the British<br />
Association of Behavioural and Cognitive Psychotherapies, Edinburgh.<br />
Tolin, D.F., Frost, R.O., Steketee, G., Gray, K.D., & Fitch, K.E. (2007,<br />
November). The economic and social burden of compulsive hoarding. In D.F.<br />
Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium<br />
presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive<br />
Therapies, Philadelphia.<br />
Tolin, D. F., Norberg, M. M., & Krystal, J. H. (<strong>2008</strong>, August). A meta-analysis<br />
of d-cycloserine and the facilitation of fear extinction and exposure therapy.<br />
Presented to the <strong>Annual</strong> Meeting of the Obsessive-Compulsive Foundation,<br />
Boston.<br />
Tolin, D.F., Steketee, G., Frost, R.O., Monteiro, M., & Fitch, K.E. (2007,<br />
November). Compulsive hoarding: Assessing family burden. Presented to the<br />
<strong>Annual</strong> Meeting of the Association of Behavioral and Cognitive Therapies,<br />
Philadelphia.<br />
Treadway, M., Frost, R.O., Steketee, G., Tolin, D.F., & Fabricant, L. (2007,<br />
November). Compulsive hoarding and generalized anxiety disorder: Features and<br />
correlates. Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and<br />
Cognitive Therapies, Philadelphia.<br />
Whiting, S.E., & Tolin, D.F. (<strong>2008</strong>, November). Psychosocial impairment in<br />
childhood anxiety: Utility and validation of the Sheehan Disability Scale-Child/<br />
Parent Version. Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral<br />
and Cognitive Therapies, Orlando, FL.<br />
Whiting, S.E., Tolin, D.F., Maltby, N., & Gray, K.D. (<strong>2008</strong>, November). Intensive<br />
(daily) cognitive behavior therapy for school refusal: A multiple baseline case<br />
series. Presented to the <strong>Annual</strong> Meeting of the Association of Behavioral and<br />
Cognitive Therapies, Orlando, FL.<br />
Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H.,<br />
Cannistraro, P., Jenike, M.A., Pitman, R., & Rauch, S. (<strong>2008</strong>, July). D-cycloserine<br />
augmentation of behavior therapy for obsessive-compulsive disorder. Presented to<br />
the British Association of Behavioural and Cognitive Psychotherapies, Edinburgh.<br />
Tolin, D.F. (2007, November). The nature and treatment of compulsive hoarding.<br />
Symposium presented to the <strong>Annual</strong> Meeting of the Association of Behavioral<br />
and Cognitive Therapies, Philadelphia.<br />
80.
Braceland Center<br />
for Mental Health and Aging<br />
Director: Karen Blank, MD<br />
Assistant Director: Charles Wilber MEd<br />
Faculty and Staff:<br />
Denise Fogel, PsyD • Jackie Cmero, OT<br />
Meghan Lawrence, LCSW • Gretchen Difenbach, PhD<br />
Karen Raigaisis, RN • Ilene West, PsyD<br />
Kheera Bandari, BS<br />
The Braceland Center’s research programs address issues related to normal<br />
aging, to medical and psychiatric disorders such as Alzheimer’s disease,<br />
and to the physical, emotional and overall well being of the elderly. As<br />
one of the four research centers at the Institute of Living, we actively<br />
collaborate with the other centers. Our research accomplishments include<br />
the following:<br />
Memory Disorders Center Electronic research database: The Memory<br />
Disorders Center (MDC) has successfully designed a comprehensive<br />
intake form for all new patients to the Memory Disorders Center. The<br />
form is electronically scanned into a database that supports a vast array<br />
of research questions and proposals. To date 103 new intakes have<br />
been entered and we have obtained written consent for inclusion in the<br />
electronic database for 100% of new MDC patients.<br />
Alzheimer’s Disease Neuroimaging Initiative (ADNI): The Braceland<br />
Center, in collaboration with the Olin Center, has been an active site<br />
for this NIH-funded multi-site, 80+ million dollar study. We have<br />
nearly completed three years of data collection with a total of 14<br />
participants. Through the Alzheimer’s Disease Neuroimaging Initiative<br />
– Grand Opportunity (ADNI-GO) Study, our site will participate in the<br />
recruitment of additional Early MCI (EMCI) participants and includes<br />
follow-up of participants originally enrolled as Cognitively Normal (CN)<br />
or Late MCI (LMCI) in the original ADNI.<br />
Cognitive training in the elderly: We have been awarded a grant from<br />
the <strong>Hartford</strong> <strong>Hospital</strong> Research Program to develop a novel approach for<br />
cognitive training in the elderly with normal aging and mild cognitive<br />
impairments including persons with mild depression. We are currently<br />
recruiting our second group of subjects into this manualized training<br />
program. Subjects receive group and computerized training sessions,<br />
genetic testing, and a subset will receive functional neuroimaging all<br />
with before and after assessment of neuropsychological and functional<br />
performance and Quality of life.<br />
Anxiety disorders, mild memory disorders and early dementia: We<br />
have gained research office approval for a study on anxiety disorders<br />
and symptoms among patients with mild memory disorders and early<br />
dementia aimed to better delineate those anxiety features that correlate<br />
with and possible help identify those at risk for cognitive decline and<br />
dementia.<br />
D-cycloserine in neuropsychological test performance in older<br />
adults: We have collaborated with researchers from the Anxiety<br />
Disorders Center on a study examining the effects of D-cycloserine on<br />
neuropsychological test performance in older adults.<br />
Financial decisional capacity and psychiatric disability: In collaboration<br />
with faculty at Yale University School of Medicine, we have received<br />
funding on two new NIH intervention grants to assess and improve<br />
financial decisional capacity in individuals with serious psychiatric<br />
disabilities, “Benefits Management for People with Psychiatric<br />
Disabilities (R34)” and “Improving Clinician Ratings of Money<br />
Mismanagement: Addictions Impact (R01)”.<br />
fMRI/PET study: We collaborate in the NIMH funded fMRI/PET study<br />
designed to advance the early detection of significant cognitive decline<br />
and early Alzheimer’s disease. To date the Memory Disorders Center<br />
has identified and recruited 14 subjects for this project.<br />
Driving simulation: Two manuscripts are in preparation from our<br />
driving study done in collaboration with the Olin Center using their<br />
virtual driving simulator. The MDC has contributed to this research by<br />
improving the assessment of decisional capacity to continue or terminate<br />
driving among normal elderly and those with cognitive decline and early<br />
dementia.
Burlingame Center for Psychiatric<br />
Research and Education<br />
Services for persons with early onset Alzheimer’s Disease : We are in<br />
the process of submitting two research proposals aimed at improving<br />
specialized services for persons with early onset Alzheimer’s Disease<br />
(occurring younger than age 65) and their families entitled “When<br />
Alzheimer’s disease strikes the young and middle aged: Improving care,<br />
family adjustment, and reducing caregiver depression”.<br />
MDC Publications and Abstracts<br />
Bullock K, Blank K. Factors that influence the completion of advance directives<br />
between Black and White older adults: A pilot investigation. Gerontological<br />
Society of America, San Francisco. Nov. <strong>2008</strong>.<br />
Bullock K, Blank K. Diversity in Geriatric Psychiatry, AAGP committee. American<br />
Association for Geriatric Psychiatry <strong>Annual</strong> Meeting, March <strong>2008</strong>.<br />
Gilliam CM, Diefenbach GJ, Catayong K, Pearlson G, Blank K, Tolin DT.<br />
Emotion Regulation and Anxiety Disorders: A Lifespan Perspective. Association<br />
for Behavioral and Cognitive Therapies, October <strong>2008</strong>.<br />
Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with<br />
major depressive disorder. Psychiatric Times 26:18-19, 20<strong>09</strong>.<br />
Tolin D, Robinson J, Gaztambide S, Horowitz S, Blank K. Ataques de nervios<br />
and psychiatric disorders in older Puerto Rican primary care patients. J of Cross-<br />
Cultural Psychology 2007; 38(6)659-669.<br />
John W. Goethe, MD, Director<br />
Faculty and Staff:<br />
Stephen Woolley, DSci • Charles Wilber, MEd<br />
Alex Cardoni, MSPharm. • Brenda Woznicki, BA<br />
Bonnie Szarek, RN • Charles Caley, PharmD<br />
Megan Ehret, PharmD<br />
The mission of the Burlingame Center for Psychiatric Research and<br />
Education is to promote excellence in psychiatric care through<br />
applied research. The Center maintains the Institute’s research<br />
infrastructure (e.g., clinical research database, Outcome Assessment<br />
Program) and utilizes this infrastructure for studies of best practices,<br />
patient outcomes and comparisons of interventional strategies. Other<br />
areas of ongoing research include:<br />
Pharmacogenetics – the goal of these studies is to utilize genotyping<br />
technology to optimize medication.<br />
Prediction and management of metabolic syndrome in psychiatric<br />
patients – the goal of these studies is to identify clinical, treatment and<br />
demographic variables that are associated with this syndrome, now<br />
widely recognized as a major health risk in psychiatric patients.<br />
Treatment resistant mood disorders – the goal of these studies is to<br />
develop optimal treatments for individuals who have not responded<br />
to conventional therapies; this research and clinical initiative includes<br />
the development of an extensive infrastructure for comprehensive<br />
patient assessment as well as novel treatments for these disorders (e.g.,<br />
Transcranial Magnetic Stimulation (TMS)).<br />
Burlingame Center Publications<br />
Blair EW, Szarek BL. Exploring the relationship of psychotropic medications to<br />
fall events in an inpatient geriatric psychiatric population. International Journal<br />
of Psychiatric Nursing Research, 14: October <strong>2008</strong>.<br />
Diefenbach GJ, Woolley SB, Goethe JW. The association between selfreported<br />
anxiety symptoms and suicidality. Journal of Nervous and Mental<br />
Disease,197:92-97, 20<strong>09</strong>.<br />
82.
Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with<br />
major depressive disorder. Psychiatric Times 26:18-19, 20<strong>09</strong>.<br />
Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated<br />
with metabolic syndrome in psychiatric inpatients receiving antipsychotics.<br />
Journal of Clinical Psychiatry, 68:22-28, 2007.<br />
Goethe JW, Szarek BL, Caley CF. Metabolic syndrome and depression: a review.<br />
Depression: Mind and Body 3:138-149, <strong>2008</strong>.<br />
Goethe JW, Szarek BL, Caley CF. Metabolic syndrome in psychiatric inpatients<br />
treated for depression. In Thakore J, Leonard BE (eds). Modern Trends in<br />
Pharmacopsychiatry: Metabolic Effects of Psychotropic Drugs 26:90-104, 20<strong>09</strong>.<br />
Goethe JW, Woolley SB, Cardoni AC, Woznicki B, Piez D. Selective serotonin<br />
reuptake inhibitor discontinuation: side effects and other factors that influence<br />
medication adherence. Journal of Clinical Psychopharmacology, 27:451-58, 2007.<br />
Goethe JW. A time of change: challenges and choices. Invited article.<br />
Connecticut Medicine 73:367-8, 20<strong>09</strong>.<br />
Goethe JW. Expanding the do no harm mandate. Invited article. Connecticut<br />
Medicine, 71:499-500, 2007.<br />
Grgas M, Ehret MJ. Psychopharmacology: much the same. Connecticut Medicine<br />
73:281-284, 20<strong>09</strong>.<br />
Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G,<br />
Goethe JW, Schwartz HI. Somatic complications of psychotropic medications in a<br />
patient with multiple CYP2 drug metabolism deficiencies. Connecticut Medicine,<br />
71:197-200, 2007.<br />
Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, Windemuth<br />
A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and<br />
risperidone-treated patients. Molecular Psychiatry, 12:474–82, 2007.<br />
Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek<br />
BL, Goethe JW. Increased carrier prevalence of deficient BYP2C9, CYP2C19 and<br />
CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.<br />
Personalized Medicine 5:579-587, <strong>2008</strong>.<br />
Sopko MA Jr. Ehret MJ. Grgas M. Desvenlafaxine: another “me too” drug? Annals<br />
of Pharmacotherapy 42:1439-46, <strong>2008</strong>.<br />
Szarek BL, Goethe JW, Woolley SB: Assessing metabolic syndrome: waist<br />
circumference versus BMI. Schizophrenia Research 108:295-296, 20<strong>09</strong>.<br />
Woolley SB, Goethe JW, Lincoln AK, Heeren T. Headache complaints and the<br />
risk of suicidal thoughts or behaviors in community-dwelling adults: results from<br />
the ECA study. Journal of Nervous and Mental Disease 196:822-828, <strong>2008</strong>.<br />
Burlingame Center Abstracts<br />
Bullock K, Szarek BL, Goethe JW. Ethnic differences in length of stay<br />
and choice of antipsychotic medication among in-patients diagnosed with<br />
schizophrenia. Presented at the annual meeting of the American Psychiatric<br />
Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Caley CF. Antipsychotics for anxiety disorders: What is the evidence? Presented<br />
at the annual Northeastern Psychiatric Pharmacotherapy Symposium, Mystic,<br />
CT, September <strong>2008</strong>.<br />
Caley CF. Utilizing a psychiatric pharmacy specialist in a college health<br />
setting. Presented at the annual meeting of the New England College Health<br />
Association, Mystic, CT, October <strong>2008</strong>.<br />
Caley CF. Optimizing ADHD medication therapy in college health: evaluating<br />
the issues. Presented at the annual meeting of the American College Health<br />
Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Caley CF. Psychotropic drug–drug interactions—the most important you<br />
should know about. Presented at the annual meeting of the American College<br />
Health Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Caley CF, Goethe JW, Woolley SB, Bardack D, Martello T, Azhar N, Ruano G,<br />
Windemuth A. Lifestyle, socioeconomics, and health history versus medications<br />
as predictors of metabolic syndrome. Presented at the annual meeting of the<br />
American Psychiatric Association May, 20<strong>09</strong>.<br />
Caley CF. Staying on your medications—a perspective from pharmacy.<br />
Presented at the 20<strong>09</strong> National Alliance of the Mentally Ill (NAMI), San<br />
Francisco, CA, July 20<strong>09</strong>.<br />
Christensen A, Ehret M, Szarek B, Goethe J. Treatment of major depressive<br />
disorder for elderly inpatients at a psychiatric facility. Presented at the annual<br />
meeting of the American Society of Health-System Pharmacists, Orlando, FL,<br />
December <strong>2008</strong>.<br />
Ehret MJ, Goethe JW, Szarek BL. Who receives guideline-based<br />
pharmacotherapy for bipolar depression? Presented at the annual meeting of<br />
the American Psychiatric Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Goethe JD Blank K, Szarek BL. Metabolic risk factors in geriatric inpatients<br />
with major depressive disorder. Presented at the annual meeting of the<br />
American Psychiatric Association, San Diego, CA, 2007.<br />
Goethe JW, Szarek BL. Is schizoaffective disorder a distinct clinical entity?<br />
Presented at the annual meeting of the American Psychiatric Association, San<br />
Francisco CA, May 20<strong>09</strong>.<br />
Grgas M, Woolley SB, Goethe JW, Ruaño G, Szarek BL, Caley C, Ehret M. An<br />
analysis of CYP450 genotype and patients’ perceived response and tolerance to<br />
their antidepressants. Presented at the College of Psychiatric and Neurologic<br />
Pharmacists, Jacksonville, FL, April 20<strong>09</strong>.
Szarek BL, Goethe JW. Diagnostic stability in patients with schizoaffective<br />
disorder compared to schizophrenia and bipolar disorder. Presented at the annual<br />
meeting of the American Psychiatric Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T. Severe headaches<br />
and the risk of subsequent suicidal thoughts or behaviors. Presented at the annual<br />
meeting of the American Psychiatric Association, San Diego, CA, 2007.<br />
Woolley SB, Goethe JW, Fredman L, Lincoln A. Heeren T. Schizophreniaspectrum<br />
disorders were associated with cardiovascular disease symptoms,<br />
independent of known risk factors for symptoms. Presented at the annual meeting<br />
of the American Psychiatric Association, San Francisco, CA, May 20<strong>09</strong>.<br />
Woznicki BA, Woolley SB, Goethe JW, Bardack S, Azhar N. Locus of control, life<br />
events, treatment history and longitudinal outcomes of treatment for depression.<br />
Presented at the annual meeting of the American Psychiatric Association, May<br />
20<strong>09</strong>.<br />
New Projects<br />
Federal<br />
Glahn, David, MD<br />
Influence of Psychosis on Brain-Behavior Endophenotypes for Bipolar Disorder.<br />
NIMH through Yale University, $1,351,780.<br />
Pearlson, Godfrey, MD<br />
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes. NIMH<br />
through Yale University, $2,816,321.<br />
Multivariate Methods for Identifying Multi-Task Multimodal Brain Imaging<br />
Biomarkers. NIBIB through MIND Institute, $10,943.<br />
Informed Data-Driven Fusion of Behavior, Brian Function, and Genes. NIMH<br />
through MIND Institute, $38,528.<br />
Stevens, Michael, PhD<br />
Language Functioning in Optimal-Outcome Children with ASD: An fMRI Study.<br />
NIMH through the University of Connecticut, $203,401.<br />
Characterizing Two Distinct ADHD Neurobiologies with fMRI. NIMH,<br />
$378,246.<br />
Tolin, David, PhD<br />
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic<br />
Disorder. NIMH, $1,144,599.<br />
Maximizing Treatment Outcome in OCD. NIMH through (University of<br />
Columbia) Research Foundation for Mental Hygiene, Inc., $34,372.<br />
Wilber, Charles, MEd<br />
Reducing the Adverse Impact of Mental Illness Stigma Among Family Caregivers.<br />
Mount Sinai School of Medicine, $264,507.<br />
Foundation<br />
Assaf, Michal, PhD<br />
Buspirone Efficacy and its Brain Correlates in the Treatment of Anxiety in Autism<br />
Spectrum Disorders. Private Donor, $40,000.<br />
Stevens, Michael, PhD<br />
Measuring Differences in Brain Activity in Adolescents with Major Depressive<br />
Disorder (MDD) using fMRI. American Foundation for Suicide Prevention,<br />
$70,000.<br />
Industry<br />
Goethe, John, MD<br />
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-<br />
Controlled Efficacy and Safety Study of Adjunctive AzD6765 in Subjects with<br />
Major Depressive Disorder (MDD) with at Least Moderate Symptomatology<br />
and a History of Poor Response to Antidepressants. AstraZeneca (MultiCenter),<br />
$1<strong>09</strong>,850.<br />
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled,<br />
Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect<br />
of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients.<br />
AstraZeneca (Multicenter), $19,000.<br />
Tolin, David, PhD<br />
A 3-Arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy,<br />
Safety, and Tolerability of Pagoclone for the Treatment of Adults with Stuttering.<br />
Indevus Pharmaceuticals, $71,688.<br />
A Phase 3, Randomized, Double Blind, Parallel Group, 10 Week Placebo<br />
Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the<br />
Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety<br />
Disorder. Pfizer, Inc., $148,392.<br />
A Multi-Center, Double-Blind, Fixed Dose Trial Examining the Safety and<br />
Efficacy of Org 25935 vs. Placebo as Augmentation to Cognitive Behavioral<br />
Therapy in Subjects with Panic Disorder. Organon USA Inc. (Investigator<br />
Initiated), $214,875.<br />
State<br />
Bullock, Karen, PhD<br />
Factors Influencing Breast and Cervical Cancer Screening Among Racially/<br />
Ethnically Diverse Women. UCONN Storrs, $1,500.<br />
Ehret, Megan, PharmD<br />
Feasibility of Administering a Pharmacist Consultation Service Targeting<br />
Inpatients with Bipolar Disorder, Most Recent Episode Depressed. ASHP through<br />
the University of Connecticut, $5,000.<br />
84.
Departmental Funds<br />
Astur, Robert, PhD<br />
Hippocampal Structure and Function in People with Depression. $8,100.<br />
Stevens, Michael, PhD<br />
An fMRI Study of the Effect of Working Memory Training on ADHD Brain<br />
Dysfunction. $1,000.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Goethe, John, MD<br />
Research Infrastructure for the Depression and Bipolar Disorders Center. Open<br />
Competition, $49,760.<br />
Stevens, Michael, PhD<br />
Linux Cluster Infrastructure Enhancement. Open Competition, $74,513.<br />
Wilber, Charles, MEd<br />
Cognitive Training in Elderly with Normal Aging and Mild Cognitive<br />
Impairments. Open Competition, $82,487.<br />
Corbera, Silvia, PhD<br />
Application of Event-Related Potentials (ERPs) to Evaluate the Effects of<br />
Coaching on Cognitive Rehabilitation in Schizophrenia. Small Grant, $300<br />
Mace, Melanie, PsyD<br />
A Survey of Regional Referring Providers’ Use of and Perceived Utility of<br />
Neuropsychological Services. Small Grant, $750.<br />
Tolin, David, PhD<br />
D-Cycloserine-Augmented CBT for Prior Treatment Nonresponders with OCD.<br />
Small Grant, $9,531.<br />
Turner Anderson, Beth, PhD<br />
Simulated Driving: Effects of Road Conditions and Visibility. Small Grant,<br />
$9,811.<br />
Unfunded<br />
Diefenbach, Gretchen, PhD<br />
Anxiety Symptoms and Disorders Among Patients with Mild Cognitive<br />
Impairment and Early Stage Dementia.<br />
Unified Treatment for Geriatric Emotional Disorders.<br />
Jacobs, Barbara, PhD<br />
Staff Nurses as Expert Judges for Content Validity of the Empowerment and<br />
Autonomy Measurement Survey.<br />
Use of an Ethics Consultation Service Registry to Identify Moral Triggers For<br />
Requesting Ethics Consultations.<br />
Niego, Sara, MD<br />
Media Literacy in Eating Disorder Treatment.<br />
Pearlson, Godfrey, MD<br />
An MRI Study of Neurobiological Markers of Trait Dysfunction in Major<br />
Depressive Disorder.<br />
Sex-Gender Differences in the Effects of Marijuana on Behavioral and Cognitive<br />
Tests.<br />
Seltzer, Jim, PhD<br />
Evaluation of BrainDance.<br />
Shagan, Dana, PsyD<br />
A Study of the Effect of Social Cognition and Interaction Training on People with<br />
Schizophrenia.<br />
Stevens, Michael, PhD<br />
ADHD Medications: Are The Benefits Worth The Risks?<br />
Tolin, David, PhD<br />
Psychological and Physiological Correlates of Anxiety.<br />
Active Projects<br />
Aikins, Deane, PhD<br />
fMRI Investigation of PTSD-Related Cognitive Deficits and DNA Tissue Banking.<br />
National Center for PTSD, $48,293.<br />
Assaf, Michal, MD<br />
Differential Diagnosis of Psychotic Patients. Donaghue Medical Research<br />
Foundation, $239,179.<br />
FMRI, PET and the Default Mode Network Classify MCI and AD. NIA, $147,600.<br />
Implicit Mentalizing in Adults with Autistic Spectrum Disorders. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $54,938.<br />
Neuronal Correlates of Implicit Social Interaction in Autism Spectrum Disorders:<br />
A Functional MRI Study. National Alliance for Autism Research, $118,968.<br />
Social Interactions in Developmental Disorders: Functional MRI Study.<br />
Departmental, $500.<br />
The Neuronal Correlates of Theory of Mind in Schizophrenia. NIMH, $164,000.<br />
Astur, Robert, PhD<br />
Amphetamine and Memory in Virtual Reality. Departmental, $3,000.<br />
Attention and Memory in Eating Disorder Populations.<br />
Cocaine-Induced Place Preference in Virtual Reality Environments R21<br />
DA020013-01. National Institute of Drug Abuse, $290,852.
Fear Conditioning During Functional Magnetic Resonance Imaging.<br />
Departmental, $400.<br />
fMRI of Virtual Reality Navigation. Departmental, $2,000.<br />
Neuroimaging Cognition in Post-Traumatic Stress Disorder.<br />
Neuroimaging of Mothers Overcoming and Managing Stress “Breaking the<br />
Cycle.” Office of Juvenile Justice and Delinquency Program/University of<br />
Connecticut, $49,500.<br />
Prospective Memory in Schizophrenia. Trinity College, $938.<br />
Sleep Dependent Consolidation of Spatial Memory. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $7,750.<br />
Virtual Navigation in Individuals with Alzheimer’s Disease During fMRI.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $49,950.<br />
Blair, Ellen, APRN<br />
Inpatient Psychiatric Unit Medications and Falls Outcomes.<br />
Bullock, Karen, PhD<br />
Dying Experiences Among Racially Diverse <strong>Hospital</strong>ized Patients: Are There<br />
Differences Between Older African Americans and Whites in End-Of-Life<br />
Treatment Outcomes? Departmental, $10,593.<br />
Caley, Charles, PharmD<br />
A Controlled, Cross-sectional Comparison of Total Homocysteine<br />
concentrations in Schizophrenic Outpatients Treated With Risperidone or<br />
Olanzapine. Jannsen Pharmaceutical, $30,000; <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds,$11,537.<br />
Tenex (guanfacine) Augmentation for the Remediation of Attention and Working<br />
Memory Deficits in Patients with Schizophrenia: A Pilot Study. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $7,198.<br />
Calhoun, Vincent, PhD<br />
Collaborative Research: Spatiotemporal Fusion of fMRI, EEG, and Genetic<br />
Data Using Independent Component Analysis. National Institute of Biomedical<br />
Imaging and BioEngineering, $886,292.<br />
Choi, James, PhD<br />
Comparison of Remediation Techniques on the WCST in Schizophrenia.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $9,851.<br />
Diefenbach, Gretchen, PhD<br />
Clinical Characteristics of OCD Spectrum Disorders: A Comparison of OCD<br />
and Trichotillomania. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $9,329.<br />
Screening for GAD Among Frail Elderly. NIMH, $147,200.<br />
The Cognitive-Enhancing Effects of D-Cycloserine Among Non-Demented<br />
Elderly. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $74,923.<br />
The Nature and Impact of Anxiety Symptoms upon Psychosocial Functioning<br />
of Older Adults with Major Depressive Disorder. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $33,371.<br />
Treatment of Late-Life Anxiety Among Home Health Care Recipients: A<br />
Feasibility Study.<br />
Ferrand, Jennifer, APRN<br />
Long-term Psychological Adjustment in Patients with Implantable Cardioverter<br />
Defibrillators. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $7,559.<br />
Folley, Bradley, PhD<br />
Modulation of Neuroimaging and Neurocognitive Correlates of Attention and<br />
Memory by Nicotine and Nicotinic Alpha-7 Receptor Genotype Polymorphisms<br />
in Schizophrenia and Healthy Controls. Philip Morris USA, Inc., $86,400.<br />
Goethe, John, MD<br />
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing<br />
the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed<br />
Protocol A7501014 (Pfizer 1014). Pfizer, $47,693.<br />
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the<br />
Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with<br />
Predominant, Persistent Negative Symptoms of Schizophrenia (Pfizer 1013).<br />
Pfizer, $86,125.<br />
A Randomized, Parallel Group, Multiple Dose, 6-week Study to Evaluate Safety,<br />
Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with<br />
Psychosis. Pfizer, $47,362.<br />
A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating<br />
the Efficacy and Safety of Add-on Oral Ziprasidone in Subjects with Acute Mania<br />
Treated with Lithium or Divalproex. Pfizer, $57,005.<br />
Adjunctive Treatment with Bupropion in Major Depressive Disorder. Glaxo Smith<br />
Kline, $60,700.<br />
DNA Diagnostics for Minimizing Side-Effects of Antipsychotics. NIH/SBIR,<br />
Genomas, $150,000.<br />
Enhancing Short-Term Memory in Patients with Schizophrenia.<br />
Information Dissemination as a Method of Improving Patient Outcome: A<br />
Demonstration Project and Study of the Outcomes of Patients with Major<br />
Depressive Disorder. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $119,375.<br />
Physiogenomic Analysis of Antipsychotic Therapies and their Metabolic Side<br />
Effects. Genomas/NIH, $100,000.<br />
Psychiatric Treatment Practices and Patient Outcomes.<br />
SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient<br />
Choices of Treatment. Merck, $112,500.<br />
86.
The Utility of Routine Cytochrome P450 Genotyping in the Selection of<br />
Type and Dosage of Antidepressant Medication. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $74,797.<br />
Griss, Melina, PhD<br />
White Matter Changes in Normal Aging: Impact on Everyday Functioning.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $16,563.<br />
Jaffe, Adam, PhD<br />
Expectancy Therapy and Medication for Smoking Cessation. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $54,432.<br />
Kiehl, Kent, PhD<br />
Brain Mechanisms of Interpersonal Judgment. Departmental, $2,400.<br />
Electrophysiological Assessment of Error Monitoring in Psychotic Illnesses.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $50,000.<br />
Functional Magnetic Resonance Imaging Correlates of Decision-Making. Yale<br />
University, $50,000.<br />
Syntactic Development and Learning Processes in Autism Spectrum Disorders.<br />
University of Connecticut, $18,250.<br />
Kurtz, Matthew, PhD<br />
Cognitive Remediation for Schizophrenia: Effects on Distal Outcome Measures<br />
and Relationship to Social-Skills Training. NARSAD, $51,130.<br />
Facial Affect Recognition, Social Functioning, and Neurocognitive Deficits in<br />
Schizophrenia.<br />
FMRI Assessment of Treatment Response in the Schizophrenia Rehabilitation<br />
Program at the Institute of Living. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment<br />
Funds, $46,447.<br />
Neurocognitive Predictors of Response to Cognitive Remediation in Patients<br />
with Schizophrenia. National Alliance for Research on Schizophrenia and<br />
Depression, $60,000.<br />
Neurocognitive Remediation for Schizophrenia. NIH, $749,579; <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $9,362.<br />
Predictors of Treatment Response to Rehabilitation in Schizophrenia. NIH,<br />
$71,450.<br />
Virtual Reality Assessment of Psychosocial Status in Patients with<br />
Schizophrenia. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,$9,690.<br />
Lothstein, Leslie, PhD<br />
Assessment of Thought Disorder in Adults: The Relationship of the Rorschach<br />
Perceptual Thinking Index, Other Rorschach Variables, and the Millon Clinical<br />
Multiaxial Inventory - III Thought Disorder Index to Diagnoses in a Psychiatric<br />
Sample. Intimacy - Sexuality Group Therapy for Impaired and Distressed<br />
Professionals.<br />
Lovejoy, David<br />
Patterns of Verbal List Learning in Mild Traumatic Brain Injury: The Role of<br />
Effort and Motivation.<br />
Meda, Shashwath, MS<br />
Characterizing the Dyslexia Phenotype Using Genetics and MR Morphology.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $9,722.<br />
Meunier, Suzanne, PhD<br />
Group Treatment for Compulsive Hoarding.<br />
Understanding Repetitive Behavior and Associated Experiences.<br />
Pearlson, Godfrey, MD<br />
A Unified Framework for Flexible Brain Image Analysis. NIH/MIND Institute,<br />
$1,000,000.<br />
Aberrant Functional Connectivity in Psychosis. NIMH, $1,564,000.<br />
Alcohol and Driving: A Functional MRI Study . NIAAA/Yale University,<br />
$1,283,384.<br />
Alzheimer’s Disease Neuroimaging Initiative . University of California, San<br />
Diego, $292,959.<br />
Amphetamine and Reward Mechanisms: fMRI Study. Yale University, $15,000.<br />
Brain Structure and Function in Schizophrenia: Neuroanatomical and<br />
Neurophysiological Predictors of Clinical Outcome in Prodromal Schizophrenia.<br />
NARSAD,$530.<br />
Computer-Based Driving Assessment in Early Alzheimer’s Disease. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $47,488.<br />
fMRI of Brain Activation During Menstrual Migraine. Departmental, $8,955.<br />
fMRI Studies of Healthy Volunteers at 3.0 Tesla. Departmental, $2,000.<br />
Human 31 - IH MRI and MRI Brain Studies of Nicotine. NIH, $53,767.<br />
Marijuana and Driving: A Functional MRI Study.<br />
Molecular Studies of Cognition and Chronic Alcoholism. NIAAA/University of<br />
Pittsburgh, $134,843.<br />
Neurocognitive Changes Associated with Behavioral Treatment in Cocaine<br />
Abusers. NIDA, $2,647,970.<br />
Physiogenomic Arrays for Clinical Neuropsychiatry. NIH subcontract through<br />
Genomas, $294,576.<br />
Quantitative Neuroimaging in Psychosis. NIMH, $2,753,077.<br />
Schizophrenia Biomarkers: Memory, Genes and fMRI. NIMH, $1,493,033.
Sex Differences in Schizophrenia. NIMH, $776,448.<br />
The Effects of Tobacco on Brain Structure and Function are Amplified by<br />
Genotype. Dept. of Public Health/University of Connecticut, $200,730.<br />
Ventral Striatal Functional Deficits and Familial Alcoholism Risk. Yale<br />
University, $466,956.<br />
Roffer, Wayne, PsyD<br />
Accuracy of a Mental Status Exam for Assessing Cognitive Dysfunction in<br />
Patients with Schizophrenia.<br />
Stevens, Michael, PhD<br />
Diffusion Tensor Magnetic Resonance Imaging Correlates of Cognitive and<br />
Functional Outcome After Closed-Head Traumatic Brain Injury. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $65,000.<br />
fMRI of CBT and CM Cocaine Dependence. Yale University, $172,183.<br />
Functional Genomics of Behavioral Control.<br />
Functional MRI Activation in Children to Monaural, Binaural and Dichotic<br />
Words. University of Connecticut, $14,000.<br />
Girls in Recovery from Life Stress (GIRLS) Study. Office of Juvenile Justice and<br />
Delinquency Program, University of Connecticut, $49,500.<br />
Neural Correlates of Trauma and Stress Treatment Change. Departmental,<br />
$6,688.<br />
Neuroimaging Cognition in Adolescent Behavior Disorders. NIMH, $798,7<strong>09</strong>.<br />
Response Inhibition in Attention-Deficit/Hyperactivity Disorder. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $65,000.<br />
Reward, Impulsivity and Cocaine Addiction: fMRI Studies. Yale University,<br />
$1,303,559.<br />
Cognitive Processes in Anxiety Disorders.<br />
Cognitive-behavioral Bibliotherapy for the Treatment of Obsessive Compulsive<br />
Disorder in Children and Adolescents.<br />
Dismantling the Neural Systems of Obsessive-Compulsive Disorder: A Symptom<br />
Provocation Study of Compulsive Hoarding. <strong>Hartford</strong> <strong>Hospital</strong> Research<br />
Endowment Funds, $53,602.<br />
Long-Term Follow-Up of Cognitive-Behavioral Therapy Patients with Anxiety<br />
Disorders.<br />
Neural Mechanisms of Compulsive Hoarding. NIMH, $1,062,000.<br />
Neuropsychological Functioning in Compulsive Hoarding.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $74,898.<br />
Psychopathology of Compulsive Hoarding. Smith College, $365,563.<br />
Stepped Care for Obsessive-Compulsive Disorder. NIMH, $596,160.<br />
Treatment of Compulsive Hoarding. Boston University, $113,072.00<br />
Virtual Reality Exposure Treatment for Combat-Related Posttraumatic Stress<br />
Disorder in Operation Iraqi Freedom and Operation Enduring Freedom Veterans.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $73,894.<br />
Woolley, Stephen, DSci<br />
Assessment of a Suicide Screening Program to Improve Detection of Post-<br />
Discharge Suicide Risk. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $27,662.<br />
Extension of the Longitudinal Study of “SSRIs in the Treatment of Depressive<br />
Disorder: Side Effects and Patient Choices of Treatment”. <strong>Hartford</strong> <strong>Hospital</strong><br />
Research Endowment Funds, $9,494.<br />
Prospective Follow-up Study of the Effects of Locus-of-Control and Life Stressors<br />
on Long-Term Outcome of Treatment for Major Depressive Disorder. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $9,723.<br />
The Effect of Pharmacotherapy on Trauma-Related Sleep Disturbance in<br />
Pediatric Populations.<br />
Tolin, David, PhD<br />
A Randomized, Double-Blind, Placebo-Controlled Trial of D-Cycloserine<br />
Augmentation of Behavior Therapy for Obsessive-Compulsive Disorder.<br />
Departmental, $245.<br />
An Internet Survey of Compulsive Hoarding.<br />
Anxiety Disorders Outcomes Protocol.<br />
Augmenting Exposure Therapy with an NMDA Agonist: A Pilot Study.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $64,865.<br />
Cognitive Differences Between Generalized Anxiety Disorder and Obsessive-<br />
Compulsive Disorder. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $10,062.<br />
88.
Radiology<br />
New Projects<br />
Federal<br />
Cronin, Edward, MD<br />
Near Infrared Optical Imaging Guided by Ultrasound: Assessing Neoadjuvant<br />
Chemotherapy Response. NIH subcontract through the University of Connecticut,<br />
$287,124.<br />
Industry<br />
Foster, John, MD<br />
Investigational Plan to Evaluate the Use of the Endologix 34mm Powerlink Cuff<br />
for Continued Access, IDE: G990139, Protocol Number: 03-023CA - Revision A.<br />
Endologix, Inc., $50,875.<br />
The SIR-Spheres(R) Registry. Sirtex Medical, $30,000.<br />
Hallisey, Michael, MD<br />
CRUX Biomedical Evaluation of the Crux Inferior Vena Cava Filter System -<br />
(“Retrieve”) Study. Crux Biomedical, Inc., $38,792.<br />
Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System<br />
in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in<br />
Subjects Who are Candidates for Endovascular Repair. Medtronic Vascular, Inc.<br />
$54,315.<br />
Unfunded<br />
Kallen, Joshua, MD<br />
Retrospective Validation of Limited Scan Range CTA for Suspected Pulmonary<br />
Embolism for Diagnostic Accuracy and Prevalence and Clinical Significance of<br />
Alternative and Secondary Diagnoses. Statistical analysis generously supported by<br />
Medical Staff funds.<br />
Coughlin, Bret, MD<br />
Gadolinium-Enhanced Tissue Visualization: A Feasibility Study.<br />
Hallisey, Michael, MD<br />
Evaluation of Prototype Inferior Vena Cava Filtration Device in Ovine.<br />
Screening Abdominal Aortic Aneurysms Based on the Stability of the Aneurysm.<br />
Evaluation of BW2R Paperwork for Patient Prescriptions.<br />
Jacunski, Joanna, MD<br />
Assessment of the GE Vascular Pack Noncontrast MRA Techniques.<br />
Kallen, Joshua, MD<br />
Exploratory Retrospective Review to Determine the Location of Pulmonary<br />
Emboli as Defined as within a Limited Scan Range or not within a Limited Scan<br />
Range.<br />
O’Loughlin, Michael, MD<br />
Evaluation of GE Healthcare’s MSLAB, MFGRE and Viz Pack.<br />
Spiegel, Gary, MD<br />
CORDIS Enterprise Vascular Reconstruction Device and Delivery System.<br />
Stein, Barry, MD<br />
AW Enterprise Application Server Prototype Evaluation.<br />
Active Projects<br />
Hallisey, Michael, MD<br />
(VALOR) Evaluation of the Medtronic AVE Thoracic Stent Graft System for the<br />
Treatment of Thoracic Aortic Aneurysms. Medtronic AVE, $52,000.<br />
Treatment IDE for use of the GORE TAG Thoracic Endoprosthesis in Subjects<br />
with Descending Thoracic Aortic Aneurysms Requiring Surgical Repair. W.L.<br />
Gore & Associates, $10,220.<br />
Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy<br />
- SAPPHIRE WW - Protocol Number P06-3603. Cordis Corporation,<br />
a Johnson and Johnson Company, $47,200.<br />
TAG) A Clinical Study Comparing Use of the Thoracic EXCLUDER Endoprosthesis<br />
to Open Surgical Repair in the Primary Treatment of Descending Thoracic<br />
Aortic Aneurysms. W.L. Gore & Associates, Inc., $78,750.<br />
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the<br />
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are Candidates<br />
for Standard Surgical Intervention. Medtronic AVE / Talent, $72,000.<br />
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the<br />
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are<br />
Not Candidates for Standard Surgical Intervention. Medtronic AVE / Talent,<br />
$50,000.<br />
An Investigation of the TALENT LPS A Low Profile Endoluminal Stent-Graft<br />
System for the Treatment of Sub-renal Abdominal Aortic Aneurysms in Patients
who are Candidates for Standard Surgical Intervention (LOW RISK). Medtronic<br />
Vascular, $10,000.<br />
An Investigation of the TALENT Endoluminal Spring Stent-Graft System for the<br />
Treatment of the Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are<br />
Candidates for Standard Surgical Intervention (Low Risk Stock Device Study).<br />
Medtronic AVE, $20,000.<br />
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the<br />
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who are Not<br />
Candidates for Standard Surgical Intervention - Emergency Protocol. Medtronic<br />
AVE, $40,000.<br />
Emergency Use of the Talent Endoluminal Spring Stent-Graft System in High<br />
Surgical Risk Patients with Thoracic Aortic Aneurysms. Medtronic AVE, $80,000.<br />
Evaluation of the Enhanced TALENT LPS Stent Graft System for the Treatment<br />
of Abdominal Aortic Aneurysm. Medtronic AVE, $50,000.<br />
The EXACT Study - Emboshield(R) and Xact(R) Post Approval Carotid Stent<br />
Trial. Abbott Vascular Devices, $22,000.<br />
Hauser, Stephen, MD<br />
Compassionate Use Protocol DMS: A Prospective Study of Adjuvant Radiation<br />
Therapy After Resection of Borderline and Malignant Phyllodes Tumors.<br />
Jacunski, Joanna, MD<br />
Retrospective Analysis of the Utility of MRI for Evaluation of Acute Abdominal<br />
Pain in Pregnant Patients.<br />
Use of 18F-FDG PET/CT for Diagnosis of Osteomyelitis of the Foot.<br />
Norton, Timothy, MD<br />
Trends in the Utilization of Radiologic Studies at <strong>Hartford</strong> <strong>Hospital</strong>.<br />
O’Loughlin, Michael, MD<br />
MRI Evaluation of the Contralateral Breast in Women with a Recent Diagnosis of<br />
Breast Cancer/ACRIN 6667. American College of Radiology Imaging Network,<br />
$170,000.<br />
Prospective Analysis of Breast MRI Outcomes in a Large <strong>Hospital</strong> Population. CT<br />
Breast Health Initiative, $49,939.<br />
Silk, Portia, MD<br />
Analysis of CT Perfusion and Salvageable Penumbra as a Function of Time in<br />
Acute Stroke. Small Grant, $10,000.<br />
Spiegel, Gary, MD<br />
Humanitarian Use Device: Neuroform Microdelivery Stent.<br />
Tubbs, Daniel, MD<br />
Contrast Enhanced Multi-Detector Computed Tomography (MDCT) as a Noninvasive<br />
Modality for the Evaluation of Active Lower Gastrointestinal Bleeding:<br />
Initial Prospective Assessment of Contrast Enhanced MDCT Verses Technetium<br />
99m Tagged Red Blood Cell Scanning at a Large Community <strong>Hospital</strong>. Berlex<br />
Laboratories, Inc., $99,769.<br />
Zink, Stephen, MD<br />
Incidental Non-cardiac Findings Seen Prospectively on Cardiac CT<br />
Angiogram (CTA).<br />
Publications and Abstracts<br />
Kallen J, Coughlin B, O’Loughlin MT, Stein B, Chhabra J. Reduced<br />
Z-axis coverage CTA versus standard Z-axis coverage CTA for pulmonary<br />
embolism. Abstract LL-CH4342-R08. Radiological Society<br />
of North America, posted online May, 20<strong>09</strong>. Available at http://<br />
rsna20<strong>09</strong>.rsna.org<br />
Kallen JA, Coughlin BF, O’Loughlin MT, Stein B. Reduced Z-axis<br />
coverage multidetector CT angiography for suspected acute pulmonary<br />
embolism could decrease dose and maintain diagnostic accuracy.<br />
Emergency Radiology 20<strong>09</strong>;17:31-35.<br />
Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB,<br />
Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman<br />
DA, Cardella JF, Standards of Practice Committee with Cardiovascular<br />
and Interventional Radiological Society of Europe (CIRSE) Endorsement.<br />
Consensus guidelines for periprocedural management of<br />
coagulation status and hemostasis risk in percutaneous image-guided<br />
interventions. Journal of Vascular & Interventional Radiology, 20 (7):<br />
S240-S249, 20<strong>09</strong>.<br />
Malloy PC. Management of pelvic hemorrhage in trauma. In Mauro<br />
MA, Murphy K, Thomson K, Venbrux A, Zollikofer CL. (Eds.) Image<br />
Guided Intervention. Saunders, pp. 907-913, <strong>2008</strong>.<br />
O’Loughlin M, McLaughlin T, Staff I, Cronin E. Prospective outcome<br />
of BIRADS category 3 “Probably Benign” breast MRI lesions. Abstract<br />
SSA01-01. Radiological Society of North America, posted online<br />
May, 20<strong>09</strong>. Available at http://rsna20<strong>09</strong>.rsna.org<br />
Richard HM, Widlus DM, Malloy PC. Percutaneous fluoroscopically<br />
guided jejunostomy placement. J Trauma, 65(5):1072-7, <strong>2008</strong>.<br />
Wingspan Stent System with Gateway PTA Balloon Catheter, a Humanitarian<br />
Use Device.<br />
Stein, Barry, MD<br />
MRI Image and Clinical Application Development Protocol.<br />
90.
Surgery<br />
Orlando C. Kirton, MD, FACS, FCCM, FCCP,<br />
Ludwig J. Pyrtek MD Chair in Surgery, Director of<br />
Surgery, Chief, Division of General Surgery<br />
The Department of Surgery continues to participate in clinical and<br />
scientific research and has contributed significantly to the surgical body<br />
of knowledge. Members of the department have presented their findings<br />
at several prestigious forums and have published in a variety of refereed<br />
journals. The Department continues to encourage its members to be<br />
involved in academic as well as clinical endeavors. It seeks to engage<br />
its staff in a variety of experiences that contribute to the growth of the<br />
department, the reputation of the institution as well as the enhancement<br />
of the individuals themselves.<br />
The faculty of the department continues to be actively involved in<br />
the education process within the institution and the community and<br />
continues to encourage the residents and fellows to pursue research<br />
activities. The Department of Surgery currently supports two surgical<br />
residents as they participate in research fellowships at the University<br />
of Connecticut. Both have been involved in conducting clinical<br />
research and basic science research and have published and presented<br />
their findings. Dr. Pavlos Papasavas, the Director of Research for the<br />
Department of Surgery has provided presentations to residents and<br />
medical students to encourage participation in research projects. In<br />
addition, he selected and trained residents for the Skills competition of<br />
the CT-Chapter of the ACS and the selected group won first prize.<br />
The Department of Surgery and the Section of Bariatric Surgery are<br />
working on establishing a Bariatric Database to provide valid data to<br />
conduct meaningful research. The Department continues to identify<br />
ways to access data for the purpose of trending and quality improvement.<br />
The Department’s own database (ORBIT) has been redesigned to<br />
facilitate the input and download of specific data from other databases<br />
(i.e. SIS). The Division of Colo-Rectal Surgery has created an on-going<br />
database for ileoanal pouch procedures and is collaborating with UConn<br />
(Storrs) on a project entitled “Psychosocial Needs Assessment of Patients<br />
with Colorectal Cancer and Partners” with the goal of addressing the area<br />
of patient and family support systems.<br />
New Projects<br />
Industry<br />
Cheema, Mohiuddin, MD<br />
PRICELESS: PRessure and Imaging - using the CardioMEMS EndoSure Sensor<br />
for Long-term follow-up after EVAR with Standard Surveillance (PRICELESS<br />
PROSPECTIVE REGISTRY). CardioMEMS, Inc., $12,250.<br />
Hull, David, MD<br />
Deceased Donor Vessel Storage: A Study of Tissue Viability for Organ<br />
Transplantation. Essential Pharmaceuticals, $3,000.<br />
A Double-Blind, Randomized, Placebo Controlled, Multi-Center Trial of<br />
Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised<br />
Patients. F. Hoffman-La Roche LTD, $62,000.<br />
Mah, John, MD<br />
Assessment of the Economic Impact on Fecal Containment in Bedridden Patients<br />
Comparing Zassi Bowel Management System (BMS) with Flexi-Seal Fecal<br />
Management System (FMS). Hollister, Inc., $17,000.<br />
McKay, Raymond, MD<br />
A Pilot Study to Assess the Histological Effects and Biomechanical Strength of a<br />
Novel, Knotless Suturing Technique in the Repair of Rotator Cuff Injury. Cordis<br />
Corporation (Investigator Initiated), $13,306.<br />
Papasavas, Pavlos, MD<br />
A Multi-Center Open-Label Clinical Evaluation of the LAP-Band AP System in<br />
Severely Obese Patients. Allergan (Multicenter), $27,850.<br />
Unfunded<br />
Allen, Brian, MD<br />
A Successful Wound Care Algorithm to Heal Venous Stasis Ulcers.<br />
Butler, Karyn, MD<br />
Is Delayed DVT Prophylaxis in the Neurocritical Care Unit Effective?<br />
Cohen, Jeffrey, MD<br />
Recurrent Diverticulitis After Laparoscopic Colectomy.<br />
Divinagracia, Thomas, MD<br />
The Natural History of Moderate Stenosis of the Carotid Artery.
Feeney, James, MD<br />
The Use of a Simulator to Improve Technique and Procedural Confidence In<br />
Emergency Cricothyroidotomy. Statistical analysis supported through <strong>Hartford</strong><br />
<strong>Hospital</strong> Small Grant.<br />
Gallagher, Robert, MD<br />
Aortic Valve Replacement - Is Age an Independent Predictor of Risk? Statistical<br />
analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Incidence and Risk Factors Associated with Post Procedure Hypotension Following<br />
Carotid Artery Endarterectomy and Carotid Artery Angioplasty.<br />
Hammond, Jonathan, MD<br />
Benefit of Prophylactic Donor Tricuspid Annuloplasty in Bicaval Orthotopic Heart<br />
Transplantation. Data support provided through <strong>Hartford</strong> <strong>Hospital</strong> small grant.<br />
Hull, David, MD<br />
Retrospective Study of Liver Transplant Pre-Procedure MELD Scores and Post-<br />
Surgical Outcomes. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant.<br />
Orlando, Rocco, MD<br />
A Prospective Study of Early Outcomes After Stapled Versus Unstapled Preformed<br />
Mesh in Laparoscopic Extraperitoneal Inguinal Herniorrhaphy.<br />
Papasavas, Pavlos, MD<br />
Bariatric Outcomes Longitudinal Database (BOLD).<br />
<strong>Hartford</strong> <strong>Hospital</strong> Bariatric Registry.<br />
Hiatal Hernia Repair at the Initial Laparoscopic Adjustable Gastric Band Operation.<br />
Massive Hernia Repair with Separation of Components Technique: A General and<br />
Plastic Surgery Combined Approach.<br />
Weight Loss Surgery and Diabetes Mellitus in Patients Undergoing Weight Loss<br />
Surgery.<br />
Paquette, Anthony, MPH<br />
Reliability of a Donation after Cardiac Death (DCD) Assessment Tool in Predicting<br />
Time to Cardiac Death after Withdrawal of Support.<br />
Ranga, Kasturi, MD<br />
Depression, Anxiety, and Quality of Life in Living Kidney Donors. Statistical<br />
analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Active Projects<br />
Alberghini, Tod, BS<br />
Clinical Significance of Solid-Phase Assay (Flow Cytometric and Luminex)<br />
Detection of Pre-Transplant HLA Antibody as Measured by Graft Survival in<br />
Renal Transplant Recipients: A Retrospective Analysis. <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant, $9,954.<br />
Histocompatability Determination for Highly Sensitized Patients.<br />
Bass, David, MD<br />
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical<br />
Study.<br />
Brown, Matthew, MD<br />
A Randomized, Open-Label, Comparative Evaluation of Conversion from<br />
Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued<br />
Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing<br />
Maintenance Therapy. Wyeth Pharmaceuticals, $213,147.<br />
Cohen, Jeffrey, MD<br />
Safety, Feasibility and Long-term Outcomes of Laparoscopic Ileal-Pouch-Anal<br />
Anastomosis: A Single Institution Case-Matched Experience.<br />
DeLucia, Orlando, MD<br />
Allergan Corporation Style 410 Silicone-Filled Breast Implant Continued Access<br />
Reconstruction/Revision Expansion (CARE) Clinical Study. Inamed, $8,300.<br />
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical<br />
Study.<br />
Drezner, David, MD<br />
A Comparison of CT Venography to Duplex Ultrasonography in the Diagnosis<br />
of DVT.<br />
Outcomes of Patients Undergoing Lower Limb Amputations.<br />
Gallagher, Robert, MD<br />
Oxygen Mapping of the Peri-sternal Chest Wall in Post-Operative Open Heart<br />
Surgery Patients.<br />
Graydon, James, MD<br />
Post-Prostatectomy Erectile Dysfunction and Urinary Incontinence: Effect of<br />
Hyperbaric Oxygen Therapy.<br />
Hull, David, MD<br />
Does Beta 2 Microglobulin Correlate with Creatinine as a Marker of Renal Function<br />
in Renal Transplant Recipients at Points of Transition, and During Stable Renal<br />
Function? Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
92.
Intimal Hyperplasia in Arteriovenous Fistulas. Roche, $18,162.<br />
Oral Infection and Inflammation in Transplant Patients. NIH/University of<br />
Connecticut, $25,000.<br />
An open label randomized, multicenter study to evaluate the efficacy and safety<br />
of early calcineurin inhibitor withdrawal in recipients of primary renal allografts<br />
maintained long-term on mycophenolate mofetil; MMF (CellCept) and sirolimus<br />
(Rapamune). Roche Hoffman - La Roche, $430,7<strong>09</strong>.<br />
Transplant Clinical Outcomes Blanket Protocol.<br />
Ivy, Michael, MD<br />
Intraoperative and Preoperative Parameters That Predict Abdominal Compartment<br />
Syndrome After Repair of Ruptured Abdominal Aortic Aneurysm.<br />
Keating, Kevin, MD<br />
A Randomized, Double-Blind, Placebo-Controlled, Phase-2b Study to Assess the<br />
Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated<br />
Intravascular Coagulation. Artisan Pharma Inc., $96,000.<br />
Kirton, Orlando, MD<br />
Advanced Laparoscopic Training Course. Departmental, $17,500.<br />
Evaluation of Sublingual Capnometry in Critically Ill Surgical Patients Subjected to<br />
a Resuscitation Protocol (SLT). Tyco Healthcare/Nelcor, $66,250.<br />
Surgery Clinical Outcomes Blanket Protocol.<br />
Mah, John, MD<br />
Application of a Web-Based Teaching Module for Instruction and Standardization<br />
of Post-Pyloric Feeding Tube Insertion.<br />
Mavanur, Arun, MD<br />
Differences Between Male and Females in the Operative Findings and Outcome of<br />
Laparoscopic Cholecystectomy.<br />
Indeterminate for Dysplasia, What Next?<br />
McIsaac, Joseph, MD<br />
Surgical Cooling Garment Phase III. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment<br />
Funds, $65,625.<br />
Miranda, Michael, MD<br />
Humanitarian Use Device: OP-1 Implant.<br />
NasirKhan, Mohammad, MD<br />
Role of Intravenous Chromium in Reducing Insulin Requirements in Critically Ill<br />
Patients.<br />
Norton, Timothy, MD<br />
Cryoablation of Irresectable Lung Tumors.<br />
Papasavas, Pavlos, MD<br />
Enterra Therapy Humanitarian Device Exemption.<br />
Pepe, Judith, MD<br />
Training Organ Procurement Organization Coordinators to Use an Esophageal<br />
Doppler Monitor for Donor Management to Improve Organs Transplanted per<br />
Donor. HRSA, $94,253.<br />
Poultsides, George, MD<br />
Hand Assisted Laparoscopic Transduodenal Resection: Initial Experience.<br />
Laparoscopic Gastric Resection: Technique and Outcomes in 25 Patients.<br />
Safety and Long-term Efficacy of Angiographic Embolization for Upper<br />
Gastrointestinal Hemorrhage: A Single Institution Experience.<br />
Reed, Michael, MD<br />
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical<br />
Study.<br />
Tamim, Patrick, MD<br />
An Analysis of Subclavian Stenosis by Duplex Ultrasonography as Evaluated in<br />
Tandem with Arterial Angiography.<br />
Tishler, Darren, MD<br />
A Randomized, Prospective Study Comparing Needle Stick Injuries with Hand<br />
versus SuturTek Device Closure of Abdominal Fascia. SutruTek Inc., $27,000.<br />
Underhill, David, MD<br />
Study 98-1 Carpentier-Edwards PERIMOUNT Plus Pericardial Bioprosthesis,<br />
Model 6900P. Edwards LifeSciences, LLC, $110,250.<br />
Publications and Abstracts<br />
Allen B, Cuzzone D, Rowin C, Perdrizet G, Babigian A. Fluoroscopic radiation<br />
burn following embolization of a spinal arteriovenous malformation. Journal of<br />
Burn Care and Research, 20<strong>09</strong>; 30(2): 349-351.<br />
Allen B, Rader C, Babigian A. Giant lipomas of the upper extremity. Canadian<br />
Journal of Plastic Surgery 2007;15(3):141-144.<br />
Antonetti M, Kirton OC, Bui D, Ademi A, Staff I, Hudson-Civetta J, Lilly R:<br />
The effects of pre- operative rofecoxib, metoclopramide, dexamethasone, and<br />
ondansetron on postoperative pain and nausea in patients undergoing elective<br />
laparoscopic cholecystectomy. Surg Endosc 2007; 21:1855-1861.<br />
Banever, T, Brautigam, RT, Pressure Ulcer Assessment Work Group. Pressure<br />
Ulcer Assessment for Physicians and Licensed Independent Practitioners<br />
Education Program. <strong>Hartford</strong> <strong>Hospital</strong> Intranet, <strong>2008</strong>.<br />
Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC,<br />
Davis K, Johannigman JA. Devil is in the details: maximizing revenue for daily<br />
trauma care. Surgery <strong>2008</strong>; 144(4): 670-676.<br />
Bokhari F, Phelan H, Holevar M, Brautigam R, Collier B, Como J, Clancy K,
Cumming J, Cullinane D, and Smith L. Diagnosis and management of pancreatic<br />
trauma. Posted on EAST.org, 20<strong>09</strong>.<br />
Brautigam RT, Schott E, and Burns K. A simulation education course for the initial<br />
management of blunt trauma. Connecticut Medicine, May 20<strong>09</strong>; 73(5): 267-271.<br />
Brautigam RT, Sheppard R, Robinson K and Jacobs LM. Evaluation and treatment<br />
of the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM and Trafton<br />
PG. Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed.,<br />
20<strong>09</strong>.<br />
Cheema M, Lukose B, Kirton OC, Gallagher J: Ligation of the subclavian artery<br />
after blunt trauma presenting as massive hemothorax.. J Trauma <strong>2008</strong>;<br />
64(4):1126-1130.<br />
Clarke CN, Tsuei B, Butler KL. Equine-related injury: a retrospective analysis of<br />
outcomes over a 10 year period. Am. J. Surg. <strong>2008</strong>;195:702-704.<br />
Crisanti, Koutzaki, Mondrinos, Lelkes, Finck. Novel methods for delivery of cellbased<br />
therapies. Journal of Surgical Research May <strong>2008</strong>;146(1):3-10.<br />
Cuzzone D, Allen B, Rowin C, Tulikangas P, Babigian A. Development of vaginal<br />
erosion and vesico-cutaneous fistula following midurethral transvaginal tape with<br />
Pelvilace for treatment of stress urinary incontinence. International Wound Journal,<br />
20<strong>09</strong>; 6:55-58.<br />
Feeney JM, Burns K, Staff I, Bai J, Rodrigues N, Fortier, Jacobs LM. Prehospital<br />
HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal<br />
aortic aneurysm. J Am Coll Surg. 20<strong>09</strong>.<br />
Finck, Moront, Newton, Timmapuri, Lyons, Rozans, DeChadarevian, Halligan.<br />
Pediatric granular cell tumor of the tracheobronchial tree. Journal of Pediatric<br />
Surgery, <strong>2008</strong>;43(3):568-70.<br />
Folcik MA, Kirton OC, Ivy ME: A two-tiered quality management program :<br />
morbidity and mortality conference data applied to resident education. Connecticut<br />
Medicine, 2007; 71(8):417-424.<br />
Fortuna GR, Mueller EW, James L, Shutter LA, Butler KL. The impact of preinjury<br />
anti-platelet or anticoagulant pharmacotherapy and outcomes following<br />
hemorrhagic brain injury. Surgery <strong>2008</strong>; 144(4): 598-605.<br />
Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating risk: a role for<br />
jak-stat signaling in post-conditioning? Am J Physiol Heart Circ Physiol. <strong>2008</strong> Oct;<br />
295(4):H1649-56.<br />
Goodman MD, Koch SE, Reid MD, Caldwell CC, Butler KL. Thermal injury<br />
activates myocardial JAK-STAT signaling. J Surg. Res. <strong>2008</strong>;144(2):342.<br />
Gross RI, Jacobs LM. Initial Assessment and Resuscitation. Airway<br />
Management: What Every Trauma Surgeon Should Know, From Intubation to<br />
Cricothyroidotomy. In Current Therapy of Trauma and Surgical Critical Care.<br />
Eds. Juan A. Asensio and Donald D. Trunkey. <strong>2008</strong>.<br />
Huffman LC, Koch SE, Butler KL. Coronary effluent from a preconditioned heart<br />
activates the JAK-STAT pathway and induces cardioprotection in a donor heart.<br />
Am J Physiol Heart Circ Physiol. <strong>2008</strong>;294:H257-H262.<br />
Hyman NH, Kozol RA, Kirton OC, Berger DL. Attending surgeon work hours<br />
restriction. Archives of Surgery. <strong>2008</strong>; 143(5): 443.<br />
Jackson S, Mueller EW, Ernst NE, Butler KL. Utility of bilateral bronchoalveolar<br />
lavage for the diagnosis of ventilator-associated pneumonia in critically ill<br />
surgical patients. Am J Surg. <strong>2008</strong>; 195:159-163.<br />
Jacobs LM, Abbensetts JMK. Acute care surgery. In A Guide for General<br />
Surgeons. Emergency Management of the Oropharynx and Neck. (Eds)<br />
Vicente H. Gracias, Patrick Reilly, Mark G. McKenney George C. Velmahos.<br />
Publisher: McGraw Hill. 20<strong>09</strong>.<br />
Jacobs LM, Burns K, Jacobs BB. Trauma death: Views of the public and<br />
trauma professionals on death and dying from injuries. Archives of Surgery.<br />
<strong>2008</strong>;143(8):730- 735.<br />
Jacobs LM, Luk SS, Sproviero J. TRAUMA Sociedad Panamericana De Trauma<br />
2nd Edition. “Trauma Hepatico”. Editors. Ricardo Ferrada, MD, Aurelio<br />
Rodriguez, MD. Pp 369-278. Published by Distribuna Editorial. Pittsburgh, PA<br />
20<strong>09</strong>.<br />
Kirton OC, Folcik M, Calabrese E, Ivy M, Keating K, Mah, J, Pepe, J, Dobkin<br />
et al: Mid Level Practitioner (MLP) work force analysis at a university affiliated<br />
teaching hospital. Arch Surg. 2007; 142:336-341.<br />
Kowal-Vern A, Poulakidas S, Barnett B, Conway D, Culver D, Ferrari M,<br />
Potenza B, KoenigM, Mah J, Majewski M, Morris L, Powers J, Stokes E, Tan<br />
M, Salstrom SJ, Zaletel C, Ambutas S, Casey K, Stein J, DeSane M, Berry K,<br />
Konz EC, Riemer MR, Cullum ME. Fecal containment in bedridden patients:<br />
economic impact of 2 commercial bowel catheters systems. Am J Crit Care.<br />
20<strong>09</strong>. 18(Suppl 3):S2-14.<br />
Mah J, Kirton O. Pharmacologic support of cardiac failure. In Asenio J, Trunkey<br />
D, editors: Current Therapy of Trauma and Surgical Critical Care. 1st ed.<br />
Philadelphia, Mosby, <strong>2008</strong> pp 598-602.<br />
Mah J, Kirton O. Splanchnic flow and resuscitation. In Gabrielli, Layon AJ, and<br />
Yu M, editors: Civetta, Taylor, and Kirby’s Critical Care. 4th ed. Philadelphia,<br />
Lippincott Williams & Wilkins,20<strong>09</strong>, pp 941-948.<br />
Mah JW, Bingham K, Dobkin ED, Malchiodi L, Russell A, Donahue S, Staff I,<br />
Ivy ME, Kirton OC. Mannequin simulation identifies common surgical ICU<br />
teamwork errors long after introduction of sepsis guidelines. Simul Healthc<br />
20<strong>09</strong> Vol.4, No. 4<br />
Mami, Moront, Pascasio, Schlichting, Finck. Ruptured abdominal aortic<br />
aneurysm in an 11-year-old boy. Journal of Pediatric Surgery <strong>2008</strong>;43(4):762-4.<br />
Master D, Piorkowski J, Zani S, Babigian A. Snowblower injuries to the hand:
Epidemiology, patterns of injury, and strategies for prevention. Annals of Plastic<br />
Surgery, <strong>2008</strong>; 61(6):613- 617.<br />
Mondrinos, Koutzaki, Poblete, Crisanti, Lelkes, Finck. In vivo pulmonary<br />
tissue engineering: contribution of donor-derived endothelial cells to construct<br />
vascularization. Tissue Engineering Part A <strong>2008</strong> Mar; 14(3):361-8.<br />
Orenstein S, Kreutzer D, Novitsky Y. Human monocyte activation by biologic and<br />
biodegradable meshes in vitro. Surgical Endoscopy. Vol. 23; Supp 1; April 20<strong>09</strong>.<br />
Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of<br />
human monocytes by human biologic meshes in vitro. Journal of Surgical Research.<br />
Vol. 151; Issue 2; pg 290.<br />
Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of mast cells<br />
in the biocompatibility of synthetic mesh in mice. Hernia. Vol. 13; Supp. 1; Sept.<br />
20<strong>09</strong>.<br />
Rader C, Piorkowski J, Bass D, Babigian A. Epulis garavidarum manum: Pyogenic<br />
granuloma of the hand occurring in pregnant women. Journal of Hand Surgery<br />
<strong>2008</strong>;33A:263-265.<br />
Rangel EL, Butler KL, Johannigman JA, Tsuei BJ, Solomkin JS. Risk factors for<br />
relapse of ventilator-associated pneumonia in trauma patients. J Trauma. 20<strong>09</strong><br />
Jul;67(1):91-5.<br />
Roszell BR, Mondrinos MJ, Seaton A, Simons DM, Koutzaki SH, Fong GH, Lelkes<br />
PI, Finck CM. Efficient derivation of alveolar type II cells from embryonic stem<br />
cells for in vivo application. Tissue Eng Part A. 20<strong>09</strong> Apr 23 epub ahead of print.<br />
Roszell, Seaton, Fong, Finck. Cell-based therapy improves cell viability and<br />
increases airway diameter in an explant model of pulmonary hypoplasia,<br />
Experimental Lung Research 1521- 0499, Volume 35, Issue 6, 20<strong>09</strong>, Pages 501 - 513<br />
Sobieraj DM, Wang F, Kirton OC. Warfarin resistance after total gastrectomy and<br />
Roux-en-Y Esophagojejunostomy. Pharmocotherapy <strong>2008</strong>; 28(12):1537- 1541<br />
Tandon, M., Poi, M., Shapiro, D. Chapter 4: Surgical nutrition. In: Kozol R.A.,<br />
Novitsky, Y.W. (Eds.) Surgery Mentor - Your Clerkship & Shelf Exam Companion,<br />
2nd edition. Philadelphia, PA. F.A. Davis Company. 20<strong>09</strong>; 31-37.<br />
Tisherman SA, Kirton OC, Ivy M, Frangos S: Acute care surgery (ACS): Are<br />
surgeons ready for a new training paradigm? Crit Care Med 2007;35/12:A122.<br />
Vignati, P. Anastomotic leaks: What is the best imaging study?<br />
DCR 2007;50:97-203<br />
Vignati, P. The efficacy and durability of super selective embolization in the<br />
treatment of lower gastrointestinal bleeding. DCR <strong>2008</strong> 51(3);301-5<br />
Zani S, Babigian A. Necrotizing fasciitis of the shoulder following routine rotator<br />
cuff repair. Journal of Bone and Joint Surgery <strong>2008</strong>; 90:1117-1120.<br />
Presentations<br />
Allen B, Babigian A. Breast Reconstruction in a 19 Year Old Female with<br />
Anhydrotic Ectodermal Dysplasia. Presented at the CTACS Scientific and<br />
<strong>Annual</strong> Meeting, Meriden, CT, 11/07.<br />
Allen B, Caputo AE, Babigian A. Pediatric Revascularization and Replantation<br />
in the Hand: Our Experience at <strong>Hartford</strong> <strong>Hospital</strong> and Connecticut Children’s<br />
Medical Center. Presented at the New England Hand Society Thirty-Sixth<br />
<strong>Annual</strong> Meeting and Scientific Program, Sturbridge, MA 12/08.<br />
Allen B, Perdrizet G, Babigian A. Hyperbaric Oxygen Therapy for Treatment of<br />
Delayed Radiation Tissue Injury. Presented at the New England Society of Plastic<br />
and Reconstructive Surgery <strong>2008</strong> <strong>Annual</strong> Meeting, Manchester, VT 6/08.<br />
Babigian, A. Moderator, Scientific Session. New England Society of Plastic and<br />
Reconstructive Surgery <strong>2008</strong> <strong>Annual</strong> Meeting, Manchester, VT 6/08.<br />
Babigian, A. Moderator, Scientific Session. New England Society of Plastic and<br />
Reconstructive Surgery 20<strong>09</strong> <strong>Annual</strong> Meeting, Boston, MA 6/<strong>09</strong>.<br />
Babigian, A. Panel Member. University of Massachusetts Plastic Surgery Practice<br />
Management Strategies Panel, Worcester, MA 12/07.<br />
Babigian, A. Soft Tissue Coverage of the Upper Extremity. Presented at the<br />
University of Massachusetts Plastic Surgery Educational Conference, 6/<strong>09</strong>.<br />
Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC,<br />
Davis K, Johannigman JA. Devil is in the Details: Maximizing Revenue for Daily<br />
Trauma Care. Proceedings of the Central Surgical Association, March <strong>2008</strong>.<br />
Butler KL, Goodman MD, Koch SE, Friend L, Afzal MR. STAT Subtype Switch<br />
in Pressure-overload Hypertrophy Improves Ischemic Tolerance in STAT-3 KO<br />
Mice. Presented at the American College of Surgeons, Papers Session, October<br />
<strong>2008</strong>.<br />
Butler, K. Academic Surgery: The Road Less Traveled. Keynote Speaker SNMA<br />
Banquet Cincinnati, OH February 4, <strong>2008</strong>.<br />
Butler, K. Cardiac Specific STAT-3 Deletion Prevents Myocardial<br />
Decompensation Following Pressure Overload. Society of Black Academic<br />
Surgeons Cleveland, OH April <strong>2008</strong>.<br />
Butler, K. Critical Illness Related Corticosteroid Insufficiency: The Heart of the<br />
Matter. Cardiology Grand Rounds <strong>Hartford</strong> <strong>Hospital</strong>, August 18, 20<strong>09</strong>.<br />
Butler, K. Gender, Science and Serendipity. <strong>Annual</strong> William Matory MD<br />
Lecture, National Medical Association July 27, 20<strong>09</strong>.<br />
Butler, K. Heparin-induced Thrombocytopenia: Who Gets HIT? Society of<br />
Black Academic Surgeons Cleveland, OH April <strong>2008</strong>.<br />
Butler, K. Procalcitonin: A Novel Biomarker for Infection in the Critically Ill
Patient. Division of Critical Care Research Forum, <strong>Hartford</strong> <strong>Hospital</strong>, March 11,<br />
20<strong>09</strong>.<br />
Butler, K. STAT Subtype Switch in Pressure-overload Hypertrophy Improves<br />
Ischemic Tolerance in STAT-3 KO Mice. American College of Surgeons, San<br />
Francisco, CA, October <strong>2008</strong>.<br />
Butler, K. Thermal Injury Activates Myocardial JAK-STAT Signaling. Academic<br />
Surgical Congress Huntington Beach, CA February 6, <strong>2008</strong>.<br />
Butler, K. Intimate Partner Violence. University of Cincinnati Brown Bag Lunch<br />
Series, May <strong>2008</strong>.<br />
Butler, K. The Impact of Pre-injury Anti-platelet and Anticoagulant<br />
Pharmacotherapy on Outcomes Following Hemorrhagic Brain Injury. Central<br />
Surgical Association Cincinnati, OH March 4, <strong>2008</strong>.<br />
Butler, K. Women in Medicine. Howard University <strong>Hospital</strong> Department of<br />
Surgery Grand Rounds November 17, <strong>2008</strong>.<br />
Clarke CN, Keegan SP, Mueller EW, Ernst NE, Butler KL. Heparin-induced<br />
Thrombocytopenia: Who Gets HIT? Proceedings of the Society of Black Academic<br />
Surgeons, April <strong>2008</strong>.<br />
Finck, C. Pulmonary Tissue Engineering. Invited Speaker, Stem Cells and Cellular<br />
Therapies in Lung Biology and Lung Diseases Conference University of Vermont,<br />
Burlington, VT 7/28/<strong>09</strong>.<br />
Finck, C. Stem Cells and Pulmonary Hypoplasia. Invited Speaker, American<br />
Thoracic Society International Conference San Diego, CA 5/19/<strong>09</strong>.<br />
Finck, C. Stem Cells and Treatment of Pulmonary Hypoplasia. Invited speaker,<br />
New England Surgical Society <strong>2008</strong> Boston, MA 9/08.<br />
Fortuna GR, Mueller EW, James LE, Shutter LA, Butler KL. The Impact of Preinjury<br />
Anti-platelet and Anticoagulant Pharmacotherapy on Outcomes Following<br />
Hemorrhagic Brain Injury. Proceedings of the Central Surgical Association, March<br />
<strong>2008</strong>.<br />
Goodman MD, Koch SE, Afzal MR, Butler KL. Compensatory STAT Subtype<br />
Activation Does Not Limit Ischemia-reperfusion Injury in Mice with Cardiac<br />
Restricted STAT-3 Deletion. Presented at the Society of University Surgeons,<br />
February 20<strong>09</strong>.<br />
Goodman MD, Koch SE, Butler KL. JAK-STAT Activation in Postconditioning<br />
is not Without RISK. Presented at the American College of Surgeons, Surgical<br />
Forum, October <strong>2008</strong>.<br />
Goodman MD, Koch SE, Butler KL. Regulating Risk: A Role for Jak-stat Signaling<br />
in Postconditioning. University of Cincinnati Dept of Surgery Resident Research<br />
Competition, First Place. June <strong>2008</strong>.<br />
Ohio Chapter, American College of Surgeons, May, <strong>2008</strong>.<br />
Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Specific STAT-3<br />
Deletion Prevents Myocardial Decompensation Following Pressure Overload.<br />
Proceedings of the Society of Black Academic Surgeons, April <strong>2008</strong>.<br />
Jackson L, Drezner D, Freund J, Palter M, Butler KL. Is Delayed DVT<br />
Prophylaxis in the Neurocritically Ill Patient Effective? Presented at the Society<br />
of Black Academic Surgeons, April 20<strong>09</strong>.<br />
Jacobs LM, Burns KJ, Luk S, Hull D. Advanced Trauma Operative Management<br />
(ATOM) Course: Participant Survey. Poster presentation. New England<br />
Surgical Society, Newport, RI. September 12, 20<strong>09</strong>.<br />
Jacobs, L. Acute Care Surgeon: Should Critical Care Management Be An<br />
Essential Component? American College of Surgeons Point/Counterpoint<br />
Trauma Conference. National Harbor, Maryland. June 9, 20<strong>09</strong>.<br />
Jacobs, L. The Advanced Trauma Operative Management Course: An<br />
Innovative Response to the technical Challenges of Trauma Surgery. Visiting<br />
Professor. Cedars-Sinai Medical Center. Los Angeles, CA. November 12, <strong>2008</strong>.<br />
Jacobs, L. An Innovation in Surgical Education in Trauma, Grand Rounds.<br />
University of Iowa. February 25, 20<strong>09</strong>.<br />
Jacobs, L. Invasive Procedures Performed by Prehospital Personnel: The<br />
Indications Should be Broad. American College of Surgeons Point/Counterpoint<br />
Trauma Conference. National Harbor, Maryland. June 8, 20<strong>09</strong>.<br />
Jacobs, L. Necrotizing Soft Tissue Infections: Is Hyperbaric Oxygen Therapy<br />
Even An Essential Adjunct? American College of Surgeons Point/Counterpoint<br />
Trauma Conference. National Harbor, Maryland. June 8, 20<strong>09</strong>.<br />
Jacobs, L. Pediatric Trauma Moderator. CT Trauma Conference. Foxwoods<br />
Resort. Ledyard, CT. April 2, 20<strong>09</strong>.<br />
Jacobs, L. Simulated Education in Trauma. Grand Rounds Speaker. Rush<br />
University, Chicago, IL. October 28, <strong>2008</strong>.<br />
Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L and Ferguson C.<br />
Rationalization of Acute Care Surgery. Panel Discussion, New England Surgical<br />
Society <strong>Annual</strong> Meeting. Newport, RI. September 12, 20<strong>09</strong>.<br />
Kowal-Vern A, Barnett B, Ferrari M, Koenig M, Mah J, Morris L, Powers J,<br />
Stokes E, Tan M, Zaletel C, Cullum M. Comparison of Economic Value of Two<br />
Indwelling Bowel Catheters in the Acute and Critical Care Setting. (Abstract<br />
396). Society of Critical Care Medicine, Gaylord Conference Center, Nashville,<br />
TN, Jan 29-Feb 2, 20<strong>09</strong>.<br />
Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of<br />
Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Performance is<br />
Preserved Following Pressure-overload Stress in STAT-3 KO Mice. Presented at the<br />
96.
Surgery<br />
Human Monocytes By Human Biologic Meshes In Vitro. Association for Academic<br />
Surgery-20<strong>09</strong> Academic Surgical Congress (February 20<strong>09</strong>) Fort Myers, FL.<br />
Orenstein S, Kreutzer D, Novitsky Y. Human Monocyte Activation by Biologic<br />
and Biodegradable Meshes In Vitro. Society of American Gastrointestinal and<br />
Endoscopic Surgeons - 20<strong>09</strong> <strong>Annual</strong> Meeting (April 20<strong>09</strong>) Phoenix, AZ.<br />
Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of Mast<br />
Cells in the Biocompatibility of Synthetic Mesh in Mice. Fourth International<br />
Hernia Congress -Joint Meeting of the American and European Hernia Societies<br />
(September 20<strong>09</strong>) Berlin, Germany.<br />
Park B, Madej O, McPhelimy C, Piccirillo B, Dahn M, Burleson JA and Menzoian<br />
JO. Predictors of Clinically Significant Post-Procedure Hypotension Following<br />
Carotid Endarterectomy and Carotid Angioplasty with Stenting. The Society for<br />
Clinical Vascular Surgery Podium Presentation, Ft. Lauderdale, FL, March 8, <strong>2008</strong>.<br />
Perdrizet G, Rader C, Allen B, Bass D, Cech A, Castiglione C, Babigian A.<br />
Coverage of Complex Scalp Wounds. Presented at the Northeast Chapter of<br />
the Undersea and Hyperbaric Medical Society Conference/Chapter Meeting,<br />
Newport RI, 11/07.<br />
Rectal Surgeons, Hollywood, Fl, 20<strong>09</strong>.<br />
Vignati P. Instructor, Laparoscopic Colon Course. American College of Surgeons,<br />
New Orleans, LA <strong>2008</strong>.<br />
Vignati P. Instructor, Laparoscopic Hartmann Closure Penn Lap Colon Course.<br />
Philadelphia, PA 2007.<br />
Vignati P. Recurrent Diverticulitis Following Laparoscopic Colectomy. American<br />
Society of Colon and Rectal Surgery, Hollywood Fl 20<strong>09</strong>.<br />
Zani S, Allen B, Babigian A. “Black Belt” Fracture: A Characteristic Injury in<br />
Trained Martial Artists. Presented at the New England Hand Society Thirty-Fifth<br />
<strong>Annual</strong> Meeting and Scientific Program, Sturbridge, MA 12/07.<br />
Zani S, Nelson S, Finck C, Babigian A. Congenital/ Infantile Fibrosarcoma of the<br />
Hand: A Multimodality Therapeutic Approach Aimed At Limb Salvage. Presented<br />
at the New England Hand Society Thirty-Sixth <strong>Annual</strong> Meeting and Scientific<br />
Program, Sturbridge, MA, 12/08.<br />
Poi MJ, Novitsky Y. Laparoscopic Ventral Hernia Repair with Closure of the<br />
Defect: The Shoelace Technique. Presented at the 4th Joint Meeting of the<br />
American Hernia Society (AHS) and The European Hernia Society (EHS); Berlin,<br />
Germany. September 20<strong>09</strong>.<br />
Poi, MJ, Liang Y, Senatus P, Onyiuke H, Novitsky YW. Laparoscopic-assisted<br />
Ventriculoperitoneal Shunt Placement. Presented at the American College of<br />
Surgeons 95th <strong>Annual</strong> Clinical Congress; Chicago, IL. October 20<strong>09</strong> (Mead/<br />
Pyrtek Fund).<br />
Poi, MJ, Novitsky, Y. Abdominal Wall Reconstruction for Multiple Recurrent<br />
Incisional Hernia with Marked Loss Of Domain. Presented at: The Hernia Repair<br />
<strong>2008</strong>; Scottsdale, AZ. March <strong>2008</strong> (Mead fund).<br />
Raad W, Onayemi A, Nelson S, Babigian A. Traumatic Forearm Arterio-Venous<br />
Malformation. Presented at the CTACS Scientific and <strong>Annual</strong> Meeting,<br />
Waterbury, CT, 10/08.<br />
Rowin C, Luu X, Nelson M, Babigian A. Squamous Cell Carcinoma of the Hand<br />
Presenting as a Painless Volar Mass. Presented at the New England Hand Society<br />
Thirty-Sixth <strong>Annual</strong> Meeting and Scientific Program, Sturbridge, MA, 12/08.<br />
Vignati P. Instructor, Laparoscopic Colon Course. American Society of Colon and
Traumatology<br />
and Emergency Medicine<br />
Lincoln Abbott, MD • Lauri Bolton, MD • Kevin Borrup, JD, MPA<br />
Karyl Burns, PhD • Brendan Campbell, MD, MPH • João Delgado, MD<br />
Michael Drescher, MD • Susan Dufel, MD • James Feeney, MD<br />
Catherine Glazer, MD • Ronald Gross, MD • Jennifer Hiscoe, RN<br />
Lenworth Jacobs, MD, MPH • Kelly Johnson-Arbor, MD<br />
Richard Kamin, MD • Joanne Kuntz, MD • Garry Lapidus, PA-C, MPH<br />
Stephen Luk, MD • Charles McKay, MD • Jacqueline McQuay, RN, MS<br />
Tahira Mirza, MD • Thomas Nowicki, MD • George Perdrizet, MD, PhD<br />
Kenneth Robinson, MD, MHCM • Hassan Saleheen, MBBS, MPH •<br />
Alan Jon Smally, MD<br />
Research is integral to the activities of the Department of Traumatology<br />
and Emergency Medicine at <strong>Hartford</strong> <strong>Hospital</strong>. Our mission<br />
includes the conduct of research to improve the clinical, operational, and<br />
educational endeavors across all divisions in the department. The divisions<br />
include the LIFE STAR Critical Care Helicopter Service, the Emergency<br />
Department, the Trauma Program, the Center for Wound Healing and<br />
Hyperbaric Medicine, Toxicology, and the Center for Emergency Medical<br />
Preparedness.<br />
Life Star<br />
The LIFE STAR Critical Care Helicopter Service has a long history of<br />
quality research. Recent projects have included studies regarding the<br />
documentation of medications administered by critical care transport<br />
teams, the use of bispectral analysis to assess sedation in patients requiring<br />
sedation and transported by helicopter, and reasons why LIFE STAR is<br />
cancelled. A recently completed study was a comparison of intra-osseous<br />
and central venous access in helicopter transport.<br />
Emergency Medicine<br />
The Division of Emergency Medicine has had numerous projects relating<br />
to the diagnosis and treatment of medical emergencies. For instance, one<br />
study is examining the interventional management of stroke in a phase III,<br />
randomized, multi-center clinical trial. This study seeks to determine if<br />
a combined IV and IA approach to recanalization is superior to standard<br />
IV rt-PA (Activase) alone. A recently completed study investigated the<br />
relationship of family history and appendicitis. Another study looked<br />
at thrombocytopenia and antiheparin antibodies in adult patients in the<br />
emergency department. A comparison of the Airtraq®α airway device<br />
versus direct laryngoscopy by paramedics in the simulated airway was<br />
also completed by our emergency physicians. A current project is a<br />
study of intimate partner violence in patients with acute overdose.<br />
Research regarding emergency department operations included a study<br />
of over crowding and another about patients who left without being<br />
seen. On the international scene a study was conducted in Israel by<br />
our Associate Chief. It was a randomized, placebo controlled trial of<br />
etoricoxib taken prophylactically to prevent Yom Kippur headache.<br />
The study was funded by Merck, Sharp, Dohme.<br />
Trauma Program<br />
A highlight of projects by the Trauma Program is the TELOS (Trauma<br />
end-of-life optimum support) best practice model supported by the<br />
Aetna Foundation. The model was developed and implemented at<br />
<strong>Hartford</strong> <strong>Hospital</strong> and will soon be disseminated nationally. Data<br />
continue to be collected to assess the Advanced Trauma Operative<br />
Management (ATOM) course that is now offered in 26 sites in the<br />
United States, Canada, Ghana, Qatar, Saudi Arabia, and Japan. A<br />
survey of over 1,000 participants in the ATOM Course was recently<br />
completed. Other projects have included examinations of the<br />
relationships of the prehospital use of HMG-Co-A Reductase Inhibitor<br />
and mortality due to hemorrhagic shock associated with ruptured<br />
abdominal aneurysm and hemorrhagic shock due to trauma. A current<br />
study is investigating the relationship of pre-hospital HMG-Co-A<br />
Reductase Inhibitor use in traumatic brain injury. Another ongoing<br />
study is examining the use of a simulator to improve technique<br />
and procedure confidence of surgical residents for emergency<br />
cricothyroidotomy. A study that was recently completed was a<br />
retrospective review of the utilization and costs of routine pelvic x rays<br />
in trauma.<br />
Toxicology and the Center for<br />
Emergency Medical Preparedness<br />
In collaboration with the Center for Emergency Medical Preparedness<br />
at <strong>Hartford</strong> <strong>Hospital</strong> the Toxicology Division has been working on a<br />
project to identify normative distributions of plasma and erythrocyte<br />
cholinesterase activity based on demographic and clinical data for<br />
use as a rule-out screen for significant nerve agent toxicity. Other<br />
projects by the Toxicology Division include a study that investigated<br />
98.
cyanmethemoglobin as an alternate laboratory test for the diagnosis of<br />
cyanide toxicity and cyanide and cyanmethemoglobin determinations<br />
in cyanide-exposed individuals. Another study was a retrospective<br />
comparison of safety and efficacy between the oral and the intravenous<br />
form of N-acetylcysteine. Other studies by members of the Toxicology<br />
Division include a comparative pharmacokinetic study of intranasal<br />
Naloxone versus intravenous Naloxone and a poison center surveillance<br />
project regarding the prescription of opioid and amphetamine-related<br />
medication mis-use and abuse. A recently approved study is an<br />
examination of the contribution of lactate, lactate dehydrogenase, and<br />
hemoglobin concentration to alterations in the plasma enzymatic/whole<br />
blood gas chromatography-flame ionization detector ratio for ethanol<br />
determinations.<br />
Center for Wound Healing and<br />
Hyperbaric Medicine<br />
Research in the Center for Wound Healing and Hyperbaric Medicine<br />
includes a collaboration with the Center for Anti-Infective Research and<br />
Development to examine the effect of hyperbaric oxygen therapy on<br />
the penetration of linezolid into subcutaneous tissue of diabetic patients<br />
with lower extremity wounds. Another project is a collaboration with the<br />
Division of Urology to study the effect of hyperbaric oxygen therapy postprostatectomy<br />
erectile dysfunction and urinary incontinence.<br />
As a community of clinicians and researchers, members of the Department<br />
of Traumatology and Emergency Medicine strive to answer research<br />
questions that will ultimately improve patient care. To achieve this goal,<br />
the department has a strong focus on scientific inquiry, scholarship, and<br />
mentoring of young professionals. Our research agenda for the future is to<br />
participate in practice-oriented translational research to promote effective<br />
dissemination and use of evidence-based guidelines, new technologies, and<br />
new ways to educate health care professionals.<br />
New Projects<br />
Industry<br />
Montminy, John, DO<br />
An Investigation of Topical Application of Gaseous Nitric Oxide on Safety and<br />
Efficacy in Venous Stasis Ulcers of the Lower Extremities. Nitric BioTherapeutics,<br />
$63,516.<br />
Drescher, Michael, MD<br />
Randomized, Placebo Controlled Trial of Etoricoxib Taken Prophylactically<br />
to Prevent Yom Kippur Headache. Merck, Sharp & Dohme (Israel-1996) Ltd.<br />
(Investigator Initiated), $18,500. Statistical analysis supported through <strong>Hartford</strong><br />
<strong>Hospital</strong> Small Grant.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Gross, Ronald, MD (Spinella, Philip, MD)<br />
Relationship Between Age of RBCs Transfused and Mortality in Critically Ill<br />
Trauma Patients. Small Grant, $9,861.<br />
Departmental Funds<br />
McKay, Charles M.D.<br />
Contribution of Lactate, Lactate Dehydrogenase, and Hemoglobin<br />
Concentration to Alterations in the Plasma Enzymatic/Whole Blood Gas<br />
Chromatography-flame Ionization Detector Ratio for Ethanol Determinations.<br />
$1,500.<br />
Unfunded<br />
Abbott, Lincoln M.D.<br />
Validation of Core Measure Pneumonia Keyword Filter.<br />
Bolton, Lauri, MD<br />
Comparison of IO and Central Venous Access in Helicopter Transport.<br />
Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Burns, Karyl, PhD<br />
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in<br />
Hemorrhagic Shock Due to Trauma. Statistical analysis supported through<br />
<strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Dufel, Susan, MD<br />
A Survey of Current Emergency Medicine Residents and Graduates of 2002-<br />
2007 Classes Regarding the ABEM Oral Board Certification Examination.<br />
Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Feeney, James, MD<br />
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in<br />
Traumatic Brain Injury. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong><br />
Small Grant.<br />
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in<br />
Hemorrhagic Shock Due to Ruptured Abdominal Aortic Aneurysm (AAA): An<br />
Exploratory Study. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong><br />
Small Grant.<br />
Retrospective Review of the Utilization and Costs of Routine Pelvic X rays in<br />
Trauma. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Jacobs, Lenworth, MD<br />
Nonoperative Management of Grade IV and V Splenic Injuries: A RECONECT<br />
(Research Consortium of New England Center for Trauma) Study.<br />
Development of Best Clinical Practice Guidelines for the Mature Trauma Patient<br />
with Rib Fractures.
Kuntz, Joanne, MD<br />
Delivering Bad News: Perceptions of Residency Directors Regarding Current<br />
Practice and Resident Education.<br />
Luk, Stephen, MD<br />
Calciphylaxis and Chronic Dialysis Therapy.<br />
Retrospective Review of Post-<strong>Hospital</strong> Complications in Victims of Blunt<br />
Abdominal Trauma (BAT).<br />
McKay, Charles, MD<br />
Digoxin Toxicity in Renal Failure with Hyperkalemia.<br />
Mirza, Tahira, MD<br />
CT Chest or CTA Chest for the Diagnosis of Blunt Aortic Injury.<br />
Thibeault, Susan, APRN<br />
Reasons for Cancellation of LIFE STAR Transport by Requester.<br />
Active Projects<br />
Abbott, Lincoln, MD<br />
Interventional Management of Stroke: A Phase III, Randomized, Multi-Center<br />
Clinical Trial to Examine Whether a Combined IV and IA Approach to<br />
Recanalization is Superior to Standard IV rt-PA (Activase) Alone. NIH subcontract<br />
through University of Cincinati, $33,221.<br />
Brautigam, Robert, MD<br />
Evaluation of the Trauma Simulation Education Course.<br />
The Development of Lower Extremity Compartment Syndrome Following<br />
Fractures of the Tibia and Fibula.<br />
Corson, Thomas, DO<br />
Reliability of Emergency Department Patients Contact Information.<br />
Delgado, João, MD<br />
Bispectral Analysis of Air Transport Patients.<br />
Prevalence of Intimate Partner Violence in Acute Overdose Patients<br />
Retrospective Comparison of Safety and Efficacy Between the Oral and the<br />
Intravenous Form of N-acetylcysteine. Rocky Mountain Poison and Drug Center,<br />
$2,200.<br />
Drescher, Michael, MD<br />
Can Family History be used as a Predictor for Appendicitis? Statistical analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Overcrowding in the Emergency Department.<br />
Frakes, Michael, APRN<br />
A Comparison of Pre-hospital Trauma Analgesia By Air and Ground EMS<br />
Providers.<br />
Effect of Line Oriented Flight Training On Team Behaviors and Beliefs at a<br />
Helicopter Air Medical Program.<br />
Effectiveness of a Read-and-Respond Checklist in Assuring Safety Behavior<br />
Compliance at a Rotor Wing Air Medical Program.<br />
Evaluation of a Modified Sign-Out Procedure on <strong>Hospital</strong> Documentation of<br />
Medications Administered by Critical Care Transport Teams.<br />
Evaluation of Helicopter Air Medical Transport Utilization by Prospective<br />
Application of Consensus Criteria.<br />
Glazer, Catherine, MD<br />
Is the Use of D Dimers in A Low Risk Population Cost Effective and Safe in<br />
Ruling Out PE? Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> small<br />
grant<br />
Gross, Ronald, MD<br />
Evaluation of Outcomes After Pancreato-Duodenal Injuries In New England<br />
<strong>Hospital</strong>s.<br />
Role of Ultrasound in Pre-<strong>Hospital</strong> Aeromedical Evacuation and Triage. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $10,128.<br />
Jacobs, Lenworth, MD<br />
Advanced Trauma Operative Management (ATOM) Course.<br />
American College of Surgeons Advance Trauma Life Support Course (ATLS).<br />
Bioterrorism Surveillance and Response Preparedness and Training. University of<br />
Connecticut, $50,000.<br />
Development, Implementation, and Testing of a Best Practice Model for End-of-<br />
Life Care in Trauma. Aetna Foundation, $295,000.<br />
Evaluation of the Advanced Trauma Operative Management (ATOM) Course.<br />
Multi-Center Trial of the Advanced Trauma Operative Management (ATOM)<br />
Course.<br />
QuikClot versus Packing For Hemostasis After Grade V Liver Injury in Swine.<br />
Z-Medica, $224,000.<br />
Kuntz, Joanne, MD<br />
Thrombocytopenia and antiheparin antibodies in adult ED patients. Glaxo Smith<br />
Kline, $9,800.<br />
Lewis, Myra, DO<br />
History Taking in Emergency Department Patients Presenting with Acute<br />
Chest Pain.<br />
Luk, Stephen, MD<br />
Crush Injuries and Hyperbaric Oxygen Therapy: Inital Experience at a Level 1<br />
Trauma Center with a Multiplace Hyperbaric Chamber.<br />
Radionecrosis Research Registry.<br />
The Role of Hyperbaric Oxygen Therapy in the Treatment of Severe Soft-Tissue<br />
Infections.<br />
Lynch, John, MD<br />
Emergency Procedures for Emergency Medicine Residents.<br />
100.
McKay, Charles, MD<br />
Comparative Pharmacokinetic Study of Intranasal Naloxone Versus Intravenous<br />
Naloxone. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $6,981<br />
Cyanmethemoglobin: An Alternative Laboratory Test for the Diagnosis of Cyanide<br />
Toxicity. Departmental, $2,460.<br />
Normative Distributions of Plasma and Erythrocyte Cholinesterase Activity in a<br />
Tertiary Care Emergency Department, Based on Demographic and Clinical Data,<br />
for Use as a Rule-Out Screen for Significant Nerve Agent Toxicity. HRSA c/o State<br />
of Connecticut, $60,250.<br />
Relationship between CPK and Aminotransferase Elevations in Rhabdomyolysis<br />
Patients. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> small grant<br />
Nowicki, Thomas, MD<br />
Airtraq Airway Device in Emergency Airway Management. Statistical analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Management of the Difficult Airway (CME - Educational Course).<br />
Perdrizet, George, MD<br />
Chart review of the treatment of delayed radiation tissue injury of soft tissue and<br />
bone with hyperbaric oxygen therapy.<br />
Development of a Stress-Sensitive Assay Using Discarded Human Red Blood Cells.<br />
Geriatric Trauma: A Comparison of Bone Fracture Healing Rates. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $43,164.<br />
Minimally Invasive Treatment of the Abdominal Compartment Syndrome: Initial<br />
Experience.<br />
Outcomes of Patients with Diabetic Foot Ulcers Treated with Hyperbaric<br />
Oxygen Therapy.<br />
Prevention of Complicated Alcohol Withdrawal Syndrome in the <strong>Hospital</strong>ized<br />
Trauma Patient: A Comparison of Intravenous Benzodiazepine vs. Ethyl Alcohol<br />
Therapies. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $65,650.<br />
Regan, Thomas, MD<br />
Variations in Usage of Emergency Medicine.<br />
Robinson, Kenneth, MD<br />
Flight Nurse Training of Surgical Skills.<br />
Patients who leave without being seen at the <strong>Hartford</strong> <strong>Hospital</strong> Emergency<br />
Department. Statistical analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Schott, Eric, PA<br />
Evaluation Of Trauma Orientation.<br />
Publications<br />
Brautigam RT, Sheppard R, Robinson K, Jacobs LM. Evaluation and treatment of<br />
the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM, Trafton PG.<br />
Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed. 20<strong>09</strong>.<br />
Brautigam RT, Schott E, Burns KJ. A simulation education course for the initial<br />
management of blunt trauma. Conn Med. 20<strong>09</strong>;73:267-271.<br />
Campbell BT, Saleheen H, Borrup K, McQuay J, Luk S, Hiscoe J, Lapidus G.<br />
Epidemiology of trauma at a level 1 trauma center. Conn Med.<br />
20<strong>09</strong>;73:389-394.<br />
Cronin D, Dufel S. Plague. E-Medicine chapter July, 20<strong>09</strong>. Available at:http://<br />
emedicine.medscape.com.<br />
Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson PD, McKay<br />
RG. Use of prehospital electrocardiograms for the treatment of patients with<br />
ST-segment elevation myocardial infarction. Conn Med. 20<strong>09</strong>;73(2):69-72.<br />
Drescher M J, Aharonson L, Peleg J, Liebman J. A study of the workforce in<br />
emergency medicine in Israel 2003. J of Emerg Med. 2007;33(4):433-437.<br />
Drescher M. Guest editorial: Patient satisfaction in the ED: nicety or necessity?<br />
Israeli J Emerg Med. 20<strong>09</strong>;9(1):3-4.<br />
Feeney J M, Burns K J, Staff I, Bai J, Rodrigues N, Fortier J, Jacobs LM.<br />
Prehospital HMG Co-A Reductase Inhibitor use and reduced mortality in<br />
ruptured abdominal aortic aneurysm. J Amer Coll Surg. 20<strong>09</strong>;2<strong>09</strong>:41-46.<br />
Goldstein RA, DesLauriers, Burda A, Johnson-Arbor K. Cocaine: history, social<br />
implications, and toxicity: a review. SEMIN DIAGN PATHOL. 20<strong>09</strong>;26:10-17.<br />
Gross RI, Jacobs LM. Initial assessment and resuscitation, airway management:<br />
what every trauma surgeon should know, from intubation to cricothyroidotomy.<br />
In: Asensio JA, Trunkey DD, editors. Current Therapy of Trauma and Surgical<br />
Critical Care. Philadelphia: WB Saunders/Elsevier; <strong>2008</strong>.<br />
Hoffman RS, Kirrane BM, Marcus SM, and the Clenbuterol Study Investigators<br />
(McKay C). A descriptive study of an outbreak of clenbuterol-containing heroin.<br />
Ann Emerg Med. <strong>2008</strong>;52:548-553.<br />
Jacobs LM, Burns KJ, Bennett Jacobs B. Trauma death: views of the public and<br />
trauma professionals on death and dying from injuries. Arch Surg.<br />
<strong>2008</strong>;143:730-735.<br />
Lefberg J, Delgado J. Hyper- and Hypo-natremia. In ToxED Online Reference<br />
based on Haddad & Winchester Clinical Management of Poisoning and Drug<br />
Overdose. Elsevier and Gold Standard. V2, <strong>2008</strong>. Available at: http://www.<br />
toxed.com.<br />
Matz, T, Abbott, L. Review article: bilateral acute angle closure glaucoma.<br />
Resident and Staff Physician. <strong>2008</strong>;(54)3:10-14.<br />
McKay CA. Chlorine. In ToxED Online Reference based on Haddad &<br />
Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier<br />
and Gold Standard. V2, <strong>2008</strong>. Available at: http://www.toxed.com.<br />
McLaughlin S, Fitch M, Deepi G, Hayden E, Kauh C, Laack T, Nowicki T et<br />
al. Simulation in graduate medical education <strong>2008</strong>: a review for emergency<br />
medicine. Acad Emerg Med. <strong>2008</strong>;15 (11):1117-1129.
Nowicki TA, Suozzi JC, Dziedzic M, Kamin R, Donahue S, Robinson K.<br />
Comparison of the use of the Airtraq with direct laryngoscopy by paramedics in<br />
the simulated airway. Prehosp Emerg Care. 20<strong>09</strong>;13:75-80.<br />
O’Toole K, Delgado J. Methemoglobinemia. In ToxED Online Reference based<br />
on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose.<br />
Elsevier and Gold Standard. V2, <strong>2008</strong>. Available at: http://www.toxed.com.<br />
O’Toole K, Delgado J. Glucose Disturbances. In ToxED Online Reference based<br />
on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose.<br />
Elsevier and Gold Standard. V2, <strong>2008</strong>. Available at: http://www.toxed.com.<br />
Phelan HA, Velmahos GC, Jurkovich GJ, et al. (Feeney J.).<br />
An evaluation of multidetector computed tomography in detecting pancreatic<br />
injury: results of a multicenter AAST study. J Trauma. 20<strong>09</strong>;66:641-647.<br />
Scalora MA, Gross RI, Burns KJ. Management of blunt hepatic trauma at a<br />
Connecticut level I trauma center. Conn Med. 2007;71:529-532.<br />
Smally, AJ. Aging in america, in your own words – emergency physicians discuss<br />
end-of-life care. Emergency Physicians Monthly. 20<strong>09</strong>;16(6).<br />
Vorih DC, Bolton LD, Marcelynas J, Nowick TA, Jacobs LM, Robinson KJ.<br />
Comparison of Nitrile gloves and Nitrile over Nomex gloves. Air Med J.<br />
20<strong>09</strong>;28:250-253.<br />
Wu AHB, Smith A, McComb R, Bowers GN, Makowski GS, McKay CA,<br />
Vena J, McDonagh J, Hopfer S, Sena SF, Malkus H, Forte E, Kelly K. Statewide<br />
hospital clinical laboratory plan for measuring cholinesterase activity for<br />
individuals suspected of exposure to nerve agent chemical weapons. Clin Toxicol.<br />
<strong>2008</strong>;46(2):110-116.<br />
Abstracts and Presentations<br />
Alhelail MA, Hoppe JA, Rhyee SH, Heard KJ, Toxicology Investigator Network<br />
(J. Delgado, et al.) Clinical course of repeated supratherapeutic ingestion of<br />
acetaminophen. Platform presentation. <strong>2008</strong> North American Congress of Clinical<br />
Toxicology, Toronto, Canada, September 13-16, <strong>2008</strong>.<br />
Brayton A, Delgado D, Flowers D, Delgado J. Prevalence of intimate partner<br />
violence in an urban ED population. New England Regional Society of Academic<br />
Emergency Medicine, Shrewsbury, MA, March 18, 20<strong>09</strong>.<br />
Buchanan JA, Phua DH, Mlynarchek SL, Heard K, Toxicology Investigator<br />
Network (J. Delgado, et al.) Serum acetaminophen levels, intravenous<br />
N-acetylcysteine infusion rate and risk of anaphylactoid reactions. Platform<br />
presentation. <strong>2008</strong> North American Congress of Clinical Toxicology, Toronto,<br />
Canada, September 13-16, <strong>2008</strong>.<br />
Chartoff S. Critical care in the air - en route care system during recent military<br />
operations. Grand Rounds, Department of Traumatology and Emergency Medicine,<br />
<strong>Hartford</strong> <strong>Hospital</strong>, <strong>Hartford</strong>, CT, July 17, <strong>2008</strong>.<br />
Chartoff S. <strong>Hartford</strong> <strong>Hospital</strong> Emergency Department mass casualty incident,<br />
a table top disaster drill. Grand Rounds, Department of Traumatology and<br />
Emergency Medicine <strong>Hartford</strong> <strong>Hospital</strong>, <strong>Hartford</strong>, CT, January 15, 20<strong>09</strong>.<br />
Chartoff S. Critical care in the air – en route care system during recent military<br />
operations. Nursing Critical Care Day, <strong>Hartford</strong> <strong>Hospital</strong>, <strong>Hartford</strong>, CT, March<br />
27, 20<strong>09</strong>.<br />
Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for<br />
coagulation studies in an emergency department stroke protocol: a time saving<br />
innovation. Scientific Assembly, American College of Emergency Physicians,<br />
Seattle WA. October, 2007. Ann Emerg Med. 2007; 50(3):S25.<br />
Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for<br />
coagulation studies in an emergency department stroke protocol: a time saving<br />
innovation. Scientific Assembly, Connecticut College of Emergency Physicians,<br />
Rocky Hill, CT, October 10, 2007.<br />
Drescher MJ. Altered standards of medical care in disasters. <strong>Annual</strong> meeting,<br />
Israeli Association of Emergency Medicine, Tel Aviv, Israel, March 11, <strong>2008</strong>.<br />
Drescher MJ, Spence A, Rockwell D, Staff I, Smally AJ. Point of care testing for<br />
coagulation studies in an emergency department stroke protocol: a time saving<br />
innovation. Poster presentation. New England Regional Society of Academic<br />
Emergency Medicine, Shrewsbury, MA, April 30, <strong>2008</strong>.<br />
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis<br />
in adults presenting to the emergency department. Scientific Assembly,<br />
Connecticut College of Emergency Physicians, Rocky Hill, CT, October 22,<br />
<strong>2008</strong>.<br />
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis<br />
in adults presenting to the emergency department. Scientific Assembly,<br />
American Academy of Emergency Medicine, Phoenix, AZ, March 2-4, 20<strong>09</strong>.<br />
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis<br />
in adults presenting to the emergency department. New England Regional<br />
Society of Academic Emergency Medicine, Shrewsbury, MA, March 18, 20<strong>09</strong>.<br />
Drescher MJ. An evidence based approach to urolithiasis in the emergency<br />
department. Fifth Mediterranean Emergency Medicine Congress, Valencia,<br />
Spain, September 14, 20<strong>09</strong>.<br />
Drescher MJ. A placebo controlled double blind and randomized trial<br />
of prophylactic etoricoxib given to prevent Yom Kippur headache. Fifth<br />
Mediterranean Emergency Medicine Congress, Valencia, Spain, September 15,<br />
20<strong>09</strong>.<br />
Drescher MJ. Family history is a predictor of appendicitis in the adult emergency<br />
department patient. Fifth Mediterranean Emergency Medicine Congress,<br />
Valencia, Spain, September 16, 20<strong>09</strong>.<br />
Dziedzic M, Suozzi J, Nowicki T. Comparison of the Airtraq optical<br />
laryngoscope to direct laryngoscopy in a manikin model for easy and difficult<br />
102.
intubations. Poster presentation. Scientific Assembly, American College of<br />
Emergency Physicians, Seattle, WA, October, 2007.<br />
Frakes M, Delgado J. Bispectral analysis of air transport patients. Poster<br />
presentation. <strong>Hartford</strong> <strong>Hospital</strong> Research Day, <strong>Hartford</strong>, CT, November, <strong>2008</strong>.<br />
Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out<br />
procedure on hospital documentation of medications administered by critical care<br />
transport teams. Poster presentation. <strong>Hartford</strong> <strong>Hospital</strong> Research Day, <strong>Hartford</strong>,<br />
CT, November, <strong>2008</strong>.<br />
Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out<br />
procedure on hospital documentation of medications administered by critical care<br />
transport teams. Poster presentation. Society of Academic Emergency Medicine,<br />
New Orleans, LA, May 14-17, 20<strong>09</strong>.<br />
Jacobs LM. Case Presentations Moderator. UT Southwestern Medical Center.<br />
Dallas, TX, October 17, 2007.<br />
Jacobs LM. Advanced Trauma Operative Management: A new and innovative<br />
method of surgical education. Distinguished Lecturer. Royce Laycock, MD,<br />
Lectureship in Surgery. UT Southwestern Medical Center, Dallas, TX, October<br />
17, 2007.<br />
Jacobs LM. New ways to education physicians in a changing time. Trends in<br />
Medicine and Surgery, Beaver Creek, CO, February 5, <strong>2008</strong>.<br />
Jacobs LM. The trauma system in Connecticut and its clinical importance. Stable<br />
spine fractures: when should we be concerned? Multidisciplinary Conference,<br />
<strong>Hartford</strong> <strong>Hospital</strong>. <strong>Hartford</strong>, CT, March 20, <strong>2008</strong>.<br />
Jacobs LM. Thoracic trauma: have we made any progress? Moderator. Looking<br />
back… moving forward. Connecticut Trauma Conference, Foxwoods Resort and<br />
Conference Center, Ledyard, CT, April 3, <strong>2008</strong>.<br />
Jacobs LM. New ways to educate practitioners in a changing time. Keynote<br />
address. Jacobi Medical Center Trauma/Emergency Medicine Symposium, Bronx,<br />
NY, May 14, <strong>2008</strong>.<br />
Jacobs LM. Splenic injuries: should the preference be angiography/embolization<br />
over operative intervention? Point/Counterpoint, American College of Surgeons,<br />
Baltimore, MD, June 10, <strong>2008</strong>.<br />
Jacobs LM. Closed head injuries and insertion of intracranial pressure monitors:<br />
should this procedure be strictly done by neurosurgeons only? Point/Counterpoint,<br />
American College of Surgeons, Baltimore, MD, June 10, <strong>2008</strong>.<br />
Jacobs LM. New topical hemostatic agents: are they cost effective? Point/<br />
Counterpoint, American College of Surgeons, Baltimore, MD, June 10, <strong>2008</strong>.<br />
Jacobs LM. Simulated education in trauma. Grand Rounds. Rush University,<br />
Chicago, IL, October 28, <strong>2008</strong>.<br />
Jacobs LM. The Advanced Trauma Operative Management Course: an innovative<br />
response to the technical challenges of trauma surgery. Visiting Professor,<br />
Cedars-Sinai Medical Center, Los Angeles, CA, November 12, <strong>2008</strong>.<br />
Jacobs LM. An innovation in surgical education in trauma. Grand Rounds.<br />
University of Iowa, Iowa City, IA, February 25, 20<strong>09</strong>.<br />
Jacobs LM, Burns KJ. Advanced Trauma Operative Management (ATOM)<br />
Course: an exemplar of simulation education scenario development. Poster<br />
presentation. American College of Surgeons Consortium of Accredited<br />
Education Institutes, Chicago, IL, March, 20<strong>09</strong>.<br />
Jacobs LM. Pediatric trauma. Moderator. Connecticut Trauma Conference,<br />
Foxwoods Resort, Ledyard, CT, April 2, 20<strong>09</strong>.<br />
Jacobs LM. Necrotizing soft tissue infections: is hyperbaric oxygen therapy<br />
even an essential adjunct? Point/Counterpoint, American College of Surgeons,<br />
National Harbor, MD, June 8, 20<strong>09</strong>.<br />
Jacobs LM. Invasive procedures performed by prehospital personnel: the<br />
indications should be broad. Point/Counterpoint, American College of<br />
Surgeons, National Harbor, MD, June 8, 20<strong>09</strong>.<br />
Jacobs LM. Acute care surgeon: should critical care management be an essential<br />
component? Point/Counterpoint, American College of Surgeons, National<br />
Harbor, MD, June 9, 20<strong>09</strong>.<br />
Jacobs L M, Burns K J, Luk S, Hull S. Advanced Trauma Operative Management<br />
(ATOM) Course: participant survey. Poster presentation. New England Surgical<br />
Society, Newport, RI, September 12, 20<strong>09</strong>.<br />
Johnson-Arbor K. Drugs of abuse for EMS providers. LIFE STAR EMS<br />
Conference, <strong>Hartford</strong>, CT, October 29, 2007.<br />
Johnson-Arbor K. Toxicologic emergencies. LIFE STAR EMS Conference,<br />
<strong>Hartford</strong>, CT, October 29, 2007.<br />
Johnson-Arbor K. Hyperbaric oxygen therapy: intracranial abscess,<br />
osteomyelitis, acute blood loss anemia, carbon monoxide poisoning. University<br />
of <strong>Hartford</strong>, <strong>Hartford</strong>, CT, CT, November 26, 2007.<br />
Johnson-Arbor K. Pressure ulcers: overview and medicolegal issues. PA/NP<br />
Grand Rounds, <strong>Hartford</strong> <strong>Hospital</strong>, <strong>Hartford</strong>, CT, March 4, <strong>2008</strong>.<br />
Johnson-Arbor K. Toxins and envenomations for the intensivist. Surgical ICU<br />
Conference, Yale New-Haven <strong>Hospital</strong>, New Haven, CT , March 18, <strong>2008</strong>.<br />
Johnson K. Chemical contamination of food, water, and medication. Toxic<br />
Industrial Chemicals and Materials Conference, American College of Medical<br />
toxicology, Knoxville, TN, May 29, <strong>2008</strong>.<br />
Johnson-Arbor K. Pressure ulcers and wounds for ED physicians. Integrated<br />
Residency in Emergency Medicine, University of Connecticut, <strong>Hartford</strong>, CT,<br />
September 23, <strong>2008</strong>.
Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a<br />
statewide survey. Poster presentation. New England Regional Society of Academic<br />
Emergency Medicine, Shrewsbury, MA, April 30, <strong>2008</strong>.<br />
Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a<br />
statewide survey. Poster presentation. Scientific Assembly, Connecticut College of<br />
Emergency Physicians, Rocky Hill, CT, October 22, <strong>2008</strong>.<br />
Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L, Ferguson C.<br />
Rationalization of acute care surgery, Panel Discussion. New England Surgical<br />
Society. Newport, RI, September 12, 20<strong>09</strong>.<br />
Luk S. Presentation, diagnosis & treatment of major bleeding pelvic vs. other<br />
sources. Orthopedic Multidisciplinary Conference, <strong>Hartford</strong> <strong>Hospital</strong>, <strong>Hartford</strong>,<br />
CT, August 1, <strong>2008</strong>.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of<br />
Alberta, Edmonton, Alberta, Canada, November 9, 2007.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of<br />
Iowa <strong>Hospital</strong>s and Clinics, Iowa City, IA, November 19, 2007.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of<br />
Texas Medical Branch, Galveston, TX, May 20, <strong>2008</strong>.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course. Massachusetts<br />
General <strong>Hospital</strong>, Boston, MA, June 1, <strong>2008</strong>.<br />
Luk S. Pelvic fracture management. Grand Rounds. University of Iowa <strong>Hospital</strong>s &<br />
Clinics, Iowa City, IA, September 30, <strong>2008</strong>.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty<br />
and site evaluator. King Abdulaziz Medical City & Hamad Medical Corp., Doha,<br />
Qatar, November 27, <strong>2008</strong>.<br />
Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty<br />
and site evaluator. Jichi Medical University, Jichi, Japan, December 18, <strong>2008</strong>.<br />
Luk S. What’s new in the diagnosis and management of pelvic trauma? William<br />
Backus <strong>Hospital</strong>, Norwich, CT, January, 20<strong>09</strong>.<br />
Martinelli CJ, Barko IR, O’Toole K, Bayer MJ. “Vitamin” B17 toxicity treated with<br />
hydroxocobalamin. Clin Toxicol. <strong>2008</strong>;46: 631.<br />
McKay CA. Interpreting biomonitoring results. Environmental Health Research<br />
Foundation web video, October 2007.<br />
McKay CA. The role of the medical toxicologist in the assessment of moldrelated<br />
complaints. American College of Medical Toxicology Practice Symposium<br />
(moderator), North American Congress of Clinical Toxicology, New Orleans, LA,<br />
October 22, 2007.<br />
McKay CA. Arsenic. Clinical/Analytical Toxicology Case Conference,<br />
Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>, CT, October 25,<br />
2007.<br />
McKay CA. Introduction/clinical neurotoxicology of chemical terrorism/<br />
delayed toxic syndromes - chemical Agents of Opportunity: Toxic Industrial<br />
Chemicals and Materials Conference, HazMat EXPO 2007, Las Vegas, NV,<br />
November 6, 2007.<br />
McKay CA. Carbon monoxide poisoning in Connecticut: an analysis of three<br />
databases using capture-recapture statistics. Undersea and Hyperbaric Medical<br />
Society Northeast Chapter <strong>Annual</strong> Scientific Meeting, Newport, RI, November<br />
10, 2007.<br />
McKay CA. Decompression theory and illness. Hyperbaric Medicine Course<br />
(HS490). University of <strong>Hartford</strong>, <strong>Hartford</strong>, CT, November 19, 2007.<br />
McKay CA. Cotinine. Clinical/Analytical Toxicology Case Conference,<br />
Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>, CT, November<br />
29, 2007.<br />
McKay CA. Environmental instrumentation/post-incident medical surveillance<br />
- chemical agents of opportunity. Toxic Industrial Chemicals and Materials<br />
Conference, American College of Medical Toxicology, Oakland, CA, December<br />
18, 2007.<br />
McKay CA. Introduction/post-incident medical surveillance - chemical agents<br />
of opportunity. International Emergency Management Conference. Emergency<br />
Medicine Learning Resource Center, Orlando, FL, January 31, <strong>2008</strong>.<br />
McKay CA. Legal (forensic) ethanol. Clinical/Analytical Toxicology Case<br />
Conference, Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>,<br />
CT, February 28, <strong>2008</strong>.<br />
McKay CA. Munchausen by proxy. Clinical/Analytical Toxicology Case<br />
Conference, Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>,<br />
CT, March 27, <strong>2008</strong>.<br />
McKay CA. Introduction and tabletop exercise. Toxic Industrial Chemicals and<br />
Materials Conference, American College of Medical Toxicology, Knoxville, TN,<br />
May 29, <strong>2008</strong>.<br />
McKay CA. Cellular toxins. American Association of Poison Control Centers<br />
Webcast, June 13, <strong>2008</strong>.<br />
McKay CA. Adulterated heroin. Clinical/Analytical Toxicology Case<br />
Conference, Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>,<br />
CT, June 19, <strong>2008</strong>.<br />
McKay CA. Food, water and medication as vehicles for terrorism and radiation<br />
- chemical agents of opportunity. Toxic Industrial Chemicals and Materials<br />
Conference. 94th Civil Support Team/National Guard, Guam, July 16, <strong>2008</strong>.<br />
McKay CA. Chemical terrorism. Connecticut Laboratory Preparedness<br />
Meeting, Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>, CT,<br />
August 4, <strong>2008</strong>.<br />
104.
McKay CA. Toxic warfare: looking beyond conventional chemical weapons.<br />
Force Health Protection Conference, United States Army Center for Health<br />
Promotion and Preventive Medicine (USACHPPM), Louisville, KY, August 5,<br />
<strong>2008</strong>.<br />
McKay CA. The psychological impact of mass chemical exposures. Force Health<br />
Protection Conference, United States Army Center for Health Promotion and<br />
Preventive Medicine (USACHPPM), Louisville, KY, August 5, <strong>2008</strong>.<br />
McKay CA. Introduction. Toxic Industrial Chemicals and Materials Conference,<br />
Force Health Protection Conference, United States Army Center for Health<br />
Promotion and Preventive Medicine; Albuquerque, NM, August 10, <strong>2008</strong>.<br />
McKay CA. Melamine-contaminated Chinese food products. Clinical/Analytical<br />
Toxicology Case Conference, Connecticut Agricultural Experiment Station, New<br />
Haven, CT, October 23, <strong>2008</strong> (with MaryJane Mattina PhD).<br />
McKay CA. Introduction/clinical psychological responses to mass exposures.<br />
Chemical agents of opportunity. Toxic Industrial Chemicals & Materials<br />
Conference, Hazmat Expo <strong>2008</strong>, Las Vegas, NV, November 5, <strong>2008</strong>.<br />
McKay CA. History & epidemiology/table top exercise. Health Consequences of<br />
Clandestine Methamphetamine Laboratories Conference, Hazmat Expo <strong>2008</strong>,<br />
Las Vegas, NV, November 5, <strong>2008</strong>.<br />
McKay CA. Medical aspects of crucifixion, symposium and banquet. FaithCare,<br />
Bloomfield, CT, November 8, <strong>2008</strong>.<br />
McKay CA. Homicidal poisoning. Clinical/Analytical Toxicology Case<br />
Conference. Connecticut Department of Public Health Laboratory, <strong>Hartford</strong>, CT,<br />
November 20, <strong>2008</strong>.<br />
McKay CA. Lethal poisoning. Caribbean Emergency Medicine Congress,<br />
University of the West Indies and the American Academy of Emergency<br />
Medicine, Barbados, West Indies, January 5, 20<strong>09</strong>.<br />
McKay CA. Chemical terrorism. Caribbean Emergency Medicine Congress,<br />
University of the West Indies and the American Academy of Emergency<br />
Medicine, Barbados, West Indies, January 7, 20<strong>09</strong>.<br />
McKay CA. Risk communication, neurotoxicology update: advances, challenges,<br />
& future directions. 7th <strong>Annual</strong> ACMT Spring Conference, American College of<br />
Medical Toxicology, San Juan, Puerto Rico, March 27, 20<strong>09</strong>.<br />
McKay CA. Mercury exposure & neurotoxicology update: advances, challenges,<br />
& future directions. 7th <strong>Annual</strong> ACMT Spring Conference, American College of<br />
Medical Toxicology, San Juan, Puerto Rico, March 28, 20<strong>09</strong>.<br />
McKay CA. Fellows-in-training: roundtable luncheon: assessment of job offers.<br />
7th <strong>Annual</strong> ACMT Spring Conference, American College of Medical Toxicology,<br />
San Juan, Puerto Rico, March 28, 20<strong>09</strong>.<br />
McKay CA. Physiologic effects of chemical terrorism. Responding to a chemical<br />
terrorism attack: training for the first responder. Connecticut Department of<br />
Public Health (with FBI, CT State Police, 14th CST, US DHS), Berlin, CT, April<br />
14, 20<strong>09</strong>.<br />
McKay CA. Use of drug testing in child protection cases. 10th <strong>Annual</strong> Child<br />
and Youth Law Forum, Cromwell, CT, June 24, 20<strong>09</strong> (presentation and panel<br />
discussion w/Attnys. Michael Besso, Scott Sandler, and Carolyn Signorelli).<br />
Mckinney C, Bolton L, Robinson K, Burns K. Characterization of patients<br />
who leave an emergency department without being seen. Scientific Assembly,<br />
American College of Emergency Physicians, Seattle, WA, October 1, 2007.<br />
Mlynarchek SL, Bogdan GM, Heard K, Dart RC, Toxicology Investigator<br />
Network (J. Delgado, et al.). Safety profile of oral versus intravenous<br />
N-acetylcysteine for acute ingestion of acetaminophen. Poster Presentation. <strong>2008</strong><br />
North American Congress of Clinical Toxicology, Toronto, Canada, September<br />
13-16, <strong>2008</strong>.<br />
Nowicki TA. Triage of NBC Casualties. Estonian National Medical Conference,<br />
Tartu, Estonia, December, 2007.<br />
Nowicki T. Nuclear and Radiation Emergencies. Estonian Military Physician<br />
Group, Tartu, Estonia, December, 2007.<br />
Nowicki T. Management of the difficult airway, skills laboratory faculty<br />
instructor. 37th Critical Care Congress, Society of Critical Care Medicine,<br />
Honolulu, HI, February 2-6, <strong>2008</strong>.<br />
Nowicki T, Dziedzic M, Suazzi J. Comparison of the Airtraq optical laryngoscope<br />
to direct laryngoscopy in a manikin model for easy and difficult intubations. New<br />
England Regional Society of Academic Emergency Medicine, Shrewsbury, MA,<br />
April 30, <strong>2008</strong><br />
Palla K, Jacobs L, Burns K, Luk S, Hull S. Survey of participants attending the<br />
Advanced Trauma Operative Management (ATOM) Course at all sites worldwide<br />
since its inception. Scientific and <strong>Annual</strong> Meeting, Connecticut Chapter<br />
American College of Surgeons, Waterbury, CT, October 24, <strong>2008</strong>.<br />
Robinson K. Developing a three-year marketing plan. Medical Director Forum,<br />
Air Medical Physician Association, Minneapolis, MN, October 1, <strong>2008</strong>.<br />
Roche KM, Hart K, Sangalli B, Lefberg J, Bayer M. Kratom: A case of a legal<br />
high. Clin Toxicol. <strong>2008</strong>;46:598.<br />
Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado J, Sundaram<br />
K. The medical needs and demographic makeup of menopausal women in a rural<br />
Nigerian village. Poster presentation. <strong>2008</strong> North American Menopause Society<br />
<strong>Annual</strong> Meeting, Orlando, FL, September 24-27, <strong>2008</strong>.<br />
Smally AJ. Management of the difficult airway. Caribbean Emergency Medicine<br />
Congress, University of the West Indies and the American Academy of<br />
Emergency Medicine, Barbados, West Indies, January 7, 20<strong>09</strong>.<br />
Zosel AE, Varney SM, Heard K, Toxicology Investigator Network<br />
(J. Delgado, et al.). Outcomes of acetaminophen ingestion patients unable to be<br />
classified as acute or repeated supratherapeutic ingestions. Poster Presentation.<br />
<strong>2008</strong> North American Congress of Clinical Toxicology, Toronto, Canada,<br />
September 13-16, <strong>2008</strong>. UROLOGY
Urology<br />
The Department of Urology continues to expand its research capacity.<br />
Recently the Department welcomed Anoop Meraney, MD. Dr.<br />
Meraney, who completed fellowships at the Cleveland Clinic and at<br />
Memorial Sloane Kettering, will be spending a portion of his time in<br />
the department reviewing its current research efforts and programs and<br />
directing the development of a comprehensive urology database which<br />
will be supported by the hospital.<br />
The Department’s current research includes important work by Drs. Joseph<br />
Wagner and Stuart Kesler comparing the results and complications of<br />
robotic prostatectomy vs traditional prostatectomy. <strong>Hartford</strong> <strong>Hospital</strong><br />
performs more robotic procedures (urologic, gynecologic, and cardiac)<br />
than any hospital in New England. The data obtained through the robotic<br />
prostatectomy studies performed at <strong>Hartford</strong> <strong>Hospital</strong> compare favorably<br />
with other high volume centers nationally and verify the excellent clinical<br />
outcomes being obtained at this institution.<br />
New Projects<br />
Unfunded<br />
Wagner, Joseph, MD<br />
Use of Robotic Assistance in Laparoscopic Ureteral Surgery.<br />
Active Projects<br />
Shichman, Steven, MD<br />
Trends in Renal Cancer Surgery: The <strong>Hartford</strong> <strong>Hospital</strong> Experience. Analysis<br />
supported by <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Nephrectomy Research Database. Database supported by<br />
<strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Publications and Presentations<br />
Ercole B, Staff I, Champagne A, Tortora J, Kesler SS, Laudone VP, and Wagner<br />
JR. Complications of Robotic Assisted Laparoscopic Prostatectomy: Review and<br />
Assessment of Risk Factors. American Urological Association New England<br />
Section <strong>Annual</strong> Meeting, Rio Grande, Puerto Rico, <strong>2008</strong>. Abstract #28, page 143.<br />
SS, Wagner JR and Laudone VP. Does Prior Abdominal Surgery Influence<br />
Outcomes or Complications of Robotic Assisted Laparoscopic Radical<br />
Prostatectomy? American Urological Association New England Section <strong>Annual</strong><br />
Meeting, Rio Grande, Puerto Rico, <strong>2008</strong>. Abstract #5, page 59.<br />
Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone<br />
VP, Wagner JR. Prostate Cancer Biochemical Recurrence Rates After Robot<br />
Assisted Laparoscopic Radical Prostatectomy. American Urological Association<br />
New England Section <strong>Annual</strong> Meeting, Washington, DC, 20<strong>09</strong>. Abstract #13,<br />
pages 83-84.<br />
Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone<br />
VP, Wagner JR. Functional Outcomes After Robot Assisted Laparoscopic<br />
Radical Prostatectomy. American Urological Association New England Section<br />
<strong>Annual</strong> Meeting, Washington, DC, 20<strong>09</strong>. Abstract #14, pages 85-86.<br />
Irwin BH and Wagner JR. Complications of robotic surgery. In Complications of<br />
Urologic Surgery: Prevention and Diagnosis. Taneja (Ed.). 4th Edition. Elsevier,<br />
20<strong>09</strong>.<br />
Myer EG and Wagner JR. Robotic-assisted laparoscopic bladder<br />
diverticulectomy. J. Urol., 178 (6): 2406-2410, 2007.<br />
Schimpf M, Gottenger E, and Wagner J. Universal ureteral stent placement at<br />
hysterectomy to identify ureteral injury: A decision analysis. BJOG, 115 (9):<br />
1151 -1158, <strong>2008</strong>.<br />
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic boari flap ureteral<br />
reimplantion. J. Endourol., 22(12): 2691-4, <strong>2008</strong>.<br />
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic distal ureteral<br />
surgery. JSLS 13(1):44-9, 20<strong>09</strong>.<br />
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic ureterocalicostomy<br />
with long-term follow-up. J. Endourol. 23(2): 293-5, 20<strong>09</strong>.<br />
Wagner JR and Schimpf MO. Robot assisted laparoscopic boari flap and ureteral<br />
reimplantation. J. Urol. 181(4): V1547, 553, 20<strong>09</strong>.<br />
Wagner JR, Schimpf MO, and Cohen JL. Robot-assisted laparoscopic ileal<br />
ureter. JSLS 12 (3): 306-9, <strong>2008</strong>.<br />
Ginzburg S, Hu F, Staff I, Tortora, J, Champagne A, Salner A, Shichman S, Kesler<br />
106.
Women’s Health Services Collaborative<br />
Management Team<br />
Joel Sorosky, MD, Janice Cousino RNC, MSN, CNS<br />
and John Greene, MD<br />
Women’s Health<br />
New Projects<br />
Industry<br />
Steinberg, Adam, DO<br />
A Phase 2, 16 Week, Multicenter, Randomized, Double Blind, Placebo Controlled<br />
Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of PF-<br />
04383119 for the Treatment of Pain Associated with Interstitial Cystitis. Pfizer,<br />
Inc.(MultiCenter), $44,163.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Collins, Sarah, MD<br />
Perioperative Exercise Tolerance and Pain Control in Women Undergoing<br />
Robotic vs Traditional Abdominal Sacral Colpopexy. Small Grant, $8,428.<br />
Patel, Minita, MD<br />
The Use of SennaS for Prevention of Post-operative Constipation After<br />
Urogynecologic Surgery: A Randomized Double Blinded Placebo Controlled<br />
Trial. Small Grant, $9,758.<br />
Unfunded<br />
Borgida, Adam, MD<br />
Determining the Significance of Nuchal Translucency and Pregnancy Associated<br />
Plasma Protein-A in Relation to Adverse Outcomes in the Euploid Fetus.<br />
Outcomes of Fetal Cystic Hygroma Detected at First Trimester Ultrasound.<br />
Predictors of Neonatal Morbidity and Mortality in the Extremely Low Birth<br />
Weight Infant.<br />
Trends in Near-Term Preterm Births at <strong>Hartford</strong> <strong>Hospital</strong>.<br />
Brown, Amy, MD<br />
The Impact of a Structured Training Program on Gynecology Residents’ Attitudes<br />
Towards Robotic Assisted Surgery.<br />
Collins, Sarah, MD<br />
Patient Characteristics Associated PISQ-12 Completion. Statistical Analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
The Impact of Flatal Incontinence on Quality of Life and Sexual Function.<br />
Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Delude, Cassandra<br />
Floor Disorders in Women Under the Age of 65: Quality of Life and<br />
Care-Seeking Behavior.<br />
Feldman, Deborah, MD<br />
Indications for Full-term NICU Admission in a Large Urban Community <strong>Hospital</strong>.<br />
Risk Factors and Clinical Implications of Cesarean Hysterectomy.<br />
Greene, John, MD<br />
An Institutional Ethnography of the Practice of Male Neonatal Circumcision.<br />
Ingardia, Charles, MD<br />
Effect of Placental Lakes on First Trimester Serum Screening Results.<br />
Johnson, Amy, MD<br />
Is Adenomyosis Associated with Preterm Delivery?<br />
LaSala, Christine, MD<br />
Causes of Overactive Bladder in Women from a Urogynecology Practice.<br />
Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Does Short Interval Pregnancy Increase Risk of Pelvic Floor Disorders?
Patel, Minita, MD<br />
A Cost Minimization Analysis of Three Surgical Procedures for Sacral<br />
Colpopexy. Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant.<br />
Bother Symptoms and Quality of Life as Related to Prolapse. Statistical Analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
The Utility of the Beef Tongue Model for Teaching Residents Anatomy and<br />
Repair of a Fourth Degree Laceration. Statistical Analysis supported through<br />
<strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Urinary Incontinence Outcomes After Sacral Colpopexy. Statistical Analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Written Survey of How Vaginal Pessaries Affect Body Image in Pelvic Organ<br />
Prolapse. Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Pope, Kisti, MD<br />
Ultrasonographic Evaluation of Post-Partum Endometrial Stripe.<br />
Spencer, Jeffrey, MD<br />
Levels of Cell-Free Fetal DNA in Maternal Plasma in Pregnant Patients with<br />
Euploid and Aneuploid Fetuses.<br />
Natural History of Isolated Fetal Intracardiac Focus and its Relationship to Down<br />
Syndrome.<br />
Active Projects<br />
Beck, Cheryl, DNSc<br />
Docosahexaenoic Acid in Pregnancy: Postpartum Depression.<br />
Borgida, Adam, MD<br />
Effect of Mode of Delivery of 23-28 Week Infants on Infant Morbidity and<br />
Mortality.<br />
Infant Neuronal Maturity and Tobacco Use in Pregnancy: Is There An<br />
Association?<br />
Pregnancy Outcomes After Prenatal Exposure to Antidepressants.<br />
Pregnancy Outcomes of Women Who <strong>Report</strong> Antepartum Depression.<br />
Trends in Down Syndrome Screening.<br />
Trends in Mode of Delivery for Clinic Versus Private Patients From 1988-2005.<br />
Brown, Susanne, RN<br />
Does Simulation Training Improve Nursing and Resident’s Clinical Performance?<br />
Collins, Sarah, MD<br />
Sexual Activity and Function in Women with Pelvic Floor Disorders.<br />
Currie, John, MD<br />
ChemoFx Registry: An Observational, Longitudinal, Multi-center Study<br />
Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid<br />
Tumor Malignancies. Precision Therapeutics, $30,031.<br />
Feldman, Deborah, MD<br />
A Comparison of Antenatal Betamethasone vs Dexamethasone in Reducing<br />
Neonatal Complications of Prematurity.<br />
Short-term Outcomes of Neonatal Congenital Heart Disease.<br />
Gonci, Mary-Ellen, APRN<br />
Oral Health and its Implications During Pregnancy.<br />
Greene, John, MD<br />
Cigarette Smoking and Effects on Infant/Child Health. UCHC, $37,025.<br />
Resident Education Research Blanket Protocol. Statistical Analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Transcatheter Arterial Embolization of Uterine Fibroids.<br />
Johnson, Amy, MD<br />
A Prospective Cohort Study Comparing the Discontinuation Rates Between<br />
Levonorgestrel-Releasing Intrauterine Systems and Etonogestrel Subdermal<br />
Single-Rod Contraceptive Implants in a Residency Clinic Population.<br />
An Institutional Review of Management Outcomes for High Grade Cervical<br />
Dysplasia in Adolescent Women.<br />
Incidence of HPV in an Inner City Population without Dysplasia. Statistical<br />
Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Is Breast Arterial Calcification (BAC) Found on Routine Mammography<br />
Associated with an Increased Risk of Cardiovascular Disease? Statistical Analysis<br />
supported through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Is Menopause the Same Cross-Culturally? Wyeth Pharmaceuticals, $4,000.<br />
The Role Of The Provider In Racial And Ethnic Disparities In Prenatal Care. CT<br />
Health Foundation, $5,000.<br />
LaSala, Christine, MD<br />
Is Isolated Rectocele Repair Associated with Post-Operative Voiding<br />
Dysfunction? Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong> Small<br />
Grant.<br />
Outcomes of Vaginal Prolapse Surgery on Urinary Continence.<br />
Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair -<br />
A Randomized Trial.<br />
Patel, Minita, MD<br />
Anal Incontinence and Impact on Sexual Function. Statistical Analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
108.
Satherlie-Deasy, Lynn, RN<br />
Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy Outcomes<br />
Among Low-Income Latinas.<br />
Schimpf, Megan, MD<br />
Are Mondays and Fridays the Busiest Days for Nursing Phone Triage in a<br />
Urogynecology Office Practice?<br />
Is There a Relationship Between Glomerular Filtration Rate and Detrusor<br />
Overactivity in Women? Statistical Analysis supported through<br />
<strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Using Color, Clarity and Smell to Predict Urinary Tract Infections in<br />
Community-Dwelling Women.<br />
Schnatz, Peter, DO<br />
Comparison of Hormonal Therapy Tapering Regimens for Mediating Hot<br />
Flashes. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $56,623.<br />
A Comparison of Skin Closure Techniques after Primary Cesarean Delivery.<br />
Ethicon, Inc., $3,000.<br />
A Retrospective Analysis of Cervical Polyps. Statistical Analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Association of Adolescent and Early Adult Pregnancy with Future Development<br />
of Postmenopausal Osteoporosis. Statistical Analysis supported through <strong>Hartford</strong><br />
<strong>Hospital</strong> Small Grant.<br />
Factors Influencing a Third-Year Medical Student’s Decision to Choose<br />
Obstetrics and Gynecology Versus Another Specialty Prior to Beginning Clinical<br />
Rotations. Departmental, $400. Statistical Analysis supported through <strong>Hartford</strong><br />
<strong>Hospital</strong> Small Grant.<br />
Relative Importance of Gender in Patients’ Selection of Obstetrics and<br />
Gynecology Provider. Statistical Analysis supported through <strong>Hartford</strong> <strong>Hospital</strong><br />
Small Grant.<br />
Shaneyfelt, Kristin, DO<br />
Is an ECC Always Necessary During the Colposcopic Evaluation of an Abnormal<br />
Pap Smear?<br />
Sorosky, Joel, MD<br />
GOG 220: Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures)<br />
for Epithelial Ovarian Cancer Diagnosis and Prognosis. GOG, $8,712.<br />
Women’s Health Clinical Outcomes Protocol. Statistical Analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Spencer, Jeffrey, MD<br />
Outcomes of Triplet Gestations Based on Chorionicity.<br />
Screening for Fetal Aneuploidy: A Patient Survey.<br />
Steinberg, Adam, MD<br />
Prolift’s Effect on Post-Operative Hematocrit. Statistical Analysis supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Stepnowski, Roxanne, PsyD<br />
Antepartum Depression Inventory: A Comparative Analysis of Performance With<br />
The Beck Depression Inventory. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds,<br />
$9,966.<br />
Taylor, Linda, MD<br />
Patient-Centered Techniques to Enhance Outcomes for Abdominal<br />
Hysterectomy. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $10,000.<br />
Tulikangas, Paul, MD<br />
A Comparison of Connective Tissue Remodeling in the Pelvic Floor of Pre and<br />
Postmenopausal Women. NIH / University of Pittsburgh, $4,820.<br />
Late-Pregnancy Fears of Labor and Delivery in Nulliparous Pregnant Women: A<br />
Survey. <strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds, $8,840.<br />
Watson, James, MD<br />
Recent Trends in VBAC at <strong>Hartford</strong> <strong>Hospital</strong>.<br />
Young, Sara, MSN<br />
Breastfeeding Education and Support Trial for Obese Women (BESTOW).<br />
Donaghue Medical Research Foundation/University of Connecticut, $20,590.<br />
Breastfeeding Education and Support Trial for Obese Women: Early Dyad<br />
Dynamics (BESTOW:EDD). University of Connecticut, $16,796.<br />
Publications and Abstracts<br />
Allen GL, Klobocista MM, Sugarman S, Gravel K, Feldman DM,<br />
Schnatz PF. Prevalence of high-risk human papillomavirus in an<br />
inner-city population with atypical squamous cells of undetermined<br />
significance. Journal of Lower Genital Tract Disease, 13(2): 63-65,<br />
April 20<strong>09</strong>.<br />
Batal I, Domsic RT, Shafer A, Medsger TA Jr, Kiss LP, Randhawa P,<br />
Bastacky S. Renal biopsy findings predicting outcome in scleroderma<br />
renal crisis. Hum Pathol. 20<strong>09</strong> Mar;40(3):332-40.<br />
Berzolla CE, Schnatz PF, O’Sullivan DM, Bansal R, Mandavilli<br />
S, Sorosky JI. Dysplasia and malignancy in endocervical polyps.<br />
Journal of Women’s Health. 16(9):1317-21, 2007 Nov.<br />
Boggess JF, Gehrig PA, Cantrell L, Shafer A, Mendivil A, Rossi E,<br />
Hanna R.Perioperative outcomes of robotically assisted hysterectomy<br />
for benign cases with complex pathology. Obstet Gynecol. 20<strong>09</strong><br />
Sep;114(3):585-93.<br />
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of
evacizumab in persistent or recurrent epithelial ovarian cancer or<br />
primary peritoneal cancer: a Gynecologic Oncology Group Study.<br />
Journal of Clinical Oncology. 25(33):5165-71, 2007.<br />
Cuzzone D, Allen B, Rowin C, Tulikangas PK, Babigian A.<br />
Development of vaginal erosion and vesicocutaneous fistula<br />
following midurethral transvaginal tape with Pelvilace. International<br />
Wound Journal. 20<strong>09</strong>;6(1):55-8.<br />
Egan J, Fang YMV, Kaminski L, Smith K, Turner G, Benn P. Changes<br />
in antenatal Down Syndrome risk assessment in the US from 2001 to<br />
2007. Am J Obstet Gynecol 2007;197: 589 (suppl).<br />
Egan J, Fang YMV, Kaminski L, Campbell W, Spencer J, Benn P.<br />
Changes in Down Syndrome screening practices in the US from<br />
2001 to 2007. Am J Obstet Gynecol 2007;197: 149 (suppl)<br />
Fang YM, Benn P, Campbell W, Bolnick J, Prabulos AM, Egan JF.<br />
Down syndrome screening in the United States in 2001 and 2007: a<br />
survey of maternal-fetal medicine specialists. Am J Obstet Gynecol.<br />
20<strong>09</strong> Jul; 201(1):97.e1-5.<br />
Fang YMV, Benn P, Egan JF. Use of the genetic sonogram in<br />
the United States in 2001 and 2007. J Ultrasound Med. <strong>2008</strong><br />
Nov;27(11):1543-8.<br />
Fang YMV, Benn P, Tribulato K, Fitzpatrick C, Bolnick J , Egan J.<br />
Down Syndrome screening strategies utilized by United States<br />
Maternal-Fetal Medicine specialists in 2007. Am J Obstet Gynecol;<br />
197: 588 (suppl).<br />
Fang YMV, Egan J, Benn P, Magidina I, Prabulos AM, Sanders M.<br />
Placental pathologic findings associated with intrauterine growth<br />
restriction, preeclampsia and normal pregnancies. Am J Obstet<br />
Gynecol. <strong>2008</strong>; 199: S97.<br />
Fang YMV, Egan JFX, Kaminsky L, Bolnick J, Prabulos A, Benn P.<br />
The growing acceptance of second trimester ultrasound to identify<br />
aneuploid fetuses: Markers used in the genetic sonogram by United<br />
States practitioners in 2001 and 2007. J Ultrasound Med <strong>2008</strong>;27:<br />
S46 (suppl).<br />
Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Benn P.<br />
Placental pathologic findings seen in preterm deliveries, intrauterine<br />
fetal demises, and uncomplicated full term deliveries. Am J Obstet<br />
Gynecol. <strong>2008</strong>; 199: S106.<br />
Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Mackeen D,<br />
Benn P. Prediction of adverse pregnancy outcome using the results of<br />
the second trimester quadruple maternal serum screening test. Am J<br />
Obstet Gynecol. <strong>2008</strong>; 199: S193.<br />
Fang YMV, Mackeen D, Dileo C, Egan J, Zelop C. Insulin glargine<br />
(Lantus) compared with neutral protamine hagedorn insulin in the<br />
treatment of pregnant diabetics. Obstet Gynecol. <strong>2008</strong>;111:108S.<br />
Fang YM, MacKeen D, Egan JF, Zelop CM. Insulin glargine compared<br />
with Neutral Protamine Hagedorn insulin in the treatment of pregnant<br />
diabetics. J Matern Fetal Neonatal Med. 20<strong>09</strong> Mar;22(3):249-53.<br />
Fang YM, Egan JF, Rombro T, Morris B, Zelop CM. A comparison of<br />
reasons for choosing obstetrician/gynecologist subspecialty training.<br />
Conn Med. 20<strong>09</strong> Mar; 73(3):165-70.<br />
Johnson AM, Schnatz PF. Gender preferences in ObGyn clinic vs<br />
private patients.<br />
Connecticut Medicine. 73(4):205-9, 20<strong>09</strong> Apr.<br />
Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro<br />
PA. Lower uterine segment involvement as a predictor for lymph node<br />
spread in endometrial cancer Gynecologic Oncology, 107:75-78,<br />
2007.<br />
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW,<br />
Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker<br />
HE4 in patients with endometrioid adenocarcinoma of the uterus.<br />
Gynecologic Oncology, 110: 196-201, <strong>2008</strong>.<br />
Moore RG, Brown AK, Miller CM, Skates S, Allard J, Verch T,<br />
Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The<br />
use of multiple novel tumor biomarkers for the detection of ovarian<br />
carcinoma in patients with a pelvic mass. Gynecologic Oncology,<br />
108:404-408, <strong>2008</strong>.<br />
Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller CM,<br />
Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK. A novel<br />
multiple marker bioassay utilizing HE4 and CA125 for the prediction<br />
of ovarian cancer in patients with a pelvic mass. Gynecologic<br />
Oncology, 112:40-46, 20<strong>09</strong>.<br />
Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M, Noto<br />
R, Brard L, Granai, CO. Isolated Sentinel lymph node dissection with<br />
conservative management in patients with squamous cell carcinoma<br />
of the vulva: A Prospective Trial. Gynecologic Oncology, 1<strong>09</strong>:65-70,<br />
<strong>2008</strong>.<br />
Nieves L, Currie J, Hoffman J Sorosky JI. Ototoxicity after<br />
intraperitoneal chemotherapy: a case report. International Journal of<br />
Gynecological Cancer. 17(5):1133-1135, September/October 2007.<br />
[Letter.][Correspondence and Brief <strong>Report</strong>]<br />
Nieves L, Hoffman J, Allen G, Currie J, Sorosky JI. Placental-site<br />
trophoblastic tumor with PET scan-detected surgically treated lung<br />
metastasis. International Journal of Clinical Oncology. 13(3):263-5,<br />
<strong>2008</strong> Jun.<br />
Patel M, O’Sullivan DM, Steinberg AC. The impact of anal<br />
110.
incontinence on sexual function. Journal of Reproductive Medicine.<br />
20<strong>09</strong>;54(8):493-499<br />
Patel M, O’Sullivan DM, Tulikangas PK. A comparison of costs<br />
for open, laparoscopic and robot assisted sacral colpopexy. Int J<br />
Urogynecol J Pelvic Floor Dysfunct. 20<strong>09</strong>(20):223-8.<br />
Rotter MA, Schnatz PF, Currier AA Jr., O’Sullivan DM. Breast<br />
arterial calcifications (BACs) found on screening mammography and<br />
their association with cardiovascular disease. Menopause. 15(2):276-<br />
81, <strong>2008</strong> Mar-Apr.<br />
Saks E, Vakili B, Steinberg AC. Primary Amenorrhea with a<br />
periumbilical abdominal mass. J of Pediatric and Adolescent<br />
Gynecology. 20<strong>09</strong>: 22 (1): E1-3<br />
Schimpf MO, O’Sullivan DM, Steinberg AC, LaSala CA, Tulikangas<br />
PK. Patterns of phone calls to a nursing triage line in a urogynecology<br />
practice. Urologic Nursing <strong>2008</strong>; 28(3):213-216.<br />
Schimpf MO, O’Sullivan DM, Steinberg AC, LaSala CA, Tulikangas<br />
PK. Is there a relationship between glomerular filtration rate and<br />
detrusor overactivity in women? Neurourol. Urodyn. 20<strong>09</strong>; 28(3):<br />
202-204<br />
Schimpf MO, Patel M, O’Sullivan DM, Tulikangas PK. Differences<br />
in quality of life in women with urge urinary incontinence compared<br />
to women with stress urinary incontinence. Int J Urogynecol J Pelvic<br />
Floor Dysfunct. 20<strong>09</strong>; 20: 781-786.<br />
Sharpless KE, O’Sullivan DM, Schnatz PF. The utility of human<br />
papillomavirus testing in the management of atypical glandular cells<br />
on cytology. Journal of Lower Genital Tract Disease. 13(2):72-8,<br />
20<strong>09</strong> Apr.<br />
Schnatz PF. A unique faith-based medical organization: the Christian<br />
Medical Fellowship. Connecticut Medicine.<br />
72(6):345-50, <strong>2008</strong> Jun-Jul.<br />
Schnatz PF, Guile MW, O’Sullivan DM. Relative importance of<br />
gender in patients’ selection of an obstetrics and gynecology provider.<br />
Connecticut Medicine. 71(9):563, 2007 Oct.<br />
Schnatz PF, Humphrey K. Reasons and principles for starting an<br />
obstetrics and gynecology scholars group. Obstetrics & Gynecology.<br />
111(4):953-8, <strong>2008</strong> Apr.<br />
Schnatz PF, Marakovits K. The next generation of menopause<br />
providers: are medical students being properly prepared? Menopause.<br />
15(5):871-4, <strong>2008</strong> Sep-Oct.<br />
Schnatz PF, Markelova NV, Holmes D, Mandavilli SR, O’Sullivan<br />
DM. The prevalence of cervical HPV and cytological abnormalities<br />
in association with reproductive factors of rural Nigerian women.<br />
Journal of Women’s Health. 17(2):279-85, <strong>2008</strong> Mar.<br />
Schnatz PF, Murphy JL, O’Sullivan DM, Sorosky JI. Patient choice:<br />
comparing criteria for selecting an obstetrician-gynecologist based<br />
on image, gender, and professional attributes. American Journal of<br />
Obstetrics & Gynecology. 197(5):548.e1-7, 2007 Nov.<br />
Schnatz PF, Ricci S, O’Sullivan DM. Cervical polyps in<br />
postmenopausal women: is there a difference in risk? Menopause.<br />
16(3):524-8, 20<strong>09</strong> May-Jun.<br />
Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham<br />
D, O’Sullivan DM. The North American Menopause Society: from<br />
abstract to publication. Menopause. 15(5):996-1001, <strong>2008</strong> Sep-Oct.<br />
Schnatz PF, Sharpless KE, O’Sullivan DM. Use of human<br />
papillomavirus testing in the management of atypical glandular cells.<br />
Journal of Lower Genital Tract Disease. 13(2):94-101, 20<strong>09</strong> Apr.<br />
Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin<br />
potentiates the effects of paclitaxel in endometrial cancer cells<br />
through inhibition of cell proliferation and induction of apoptosis.<br />
Int J Cancer. 20<strong>09</strong> Aug 17.<br />
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology. 111(2,<br />
Part 1):436-447, February <strong>2008</strong>.<br />
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology.<br />
112(1):186-187, July <strong>2008</strong>. [Letter.][Departments: Letters to the<br />
Editor]<br />
Spencer J, Fang YMV, Borgida A, Benn P, Egan J. Patient’s<br />
understanding of first trimester aneupliody screening based on<br />
counseling time. Obstet Gynecol. <strong>2008</strong>;111:38S.<br />
Spencer JV, Ingardia CJ, Nold CJ, Borgida AF, Herson VC, Egan<br />
JFX. Perinatal and neonatal outcomes of triplet gestations based<br />
on placental chorionicity. American Journal of Perinatology.<br />
20<strong>09</strong>;26:587-90.<br />
Steinberg AC, Collins SA, O’Sullivan, DM. The impact of flatal<br />
incontinence on quality of life. American Journal of Obstetrics and<br />
Gynecology. 20<strong>09</strong>;201.<br />
Werden J, Schnatz PF, Mandavilli S, Allen G, Murphy J, Greene<br />
JF; Egan JF, Sorosky JI. Prevalence of the human papillomavirus in<br />
an inner-city indigent population with previously normal pap tests.<br />
Journal of Lower Genital Tract Disease. 12(4):287-292, October<br />
<strong>2008</strong>.<br />
Presentations
Allen GL, Klobocista M, Sugarman S, Gravel K, Schnatz PF.<br />
Prevalence of High Risk Human Papilloma Virus in an Inner<br />
City Population with Atypical Squamous Cells of Undetermined<br />
Significance. Presented March 17th, <strong>2008</strong> at the biennial ASCCP<br />
meeting in Lake Buena Vista, FL.<br />
Borgida AF, Hopkins S, St- Aubin C, Feldman DM, Fang YM,<br />
Ingardia CJ. Trends in near-term preterm birth. Presented at the<br />
Society for Maternal Fetal Medicine, San Diego, February 20<strong>09</strong>.<br />
Brown AK, Clements A, Robison K, Allard JW, Somers E, Theil R,<br />
Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring<br />
patients with epithelial ovarian cancer. Presented at the 7th Biennial<br />
Ovarian Cancer Research Symposium of the Marcia Rivkin Center,<br />
September <strong>2008</strong>.<br />
Brown AK, Currie J, Sorosky, JI. A retrospective comparison of<br />
clinical outcomes between laparotomy and robotic hysterectomy<br />
for endometrial cancer. Presented at the International Gynecologic<br />
Oncology Robotics Symposium, November, <strong>2008</strong>.<br />
Brown AK, Raughley M, Robison K, Miller C, Allard JW, Kurman<br />
R, Granai CO, Moore R. Comparison of a novel multiple biomarker<br />
assay to the risk of malignancy index in the prediction of epithelial<br />
ovarian cancer in patients with a pelvic mass. Presented at the 7th<br />
Biennial Ovarian Cancer Research Symposium of the Marcia Rivkin<br />
Center, September, <strong>2008</strong>.<br />
Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications<br />
of prenatally diagnosed marginal placental cord insertion. Society for<br />
Maternal Fetal Medicine, San Diego, February 20<strong>09</strong>.<br />
Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications<br />
of prenatally diagnosed marginal placental cord insertion. American<br />
Institute of Ultrasound in Medicine, New York, April 20<strong>09</strong>.<br />
Carbone J, Schnatz PF, Werden J. Stump the Professor: Post Partum<br />
Patient with Acute Chest Pain. Presented September 29th, at the<br />
2007 annual ACOG District I meeting in Newport, Rhode Island.<br />
Clements A, Brown AK, Miller C, Robison K, Allard JW, Granai CO,<br />
Moore R. Utility of a Novel Serum Tumor Marker HE4 to Predict<br />
Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of<br />
the Uterus. Presented at the <strong>2008</strong> NEAGO <strong>Annual</strong> Meeting, June<br />
<strong>2008</strong>.<br />
Clements A, Brown AK, Robison K, Allard JW, Somers E, Theil R,<br />
Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring<br />
patients with epithelial ovarian cancer. Presented at the <strong>2008</strong><br />
NEAGO <strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
Collins SA, O’Sullivan DM, LaSala CA. Factors which correlate<br />
with PISQ-12 completion in an academic urogynecology population.<br />
Poster Presentation at the American Urogynecological Society<br />
Meeting, September, 20<strong>09</strong>.<br />
Currie C, Brown AK, Sorosky JI, Mandavilli S, Joyner A, Currie<br />
J. Endometrial Carcinoma of Fallopian Tube with Metastasis and<br />
Extension to the Obturator Space: A Case <strong>Report</strong>. Presented at the<br />
20<strong>09</strong> NEAGO meeting, June 20<strong>09</strong>.<br />
Cushman N, Currie J, Romak J, Sorsoky JI, Brown AK. Vulvar Polyps<br />
Secondary to Crohn’s Disease. Presented at the <strong>2008</strong> NEAGO<br />
<strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and<br />
When. American College of Obstetricians and Gynecologists <strong>Annual</strong><br />
Clinical Meeting, New Orleans, LA <strong>2008</strong>.<br />
Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and<br />
When. American College of Obstetricians and Gynecologists <strong>Annual</strong><br />
Clinical Meeting, Chicago, IL, May 5, 20<strong>09</strong>.<br />
Greene, JF. A comparison of ACGME Resident Statistics with<br />
Institutional Totals. Association of Professors in Gynecology and<br />
Obstetrics/Coundil on Residency Education in Obstetrics and<br />
Gynecology <strong>Annual</strong> Meeting, March, 20<strong>09</strong>, San Diego, CA. Awarded<br />
third best oral presentation.<br />
Joyner A, Sorosky JI, Mandavilli S, Brown AK, Currie, J .<br />
Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery<br />
Embolization for Leiomyomas: A Case <strong>Report</strong>. Presented at the 20<strong>09</strong><br />
NEAGO meeting, June 20<strong>09</strong>.<br />
Maclaughlan S, Brown AK, Miller C, Robison K, Allard JW, Granai<br />
CO, Bast R, Moore R. Differential expression of CA125 and a novel<br />
serum tumor marker HES in epithelial ovarian cancer. Presented at<br />
the <strong>2008</strong> NEAGO <strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
McNamara J, Smith K, Feldman DM, Fang YM, Ingardia CJ, Borgida<br />
AF. Predicting survival among neonates born at 24 weeks gestation.<br />
Society for Maternal Fetal Medicine, San Diego, February 20<strong>09</strong>.<br />
Moore R, McMeekin S, Brown AK, DiSilvestro P, Miller C, Allard J,<br />
Gajewski W, Kurman R, Bast R, Skates S. A Novel Multiple Marker<br />
Bioassay Utilizing HE4 and CA125II for the Prediction of Ovarian<br />
Cancer in Patients with a Pelvic Mass. Presented at the <strong>2008</strong> SGO<br />
<strong>Annual</strong> Meeting, March <strong>2008</strong>.<br />
Nwana C, Johnson A, Egan J, Dumont T. Racial and Ethnic<br />
Disparities in Prenatal Care. Poster presented at the 20<strong>09</strong> ACOG.<br />
Patel M, LaSala CA, Tulikangas P, Steinberg AC. Beef tongue<br />
model versus instructional video for teaching residents fourth<br />
degree laceration repair. Poster presentation at 30th annual<br />
American Urogynecologic Society meeting, September 24-26, 20<strong>09</strong>,<br />
Hollywood, Florida.<br />
112.
Women’s Health<br />
Patel M, Mellen C, O’Sullivan DM, LaSala, CA. Impact of pessary<br />
use on prolapse symptoms, quality of life and body image. Oral<br />
presentation at the American Urogynecological Society Meeting,<br />
September, 24-26, 20<strong>09</strong>, Hollywood, Florida.<br />
Patel M, O’Sullivan D, LaSala C. Do bowel symptoms change after<br />
pelvic organ prolapse surgery? Poster presentation at 30th annual<br />
American Urogynecologic Society meeting, September 24-26, 20<strong>09</strong>,<br />
Hollywood, Florida.<br />
Patel M, Schimpf, MO, O’Sullivan DM, LaSala, CA. The use of<br />
SennaS® for post-operative constipation after pelvic reconstructive<br />
surgery: a randomized, double blinded, placebo-controlled trial.<br />
Oral presentation at the 30th annual American Urogynecologic<br />
Society Meeting, September 24-26, 20<strong>09</strong>, Hollywood, Florida.<br />
Best scientific presentation award.<br />
Patel M, Tulikangas P. Does size matter? A comparison of bother<br />
and quality of life in women with prolapse. Poster presentation at<br />
the 35th annual Society of Gynecologic Surgeons Meeting, March<br />
30-April 1, 20<strong>09</strong>, New Orleans, Louisiana.<br />
Patel M, Tulikangas P. Evaluation of prolapse type and pelvic floor<br />
symptoms: is every prolapse the same? Poster presentation at 30th<br />
annual American Urogynecologic Society meeting, September 24-26,<br />
20<strong>09</strong>, Hollywood, Florida.<br />
Platt L, Brown AK, Mandavilli S, Currie J, Sorosky, JI. Complex<br />
Atypical Hyperplasia and the Incidence of Endometrial Cancer at the<br />
Time of Hysterectomy. Presented at the 20<strong>09</strong> NEAGO meeting, June<br />
20<strong>09</strong>.<br />
Platt L, Currie J, Hoffman J, Sorosky JI, Brown AK. Managing<br />
Patients with Pseudomyxoma Peritonei. Presented at the <strong>2008</strong><br />
NEAGO <strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
Platt L, Sorosky JI, Currie J, Brown AK. An unusual presentation of<br />
metastatic papillary serous ovarian cancer. Presented at the <strong>2008</strong><br />
NEAGO <strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
Raughley M, Brown AK, Robison K, Miller C, Allard JW, Kurman<br />
R, Granai CO, Moore R. Comparison of a novel multiple biomarker<br />
assay to the risk of malignancy index in the prediction of epithelial<br />
ovarian cancer in patients with a pelvic mass. Presented at the <strong>2008</strong><br />
NEAGO <strong>Annual</strong> Meeting, June <strong>2008</strong>.<br />
Schnatz PF. Medical Missions Provide Education, Experience, and an<br />
Example of Professionalism for Students and Residents. Presented at<br />
the annual APGO Faculty Development Seminar; Women’s Health<br />
Education, Think Globally, Teach Locally, January 13th, 20<strong>09</strong>.<br />
Schnatz PF. ObGyn Scholars: Developing a Student Interest Group<br />
and Learning from Past Experiences. Presented at the annual APGO<br />
Faculty Development Seminar; The Ob-Gyn Curriculum: The Ideal,<br />
The Practical, The Hidden. Kapalua, Maui, Hawaii. January 22nd,<br />
<strong>2008</strong>.<br />
Schnatz PF. Preparing the Next Generation of Menopause Providers.<br />
Presented October 4th, 2007 at the NAMS 18th <strong>Annual</strong> Meeting in<br />
Dallas, Texas.<br />
Schnatz PF, Johnson AM, Hemphill M, Tortora J. Sexual Dysfunction<br />
in Patients of an Inner City Menopause Clinic. Presented September<br />
26th, <strong>2008</strong> at the NAMS 19th <strong>Annual</strong> Meeting in Orlando, Florida.<br />
Schnatz PF, Kubica L, Murphy J, and O’Sullivan DM. The Risk<br />
of Cardiovascular Disease in Women with a History of Low Birth<br />
Weight. Presented October 5th, 2007 at the NAMS 18th <strong>Annual</strong><br />
Meeting in Dallas, Texas.<br />
Schnatz PF, Pattison K, and O’Sullivan DM. The Association of Breast<br />
Disease and Atypical Glandular Cells. Presented at the NAMS 20th<br />
<strong>Annual</strong> Meeting in San Diego, California, October, 20<strong>09</strong>.<br />
Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham<br />
D, O’Sullivan DM. The North American Menopause Society: From<br />
Abstract to Publication. Presented September 26th, <strong>2008</strong> at the<br />
NAMS 19th <strong>Annual</strong> Meeting in Orlando, Florida.<br />
Schnatz PF, Sharpless KE, Bansal R. Use of Human Papillomavirus<br />
Testing in the Management of Atypical Glandular Cells. Presented<br />
March 19th and 20th, <strong>2008</strong> at the biennial ASCCP meeting in Lake<br />
Buena Vista, FL.<br />
Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado<br />
J, Sundaram K. The Medical Needs and Demographic Makeup
of Menopausal Women in a Rural Nigerian Village. Presented<br />
September 26th, <strong>2008</strong> at the NAMS 19th <strong>Annual</strong> Meeting in<br />
Orlando, Florida.<br />
Sharpless KE, Bansal R, O’Sullivan DM, Schnatz PF. The Utility<br />
of Human Papillomavirus Testing in the Management of Atypical<br />
Glandular Cells on Cytology. Presented March 17th, <strong>2008</strong> at the<br />
biennial ASCCP meeting in Lake Buena Vista, FL and winner of the<br />
best overall resident presentation.<br />
Sorosky JI. Abnormal Cervical Cytology Complicating Pregnancy.<br />
American College of Obstetricians and Gynecologists <strong>Annual</strong><br />
Clinical Meeting, New Orleans, LA <strong>2008</strong>.<br />
Presented March 20th, <strong>2008</strong> at the biennial ASCCP meeting in Lake<br />
Buena Vista, FL.<br />
Umenyi C, Waszczak W, Schnatz PF, and Mandavilli S. Incidence<br />
of high risk HPV (HR-HPV) and cervical dysplasia in Nigeria.<br />
Presented at the American Society of Cytopathology’s 55th <strong>Annual</strong><br />
Scientific Meeting; November 2-6, 2007 in Houston, Texas.<br />
Werden J, Schnatz PF, Mandavilli S, Allen G, Greene JF, Sorosky JI.<br />
Prevalence of the Human Papillomavirus in an Inner City Indigent<br />
Population with Previously Normal Pap Tests. Presented at the<br />
2007 annual ACOG District I meeting in Newport, Rhode Island,<br />
September, 2007.<br />
Sorosky JI. Endometrial Hyperplasia. American College of<br />
Obstetricians and Gynecologists <strong>Annual</strong> Clinical Meeting, Chicago,<br />
IL, May 4, 20<strong>09</strong>.<br />
Sorosky JI. Management of Atypical Glandular Cells (AGC) on<br />
Pap Smear Screen Screening. American College of Obstetricians and<br />
Gynecologists <strong>Annual</strong> Clinical Meeting, New Orleans, LA <strong>2008</strong>.<br />
Sorosky JI. Management of Atypical Glandular Cells, (AGC),<br />
the Consensus Guidelines. American College of Obstetricians and<br />
Gynecologists <strong>Annual</strong> Clinical Meeting, Chicago, IL, May 5, 20<strong>09</strong>.<br />
Sorosky JI. Techniques in Abdominal Wound Closure. American<br />
College of Obstetricians and Gynecologists, <strong>Annual</strong> Clinical<br />
Meeting, Chicago, IL, May 4, 20<strong>09</strong>.<br />
Sorosky JI. Techniques in Abdominal Wound Closure. American<br />
College of Obstetricians and Gynecologists, <strong>Annual</strong> Clinical<br />
Meeting, New Orleans, LA <strong>2008</strong>.<br />
Steinberg AC, Collins SA, O’Sullivan DM. The Impact of Flatal<br />
Incontinence on Quality of Life. Poster Presentation at the Society<br />
for Gynecological Surgeons, New Orleans, LA April, 20<strong>09</strong>.<br />
St- Aubin C, Hopkins S, Feldman DM, Fang YM, Ingardia CJ,<br />
Borgida AF. Mode of delivery and neonatal respiratory morbidity in<br />
near-term preterm births. Society for Maternal Fetal Medicine, San<br />
Diego, February, 20<strong>09</strong>.<br />
Surette AM, Schnatz PF, O’Sullivan DM, Sharpless KE. Delayed<br />
Diagnosis Following Atypical Glandular Cells on Cervical Cytology.
Other Departments &<br />
Collaborations<br />
New Projects<br />
<strong>Hartford</strong> <strong>Hospital</strong> Research Endowment Funds<br />
Kureshi, Inam, MD, Neurosurgery<br />
Craniotomy for Intraventricular Lesions. Small Grant for Statistics Database<br />
Support.<br />
Mort,Thomas, MD, Anesthesiology<br />
Comparison of Standard Laryngoscopy vs. Video/Optical Laryngoscopy in<br />
Exchanging an ETT in the High Risk Difficult Airway Patient. Supported<br />
through <strong>Hartford</strong> <strong>Hospital</strong> Small Grant.<br />
Federal<br />
Baker, William, PharmD, Pharmacy<br />
Epilepsy Medication CERs. AHRQ, $342,651.<br />
Human Growth Hormone in Patients With Cystic Fibrosis. AHRQ, $342,710.<br />
Kureshi, Inam, MD, Neurosurgery<br />
A Randomized Multicenter Clinical Trial of Unruptured Brain Arteriovenous<br />
Malformations (ARUBA). National Institute of Neurological Disorders through<br />
Columbia University, $56,700.<br />
Foundation<br />
Colby, Jennifer, PharmD, Pharmacy<br />
Predictors of Medication Non-Adherence Among Urban Latinos: A Cross-<br />
Sectional Analysis of Patients Enrolled in the Diabetes Among Latinos Best<br />
Practices (DIALBEST) Trial. American Society HealthSystems Pharmacists,<br />
$5,184.<br />
Industry<br />
Baker, William, PharmD, Pharmacy<br />
Biologic and Non-Biologic Systemic Treatments for Moderate to Severe Plaque<br />
Psoriasis: A Systematic Review and Meta-Analysis. Pfizer, $100,000.<br />
Kureshi, Inam, MD, Neurosurgery<br />
S.T.I.C.H. II - Surgical Trial in Lobar Intracerebral Hemorrhage. Newcastle<br />
upon Tyne <strong>Hospital</strong> NHS Trust, $6,410.<br />
Unfunded<br />
Delgado, Danica, MSW, Social Work<br />
The Domestic Violence Learning Needs of Health Care Social Workers.<br />
Lehmann, William, MD, Otolaryngology<br />
Methods of Education for Patients Undergoing Tonsillectomy.<br />
McLaughlin, Tara, PhD, Research Administration<br />
Utilizing Focus Groups to Support Community Health Collaborations.<br />
Nailor, Michael, PharmD, Pharmacy<br />
Approach to Enhance the Likelihood of Initial Effective Antibacterial Therapy:<br />
Examining Cross-Resistance.<br />
O’Sullivan, David, PhD, Research Administration<br />
Blanket Protocol for Endocrinology/Diabetes Mellitus Outcomes.<br />
Wang, Fei, PharmD, Pharmacy<br />
Health Literacy and Prescription Medication Adherence in Urban Latino Patients<br />
New Collaborations<br />
Herson, Victor, MD, CCMC<br />
Epigenetic Modifications of Human Umbilical Cord Vessel Endothelium.<br />
Clinical Factors Determining the Care Needs For 35 Week Infants.<br />
Kurtz, Matthew, PhD, Wesleyan University<br />
Neurological Soft Signs, Neurocognitive Measures, and Everyday Life Skills.<br />
Wesleyan University, $700.<br />
Lapidus, Garry, PA-C, CCMC<br />
Safe Transportation of Normal Newborns at <strong>Hospital</strong> Discharge.<br />
The Epidemiology of Trauma Presenting to a Level One Trauma Center.<br />
Nichols, Mary, Wesleyan University<br />
Narrative Coherence and Neurocognition in Schizophrenia: The Effects of Illness<br />
Duration. Wesleyan University, $600.<br />
Oncken, Cheryl, MD, University of Connecticut Health Center<br />
Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy.<br />
UCHC, $1,500.<br />
Wang, Fei, PharmD, University of Connecticut<br />
Establishing Benchmarks for the Medical Office Survey On Patient Safety<br />
(SOPS). The Oregon Health and Science University, $200.<br />
Active Projects<br />
Chhabra, Jyoti, PhD, Research Administration<br />
Examining Behavioral Risk Factors, Chronic Disease and Health Related Polysyndromes<br />
in <strong>Hartford</strong> CT. DPH subcontract through the City of <strong>Hartford</strong>,<br />
$80,000.<br />
Gaudio, Paul, MD, Ophthalmology<br />
Detection of Triamcinolone Acetonide in Human Intraocular Fluids. Small Grant,<br />
$9,900.
McIsaac, Joseph, MD, Anesthesiology<br />
• Power Quality in the Operating Room Pilot Study.<br />
• Dental Pressure During Intubation Pilot Study.<br />
• The Brain Temperature Tunnel During General Anesthesia.<br />
• Minimum Training for Successful Cricothyroidotomy: The Effect of an<br />
Adverse Environment.<br />
• High Fidelity Simulation: Assessment of its Role in Resident Education.<br />
• A Multi-Center Survey of Anesthesiologists Attitudes and Abilities in Difficult<br />
Airway Management Using Simulation-Based Performance Evaluation.<br />
McLaughlin, Tara, PhD, Research Administration<br />
• An Assessment of the Homeless of <strong>Hartford</strong>, 2002. <strong>Hartford</strong> Health Dept,<br />
$33,750.<br />
• Evaluating the <strong>Hartford</strong> Continuum of Care’s “Increased Demands for Shelter<br />
Care” Project. <strong>Hartford</strong> Foundation for Public Giving & City of <strong>Hartford</strong>,<br />
$18,500.<br />
• A Brief Assessment of the Homeless of <strong>Hartford</strong>, 2004. City of <strong>Hartford</strong>,<br />
$1,200.<br />
• <strong>Hartford</strong> Resident Survey of Environmental Issues.<br />
• 2005 Census of the Homeless of <strong>Hartford</strong>. Community Renewal Team, $1,700.<br />
• 2006 Census of the Homeless of <strong>Hartford</strong>. Community Renewal Team, $1,500.<br />
Active Collaborations<br />
Anderson, Elizabeth, PhD<br />
Exploration of the Effect of Nausea, Self-efficacy, and Health Care Relationships<br />
on Medication Adherence in AIDS Patients. Donaghue Medical Research<br />
Foundation, $4300.<br />
Claus, Elizabeth, MD<br />
Genetic Epidemiology of Breast Carcinoma In Situ.<br />
Epperson, Neill, MD<br />
The Role of GABA and Neurosteroids in Postpartum Depression.<br />
The Impact of Fluoxetine Treatment on GABA and Neurosteroid Levels in<br />
Women with Premenstrual Dysphoric Disorder.<br />
Fisher, Jeffrey, PhD<br />
Changing Antiretroviral Therapy (ART) Adherence Behavior. NIH subcontract<br />
through the University of Connecticut (Storrs), $326,482.<br />
Ferris, Ann, PhD<br />
Assessment of the Prevalence of Anemia, and its Correlates and Predictors,<br />
Among Low Income Two Year Olds in <strong>Hartford</strong>, CT.<br />
Hadler, James, MD<br />
Surveillance of Connecticut for Organisms Causing Neonatal Sepsis.<br />
Horan, Mary, MA<br />
Ethical Force Program’s Organizational Toolkit for Patient-Centered<br />
Communication (Windham).<br />
Jones, Beth. PhD<br />
Glutathione-S-Transferase Polymorphisms, Race, and Survival from Cancer.<br />
Kenny, Anne, MD<br />
Testosterone Effects on Bone Frailty in Men with Osteoporosis.<br />
Lammi-Keefe, Carol, PhD<br />
Can DHA-functional Food in Pregnancy Enhance Infant Neurobehavioral<br />
Development?<br />
Park, Crystal, PhD<br />
Feasibility Study of Gender Differences in Psychosocial Determinants of<br />
Recovery Following MI. UCHC Center for Interdisciplinary Research on<br />
Women’s Health, $2,400.<br />
Predicting and Understanding Positive Life Changes in Young Adult Cancer<br />
Survivors: Types, Trajectories, Predictors, and Relations with Adjustment. Lance<br />
Armstrong Foundation, $500.<br />
Price, Thomas, PhD<br />
Magnetic Resonance Spectroscopy Studies of Statin-Induced Myopathy. <strong>Hartford</strong><br />
<strong>Hospital</strong> Research Endowment Funds, $11,824.<br />
Risch, Harvey, MD<br />
Case Control Study of Ovarian Cancer Hormonal Etiology.<br />
<strong>Hartford</strong> <strong>Hospital</strong> Case Control Study of Pancreas Cancer Etiology Factors.<br />
Windham <strong>Hospital</strong> Case Control Study of Pancreas Cancer Etiology Factors.<br />
Swede, Helen, PhD<br />
Prognostic Value of Intra-Chromosomal Genomic Instability in Colon Cancer.<br />
Wagner, Joseph, MD<br />
Influence of Patient Size and Prostate Weight on Operative and Peri-Operative<br />
Outcomes for Robot-assisted Radical Prostatectomy.<br />
Woods, Scott, MD<br />
Atypical Antipsychotic Medications: Outcomes and Costs.<br />
Yale University, $8,960.<br />
Longitudinal Follow-Up of Patients Undergoing Evaluation for the Schizophrenia<br />
Prodrome. NIMH, Yale University Subcontract, $11,382.<br />
Yu, Herbert, MD<br />
<strong>Hartford</strong> <strong>Hospital</strong> Epidemiologic Study of Uterus Cancer.<br />
Heimer, Robert, PhD<br />
Unexplained Deaths Related to Bioterrorism.<br />
Windham <strong>Hospital</strong> Epidemiologic Study of Uterus Cancer.<br />
Zheng, Tongzhang, MD<br />
The Role of Epstein-Barr Virus in the Etiology of Hodgkin’s Disease.<br />
116.
<strong>Hartford</strong> <strong>Hospital</strong> Research Program 80 Seymour St. <strong>Hartford</strong>, CT<br />
Staff photos by: Kevin Hagan • Design by: Anthony Tropea